DOI,Title,Authors,Abstract,Journal,Date
10.2147/NSS.S467531,effect acute sleep deprivation sporting performance athletes :,"Gong M, Sun M, Sun Y, Jin L, Li S","objective : use meta-analysis to comprehensively and quantitatively evaluate impact acute sleep deprivation different sport performance athlete , study aim to provide scientific guidance coach optimize and adjust training and competition arrangement . methods : establish literature inclusion and exclusion criterion , conduct search both chinese and english database . use stata 14 . 0 , analyze 75 indicator 27 include literature , focus three aspect : impact acute sleep deprivation overall athletic performance , impact sporting performance various athletic ability , and disparity athletic performance morning and afternoon follow acute sleep deprivation . result : effect size acute sleep deprivation overall athletic performance be -0 . 56 ( p<0 . 05 ) . sub-analyse reveal effect size -0 . 23 ( p<0 . 05 ) whole night sleep deprivation , -1 . 17 ( p<0 . 05 ) partial sleep deprivation end night , and -0 . 25 ( p>0 . 05 ) partial sleep deprivation beginning night . effect size acute sleep deprivation high intensity intermittent exercise , skill control , speed , aerobic endurance , and explosive power indicator be -1 . 57 , -1 . 06 , -0 . 67 , -0 . 54 , and -0 . 39 respectively ( p<0 . 05 ) . effect size acute sleep deprivation overall athletic performance morning and afternoon be -0 . 30 , and -1 . 11 , respectively ( p<0 . 05 ) . conclusion : acute sleep deprivation significantly impair overall athletic performance athlete , more pronounced negative impact observe partial sleep deprivation end night . various type exercise performance be adversely affect acute sleep deprivation , magnitude impact rank high intensity intermittent , skill control , speed , aerobic endurance , and explosive power . follow acute sleep deprivation , athlete ' overall sporting performance afternoon be inferior morning .",Nature and science of sleep,01/01/2024
10.1016/j.drudis.2013.04.001,sclerostin : human mutation have help reveal new target treatment,"Robinson MK, Caminis J, Brunkow ME","1990 be tremendous mood optimism pharmaceutical scientist identification disease-associated variation human genome would result surge new drug target ( ' gene-to-drug ' mantra ) . to date expect deluge new drug have not arrive . however , small number drug arise directly study rare human disorder show mendelian inheritance be now enter late stage clinical trial . here describe advantage approach and discuss background and early clinical trial finding antibody direct target identify way .",Drug discovery today,01/07/2013
10.1038/s41586-025-09588-6,autoimmune response c9orf72 protein amyotrophic lateral sclerosis .,"Michaelis T, Lindestam Arlehamn CS, Johansson E, Frazier A, Berry JD, Cudkowicz M, Goyal NA, Fournier C, Snyder A, Kwan JY, Crook J, Phillips EJ, Mallal SA, Ravits J, Marder KS, Sidney J, Sulzer D, Sette A","amyotrophic lateral sclerosis ( als ) be neurodegenerative disease characterize progressive loss motor neuron . neuroinflammation be apparent affected tissue , include increase t cell infiltration and activation microglia , particularly spinal cord(1 , 2 ) . autoimmune response be think to have key role als pathology , and be hypothesize t cell contribute rapid loss neuron disease progression(3 , 4 ) . however , now have be reported target autoimmune response . here show als be associate recognition c9orf72 antigen , and map specific epitope be recognize . show response be mediate cd4(+ ) t cell preferentially release and il-10 , and",Nature,01/10/2025
10.1038/s41593-025-02062-6,muscle-derive mir-126 regulate tdp-43 axonal local synthesis and nmj integrity,"Ionescu A, Ankol L, Ganapathy Subramaniam A, Altman T, Magen I, Cohen Y, Danino Y, Gradus-Pery T, Niv Y, Bar Avi O, Geller D, Ibraheem A, Cheng R, Steinberg N, Alfahel L, Duc P, Ergul-Ulger Z, Arslan D, Tan E, Rage F, Riva N, Quattrini A, Bekircan-Kurt CE, Israelson A, Dori A, Hornstein E, Perlson E","amyotrophic lateral sclerosis ( als ) be characterize neuromuscular junction ( nmj ) disruption and neurodegeneration . recent finding highlight pivotal role tar dna-binding protein 43 ( tdp-43 ) form axonal pathological condensate and facilitate nmj disruption inhibition local protein synthesis . however , mechanism drive local tdp-43 accumulation remain unknown . here identify tdp-43 axonal accumulation peripheral nerve sod1 patient and mouse stem aberrant local synthesis . be non-cell-autonomous process drive muscle-derived mir-126a-5p extracellular vesicle ( ev ) . inhibit muscle secretion mir-126a-5p prompt presynaptic",Nature neuroscience,03/10/2025
10.1038/s41573-025-01291-5,vivo chimeric antigen receptor ( car)-t cell therapy .,"Bot A, Scharenberg A, Friedman K, Guey L, Hofmeister R, Andorko JI, Klichinsky M, Neumann F, Shah JV, Swayer AJ, Trudeau K, Weissman D, Stephan MT, Buchholz CJ, June CH","chimeric antigen receptor ( car)-t cell therapy have transform outcome patient haematological malignancy , yet use be limit labour-intensive manufacturing , constrain production capacity and variable clinical performance . vivo car-t cell engineering , car-t cell be generate directly patient 's body , seek to overcome challenge eliminate need ex vivo cell processing and complex logistic , as well improve clinical performance . recent advance virology , rna medicine and nanotechnology have catalyse radical overhaul approach , use target delivery system such lentiviral vector and lipid nanoparticle to introduce car-encode genetic material endogenous t cell . early clinical study have show efficient transduction , sustain car expression and initial sign antitumour activity , establish proof concept . review explore underlie technology - include rna deliver lipid nanoparticle and engineer viral vector - and discuss be be adapt to develop more broadly applicable , scalable , safe and effective car-t cell therapy . remove need ex vivo manipulation and chemotherapeutic conditioning , strategy could enable wide application car-t cell therapy not just blood cancer but autoimmune disease ex vivo car-t cell therapy have show strong promise , such systemic lupus erythematosus .",Nature reviews. Drug discovery,30/09/2025
10.1016/j.jns.2024.123303,multi-omic characterization effect ocrelizumab patient,"Kornilov SA, Price ND, Gelinas R, Acosta J, Brunkow ME, Gervasi-Follmar T, Winger RC, Aldershoff D, Lausted C, Troisch P, Smith B, Heath JR, Repovic P, Cohan S, Magis AT","study examine change plasma proteome , metabolome , and lipidome n = 14 patient relapsing-remitting multiple sclerosis ( rrms ) initiate treatment ocrelizumab , assay baseline , 6 month , and 12 month . analysis > 4000 circulate biomarker identify depletion b-cell associate protein early effect observe follow ocrelizumab ( ocr ) initiation , accompany reduction plasma abundance cytokine and cytotoxic protein , marker neuronaxonal damage , and biologically active lipid include ceramide and lysophospholipid , 6 month . b-cell depletion be accompany decrease b-cell receptor and cytokine signaling but pronounce increase circulate plasma b-cell activate factor ( baff ) . be follow upregulation number signal and metabolic pathway 12 month . patient high baseline brain mri lesion load demonstrate both high level cytotoxic and structural protein plasma baseline and more pronounce biomarker change trajectory time . digital cytometry identify putative increase myeloid cell and pro-inflammatory subset t-cells . therapeutic effect ocrelizumab extend cd20-mediated b-cell lysis and implicate metabolic reprogramming , juxtapose early normalization immune activation , cytokine signaling and metabolite and lipid turnover periphery change dynamic immune cell activation or composition . identify baff increase follow cd20 depletion tentative compensatory mechanism contribute reconstitution target b-cells , necessitate further research .",Journal of the neurological sciences,15/12/2024
10.1038/s41591-025-03978-z,systematic review and meta-analysis efficacy and safety,"McGowan B, Ciudin A, Baker JL, Busetto L, Dicker D, Frühbeck G, Goossens GH, Monami M, Sbraccia P, Martinez-Tellez B, Woodward E, Yumuk V","systematic review and network meta-analysis evaluate efficacy and safety obesity management medication ( omms ) term reduce body weight and impact obesity-related complication . here medline and embase search be perform 31 january 2025 randomize control trial compare omm placebo/active comparator adult . primary endpoint be percentage total body weight loss ( tbwl% ) end study . secondary endpoint be tbwl% 1 , 2 and ≥3 year , lipid profile , blood pressure , hemoglobin a1c , fast plasma glucose , mental health , serious adverse event , quality life , cardiovascular morbidity and mortality , remission obesity-related complication and all-cause mortality . fifty-six clinical trial be identified-orlistat ( 22 ) , semaglutide ( 14 ) , liraglutide ( 11 ) , tirzepatide ( 6 ) , naltrexone/bupropion ( 5 ) and phentermine/topiramate ( 2)-enrolling 60 , 307 patient ( 32 , 598 omm and 27 , 709 placebo ) . omms show significantly great tbwl% placebo ( p < 0 . 0001 ) , more 10 % semaglutide and tirzepatide . tirzepatide and semaglutide show normoglycemia restoration , remission type 2 diabete and reduction hospitalization heart failure . semaglutide be effective reduce major adverse cardiovascular event and reduce pain knee osteoarthritis . tirzepatide be effective remission obstructive sleep apnea syndrome and metabolic dysfunction-associated steatohepatitis . result support need to individualize selection omms .",Nature medicine,02/10/2025
10.1126/science.adr7403,intercellular communication brain dendritic nanotubular network .,"Chang M, Krüssel S, Parajuli LK, Kim J, Lee D, Merodio A, Kwon J, Okabe S, Kwon HB","intercellular nanotubular network mediate material exchange , but existence neuron remain to be explore detail . identify long , thin dendritic filopodia form direct dendrite-dendrite nanotube ( dnts ) mammalian cortex . super-resolution microscopy dissociate neuron reveal dnt ' actin-rich composition and dynamic , enable long-range calcium ion ( ca(2 + ) ) propagation . imaging and machine learning-base analysis validate situ dnt anatomically distinct synaptic spine . dnt actively transport small molecule and human amyloid-β ( aβ ) ; dnt density increase plaque formation medial prefrontal cortex app/ps1 mouse ( app , aβ precursor protein ; ps1 , presenilin-1 ) , suggest dendrite-dnt network might play role alzheimer 's disease pathology . computational model dnt-mediated aβ propagation recapitulate early amyloidosis , predict selective intracellular accumulation . finding uncover nanotubular connectivity layer brain , extend neuronal communication classical synapsis .","Science (New York, N.Y.)",02/10/2025
10.1126/science.adu4235,localized glutamine leakage drive spatial structure root microbial,"Tsai HH, Tang Y, Jiang L, Xu X, Dénervaud Tendon V, Pang J, Jia Y, Wippel K, Vacheron J, Keel C, Andersen TG, Geldner N, Zhou F","plant root release exudate to encourage microbiome assembly , influence function and stress resilience plant . specific exudate drive spatial colonization pattern remain largely unknown . study , demonstrate endodermal casparian strips-forming root 's extracellular diffusion barrier-restrict nutrient leakage rhizosphere , coincide and control spatial colonization pattern rhizobacteria . find vasculature-derived glutamine leakage be major bacterial chemoattractant and enhancer proliferation , define previously unknown pathway root exudate formation . bacteria defective amino acid chemoperception display reduce attraction leakage site , and root casparian strip defect display bacterial overproliferation , dependent bacterial capacity amino acid metabolization . associated chronic immune stimulation suggest endodermal nutrient restriction be crucial regulate microbial colonization and assembly , limit excessive proliferation could compromise plant health .","Science (New York, N.Y.)",02/10/2025
10.1038/nri3650,foxp3 and scurfy : begin .,"Ramsdell F, Ziegler SF","have be 65 year scurfy mutation arise spontaneously mouse oak ridge national laboratory united states , and be 13 year molecular cloning forkhead box p3 ( foxp3 ) gene be report . timeline article , review event have occur and time . be not mean exhaustive review biology foxp3 or regulatory t cell , rather be attempt to highlight landmark event have demonstrate importance foxp3 immune function . event have drive , and continue to drive , extensive research effort to fully understand role regulatory t cell immune system .",Nature reviews. Immunology,01/05/2014
10.1186/s13058-025-02123-5,hsa-mir-155-5p expression primary breast tissue may have potential,"Koyama Y, Muguruma M, Horimoto Y, Narui K, Yamada A, Yamada K, Yamamoto S, Orihara S, Kaise H, Kogure A, Yoshioka Y, Ochiya T, Ishikawa T","background : know incidence brain metastasis breast cancer , useful biomarker have be clinically establish breast cancer brain metastasis ( bcbm ) . present study , aim to examine expression micrornas ( mirnas ) relate bcbm formalin-fixed paraffin-embedded ( ffpe ) tissue to identify usefulness predictive biomarker breast cancer brain recurrence ( bcbr ) . methods : pair primary breast and metastatic site tissue sample be collect 38 patient experience first recurrence metastasis single distant organ ( brain/lungs/liver/bone = 11/12/9/6 patient ) january 2007 and december 2021 five institution japan . evaluate expression 15 mirnas ffpe specimen untreated breast and metastatic site same patient use quantitative polymerase chain reaction . result : analysis select 15 mirnas reveal hsa-mir-155-5p exhibit significant bcbr-specific overexpression untreated primary breast tissue ( p < 0 . 001 ) . two other mirnas , hsa-mir-150-5p and hsa-mir-20b-5p , exhibit moderate ( ρ = 0 . 587 ) and weak ( ρ = 0 . 350 ) positive correlation hsa-mir-155-5p , respectively . bcbr prediction model demonstrate high discrimination ability hsa-mir-155-5p ( auc = 0 . 960 ) . localization hsa-mir-155-5p primary breast cancer tissue situ hybridization confirm hsa-mir-155-5p be uniformly stain breast cancer cell . conclusion : hsa-mir-155-5p expression untreated primary breast tissue may be valuable biomarker predict bcbr . personalized escalation strategy be expect to be helpful conquer brain metastasis .",Breast cancer research : BCR,29/09/2025
10.1186/s12933-025-02939-7,joint effect triglyceride glucose index and obesity-related derivative,"Ruan X, Ling Y, Chen J, Xiang Y, Ruan H, Zhang W, Jing L, Gao X, He Y, Lu X, Chang T, Xu J, Chen J","background : triglyceride-glucose ( tyg ) index , tyg-body mass index ( tyg-bmi ) , tyg-waist circumference ( tyg-wc ) , tyg-waist-to-height ratio ( tyg-whtr ) , and estimate glucose disposal rate ( egdr ) serve surrogate marker insulin resistance ( ir ) and be associate cardiometabolic disease ( cmd ) . however , joint effect tyg-related index and egdr cardiometabolic multimorbidity ( cmm ) risk remain unclear . study aim to assess both separate and combined effect tyg-related index and egdr cmm . methods : datum study derive china health and retirement longitudinal study ( charls ) . tyg-related index and egdr be dichotomize median level participant categorization . univariate and multivariate cox regression and restrict cubic spline ( rcs ) analyze effect tyg-related index and egdr cmm , receiver operate characteristic ( roc ) curve , net reclassification improvement ( nri ) and integrate discrimination improvement ( idi ) assess predictive performance . meanwhile , mutual mediating effect and interaction effect be far assess . result : study include 5 , 854 participant ( male : 47 . 5 % , median age : 57 . 0 year ) . compare low tyg-related index plus high egdr , high tyg-related index plus low egdr have elevate cmm risk : tyg ( hr 3 . 59 , 95 % ci 2 . 28-5 . 65 ) , tyg-bmi ( hr 3 . 40 , 95 % ci 2 . 30-5 . 02 ) , tyg-wc ( hr 3 . 85 , 95 % ci 2 . 58-5 . 75 ) , and tyg-whtr ( hr 3 . 62 , 95 % ci 2 . 43-5 . 39 ) . furthermore , addition tyg-related index combine egdr basic model significantly improve cmm risk prediction : tyg ( auc 0 . 713 , nri 0 . 363 , idi 0 . 008 , all p < 0 . 05 ) ; tyg-bmi ( auc 0 . 729 , nri 0 . 479 , idi 0 . 011 , all p < 0 . 05 ) ; tyg-wc ( auc 0 . 716 , nri 0 . 419 , idi 0 . 010 , p < 0 . 05 ) ; and tyg-whtr ( auc 0 . 717 , nri 0 . 379 , idi 0 . 010 , p < 0 . 05 ) . moreover , mediation analysis demonstrate egdr significantly mediate tyg-related index ' association cmm , only obesity-related tyg index mediate association egdr and cmm . notably , significant additive or multiplicative interaction be observe tyg-related index and egdr cmm risk . conclusion : high tyg-relate index and low egdr be independently and jointly associate high cmm risk . joint application tyg-related index and egdr could improve early identification and prevention cmm .",Cardiovascular diabetology,02/10/2025
10.1001/jamanetworkopen.2025.35573,cardiovascular health changes young adults and risk later-life,"Guo JW, Ning H, Allen NB, Perak AM, Walker JM, Pettee Gabriel K, Lloyd-Jones DM","importance : association midlife cardiovascular health ( cvh ) , measure once , incident cardiovascular disease ( cvd ) be well describe . less be know pattern young adulthood cvh , include change and association later-life cvd outcome . objective : to model pattern change population-level and individual-level cvh young adulthood and to assess be associate incident cvd later life . design , setting , and participant : coronary artery risk development young adults ( cardia ) study be prospective longitudinal cohort study enrol black and white participant age 18 to 30 year 1985 and 1986 subsequent follow-up examination next 35 year 4 urban us center . participant at least 3 cvh measurement young adulthood and subsequent follow-up assessment incident cvd event be include . analysis be conduct october 26 , 2023 , may 15 , 2024 . exposures : cvh be measure use american heart association life 's essential 8 score . pattern cvh change young adulthood ( examination year 0 to 20 ) be model population-level trajectory and assess individual-level cvh status change . main outcomes and measures : incident cvd ( myocardial infarction , heart failure , stroke , coronary revascularization , and cvd death ) year 20 . result : be 4241 participant young adulthood ( 2354 [ 55 . 5 % ] female , 2042 48 . 1 % ] self-identifie black and 2199 51 . 9 % ] self-identifie white ) mean ( sd ) baseline age 24 . 9 ( 3 . 6 ) year . trajectory analysis , 4 distinct cvh trajectory pattern be identify . compare persistently high cvh trajectory , moderate-to-low decline and moderate decline cvh trajectory have substantially high risk incident cvd . ahr incident cvd event range 2 . 15 ( 95 % ci , 1 . 04-4 . 47 ) persistently moderate pattern 9 . 96 ( 95 % ci , 4 . 75-20 . 86 ) moderate-to-low decline pattern . cvh status change analysis ( n = 2857 ) , compare stable moderate cvh young adulthood , stable high cvh have low risk ( adjust hazard ratio [ ahr ] , 0 . 25 [ 95 % ci , 0 . 09-0 . 69 ] ) , and stable low cvh have high risk ( ahr , 5 . 91 [ 95 % ci , 2 . 38-14 . 66 ] ) incident cvd . 10-point decrease life 's essential 8 score year 0 and 20 be associate 53 % increase cvd risk ( ahr , 1 . 53 [ 95 % ci , 1 . 31-1 . 78 ] ) . conclusions and relevance : prospective cohort study young adult , unfavorable pattern cvh change young adulthood be associate marked elevation risk incident cvd . datum suggest achieve and maintain high cvh young adulthood strategy primordial prevention be important prevention later-life cvd .",JAMA network open,01/10/2025
10.1016/j.immuni.2025.09.011,"obesity , diabetes , and inflammation : pathophysiology and clinical implication .","Donath MY, Drucker DJ","obesity and related disorder , include type 2 diabete and liver , kidney , and cardiovascular disease , be now recognize chronic inflammatory condition . here , review mechanism underlie inflammation setting and may contribute pathology . nutrient excess trigger immune activation pattern recognition receptor and nlrp3 inflammasome , lead interleukin ( il)-1β production and downstream cytokine cascade . initially adaptive , inflammation promote tissue remodeling and metabolic compensation , but chronic activation contribute insulin resistance , cell dysfunction , and end-organ damage . discuss current therapeutic option , focus glucagon-like peptide-1 ( glp-1 ) receptor agonist , , alone or combine additional bioactive moiety , exert notable anti-inflammatory effect . effect glp-1 medicine be independent glucose control or weight loss , and be attribute direct signaling immune glp-1 receptor ( glp-1r ) and , indirectly , central nervous system circuit . understand mechanism may unlock further therapeutic potential chronic inflammatory disease .",Immunity,03/10/2025
10.1038/s41586-025-09539-1,proteotoxic stress response drive t cell exhaustion and immune evasion .,"Wang Y, Ma A, Song NJ, Shannon AE, Amankwah YS, Chen X, Wu W, Wang Z, Saadey AA, Yousif A, Ghosh G, Mandula JK, Velegraki M, Xiao T, Wen H, Huang SC, Wang R, Beusch CM, Dawood AS, Gordon DE, Abdel-Hakeem MS, Ghoneim HE, Xin G, Searle BC, Li Z","chronic infection and cancer cause t cell dysfunction know exhaustion . cell state be cause persistent antigen exposure , suboptimal co-stimulation and plethora hostile factor dampen protective immunity and limit efficacy immunotherapies(1-4 ) . mechanism underlie t cell exhaustion remain poorly understand . here analyse proteome cd8(+ ) exhausted t ( t(ex ) ) cell multiple state exhaustion context chronic viral infection and cancer . show be non-stochastic pathway-specific discordance mrna and protein dynamic t effector ( t(eff ) ) and t(ex ) cell . identify distinct proteotoxic stress response ( psr ) t(ex ) cell , term t(ex)-psr . contrary canonical stress response induce reduction protein synthesis(5 , 6 ) , t(ex)-psr involve increase global translation activity and upregulation specialized chaperone protein . t(ex)-psr be far characterize accumulation protein aggregate and stress granule and increase autophagy-dominant protein catabolism . establish disruption proteostasis alone can convert t(eff ) cell t(ex ) cell , and link t(ex)-psr mechanistically persistent akt signal . finally , disruption t(ex)-psr-associate chaperones cd8(+ ) t cell improve cancer immunotherapy preclinical model . moreover , high t(ex)-psr t cell patient cancer confer poor response clinical immunotherapy . collectively , finding indicate t(ex)-psr be hallmark and mechanistic driver t cell exhaustion , raise possibility target proteostasis pathway approach cancer immunotherapy .",Nature,01/10/2025
10.1016/j.immuni.2012.02.019,disruption fnip1 reveal metabolic checkpoint controlling b lymphocyte,"Park H, Staehling K, Tsang M, Appleby MW, Brunkow ME, Margineantu D, Hockenbery DM, Habib T, Liggitt HD, Carlson G, Iritani BM","coordination nutrient and energy availability cell growth and division be essential proper immune cell development and function . use chemical mutagenesis strategy mouse , identify pedigree have complete block b cell development pre-b cell stage result deletion fnip1 gene . enforce expression immunoglobulin transgene fail to rescue b cell development . essential pre-b cell signal molecule be activate normally fnip1-null pre-b cell , metabolic regulator ampk and mtor be dysregulate , result excessive cell growth and enhance sensitivity apoptosis response metabolic stress ( pre-b cell receptor crosslinking , oncogene activation ) . result indicate folliculin-interacte protein 1 ( fnip1 ) be vital b cell development and metabolic homeostasis and reveal metabolic checkpoint may ensure pre-b cell have sufficient metabolic capacity to support division , limit lymphomagenesis cause deregulated growth .",Immunity,25/05/2012
10.1056/NEJMoa2508170,sotatercept pulmonary arterial hypertension first year,"McLaughlin VV, Hoeper MM, Badesch DB, Ghofrani HA, Gibbs JSR, Gomberg-Maitland M, Preston IR, Souza R, Waxman AB, Kopeć G, Meyer G, Olsson KM, Fu W, Shi Y, Miller B, Kim SS, Mackenzie HS, Brambatti M, Patel MJ, Koglin J, Cornell AG, Humbert M","background : sotatercept , activin-signale inhibitor , reduce morbidity and mortality patient long-standing pulmonary arterial hypertension . effect patient pulmonary arterial hypertension first year diagnosis be unclear . method : phase 3 trial , enrol adult patient world health organization functional class ii or iii pulmonary arterial hypertension have receive diagnosis less 1 year early , have intermediate or high risk death , and be receive double or triple background therapy . patient be randomly assign to receive add-on therapy subcutaneous sotatercept ( start dose , 0 . 3 mg kilogram body weight ; escalate to target dose , 0 . 7 mg kilogram ) or placebo 21 day . primary end point be clinical worsening , composite death cause , unplanned hospitalization last least 24 hour worsen pulmonary arterial hypertension , atrial septostomy , lung transplantation , or deterioration performance exercise testing pulmonary arterial hypertension , assess time-to-first-event analysis . result : trial be stop early owe loss clinical equipoise reporting positive result previous sotatercept trial . total 320 patient be include ( 160 sotatercept and placebo group ) . median duration follow-up be 13 . 2 month . least one primary end-point event occur 17 patient ( 10 . 6 % ) sotatercept group and 59 patient ( 36 . 9 % ) placebo group ( hazard ratio , 0 . 24 ; 95 % confidence interval , 0 . 14 0 . 41 ; p<0 . 001 ) . deterioration performance exercise testing pulmonary arterial hypertension occur 8 patient ( 5 . 0 % ) sotatercept group and 46 patient ( 28 . 8 % ) placebo group ; unplanned hospitalization worsen pulmonary arterial hypertension occur 3 patient ( 1 . 9 % ) and 14 patient ( 8 . 8 % ) , respectively ; and death cause occur 7 patient ( 4 . 4 % ) and 6 patient ( 3 . 8 % ) . case atrial septostomy or lung transplantation occur . most common adverse event sotatercept be epistaxis ( 31 . 9 % ) and telangiectasia ( 26 . 2 % ) . conclusion : adult pulmonary arterial hypertension have receive diagnosis less 1 year early , addition sotatercept background therapy result low risk clinical worsening placebo . ( fund merck sharp and dohme , subsidiary merck [ rahway , nj ] ; hyperion clinicaltrials.gov number , nct04811092 . ) .",The New England journal of medicine,30/09/2025
10.1016/j.cell.2025.08.033,epithelial-mesenchymal transition .,"Zhang CX, Huang RY, Sheng G, Thiery JP","epithelial-mesenchymal transition ( emt ) be fundamental mechanism involve morphogenesis metazoan . evolutionarily conserve multi-stage process , cell acquire quasi-epithelial multiple intermediate morphology epithelial and mesenchymal attribute , rarely reach complete mesenchymal phenotype . complex evolutionary-conserve morphogenetic movement gastrulation be describe extensively , exemplify extent epithelial cell plasticity animal kingdom . nonetheless , single-gene knockout can modify mode gastrulation achieve same body plan . numerous interconnected mechanism drive different degree emt , include surface receptor signal , metabolism , and epigenetic . emt be reactivate adult tissue repair and disease , particularly cancer initiation , progression metastasis , and refractoriness treatment . emt also contribute dormancy and drug tolerance , lead minimal residual disease origin recurrence . multiple emt state coexist tumor , create dynamic ecosystem generate inflammatory microenvironment , stemness , invasion , and metastasis . review provide in-depth description aspect recent controversy and offer new opportunity to far explore multiple function emt . examine potential attribute emt tissue repair , fibrosis , and cancer progression can provide new opportunity therapeutic intervention .",Cell,02/10/2025
10.1016/j.immuni.2025.09.007,notch3 destabilize regulatory t cell to drive autoimmune neuroinflammation,"Benamar M, Contini P, Schmitz-Abe K, Lanzetta O, Getachew F, Bachelin C, Leyva Castillo JM, Wang M, Oktelik FB, Perrot O, Batamack Y, Arbag SN, Stephen-Victor E, Harb H, Agrawal PB, Louapre C, Ivaldi F, Uccelli A, Inglese M, Angelini C, Zujovic V, De Palma R, Chatila TA",immune regulatory defect promote neuroinflammation multiple sclerosis ( ms ) remain unclear . show specific regulatory t ( treg ) cell subpopulation express notch3 be increase individual ms and mouse experimental autoimmune encephalomyelitis ( eae ) . notch3(+ ) treg cell be induce gut microbiota receptor ( tlr)-dependent mechanism . then translocate central nervous system ( cns ) eae promote disease severity . notch3 interact delta-like ligand 1 ( dll1 ) microglia to subvert treg cell t helper 17 ( th17 ) cell . notch3 deletion treg cell prevent eae onset stabilize treg cell and simultaneously promote expansion tissue-resident treg cell population express neuropeptide y receptor 1 ( npy1r ) and suppress pathogenic ifn-γ(+ ) and,Immunity,02/10/2025
10.1126/science.adr5048,comprehensive genetic catalog human double-strand break repair .,"de Alba EL, Salguero I, Giménez-Llorente D, Montes-Torres J, Fernández-Sanromán Á, Casajús-Pelegay E, Terrón-Bautista J, Barroso-González J, Bernal JA, Macintyre G, Fernández-Leiro R, Losada A, Cortés-Ledesma F","analysis dna sequence outcome provide molecular insight double-strand break ( dsb ) repair mechanism . use parallel in-pool profiling cas9-induced insertion and deletion ( indel ) genome-wide knockout library , present comprehensive catalog assess influence nearly human gene dsb repair outcome . resource uncover uncharacterized mechanism , pathway , and factor involve dsb repair , include oppose role xlf and paxx , molecular explanation cas9-induced multinucleotide insertion , hltf function cas9-induced dsb repair , involvement saga complex microhomology-mediated end joining , and indel mutational signature link vhl loss , renal carcinoma , and hypoxia . result exemplify potential repairome to drive future discovery dsb repair , crispr-cas gene editing and etiology cancer mutational signature .","Science (New York, N.Y.)",02/10/2025
10.36401/JQSH-23-28,factor affecting pregnancy complications ghana .,"Wiafe YK, Asamoah A, Akweongo P, Kumah A","introduction : prevalence maternal mortality continue to be significant health concern world . ghana , pregnancy-related complication previous 5 year account 12 % death woman 15 to 49 year . more half death be avoidable early assessment have be do . however , assessment pooled prevalence pregnancy-related complication pregnant woman to inform policy be limited . study seek to determine factor contribute pregnancy complication ghana . methods : use systematic sampling technique , facility-based cross-sectional study be conduct 415 pregnant woman attend antenatal care ( anc ) service mamprobi hospital . bivariate and multiple logistic regression analysis be conduct to test significant factor determine pregnancy complication . result regression analysis be report odd ratio . statistical significance be set p < 0 . 05 . result : mean age participant be 31 . 6 ± 6 . 6 year . incidence pregnancy complication pregnant woman be 51 . 8 % ( 95 % ci , 0 . 47-0 . 56 ) incidence pregnancy complication woman be significantly determine age ( adjust odd ratio [ aor ] , 6 . 1 ; ci , 1 . 19-30 . 76 ) , record pregnancy complication ( aor , 2 . 5 ; ci , 1 . 35-4 . 49 ) , anc visit ( aor , 6 . 1 ; ci , 2 . 14-17 . 70 ) , and family history pregnancy complication ( aor , 3 . 6 ; ci , 1 . 25-10 . 40 ) . other significant factor include record abortion ( aor , 7 . 8 ; ci , 4 . 21-14 . 32 ) , knowledge obstetric danger sign ( aor , 2 . 4 ; ci , 1 . 21-4 . 88 ) , and experience least one obstetric danger sign pregnancy ( aor , 6 . 6 ; ci , 3 . 30-13 . 29 ) . conclusion : incidence pregnancy complication be comparatively high woman use anc service mamprobi hospital . early initiation anc service pregnant woman be essential tool address challenge early onset pregnancy complication , include anemia pregnancy and preeclampsia . midwife and other health worker engage pregnant woman should encourage client to initiate anc visit early stage .",Global journal on quality and safety in healthcare,01/11/2024
10.1038/s41571-025-01077-z,"tumour microenvironment pancreatic cancer - new clinical challenge , but","Kung HC, Zheng KW, Zimmerman JW, Zheng L","patient advanced-stage pancreatic ductal adenocarcinoma ( pdac ) predominantly receive chemotherapy , and initial response patient , most will have disease progression and often dismal outcome . lack clinical effectiveness partly reflect not only cancer cell-intrinsic factor but also presence tumour microenvironment ( tme ) preclude access systemic therapy and circulate immune cell primary tumour , as well support growth pdac cell . combine improve preclinical model pdac , advance single-cell spatial multi-omic and machine learning-base model have provide novel method untangle complexity tme . review , focus desmoplastic stroma and both intratumoural and intertumoural heterogeneity pdac , emphasis cancer-associated fibroblast and surround immune cell niche . describe new approach convert immunologically ' cold ' pdac tme ' hot ' tme prime t cell activation , overcome t cell exhaustion and unravel myeloid cell-mediated immunosuppression . furthermore , explore integrate target involve tme , such point convergence tumour , stromal and immune cell metabolism as well oncogenic kras signal . finally , build experience fail clinical trial past , consider evolve comprehensive understanding tme will ensure future success develop more effective therapy patient pdac .",Nature reviews. Clinical oncology,03/10/2025
10.1038/s41467-025-63880-7,mtch2 modulate cpt1 activity to regulate lipid metabolism adipocyte .,"Wu C, Wang T, Ghosh A, Long F, Sharma AK, Dahlby T, Noé F, Severi I, Colleluori G, Cinti S, Giordano A, Ding L, Khandelwal R, Kostidis S, Giera M, Balazova L, Gardeux V, Abu-Nawwas L, Deplancke B, Chourasia S, Kleiner S, Hamilton BS, Alcántara JMA, Ruiz JR, Blüher M, Pekcec A, Balaz M, Gross A, Neubauer H, Wolfrum C","metabolic disorder , include obesity and metabolic-associated steatohepatitis , arise chronic energy surplus . thus , enhance energy dissipation increase respiration hold significant therapeutic potential metabolic disorder . comprehensive analysis human and murine adipose tissue , functional screen , identify mitochondrial carrier homolog 2 , mitochondrial outer membrane protein , pivotal regulator mitochondrial metabolism . intriguingly , expression adipose tissue be strong determinant obesity human . adipocyte-specific ablation mitochondrial carrier homolog 2 improve mitochondrial function and whole-body energy expenditure , independent uncouple protein 1 . furthermore , mitochondrial carrier homolog 2 regulate mitochondrial influx free fatty acid modulate sensitivity carnitine palmitoyltransferase 1 malonyl-coa direct physical interaction , lead enhanced energy expenditure adipocytes/adipose tissue . here show mitochondrial carrier homolog 2 function negative regulator energy metabolism adipocyte and represent potential target treat obesity and related metabolic disorder .",Nature communications,03/10/2025
10.1038/s41568-025-00869-w,unveil molecular and immunological driver antibody-drug conjugate,"Zippelius A, Tolaney SM, Tarantino P, Balthasar JP, Thurber GM","decade investment , antibody-drug conjugate ( adcs ) be finally demonstrate potential , mark grow number clinical approval , application early line treatment and integration drug combination , include immunotherapy . progress have spur investment develop new adcs and expand use approve adcs clinical practice . design adcs be complex , involve multiple molecular component interact both tumour and host tissue microenvironment . review , explore molecular and immunological factor influence adc efficacy and toxicity . describe molecular component adcs determine systemic , tissue and cellular distribution , ultimately dictate therapeutic efficacy . interaction also determine toxicity profile and set limitation maximum dosing . finally , discuss impact adc treatment immune cell , emphasize distinct but interconnected role immunogenic cell death , activation immune cell such dendritic cell and antibody-fc interaction . mechanism be crucial increase efficacy direct cytotoxic effect payload . provide insight intricate interaction adcs , review aim to inform rational design combination therapy and guide development next generation clinically effective adcs .",Nature reviews. Cancer,02/10/2025
10.1016/j.immuni.2025.09.004,eomesodermin(+ ) cd4(+ ) t cell be critical curative immunotherapy outcome .,"Zhang P, Haeseleer F, Waltner OG, Gartlan KH, Bhise SS, Minnie SA, Adams RC, Yeh AC, Ensbey KS, Legg SRW, Sekiguchi T, Atilla E, Nemychenkov NS, Nelson EL, Joshi T, Liang EC, Hirayama AV, Abe K, Koyama M, Clouston AD, Gauthier J, Furlan SN, Hill GR","interleukin 10 ( il-10)-produce cd4(+ ) type-1 regulatory t cell ( tr1 ) promote immune tolerance chronic infection , autoimmunity , and transplantation . however , specific eomesodermin ( eomes)-dependent stage tr1 differentiation and function remain unclear . use preclinical model bone marrow transplantation ( bmt ) , demonstrate tr1 differentiation trajectory vivo eomes(+)il-10(- ) eomes(+)il-10(+ ) subset acquisition cytokine , cytolytic , and exhaustion feature . eomes(+)cd4(+ ) fraction represent dominant cytotoxic subset bmt , mediate graft-versus-leukemia effect limit inflammation . cd19-targeted chimeric antigen receptor ( car ) t cell immunotherapy , eomes drive same cd4(+ ) tr1 phenotype control cytolysis , mitigate immune toxicity and promote persistence . individual high-grade b cell lymphoma have long-term disease control receive commercial cd19-targeted car t cell , eomes(+ ) tr1 cell represent stable population comprise 40%-80 % cd4(+ ) car t cell population . hence , eomes control regulatory and cytotoxic program cd4(+ ) t cell , essential curative immunotherapy outcome .",Immunity,02/10/2025
10.1038/s41564-025-02114-4,generative artificial intelligence approach discovery antimicrobial,"Wang Y, Zhao L, Li Z, Xi Y, Pan Y, Zhao G, Zhang L","discovery novel antimicrobial peptide ( amp ) clinical superbug be urgently need to address ongoing antibiotic resistance crisis . amp be promise candidate broad-spectrum activity , rapid bactericidal mechanism and reduced likelihood induce resistance compare conventional antibiotic . here , pre-trained protein large language model ( llm ) , proteogpt , be establish and far develop multiple specialized subllms to assemble sequential pipeline . pipeline enable rapid screening hundred million peptide sequence , ensure potent antimicrobial activity and minimize cytotoxic risk . transfer learning , endow llms different domain-specific knowledge to achieve high-throughput mining and generation amp unified methodological framework . notably , mine and generate amp exhibit reduce susceptibility resistance development icu-derive carbapenem-resistant acinetobacter baumannii ( crab ) and methicillin-resistant staphylococcus aureus ( mrsa ) vitro . amp also show comparable or superior therapeutic efficacy vivo thigh infection mouse model compare clinical antibiotic , cause organ damage and disrupt gut microbiota . mechanism action amp involve disruption cytoplasmic membrane and membrane depolarization . overall , study present generative artificial intelligence approach discovery novel antimicrobial multidrug-resistant bacteria , enable efficient and extensive exploration amp space .",Nature microbiology,03/10/2025
10.1186/s12943-025-02459-8,reprogramme cellular senescence and age clock advanced cancer,"Yang H, Liu D, Qiu L, Wang R, Zhang C, Yu D, Zhong Q, Yuki N, Song Z, Zhu T, Ju H, Hong W, Zhu J","cellular senescence have gradually be recognize key process , not only inhibit occurrence early tumor but also promote advanced malignant progression secretory and immunomodulatory function . initially , cellular senescence manifest irreversible cell cycle arrest , but now encompass broad phenotype regulate p53-p21cip1 and p16ink4a-rb pathway . secretory phenotype relate aging can recruit immune effector to clear new tumor cell , persistent senescent cell population often trigger chronic inflammation , promote immune escape and fibrosis . review , first discuss molecular underpinning cellular senescence , highlight induction pathway and diverse physiological or pathological role . then examine composition tumor microenvironment , senescent cell accumulate and secrete pro-inflammatory cytokine , reshape immune surveillance and extracellular matrix architecture . backdrop , explore aging clock refine understanding individual susceptibility malignancy distinguish biological chronological aging . also present current therapeutic prospect , include senolytic agent target senescent stromal cell promote tumor growth , and utilization age clock metric to tailor immunotherapy more effectively old patient . finally , consider major challenge face clinical translation , standardize multi-omic datum pipeline to clarify ethical implication measure biological age . bridge senescence biology geroscience and cutting-edge oncology , posit age clock may catalyze transformation cancer care , enable more personalize , effective , and age-conscious treatment strategy .",Molecular cancer,02/10/2025
10.1038/s41586-025-09391-3,monoclonal antibodie protect pandrug-resistant klebsiella pneumoniae .,"Roscioli E, Zucconi Galli Fonseca V, Bosch SS, Paciello I, Maccari G, Cardinali G, Batani G, Stazzoni S, Tiseo G, Giordano C, Yuwei S, Capoccia L, Cardamone D, Ridelfi M, Troisi M, Manganaro N, Mugnaini C, De Santi C, Ciabattini A, Cerofolini L, Fragai M, Licastro D, Wyres K, Dortet L, Barnini S, Nicolau DP, Menichetti F, Falcone M, Abdelraouf K, Sala C, Kabanova A, Rappuoli R","' silent pandemic ' cause antimicrobial resistance require innovative therapeutic approach . human monoclonal antibodie ( mabs ) , be most transformative and safe drug oncology(1 ) and autoimmunity(2 ) , be rarely use infectious disease and not yet use antimicrobial resistance(3 ) . here apply antigen-agnostic strategy to isolate extremely potent human mabs klebsiella pneumoniae sequence type 147 ( st147 ) , hypervirulent and pandrug-resistant lineage be spread globally . isolated mabs target kl64 capsule and o-antigen . however , mabs display bactericidal activity picomolar range vitro , only capsule-specific mabs be protective fulminant bloodstream infection st147 and two geographically and genetically distant carbapenem-resistant kl64-bearing k . pneumoniae . protection observe vivo correlate vitro bacterial uptake macrophage and enchain bacterial growth . study thus describe mab protect pandrug-resistant k . pneumoniae and provide strategy to isolate mabs and identify mabs confer protection bacteria antimicrobial resistance .",Nature,01/10/2025
10.1038/s41584-025-01305-x,novel approach stratified management knee osteoarthritis .,"Fuggle NR, Chapurlat R, Laslop A, Al-Daghri N, Alokail M, Thiyagarajan JA, Balkowiec-Iskra E, Berenbaum F, Bemden AB, Borg JJ, Bruyère O, Burlet N, Cavalier E, Rosa MM, Conaghan PG, Cooper C, Dennison EM, Englund M, Im GI, Haugen IK, Hiligsmann M, Kurth A, Lane N, Lories R, Marlovits S, Matijevic R, Mobasheri A, Ormarsdóttir S, Yerro MCP, Radermecker RP, Rannou F, Sepodes B, Silverman S, Torre C, Veronese N, Rizzoli R, Reginster JY, Harvey NC","knee osteoarthritis be highly prevalent whole-joint disease be associate substantial morbidity . step change be to be make management knee osteoarthritis , novel patient stratification approach be need to identify most effective treatment individual patient . numerous method stratify patient knee osteoarthritis can be employ ; clinical presentation , include co-morbidity and pain phenotype , can influence treatment decision , and be rich history imaging biomarker use , conventional radiograph and , development , mri , identify patient risk disease progression , and latter facilitate detection synovitis . development novel biochemical biomarker and rapid growth ' -omic ' technology provide fresh opportunity to deploy advance stratification patient knee osteoarthritis . health economic landscape area be develop , and scope work have highlight need further study .",Nature reviews. Rheumatology,03/10/2025
10.1016/j.neuron.2025.09.004,astrocyte-mediated central amygdala microcircuit gate comorbid anxiety symptom,"Zan GY, Yao SY, Deng YZ, Jiang YH, Ye RF, Chen Y, Long JD, Cheng YJ, Chai JR, Xu C, Zhao M, Liu ZQ, Liu JG, Wang YJ","comorbid anxiety symptom be prominent affective component chronic pain , yet central mechanism underlie symptom remain elusive . central amygdala ( cea ) regulate nociceptive processing and associate anxiety chronic pain . however , specific microcircuit and cell type cea regulate pain-related anxiety have not be fully elucidate . study , discover microcircuit cea wherein dynorphinergic neuron lateral subdivision central amygdala ( cel ) project medial subdivision ( cem ) , activation gate anxiogenic effect associate chronic pain . dynorphin-mediate activation cem astroglial kappa opioid receptor ( kor ) , dependent corticotropin-releasing factor ( crf ) receptor 2 signal , enhance cem neuron excitability promote n-methyl-d-aspartate receptor ( nmdar ) activation , likely release gliotransmitter d-serine . behaviorally , kor-mediate bidirectional communication cea peptidergic neuron and astrocyte modulate anxiogenic effect chronic pain . finding reveal neuroglial microcircuit underlie pain-associated anxiety and suggest potential target therapeutic intervention .",Neuron,02/10/2025
10.1038/s41593-025-02064-4,brain tumor induce widespread disruption calvarial bone and alteration,"Dubey A, Yamashita E, Stangeland B, Abbas I, Fooksman D, Harris RA, Palmer GM, Koba WR, Zhang J, Himes BT, Lu OR, Ho WS, Kuiper RV, Huffman D, Wu Z, Uchida Y, Ishii M, Welch RL, Fiedler AF, Reynolds D, Hosainey SAM, Dobrenis K, Ye Q, Fisher K, Killian N, Stanley ER, Eskandar E, Behnan J","skull marrow niche have recently be identify reservoir supply brain monocyte and neutrophil context disease and injury , but role brain cancer remain unknown . here show glioblastoma , most malignant type brain tumor , induce calvarial bone abnormality murine model and patient glioblastoma , alter osteoclast activity and increase number skull channel mouse . single-cell rna sequence reveal glioblastoma-mediated alteration immune landscape skull marrow and femoral bone marrow , include expansion neutrophil and deterioration various b cell subset . vivo inhibition bone resorption reduce bone abnormality , but promote tumor progression mesenchymal subtype tumor . also abolish survival benefit checkpoint inhibitor anti-pd-l1 , reduce activate t cell and increase inflammatory neutrophil number . together , datum provide insight brain tumor affect skull bone and immune environment .",Nature neuroscience,03/10/2025
10.1136/gutjnl-2025-334988,dpp-4 inhibitor alleviate gut-brain axis pathology parkinson 's disease .,"Jeong SH, Kim YJ, Shin JY, Oh KW, Lee JW, Lee PH","background : dipeptidyl peptidase-4 inhibitor ( dpp-4is ) have be report to exhibit therapeutic effect parkinson 's disease ( pd ) , increase potential drug repurposing . one aspect pd pathogenesis be think to be associate gut-brain axis , α-synuclein gut be transmit brain vagus nerve ( vn ) . objective : explore sitagliptin , dpp-4i , exhibit protective effect low-dose rotenone-treated gut-brain axis-associated pd model . design : to explore effect sitagliptin , use oral rotenone-treated mouse model , show spread pathological α-synuclein intestine stereotypic manner vn midbrain motor deficit . result : sitagliptin mitigate rotenone-induced gut inflammation and toll-like receptor 2 ( tlr2 ) expression , reduce α-synuclein accumulation gut , vn and brain and lessen neuronal loss medulla and midbrain recovery motor performance . addition , sitagliptin suppress inflammation response tlr2 agonist and rotenone macrophage , enteric glial cell and enteroendocrine cell line vitro . secretin tumour cell 1 , enteroendocrine cell line , sitagliptin also decrease rotenone-induced endogenous α-synuclein level . beneficial effect sitagliptin be maintain even glucagon-like peptide-1 receptor blockade . notably , sitagliptin significantly alter gut microbiome , shift profile may counteract pd pathology . conclusion : finding demonstrate sitagliptin alleviate α-synuclein deposition gut and brain modulation tlr2-mediate inflammation and alter gut microbiome composition more favourable profile , indicate dpp-4is can offer novel therapeutic avenue manage pd .",Gut,02/10/2025
10.1016/S0140-6736(25)01039-6,effect repurposed simvastatin disability progression secondary,"Chataway J, Williams T, Blackstone J, John N, Braisher M, De Angelis F, Bianchi A, Calvi A, Doshi A, Apap Mangion S, Wade C, Bordea E, Merry R, Barton G, Lyle D, Jarman E, Mahad D, Shehu A, Arun T, McDonnell G, Geraldes R, Craner M, Hillier C, Ganesalingam J, Fisniku L, Hobart J, Spilker C, Robertson NP, Kalra S, Pluchino S, Harikrishnan S, Mattoscio M, Harrower T, Young C, Lee M, Chhetri SK, Ahmed F, Rog D, Silber E, Gallagher P, Duddy M, Straukiene A, Nicholas R, Rice C, Tebbs S, Hawton A, Hunter R, Giovannoni G, Ciccarelli O, Beveridge J, Nixon S, Thompson AJ, Greenwood J, Pearson OR, Evangelou N, Sharrack B, Galea I, Gray E, Pavitt S, Chandran S, Ford HL, Frost C, Nicholas JM","background : success immune modulation treatment relapse multiple sclerosis , disability progression be major problem drive multiple mechanism . comorbiditie ( eg , vascular risk ) and ageing be think to augment neurodegenerative pathology . phase 2b ms-stat trial simvastatin ( 80 mg ) placebo secondary progressive multiple sclerosis ( spms ) , adjusted difference brain atrophy rate group be -0·254 % year : 43 % reduction . phase 3 ms-stat2 trial , aim to assess efficacy simvastatin placebo slow progression disability spms . methods : phase 3 , randomise , double-blind , parallel group , placebo-controlled clinical trial be conduct 31 neuroscience centre and district general hospital uk . participant age 18-65 year diagnosis spms and expanded disability status scale ( edss ) 4·0 and 6·5 be eligible and randomly assign ( 1 :1 ) oral simvastatin ( 80 mg ) or match placebo to 4·5 year , base minimisation algorithm independent and secure online randomisation service . participant , site investigator , and trial coordinating team be mask treatment allocation . primary outcome be time to 6-month edss confirm disability progression ( increase at least 1 point edss score baseline visit be less 6·0 or increase 0·5 point edss score baseline visit be 6·0 or more ) assess randomly assign participant ( intention-to-treat analysis ) imputation . study be register clinicaltrials.gov ( nct03387670 ) and be isrctn registry ( isrctn82598726 ) . study be complete . finding : may 10 , 2018 , and july 26 , 2024 , 1079 patient be screen eligibility and 964 participant be randomly assign , 482 ( 50 % ) placebo group and 482 ( 50 % ) simvastatin group . of 964 participant , 704 ( 73 % ) be female and 260 ( 27 % ) be male , mean age 54 year ( sd 7 ) . 173 ( 36 % ) 482 participant placebo group and 192 ( 40 % ) 482 participant simvastatin group have 6-month confirm disability progression ( adjust hazard ratio 1·13 [ 95 % ci 0·91 1·39 ] , p=0·26 ) . emergent safety issue be see , be one serious adverse reaction ( rhabdomyolysis ) simvastatin group . 12 ( 2 % ) 482 participant placebo group and five ( 1 % ) 482 participant simvastatin group have cardiovascular serious adverse event . interpretation : ms-stat2 trial do not show treatment effect simvastatin slow disability progression spms . simvastatin use multiple sclerosis should be confine exist vascular indication . funding : national institute health and care research health technology assessment programme , uk multiple sclerosis society , and us national multiple sclerosis society .","Lancet (London, England)",01/10/2025
10.1016/j.ccell.2025.09.004,neoadjuvant treatment ibi310 plus sintilimab locally advanced msi-h/dmmr,"Wang F, Chen G, Qiu M, Ma J, Mo X, Liu H, Li Y, Ding P, Wan X, Hu Y, Huang X, Jiang W, Wu X, Luo J, Zhou Y, Li L, Sun Y, Wang Q, Wang N, Jiang W, Yuan W, Li L, Liu L, Yuan X, Wang G, Song Z, Liu H, Ge J, Wang Y, Zhao P, Li T, You J, Tang J, Du X, Lin J, Zhang R, Fu Z, Xu J, Zhong H, Kang L, Deng Y, Lu X, Guo Q, Zhou H, Xu RH","neoadjuvant immunotherapy show promise efficacy locally advanced microsatellite instability-high or mismatch repair-deficient ( msi-h/dmmr ) colon cancer , dual immune checkpoint inhibition provide additional benefit anti-pd-1 monotherapy remain unclear . randomized phase 1b trial ( nct05890742 ) evaluate neoadjuvant regimen ibi310 ( anti-cytotoxic t lymphocyte-associate antigen 4 [ ctla-4 ] ) plus sintilimab ( n = 52 ) sintilimab monotherapy ( n = 49 ) . surgery be perform 51 and 45 patient , respectively . primary endpoint , pathological complete response ( pcr ) rate , be significantly high combination compare monotherapy arm modify intent-to-treat ( mitt ) population ( 78 . 4 % 46 . 7 % , p = 0 . 0015 ) , consistent result intent-to-treat ( itt ) population ( 76 . 9 % 42 . 9 % ) . safety arm be comparable and manageable new safety signal . median follow-up 21 . 4 month , disease recurrence occur . one death occur arm postoperative complication and adverse event . finding demonstrate add benefit neoadjuvant ibi310 plus sintilimab sintilimab monotherapy locally advanced",Cancer cell,02/10/2025
10.1021/acs.jproteome.9b00569,measurement organ-specific and acute-phase blood protein levels early lyme,"Zhou Y, Qin S, Sun M, Tang L, Yan X, Kim TK, Caballero J, Glusman G, Brunkow ME, Soloski MJ, Rebman AW, Scavarda C, Cooper D, Omenn GS, Moritz RL, Wormser GP, Price ND, Aucott JN, Hood L","lyme disease result infection human spirochete borrelia burgdorferi . first and most common clinical manifestation be circular , inflame skin lesion refer erythema migran ; later manifestation result infection other body site . laboratory diagnosis lyme disease can be challenge patient erythema migrans time delay development specific diagnostic antibody borrelia . reliable blood biomarker early diagnosis lyme disease patient erythema migran be need . here , perform select reaction monitoring , target mass spectrometry-based approach , to measure select protein ( 1 ) be know to be predominantly express one organ ( i.e. , organ-specific blood protein ) and blood concentration may change result lyme disease , or ( 2 ) be involve acute immune response . longitudinal cohort 40 lyme disease patient and 20 healthy control , identify 10 protein significantly alter serum level patient time diagnosis , and also develop 10-protein panel identify multivariate analysis . independent cohort patient erythema migrans , six protein , apoa4 , c9 , crp , cst6 , pglyrp2 , and s100a9 , be confirm to show significantly alter serum level patient time presentation . nine 10 protein multivariate panel be also verify second cohort . protein , primarily innate immune response protein or protein specific liver , skin , or white blood cell , may serve candidate blood biomarker require further validation to aid laboratory diagnosis early lyme disease .",Journal of proteome research,03/01/2020
10.1186/s12902-025-02043-7,efficacy and safety variable-dose metformin adjunctive therapy insulin,"Li C, Qiao L, Li T","background : adolescent type 1 diabetes ( t1d ) be complicate insulin resistance , dyslipidemia , and heighten cardiovascular risk . adjunctive metformin therapy lack optimize dosing , conduct network meta-analysis ( nma ) to rigorously assess dose-dependent efficacy and safety metformin combine insulin population . methods : totally 764 adolescent ( aged 10-19 year ) meet inclusion criterion be involve . assess five metformin regimen : 1 . 0 g/day , 1 . 7 g/day , 2 . 0 g/day , weight-based ( ≤ 60 kg :1 . 0 g/day ; ≥60 kg : 2 . 0 g/day ) , and multi-tiered weight-based ( < 50 kg :1 . 0 g ; 50-75 kg :1 . 5 g ; ≥75 kg : 2 . 0 g ) . outcomes include hba1c , bmi/bmi-z , insulin dose , lipid profile , and adverse event . bayesian nma be perform use r 4 . 4 . 1 , effect size report mean difference ( md ) or relative risk ( rr ) 95 % confidence interval ( ci ) . surface cumulative rank curve ( sucra ) value rank intervention . result : consequently , metformin 2 . 0 g/day significantly reduce bmi ( md=-0 . 6 kg/m² , 95%ci :-0 . 68 , -0 . 52 ) and ldl-c ( md=-12 . 78 mg/dl , 95%ci : -21 . 17 , -0 . 49 ) placebo . dose 1 . 0 g/day , 2 . 0 g/day , and 60 weight-based regimen significantly reduce daily insulin requirement . metformin 2 . 0 g/day and 50 weight-based regimen reduce total cholesterol . regimen significantly lower hba1c or triglyceride placebo . dose demonstrate safety profile comparable placebo regard gastrointestinal event , hypoglycemia , diabetic ketoacidosis ( dka ) , and transaminase elevation ( rr not significant ) . conclusion : to sum , adjunctive metformin 2 . 0 g/day offer significant benefit weight management , insulin dose reduction , and lipid improvement ( ldl-c , total cholesterol ) adolescent t1d , favorable safety profile dose , will represent viable therapeutic option .",BMC endocrine disorders,03/10/2025
10.1186/s12916-025-04365-8,change accelerate aging and risk cardiovascular disease and mortality :,"Zhang JJ, Yu HC, Geng TT, Chen SH, Wang YX, Guo H, Zhang XM, He MA, Gao JL, Liu G, Liao YF, Wu SL, Pan A","background : accelerate aging be dynamic process , yet few study examine association change accelerate aging cardiovascular disease ( cvd ) and mortality . study aim to evaluate association three prospective cohort china and uk . methods : datum be draw kailuan cohort ( n = 107 , 830 ) , dongfeng-tongji ( dftj ) cohort ( n = 14 , 032 ) , and uk biobank ( n = 316 , 087 ) . accelerate aging be assess phenoage and klemera-doubal method ( kdm ) age , measure baseline ( kailuan cohort : 2006-2009 ; dftj cohort : 2008-2010 ; uk biobank : 2006-2010 ) and first follow-up ( kailuan cohort : 2010-2013 ; dftj cohort : 2013 ; uk biobank : 2012-2013 ) . change accelerate aging be classify persistent accelerated aging , recovery accelerated aging , delay accelerated aging , and stable non-accelerated aging . cox proportional hazard model be use to estimate hazard ratio ( hrs ) and 95 % confidence interval ( ci ) . meta-analysis be perform to summarize estimate three cohort . result : median follow-up period be 10 . 3-15 . 9 year three cohort . define accelerate aging phenoage , baseline accelerate aging be significantly associate increase risk cvd ( pool hr : 1 . 41 , 95 % ci : 1 . 25 , 1 . 60 ) and mortality ( pool hr : 1 . 47 , 95 % ci : 1 . 33 , 1 . 63 ) . compare participant persistent accelerated aging , participant recover accelerate aging ( pool hr cvd : 0 . 76 , 95 % ci : 0 . 72 , 0 . 81 ; pool hr mortality : 0 . 84 , 95 % ci : 0 . 78 , 0 . 89 ) , delay accelerate aging ( pool hr cvd : 0 . 75 , 95 % ci : 0 . 70 , 0 . 79 ; pool hr mortality : 0 . 77 , 95 % ci : 0 . 72 , 0 . 83 ) or maintain non-accelerated aging ( pool hr cvd : 0 . 59 , 95 % ci : 0 . 48 , 0 . 71 ; pool hr mortality : 0 . 58 , 95 % ci : 0 . 55 , 0 . 62 ) exhibit decrease risk cvd and mortality . define accelerate aging kdm age , result remain consistent phenoage . conclusion : accelerate aging be significant risk factor cvd and mortality . recover or delay accelerate aging , or maintain non-accelerated aging , be associate reduce risk cvd and mortality .",BMC medicine,03/10/2025
10.1126/science.ady2167,engineer geminivirus replicon enable rapid planta direct evolution .,"Zhu H, Qin X, Wei L, Jiang D, Zhang Q, Wang W, Liang R, Zhang R, Zhang K, Liu G, Zhao KT, Chen K, Qiu JL, Gao C","direct evolution can rapidly generate genetic variant new and enhanced property , yet efficient platform perform such evolution directly plant cell have be lack . develop geminivirus replicon-assiste planta directed evolution ( grape ) , system link gene function geminivirus rolling circle replication ( rcr ) to enable high-throughput selection desire activity . grape support screening 10(5 ) variant single nicotiana benthamiana leaf four day . use grape , evolve immune receptor nrc3 to resist inhibition nematode effector sprysec15 and broaden recognition spectrum rice immune receptor pikm-1 to recognize six allele fungal effector avr-pik . grape provide rapid , scalable , and generalizable platform direct evolution diverse gene plant cellular context .","Science (New York, N.Y.)",02/10/2025
10.1038/s41586-025-09542-6,polygenic and developmental profile autism differ age diagnosis .,"Zhang X, Grove J, Gu Y, Buus CK, Nielsen LK, Neufeld SAS, Koko M, Malawsky DS, Wade EM, Verhoef E, Gui A, Hegemann L, Geschwind DH, Wray NR, Havdahl A, Ronald A, St Pourcain B, Robinson EB, Bourgeron T, Baron-Cohen S, Børglum AD, Martin HC, Warrier V","autism have historically be conceptualize condition emerge early childhood(1 , 2 ) , many autistic people be diagnose later life(3-5 ) . be unknown earlier- and later-diagnosed autism have different developmental trajectory and genetic profile . use longitudinal datum four independent birth cohort , demonstrate two different socioemotional and behavioural trajectory be associate age diagnosis . independent cohort autistic individual , common genetic variant account approximately 11 % variance age autism diagnosis , similar contribution individual sociodemographic and clinical factor , typically explain less 15 % variance . far demonstrate polygenic architecture autism can be break two modestly genetically correlate ( r(g ) 0 . 38 , s. e. = 0 . 07 ) autism polygenic factor . one factor be associate early autism diagnosis and low social and communication ability early childhood , but be only moderately genetically correlate attention deficit-hyperactivity disorder ( adhd ) and mental-health condition . conversely , second factor be associate late autism diagnosis and increase socioemotional and behavioural difficulty adolescence , and have moderate to high positive genetic correlation adhd and mental-health condition . finding indicate earlier- and later-diagnosed autism have different developmental trajectory and genetic profile . finding have important implication conceptualize autism and provide model to explain diversity find autism .",Nature,01/10/2025
10.1038/s41577-025-01221-x,regulators cd8(+ ) t cell exhaustion .,"Sun Q, Dong C","t cell exhaustion be adaptive and distinct cell fate emerge response persistent antigen stimulation , primarily chronic infection and cancer . be characterize progressive loss effector function and sustain expression multiple inhibitory receptor . progression t cell exhaustion be drive persistent antigen stimulation t cell receptor and be modulate signal co-stimulatory and inhibitory molecule as well microenvironmental factor such cytokine , metabolite and neuronal factor . extrinsic cellular factor reshape t cell transcriptome , epigenome and metabolism state exhaustion critical intrinsic cell regulator . review , summarize current understanding regulator involve t cell exhaustion , highlight role direct fate and functionality distinct exhausted t cell subset and may be harness development improved immunotherapy cancer and chronic infection .",Nature reviews. Immunology,01/10/2025
10.1016/j.anai.2025.09.014,basic mechanisms itch and advances clinical management .,"Coscarella G, Edwards E, Yosipovitch G","chronic pruritus require comprehensive assessment and management profound impact quality life . etiology pruritu be diverse , encompass dermatologic , neuropathic , systemic , psychogenic , and mixed cause . pruritogen activate c and aδ fiber histaminergic and non-histaminergic pathway . increase evidence highlight role th2 cytokine , particularly interleukin ( il)-4 , il-13 , and il-31 , directly stimulate sensory neuron and perpetuate itch-scratch cycle . itch perception arise dynamic interaction immune system and peripheral and central nervous system . signal transmit sensory fiber be process dorsal horn and relay thalamic and cortical center , reinforce chronicity . diagnostic evaluation begin detailed history and examination , complement laboratory testing such complete blood count , kidney , liver , glucose , and thyroid function test to uncover systemic or neurologic contributor . dermatologic condition , topical immunomodulators-including corticosteroid , calcineurin inhibitor , and pde4 inhibitors- be first-line option localized itch . extensive itch may require systemic immunosuppressant or phototherapy . biologic agent target il-4/il-13 and il-31 pathway have revolutionize treatment atopic dermatitis and prurigo nodularis , jak-stat inhibitor also offer significant antipruritic effect atopic dermatitis and . neuropathic itch may respond topical anesthetic : menthol , pramoxine , capsaicin , or compound ketamine-amitriptyline-lidocaine formulation , as well systemic gabapentinoid and antidepressant . systemic or intractable pruritus may benefit kappa opioid receptor agonist . new drug target mast cell such btk inhibitor , c-kit inhibitor , and mrgprx2 antagonist have robust anti-pruritic effect mast cell-mediated disease . supportive measure , include psychosocial intervention , remain integral long-term management .","Annals of allergy, asthma & immunology : official publication of the American",02/10/2025
10.1007/s11033-025-11081-2,unravel multifactorial pathophysiology polycystic ovary syndrome :,"Senthilkumar H, Chauhan SC, Arumugam M","polycystic ovary syndrome ( pcos ) be complex , multifactorial metabolic and endocrine disorder reproductive-age woman . review discuss interlinked role lifestyle , metabolic dysregulation , insulin resistance , neuroendocrine impairment , genetic predisposition , and post-translational modification ( ptm ) pcos pathogenesis . lifestyle component , especially lead obesity and insulin resistance , worsen hyperandrogenism , ovulatory dysfunction , and inflammation . dietary treatment such , dash diet and caloric restriction , particularly metformin , have be prove to improve metabolic and reproductive parameter . environmental toxin , such endocrine-disrupting chemical ( edcs ) and advanced glycation end-product ( ages ) , far compromise ovarian function and hormone regulation . oxidative stress and insulin resistance , drive mitochondrial malfunction and chronic inflammation , create self-perpetuating vicious cycle compromise oocyte quality and worsens metabolic imbalance . neuroendocrine disruption , characterize increase gnrh and lh pulsatility , be initiate dysregulate kisspeptin , dynorphin , and neurokinin b signal kndy neuron , modify gabaergic input , and increase amh and androgen . ptm such phosphorylation , methylation , acetylation , and ubiquitination also play essential role granulosa cell function , ar signaling , insulin sensitivity , and oocyte maturation . current and novel treatment option vary lifestyle modification and pharmacological intervention ( e.g. , metformin , glp-1 receptor agonist , myoinositol , vitamin d , and statin ) regenerative measure mesenchymal stem cell and fecal microbiota transplantation . new therapy focus ptm and neuroendocrine regulator remain future hope . multidisciplinary individualized management be critical successful pcos therapy and avert long-term complication .",Molecular biology reports,04/10/2025
10.1136/jitc-2025-012201,target immunosuppressive macrophage csrp2-regulate ccl28 signal,"Chen C, Su S, Wang P, Ye X, Yu S, Gong Y, Li Z, Li J, Hu Z, Huang X","background : comparable survival benefit have be obtain , drug resistance remarkably reduce lenvatinib clinical efficacy . here , aim to identify potential mechanism cysteine and glycine-rich protein 2 ( csrp2 ) regulate development hepatocellular carcinoma ( hcc ) and participate resistance lenvatinib . method : harness rna sequencing , multiplex immunofluorescence stain , and hydrodynamic tail vein ( htv ) injection hcc model to systematically explore function csrp2 hcc progression . to precisely delineate immunosuppressive macrophage , influence csrp2-regulate c-c motif chemokine ligand 28 ( ccl28 ) signal , respond lenvatinib-induced cytotoxicity , establish in vitro co-culture system and conduct functional cytotoxicity assay . result : use rna sequencing , multiplex immunofluorescence stain and htv injection hcc mouse model , identify csrp2 one most significantly upregulate gene hcc tissue . csrp2 overexpression drive anti-lenvatinib resistance induce high level tumor-associated macrophage ( tam ) infiltration and reshape immunosuppressive microenvironment . then flow cytometry , mass spectrometry and chromatin immunoprecipitation be conduct to clarify underlying mechanism csrp2 . show csrp2 promote phosphorylation activate transcription factor 2 ( atf2 ) thr69/71 , lead transcriptional activation ccl28 expression . hcc-derive ccl28 recruit tam to drive immunosuppression and anti-lenvatinib tolerance . bi6901 , potent and selective ccr10 antagonist , block tam recruitment and enhance t-cell activation . combine ccr10 inhibition improve therapeutic benefit anti-lenvatinib hcc . conclusion : result illustrate csrp2 regulate tumor microenvironment to promote hcc growth and drive lenvatinib tolerance csrp2/atf2/ccl28 axis . target pathway could synergize lenvatinib to treat hcc more effectively .",Journal for immunotherapy of cancer,02/10/2025
10.3171/2025.5.JNS25786,"impact glp-1 receptor agonist stroke , subarachnoid hemorrhage , and","Costa M, O'Leary S, Price AM, Young CC, Srinivasan VM, Kan P","objective : author evaluate glucagon-like peptide-1 receptor agonist ( glp-1-ras ) improve outcome patient aneurysmal subarachnoid hemorrhage ( asah ) , spontaneous intracerebral hemorrhage ( sich ) , and acute ischemic stroke ( ais ) and reduce overall incidence event . method : retrospective study leverage trinetx datum ( 2014-2024 ) to identify patient , sich , or ais . individual receive exenatide , lixisenatide , semaglutide , dulaglutide , liraglutide , or tirzepatide 8 week diagnosis be propensity match control . outcome ( e.g. , mortality , rebleeding/recurrence , seizure , hydrocephalus ) be assess 6 and 12 month ; incidence rate stroke type be examine 1 and 2 year . result : patient , glp-1-ra use 6 month reduce rebleeding ( or 0 . 73 , p = 0 . 003 ) and mortality ( or 0 . 41 , p < 0 . 001 ) and 1 year lower cognitive deficit ( or 0 . 63 , p = 0 . 034 ) and mortality ( or 0 . 39 , p < 0 . 001 ) . sich patient , glp-1-ras decrease hydrocephalus ( or 0 . 37 , p = 0 . 005 ) and seizure ( or 0 . 56 , p = 0 . 007 ) 6 month , persistent benefit 1 year ( hydrocephalus , or 0 . 38 , p = 0 . 007 ; seizure , or 0 . 63 , p = 0 . 018 ) , low mortality ( or 0 . 45-0 . 40 , both p < 0 . 001 ) and rebleeding ( or 0 . 70-0 . 69 , both p < 0 . 001 ) rate . ais patient , mortality fall 6 month ( or 0 . 27 , p < 0 . 001 ) and 1 year ( or 0 . 44 , p < 0 . 001 ) , reduced recurrence ( or 0 . 60 , p < 0 . 001 ) and lower hydrocephalus ( or 0 . 32 , p < 0 . 001 ) and seizure ( or 0 . 43 , p < 0 . 001 ) rate 6 month . 1 year , glp-1-ra user have low incidence rate sah ( or 0 . 64 , p = 0 . 001 ) , ich ( or 0 . 62 , p < 0 . 001 ) , and ais ( or 0 . 82 , p = 0 . 003 ) , be sustain 2 year ( or 0 . 77-0 . 87 , p < 0 . 05 ) . adverse event be similar . conclusion : glp-1-ras be associate improved survival and few complication stroke subtype , plus reduce hemorrhagic and ischemic stroke incidence . prospective trial be warrant to confirm observation .",Journal of neurosurgery,03/10/2025
10.1038/s41551-025-01513-6,enzyme-converted o kidney allow abo-incompatible transplantation,"Zeng J, Ma M, Tao Z, Rao Z, Wu C, Yin S, Jiang X, Chen G, Wang Z, Huang D, Zhu M, Liu L, Huo W, Yang H, Guo H, Chen G, Li F, Zheng C, Huang D, Rahfeld P, Kizhakkedathu JN, Withers SG, Lu X, Zhang K, Lin T, Song T","abo-incompatible kidney transplantation be widely use to meet escalate need organ . current recipient-centric desensitization protocol involve antibody depletion plasmapheresis increase risk infection , perioperative bleed event and cost . here present donor-centric desensitization protocol , convert type-a kidney enzyme-converted o kidney hypothermic perfusion to remove antigen kidney . ex vivo model result antibody-mediated injury . encourage , enzyme-converted o kidney be transplant type-o brain-dead recipient high titre anti-a antibody , and hyperacute rejection be observe . graft be well tolerate evidence antibody-mediated rejection 2 day . antibody-mediate lesion and complement deposition be find start 3 day post-transplant , coincide a-antigen regeneration , and later high banff score , suggest immune-mediated response . single-cell sequencing confirm elevated expression accommodation-related gene , suggest potential longer-term tolerance . study provide donor-centric organ engineering strategy and have potential to broaden reach",Nature biomedical engineering,03/10/2025
10.1212/WNL.0000000000213904,longitudinal association polygenic risk score plasma t-tau incident,"Mourtzi N, Charisis S, Ntanasi E, Hatzimanolis A, Ramirez A, Sampatakakis SN, Yannakoulia M, Kosmidis MH, Dardiotis E, Hadjigeorgiou G, Sakka P, Mamalaki E, Papandreou C, Georgakis MK, Scarmeas N","background and objective : elevated level total tau ( t-tau ) be key biomarker neurodegeneration , often see alzheimer disease ( ad ) . identify individual increase risk ad use minimally invasive biomarker can enable early intervention . develop polygenic risk score ( prs ) plasma t-tau and examine association risk develop clinical endophenotype ad pathology . methods : longitudinal cohort study use datum hellenic longitudinal investigation aging and diet ( heliad ) study , involve individual age 65 year or old , free ad , or amnestic mild cognitive impairment ( amci-an ad prodrome ) baseline . primary exposure be prstau , prs base common genetic variant link to plasma tau level . primary outcome be amci or ad incidence . assess association prstau level and amci/ad risk use cox regression model adjust age , sex , education , apoe ε4 allele carriership , and population structure . seek replication sample uk biobank ( ukb ) participant age 60 year or old prevalent dementia . result : heliad sample , 618 cognitively healthy participant ( mean age 73 . 37 year , 58 . 4 % female ) , follow 2 . 92 ± 0 . 80 year , 73 develop ad/amci . 1 sd increase prstau be link 29 % high ad/amci risk ( hazard ratio [ hr ] 1 . 290 , 95 % ci 1 . 006-1 . 654 ) . stratified analysis reveal great effect estimate woman ( hr 1 . 451 , 95 % ci 1 . 023-2 . 058 ) and young participant ( hr 1 . 866 , 95 % ci 1 . 175-2 . 962 ) , result man and old participant do not reach statistical significance . ukb sample ( n = 142 , 637 , mean age 64 . 2 year , 52 % female ) , 2 , 737 participant develop ad 12 . 9 ± 2 . 4 year follow-up . high prstau be also link increase ad risk ( hr 1 . 046 , 95 % ci 1 . 007-1 . 086 ) . discussion : result support potential utility prs plasma t-tau predict ad/amci incidence . relationship genetic predisposition elevated plasma level and ad pathology might be influence sex and age , suggest factor should be consider ad genetic risk modeling . prs could serve early indicator genetic propensity tau pathology , enhance exist ad diagnostic and risk stratification algorithm .",Neurology,11/11/2025
10.1038/s41586-025-09589-5,dietary cysteine enhance intestinal stemness cd8(+ ) t cell-derive il-22 .,"Chi F, Zhang Q, Shay JES, Han S, Ten Hoeve J, Yuan Y, Yang Z, Shin H, Block S, Solanki S, Shah YM, Vander Heiden MG, Agudo J, Yilmaz ÖH","fundamental question physiology be understand tissue adapt and alter cellular composition response dietary cues(1-8 ) . mammalian small intestine be maintain rapidly renew lgr5(+ ) intestinal stem cell ( iscs ) respond macronutrient change such fast regimen and obesogenic diet , yet specific amino acid control isc function homeostasis and injury remain unclear . here demonstrate dietary cysteine , semi-essential amino acid , enhance isc-mediate intestinal regeneration follow injury . cysteine contribute to coenzyme ( coa ) biosynthesis intestinal epithelial cell , promote expansion intraepithelial cd8αβ(+ ) t cell and production interleukin-22 ( il-22 ) . enhance il-22 signal directly augment isc reparative capacity injury . mechanistic involvement pathway drive effect cysteine be demonstrate several finding : coa supplementation recapitulate cysteine effect , epithelial-specific loss cystine transporter slc7a11 block response , and mouse cd8αβ(+ ) t cell lack il-22 or depletion cd8αβ(+ ) t cell fail to show enhance regeneration cysteine treatment . finding highlight couple cysteine metabolism iscs and cd8(+ ) t cell augment intestinal stemness , provide dietary approach exploit isc and immune cell crosstalk ameliorate intestinal damage .",Nature,01/10/2025
10.1016/j.molcel.2025.08.029,need nomenclature nucleosome .,"Keogh MC, Almouzni G, Andrews AJ, Armache KJ, Arrowsmith CH, Baek SH, Bedford MT, Bernstein E, Côté J, David Y, Denu JM, Fierz B, Garcia BA, Glass KC, Gozani O, Helin K, Henikoff S, Jensen ON, Josefowicz SZ, Kelleher NL, Kutateladze TG, Lindner HH, Lu C, Luger K, Mallick P, Musselman CA, Muir TW, Paša-Tolić L, Schneider R, Shi X, Shi Y, Sidoli S, Smith LM, Tyler JK, Wolberger C, Workman JL, Strahl BD, Young NL","histone post-translational modification ( ptm ) be crucial eukaryotic genome regulation , range report function and mechanism action . often study individually , have long be recognize modification function combinatorial synergy or antagonism . interplay may involve ptm same histone , same nucleosome ( contain histone octamer ) , or nucleosome higher-order chromatin . give , field must distinguish ever great complexity , and context be study , brevity and precision . proteoform be introduce to define individual form protein sequence and ptm , follow nucleoform to describe particular gathering histone individual nucleosome . be now need to define specific form entity prose provide space experimental nuance . end , introduce nomenclature can express discrete ptm , proteoform , nucleoform , or situation define ptm exist uncertain context . specifically design chromatin field , adaption framework could be use to describe-and thus proteoform be configure functionally distinct complex biology .",Molecular cell,02/10/2025
10.1038/s41392-025-02426-1,rapid amyloid-β clearance and cognitive recovery multivalent modulation,"Chen J, Xiang P, Duro-Castano A, Cai H, Guo B, Liu X, Yu Y, Lui S, Luo K, Ke B, Ruiz-Pérez L, Gong Q, Tian X, Battaglia G","blood‒brain barrier ( bbb ) be highly selective permeability barrier safeguard central nervous system ( cns ) potentially harmful substance regulate transport essential molecule . dysfunction be increasingly recognize pivotal factor pathogenesis alzheimer 's disease ( ad ) , contribute accumulation amyloid-β ( aβ ) plaque . present novel therapeutic strategy target low-density lipoprotein receptor-relate protein 1 ( lrp1 ) bbb . design leverage multivalent nature and precise size lrp1-targete polymersome to modulate receptor-mediated transport , bias lrp1 traffic transcytosis and thereby upregulate expression to promote efficient aβ removal . ad model mouse , intervention significantly reduce brain aβ level nearly 45 % and increase plasma aβ level 8-fold 2 h , measure elisa . multiple imaging technique confirm reduction brain aβ signal treatment . cognitive assessment reveal treat ad mouse exhibit significant improvement spatial learning and memory , performance level comparable wild-type mouse . cognitive benefit persist to 6 month post-treatment . work pioneer new paradigm drug design , function arise supramolecular nature nanomedicine , harness multivalency elicit biological action membrane trafficking level . finding also reaffirm critical role bbb ad pathogenesis and demonstrate target bbb can make therapeutic intervention significantly more effective . establish compelling case bbb modulation and lrp1-mediated aβ clearance transformative foundation future ad therapy .",Signal transduction and targeted therapy,07/10/2025
10.1002/cac2.70056,efficacy and safety glecirasib solid tumor kras g12c mutation :,"Li J, Deng T, Gu Y, Blanco AC, Li Z, Bai C, Wu L, Huang J, Li X, Yao Y, Song Z, Li Y, Liu L, Xing L, Wu W, Martínez-Pérez J, Hubert A, Zugazagoitia J, Zhang J, Wang Y, Zhao Y, Wen G, Xia G, Zhong D, Chen X, Jiang K, Wang-Gillam A, Ding Y, Liu S, Rao Z, Liu X, Shen L","background : glecirasib , inhibitor kirsten rat sarcoma viral oncogene homolog glycine-to-cysteine substitution codon 12 ( kras g12c ) , have exhibit clinical activity non-small-cell lung cancer ( nsclc ) and colorectal cancer ( crc ) . here , investigate efficacy and safety glecirasib patient pancreatic ductal adenocarcinoma ( pdac ) and other solid tumor ( exclude nsclc and crc ) rarely harbor kras g12c mutation but effective treatment option remain limited . method : conduct and analyze two open-label , phase i/ii trial adult patient kras g12c mutant solid tumor , glecirasib be administer orally . two trial have similar eligibility criterion and endpoint but differ region patient recruitment . perform pool analysis patient , exclude nsclc and crc , trial . primary endpoint pooled population be objective response rate ( orr ) . efficacy and safety be assess patient receive at least one dose glecirasib . result : june 30 , 2024 , pool analysis include 54 patient be treat glecirasib : 32 pdac , 8 biliary tract cancer ( btcs ) , 4 small intestinal cancer , 3 gastric cancer , 2 appendiceal cancer , and 5 other tumor . baseline , 24 receive ≥ two prior line systemic therapy . 53 efficacy-evaluable patient , confirm orr be 50 . 9 % ( 95 % confidence interval [ ci ] , 36 . 8%-64 . 9 % ) , orr 46 . 9 % ( 95 % ci , 29 . 1%-65 . 3 % ) pdac patient . other solid tumor , orr be 71 . 4 % ( 5/7 ) btc , 100 % ( 4/4 ) small intestinal cancer , and 66 . 7 % ( 2/3 ) gastric cancer . median progression-free survival and median overall survival be 6 . 9 and 10 . 8 month , respectively , overall population , and 5 . 5 and 10 . 8 month , respectively , patient pdac . treatment-related adverse event ( trae ) grade occur 94 . 4 % patient , grade ≥ 3 trae 27 . 8 % . fatal trae or trae lead treatment discontinuation occur . conclusion : glecirasib show promise efficacy and be well tolerate patient pdac and other advanced solid tumor ( nsclc and crc ) , warrant far expedite clinical development patient population . trial registration : clinicaltrials.gov identifi : nct05009329 and nct05002270 .","Cancer communications (London, England)",02/10/2025
10.1126/science.ads8728,gcn1 couple gcn2 ribosomal state to initiate amino acid response pathway,"Zhou C, Zhang M, Murray J, Paulo J, Gygi S, Shao S, Whitman M, Keller T","nutrient deprivation , activation protein kinase gcn2 regulate cell survival and metabolic homeostasis . addition amino acid stress , gcn2 be activate variety cellular stress . gcn2 activation have be link association uncharged trnas , specific ribosomal protein , and condition translational arrest , but relative contribution activation be unclear . here , use vitro translation to reconstitute gcn2 activation amino acid stress and compare collide ribosome population induce diverse translational stressor . initiation gcn2 signal require di-ribosome sensor gcn1 , recruit gcn2 to ribosome collision-dependent manner , gcn2 becomes activate key ribosomal interaction and stably associate collide ribosomes . finding define molecular requirement and dynamic gcn2 activation .","Science (New York, N.Y.)",02/10/2025
10.1126/scitranslmed.adn9216,s-nitrosoglutathione reductase therapeutic target diabetic vascular,"Zhao S, Song T, Tang X, Fan C, Yang Y, Zhang Z, Xia Y, Zhang Y, Cao J, Wang Z, Shi Z, Tang X, Wang D, Yin G, Zhang S, Gao Y, Chen H, Wang L, Chen F, Wang H, Yu B, Cao Y, Sun K, Liu X, Wang X, Yan C, Han Y, Han Y, Xie L, Ji Y","endothelial dysfunction be one early process diabete and major contributor diabetic vascular complication , often exhibit limited response glucose-lowering therapy . identify up-regulate s-nitrosoglutathione reductase ( gsnor ) critical factor associate diabetic vascular complication unbiased proteomic . elevated gsnor expression be observe endothelium patient type 2 diabete and streptozotocin ( stz)-induce type 1 diabetes mouse as well db/db type 2 diabetes mouse model . genetic ablation endothelial gsnor promote angiogenesis , maintain vascular permeability , and improve vasodilation type 1 diabetes mouse induce stz . gsnor deficiency protect high glucose-induced endothelial dysfunction vitro , evidence rescue tube formation , enhance spheroid sprouting , maintain barrier integrity , and reduce permeability . mechanistically , gsnor orchestrate endothelial dysfunction independently enzymatic activity bind transcription factor",Science translational medicine,01/10/2025
10.1038/s41392-025-02427-0,transarterial chemoembolization plus atezolizumab and bevacizumab patient,"Wang K, Feng J, Yu H, Cheng Y, Xiang Y, Liu Z, Qin Y, Liu E, Shan Y, Fan C, Zhai J, He D, Zhou H, Tang Y, Shi J, Guo W, Yan M, Yu L, Kudo M, Cheng S","transarterial chemoembolization ( tace ) be standard treatment intermediate-stage hepatocellular carcinoma ( hcc ) , yet efficacy standalone therapy remain suboptimal . phase 2 trial ( chictr2100049829 ) evaluate feasibility and safety tace combine atezolizumab and bevacizumab patient intermediate-stage hcc . participant receive tace follow atezolizumab and bevacizumab disease progression , unacceptable toxicity , or death . primary endpoint be objective response rate ( orr ) assess response evaluation criteria solid tumors ( recist ) v1 . 1 . secondary endpoint include progression-free survival ( pfs ) , overall survival ( os ) , orr modify recist ( mrecist ) , disease control rate ( dcr ) , time to response ( ttr ) , duration response ( dor ) , and adverse event ( aes ) . august 21 , 2021 and april 10 , 2023 , 45 patient be enrol . data cutoff september 30 , 2024 , median follow-up be 26 . 7 month . orr be 47 % recist v1 . 1 and 67 % mrecist . median pfs be 17 . 9 month , and median os be 33 . 0 month . dcr be 87 % ( recist v1 . 1 ) and 91 % ( mrecist ) . median ttr be 11 . 9 week ( recist v1 . 1 ) and 4 . 9 week ( mrecist ) , median dor 36 . 6 week ( recist v1 . 1 ) and 44 . 4 week ( mrecist ) . 45 patient , 44 experience ae grade , 20 reporting grade 3-4 aes ; grade 5 ae be observe . tace combine atezolizumab and bevacizumab appear safe and feasible intermediate-stage hcc , support further investigation large study .",Signal transduction and targeted therapy,06/10/2025
10.1016/S2468-1253(25)00198-0,etrasimod induction and maintenance treatment patient moderately,"Wu K, Zheng C, Cao Q, Ding Y, Gao X, Zhong J, Chiu CT, Zhang H, Wang X, Wang B, Liang J, Liu X, Zhou Y, Xu B, Kim TO, Shen X, Chen D, Chen W, Liu Y, Shen J, Liu F, Ding X, Zhan Q, Chou JW, Zeng S, Lin Y, Ying L, Chen X","background : etrasimod be oral , once-daily sphingosine 1-phosphate ( s1p ) receptor modulator treatment active ulcerative colitis . randomise , placebo-controlle , double-blind phase 3 enlight uc study , also know es101002 study , aim to evaluate efficacy and safety etrasimod patient moderately severely active ulcerative colitis east asia . methods : use central interactive web response system , 12-week induction period , adult ( aged 18-75 year , inclusive ) moderately severely active ulcerative colitis ( modify mayo score [ mms ] 4-9 endoscopic subscore ≥2 and rectal bleed subscore ≥1 ) and inadequate response , loss response , or intolerance at least one ulcerative colitis treatment be randomly assign ( 2 :1 ) once-daily oral etrasimod 2 mg or placebo . patient and study staff be mask treatment assignment . patient be enrol 52 hospital china , taiwan , and souh korea . randomisation be stratify previous treatment status and baseline disease activity . patient have mms clinical response induction period week 12 be re-randomly assign ( 1 :1 ) once-daily oral etrasimod 2 mg or placebo 40-week maintenance period . randomisation be stratify induction period treatment , previous exposure biological or jak inhibitor , and concomitant use oral corticosteroid induction period baseline . primary efficacy outcome be mms clinical remission ( stool frequency subscore=0 [ or stool frequency subscore=1 ≥1 point decrease induction period baseline ] , rectal bleed subscore=0 , and endoscopic subscore ≤1 [ exclude friability ] ) , assess induction and maintenance period separately ( induction period week 12 and maintenance period week 40 ) . primary efficacy analysis use full analysis set ( fas ) , include patient be randomly assign and receive at least one dose study treatment induction period , and re-randomly assign patient show clinical response induction period week 12 and receive at least one dose study treatment maintenance period . safety analyse treatment period use safety analysis set ( saf ) , include patient receive amount study drug correspond treatment period . enlight uc be register ( nct04176588 ) and study be complete . finding : 606 patient be screen sept 25 , 2019 , and april 27 , 2023 , and 340 be randomly assign induction period and treat ( fas : 228 patient [ 88 female and 140 male ] assign etrasimod and 112 patient [ 44 female and 68 male ] assign placebo ) . 157 patient show clinical response induction period be re-randomly assign and treat maintenance period ( fas : 77 patient [ 35 female and 42 male ] assign etrasimod and 80 patient [ 32 female and 48 male ] assign placebo ) . significantly great proportion patient treat etrasimod treat placebo , show clinical remission induction week 12 ( 57 [ 25·0 % ] 228 patient six [ 5·4 % ] 112 patient ; adjusted difference 20·4 % ; 95 % ci 13·4%-27·4 % ; p<0·0001 ) and maintenance period week 40 ( 37 [ 48·1 % ] 77 patient 10 [ 12·5 % ] 80 patient ; adjust difference 35·9 % ; 95 % ci 22·5%-49·2 % ; p<0·0001 ) . induction period , most frequently report treatment-emergent adverse event ( teae ) be increase alt ( 22 [ 10 % ] etrasimod group one [ 1 % ] placebo group ) . maintenance period , most frequently report teae be upper respiratory tract infection ( 14 [ 18 % ] etrasimod group 14 [ 17 % ] placebo group ) . induction and maintenance period , most teae be mild to moderate severity . five ( 2 % ) 228 patient treat etrasimod and four ( 4 % ) 112 patient treat placebo discontinue study treatment teae induction period , and one ( 1 % ) 77 patient treat etrasimod and one ( 1 % ) 81 patient treat placebo discontinue study treatment teae maintenance period . grade 4 or high teae , malignancy , or death be report . interpretation : etrasimod be effective and well tolerate oral induction and maintenance treatment patient moderately severely active ulcerative colitis east asia . funding : everest medicines . translation : chinese translation abstract see supplementary materials section .",The lancet. Gastroenterology & hepatology,30/09/2025
10.1038/s41588-025-02336-6,target histone h2b acetylate enhanceosome p300/cbp degradation,"Luo J, Chen Z, Qiao Y, Tien JC, Young E, Mannan R, Mahapatra S, Bhattacharyya R, Xiao L, He T, Eyunni S, Zhang Y, Zheng Y, Su F, Cao X, Wang R, Cheng Y, Seri R, George J, Shahine M, Miner SJ, Rees MG, Ronan MM, Roth JA, Vaishampayan U, Wang M, Wang S, Parolia A, Chinnaiyan AM","prostate cancer be drive oncogenic transcription factor enhanceosome comprise chromatin and epigenetic regulator . lysine acetyltransferase p300 and creb-binde protein ( cbp ) be key cofactor activate enhancer histone acetylation . here identify p300/cbp-mediate multisite histone h2b n-terminal acetylation ( h2bntac ) defining feature oncogenic enhanceosome androgen receptor ( ar)-positive prostate cancer . p300/cbp be essential ar and ets transcription factor erg transcriptional activity , and dual degradation eliminate h2bntac and histone h3 lysine 27 acetylation hyperactive enhancer , lead strong suppression oncogenic transcription target either paralog or bromodomain alone . cytotoxicity profile > 900 cell line reveal tumor high h2bntac , include ar-positive prostate cancer , be selectively dependent p300/cbp . preclinical model , systemic p300/cbp degradation inhibit tumor growth , synergize ar antagonist and show evident toxicity . finding position h2bntac epigenetic marker enhancer addiction and establish dual p300/cbp degradation promising therapeutic strategy enhancer-driven cancer .",Nature genetics,03/10/2025
10.1126/sciimmunol.ads0449,immunology brain tumor .,"Bunse L, Bunse T, Kilian M, Quintana FJ, Platten M","brain tumor represent unique challenge cancer immunotherapy location immune privileged site . however , brain tumor immune microenvironment be dictate more tumor type location brain per se . feature be reflect high immunogenicity and response immunotherapy metastatic brain tumor compare primary brain tumor . immunotherapy brain tumor aim induce and boost tumor t cell response use vaccine , immune checkpoint inhibitor , or adoptive t cell therapy . fundamental challenge field be such brain tumor-targete t cell gain access brain tumor and maintain function hostile immunosuppressive microenvironment . here , review current knowledge cellular and molecular determinant antigenicity brain tumor and immunosuppressive brain tumor microenvironment . expand and exploit knowledge will provide key effective combinatorial therapy .",Science immunology,03/10/2025
10.1186/s10194-025-02145-6,hallmarks primary headache : part 3 - cluster headache .,"Coppola G, Arruda MA, Ashina M, Barloese M, Belin AC, Bottiroli S, Chowdhury D, De Icco R, Di Lorenzo C, Di Stefano G, Edvinsson JCA, Evers S, Ferraro S, Fronczek R, García-Azorín D, Goadsby PJ, Grazzi L, Holle D, Jansen JJ, Gil-Gouveia R, Lambru G, Lanteri-Minet M, Lisicki M, Mitsikostas DD, Monteith T, Montisano DA, Obermann M, Pan LH, Peng KP, Peres M, Petrušić I, Cecchini AP, Vila-Pueyo M, Raggi A, Rainero I, Sandrini G, Sebastianelli G, Takizawa T, Tanprawate S, Tassorelli C, Truini A, Valeriani M, Vuralli D, Waliszewska-Prosół M, Wang SJ, Wang Y, Wijeratne T, Martelletti P","background : cluster headache ( ch ) be rare primary headache disorder characterize recurrent episode strictly unilateral excruciating pain accompany trigemino-autonomic sign , significantly impact quality life , social interaction , and occupational functioning be affect . to promote well understanding disable condition and to foster research topic , review provide comprehensive description hallmark ch , include clinical presentation , diagnostic challenge , pathophysiology , and current and novel therapeutic target . conclude describe disease burden and advocate significant improvement healthcare system , and promote health equity , as well reduce stigma . principal finding : distinctive clinical and chronobiological feature , ch may be mistake other primary headache disorder or different type orofacial pain . key pathogenic characteristic include activation trigeminal-autonomic system release several neuropeptide , involvement hypothalamus regulate circadian rhythm , genetic variant , and mesolimbic system . invasive and non-invasive neuromodulation treatment have be use to target trigemino-cervical , parasympathetic , and hypothalamic system . additionally , novel therapeutic target be currently be study . canonical therapy , several complementary approach have be explore year , most evidence derive uncontrolled research involve individual do not respond standard pharmacological treatment . advancement understanding complex disease , ch continue to pose considerable social , economic , and psychological challenge . advocacy be essential and should prioritize early diagnosis , alleviate stigma , provide specialized training healthcare professional , and offer support and patient association . conclusion : ch be characterise complex , multifactorial , pathophysiology be still not fully understand . precise diagnosis , additional research study , and robust psychosocial and institutional support be necessary to improve quality life individual affect debilitate condition .",The journal of headache and pain,02/10/2025
10.1111/os.13380,relook risk factors proximal junctional kyphosis early onset,"Yang B, Xu L, Zhou Q, Qian Z, Wang B, Zhu Z, Qiu Y, Sun X","objective : grow rod surgery be mainstay treatment early-onset scoliosis ( eos ) proximal junctional kyphosis ( pjk ) be one most commonly report postoperative complication . seek to investigate impact location upper instrument vertebra ( uiv ) relation sagittal apex proximal junctional kyphosis eos traditional grow rod ( gr ) treatment . methods : total 102 eos patient receive traditional grow rod treatment follow-up at least 2 year 2009 and 2020 be retrospectively review . radiographic measurement be perform before and index surgery and late follow-up . investigate coronal cobb angle and spinopelvic parameter whole spine . location uiv , apex , low instrument vertebra ( liv ) , inflection vertebra ( iv ) , number and distance uiv-apex , liv-apex and",Orthopaedic surgery,01/08/2022
10.1186/s12909-021-02946-8,familiarity and genetic literacy medical student indonesia .,"Swandayani YM, Cayami FK, Winarni TI, Utari A","background : be lack genetic knowledge health care professional especially develop country such indonesia . base experience , genetic disorder receive less attention medical education and professional . study aim to determine familiarity and literacy genetic medical student indonesia . method : total 1003 indonesian medical ( pre-clinical and clinical ) student complete rapid estimate adult literacy genetics ( real-g ) questionnaire total score seven familiarity and eight genetic literacy . mann-whitney u test be use to compare familiarity and genetic literacy score pre-clinical and clinical student . result : average score familiarity and genetic literacy be 5 . 63 ± 0 . 96 and 6 . 37 ± 0 . 83 , respectively . genetic familiarity be high ( p = 0 . 043 ) clinical student pre-clinical student , be significant difference genetic literacy ( p = 0 . 362 ) pre-clinical and clinical student . genetic familiarity do not impact level genetic literacy . however , medical student ' genetic literacy be influence demographic characteristic , such age , sex , university type , genetic learning experience , university accreditation , and university location . conclusion : general , indonesian medical student have relatively good familiarity and literacy genetic further study be necessary to accurately measure genetic familiarity and literacy medical student and general public .",BMC medical education,09/10/2021
10.1126/sciadv.adw7376,pp2a-b55α phosphatase be master regulator mitochondrial degradation and,"Cianfanelli V, Nanni M, Corrà S, Mauri S, Sumpton D, Lilla S, De Cegli R, Bordi M, Milletti G, Ferraina C, Hall A, Petraroia M, Clausi V, Giorda E, Scarsella M, Barbiera A, Cadeddu G, Colasanti M, Persichini T, Maeda K, Maya-Mendoza A, Bartek J, Di Malta C, Locatelli F, Zanivan S, Ismail S, Ziviani E, Cecconi F","mitochondrial homeostasis rely tight balance mitochondrial biogenesis and degradation . mitophagy be one main pathway involve clearance damaged or old mitochondria , coordination mitochondrial biogenesis be poorly characterize . here , unbiased approach include last-generation liquid chromatography couple mass spectrometry and transcriptomic , identify protein phosphatase pp2a-b55α/ppp2r2a parkin-dependent regulator mitochondrial number . mitochondrial damage , pp2a-b55α determine amplitude mitophagy induction and execution regulate both early and late mitophagy event . few minute insult , ulk1 be release inhibitory regulation pp2a-b55α , 2 to 4 hour later , pp2a-b55α promote nuclear translocation tfeb , master regulator autophagy and lysosome gene , to support mitophagy execution . moreover , pp2a-b55α control transcriptional program mitochondrial biogenesis stabilize parkin substrate and pgc-1α inhibitor paris . pp2a-b55α target rescue neurodegenerative phenotype fly model parkinson 's disease , thus suggest potential therapeutic application .",Science advances,03/10/2025
10.1038/s41467-025-64173-9,creative experience and brain clock .,"Coronel-Oliveros C, Migeot J, Lehue F, Amoruso L, Kowalczyk-Grębska N, Jakubowska N, Mandke KN, Seabra JP, Orio P, Campbell D, Gonzalez-Gomez R, Prado P, Cuadros J, Tagliazucchi E, Cruzat J, Legaz A, Medel V, Hernandez H, Fittipaldi S, Altschuler F, Moguilner S, Baez S, Santamaria-Garcia H, González-Hernández A, Bonilla-Santos J, Güntekin B, Babiloni C, Abasolo D, Di Caterina G, Yener GG, Escudero J, Ochoa-Gómez JF, Soto-Añari M, Bruno MA, Valdes-Sosa PA, Anghinah R, Gonzalez-Montealegre RA, Clark RA, García AM, Kaltwasser L, Schürmann M, Meier JM, Brzezicka A, Whelan R, Lawlor B, Robertson IH, Bailey C, Melloni L, Sajnani N, Ibanez A","creative experience may enhance brain health , yet metric and mechanism remain elusive . characterize brain health use brain clock , capture deviation chronological age ( i.e. , accelerate or delay brain aging ) . combine m/eeg functional connectivity ( n = 1 , 240 ) machine learn support vector machine , whole-brain modeling , and neurosynth metanalyse . framework , reanalyze previously publish dataset expert and match non-expert participant dance , music , visual art , and video game , pre/post-learne study ( n = 232 ) . find delay brain age domain and scalable effect ( expertise>learne ) . high level expertise and performance , great delay brain age . age-vulnerable brain hub show increase connectivity link creativity , particularly area relate expertise and creative experience . neurosynth analysis and computational modeling reveal plasticity-driven increase brain efficiency and biophysical coupling , creativity-specific delay brain aging . finding indicate domain‑independent link creativity and brain health .",Nature communications,03/10/2025
10.1016/S0140-6736(25)01625-3,anti-cytokine biologic asthma adult .,"Israel E, Wechsler ME, Jackson DJ, Moore WC","estimate 3-10 % patient asthma be unable to reach full control currently available inhaled therapy . large proportion patient , asthma can be drive whole or part type 2 ( t2 ) inflammation , be usually initiate immunological response stimulation mucosal surface . introduction monoclonal antibody , target t2 inflammatory process , provide important option population . past decade , five anticytokine biologic ( acb ) block specific t2 inflammatory cytokine have be introduce . three biologic , mepolizumab , reslizumab , and benralizumab , inhibit il-5 or il-5 receptor pathway ; dupilumab block and il-13 activity il-4 receptor-alpha ; and tezepelumab prevent activation thymic stromal lymphopoietin cytokine production cascade . drug reduce exacerbation and improve lung function and patient-reported asthma quality life individual history asthma exacerbation and evidence t2 inflammation . also allow oral corticosteroid reduction or elimination patient dependent therapy asthma control . effect acb vary degree t2 inflammation , be most easily assess blood eosinophil count and exhale nitric oxide . use acb guide biomarker and phenotypic characteristic patient severe asthma allow personalised medicine approach increase likelihood improvement .","Lancet (London, England)",29/09/2025
10.1186/s12916-025-04311-8,investigate relationship plasma micrornas and colorectal cancer risk,"Bouras E, Papagiannopoulos CK, Mustafa R, Sobieski D, Schmit SL, Wu AH, Brenner H, Li CI, Chan AT, Pellatt AJ, Zheng W, Keku TO, Moreno V, Um CY, Van Guelpen B, Phipps AI, Pai RK, Lewis SJ, Martin RM, Gunter MJ, Peters U, Dehghan A, Tsilidis KK","background : micrornas ( mirnas ) be short , single-stranded rnas function post-transcriptional regulator gene expression . circulate mirnas have be link carcinogenesis , have not yet be systematically investigate relation risk colorectal cancer ( crc ) . methods : use mendelian randomization ( mr ) and colocalization analysis to investigate association genetically predict plasma mirna concentration ( 2083 mirnas 710 individual ) risk crc ( 58 , 221 case and 67 , 694 control ) . mirnas associate crc risk , also investigate association circulate plasma protein ( 4907 protein 35 , 559 participant ) , bidirectionally , use mr . perform pathway enrichment analysis ( pea ) to explore downstream molecular pathway . result : association five mirnas crc be find mr and support colocalization analysis . specifically , mir-146a-5p , mir-21-5p , and mir-4707-3p be positively , and mir-1908-5p and mir-6810-3p be inversely associate crc risk . several protein association be find mirnas ( range protein p < 0 . 05 : 78-796 ; 211 fdr < 5 % ) , and 11 pathway be identify pea , include regulation erb-b2 receptor tyrosine kinase 4 ( mir-6810-3p ) and insulin-like growth factor pathway ( mir-1908-5p ) . conclusion : result support potential implication mir-146a-5p , mir-21-5p , mir-4707-3p , mir-1908-5p , and mir-6810-3p crc risk . however , downstream effect should be elucidate can be utilize preventive target .",BMC medicine,02/10/2025
10.1016/j.molcel.2025.09.006,parp1 auto-modification promote faithful okazaki fragment processing and limit,"Elsborg JD, Munk SHN, Adelantado-Rubio A, Pék R, Fábian Z, Imburchia V, Zentout S, Hendriks IA, Buch-Larsen SC, Smith R, Bartek J, Duxin JP, Huet S, Maya-Mendoza A, Nielsen ML","poly(adp-ribose ) polymerase ( parp ) inhibitor have prove efficacy treat tumor defective homologous recombination synthetic lethality . response dna break , parp1 be primary adp-ribosylation writer , modify ( auto-modification ) and other protein to facilitate repair . however , enzymatic inhibition block process , make difficult to dissect distinct functional role . use proteomic and site-directed mutagenesis , identify parp1 mutant deficient auto-modification , yet retain catalytic activity . separation-of-function mutant reveal parp1 auto-modification slow dna replication fork progression but be dispensable repair factor recruitment . instead , auto-modification promote timely release parp1 dna break site and prevent formation replication stress . simultaneous inhibition fen1 and loss parp1 auto-modification give rise synthetic lethality , implicate auto-modification okazaki fragment processing . result demonstrate trap parp dna break impede repair factor accessibility , constitute important dimension",Molecular cell,02/10/2025
10.1093/inthealth/ihaf112,impact covid-19 pandemic quality life adult diabete,"Sseguya W, Bahendeka S, MacLennan S, Guntupalli AM","background : coronavirus disease 2019 ( covid-19 ) pandemic be associate unprecedented healthcare , economic and social disruption impact person diabete mellitus ( pwdm ) . aim to establish quality life ( qol ) person diabetes rural uganda be impact covid-19 pandemic , use pre-pandemic , pandemic and post-pandemic self-reported qol score . method : survey 410 pwdm ≥30 y age three rural district south-western uganda . median qol score be compute and variation three time period be analyse use friedman analysis variance and mcnemar test appropriate . logistic regression be use to identify factor associate qol . p-value < 0 . 05 indicate statistical significance . result : overall median qol score be 67 . 2 ( pre-pandemic ) , 62 . 4 ( pandemic ) and 68 . 8 ( post-pandemic ) ( p<0 . 001 ) . be 75 % increase proportion participant unsatisfactory qol pandemic ( p<0 . 001 ) . have diabetes complication ( p<0 . 001 ) , chronic comorbidity ( p=0 . 012 ) , formal education ( p<0 . 003 ) and travel healthcare use non-motorised transport ( < 0 . 001 ) be independently associate post-pandemic unsatisfactory qol . conclusion : covid-19 pandemic cause significant deterioration qol rural pwdm , raise need policy to prioritise consideration evolving need design measure future similar widespread emergency .",International health,07/10/2025
10.1136/jitc-2025-012991,spatial transcriptomic profiling metastatic renal cell carcinoma identify,"Kalogirou C, Krebs M, Kunz AS, Hahn O, Kübler H, Schwinger M, Hartmann A, Schmieder A, Eckstein M","background : metastatic renal cell carcinoma ( mrcc ) still lack tissue-based biomarker predict benefit first-line immune checkpoint inhibitor ( ici ) regimen . high-resolution spatial transcriptomic can dissect tumor microenvironment ( tme ) and reveal prognostic niche invisible bulk assay , offer path precision immunotherapy . methods : formalin-fixed , paraffin-embedded sample 12 therapy-naïve patient mrcc treat",Journal for immunotherapy of cancer,02/10/2025
10.1001/jamaneurol.2025.3662,optimal antithrombotics ischemic stroke and concurrent atrial fibrillation,"Okazaki S, Tanaka K, Yazawa Y, Doijiri R, Koga M, Ihara M, Yamamoto S, Kamiyama K, Honda Y, Uchida K, Yoshimoto T, Asakura K, Omae K, Tanaka K, Maeda H, Yamamoto H, Hirano T, Toyoda K, Iguchi Y, Noguchi T, Okada Y, Kitagawa K, Sakai N, Yamagami H","importance : patient ischemic stroke and concurrent nonvalvular atrial fibrillation and atherosclerotic cardiovascular disease be elevated risk recurrent ischemic event . combined anticoagulant and antiplatelet therapy may reduce ischemic risk , also increase bleed , and optimal antithrombotic strategy remain uncertain . objective : to determine add antiplatelet agent to anticoagulant therapy influence net clinical benefit patient ischemic stroke or transient ischemic attack and concurrent nonvalvular atrial fibrillation and atherosclerotic cardiovascular disease . design , setting , and participant : multicenter , open-label randomize clinical trial be conduct 41 site japan november 2016 march 2025 . eligible patient have ischemic stroke or transient ischemic attack 8 to 360 day onset , nonvalvular atrial fibrillation , and at least 1 manifestation atherosclerotic cardiovascular disease ( carotid or intracranial artery stenosis , noncardioembolic stroke , ischemic heart disease , or peripheral artery disease ) . datum be analyze april 16 , 2024 , october 14 , 2024 . intervention : patient be randomize to receive combination therapy ( anticoagulant plus antiplatelet ) or anticoagulant monotherapy . main outcomes and measures : primary outcome be composite ischemic cardiovascular event and major bleeding 2 year . secondary outcome include ischemic cardiovascular event ; safety outcome include major and clinically relevant nonmajor bleeding . result : total , 316 patient be randomize combination therapy ( n = 159 ) or monotherapy ( n = 157 ) ( mean [ sd ] age , 77 . 2 [ 7 . 4 ] year ; 90 female patient [ 28 . 5 % ] ) . trial be terminate july 18 , 2023 , interim analysis futility . cumulative incidence primary outcome be 17 . 8 % combination therapy group and 19 . 6 % monotherapy group ( hazard ratio [ hr ] , 0 . 91 ; 95 % ci , 0 . 53-1 . 55 ; p = .64 ) . ischemic cardiovascular event occur 11 . 1 % and 14 . 2 % ( hr , 0 . 76 ; 95 % ci , 0 . 39-1 . 48 ; p = .41 ) , and major and clinically relevant nonmajor bleeding occur 19 . 5 % and 8 . 6 % ( hr , 2 . 42 ; 95 % ci , 1 . 23-4 . 76 ; p = .008 ) combination therapy and monotherapy group , respectively . conclusion and relevance : randomize clinical trial , patient ischemic stroke or transient ischemic attack and concurrent nonvalvular atrial fibrillation and atherosclerotic cardiovascular disease , add antiplatelet agent to anticoagulant therapy provide net clinical benefit anticoagulant monotherapy , high bleeding risk . trial registration : clinicaltrials.gov identifier : nct03062319 .",JAMA neurology,06/10/2025
10.1186/s12943-025-02442-3,circrna promote esophageal squamous cell carcinoma progression inhibit,"Tan S, Ming Y, Guo J, Liu W, Ma H, Liu Y, Xu Z, Gu-Ha AL, Dai L, Lin YD, Peng Y","background : esophageal squamous cell carcinoma ( escc ) be highly aggressive malignancy poor prognosis and limited treatment option . circular rnas ( circrnas ) be frequently dysregulate escc , functional role and molecular mechanism tumor progression remain largely unexplored . method : characterize circrna use rt-pcr , sanger sequencing , and fluorescent situ hybridization . gain- and loss-of-function study vitro and vivo be perform to assess circrna function . molecular interaction be investigate rna pull-down assay couple mass spectrometry , electrophoretic mobility shift assay , co-immunoprecipitation , and immunoblot analysis . clinical relevance be evaluate rt-qpcr and immunohistochemistry patient specimen . result : identify circlnf , novel circrna derive long non-coding rna firre gene , be significantly upregulate escc . functional assay demonstrate circlnf promote proliferative and migratory capacity cultured cell and accelerate tumor progression and metastasis animal model . mechanistically , circlnf directly interact igf2bp family protein "" cauc "" motif , protect trim25-mediate ubiquitination and proteasomal degradation . importantly , circlnf expression positively correlate igf2bp1 protein level escc patient tissue , underscore clinical relevance circlnf-igf2bp axis escc progression . conclusion : finding reveal oncogenic role circlnf escc inhibit trim25-mediate proteasomal degradation igf2bp protein and highlight circlnf potential therapeutic target escc .",Molecular cancer,03/10/2025
10.1016/j.ebiom.2025.105941,poor sleep health be associate old brain age : role systemic,"Miao Y, Wang J, Li X, Guo J, Ekblom MM, Sindi S, Zhang Q, Dove A","background : poor-quality sleep have be link increase dementia risk . investigate relationship healthy sleep pattern and old brain age , and extent to be mediate systemic inflammation . methods : study include 27 , 500 adult uk biobank ( mean age 54 . 7 y , 54 . 0 % female ) . presence five self-reported healthy sleep characteristic ( early chronotype , 7-8 h daily sleep , insomnia , snoring , excessive daytime sleepiness ) be sum healthy sleep score ( 0-5 pt ) and use to define three sleep pattern : healthy ( ≥4 pt ) , intermediate ( 2-3 pt ) , and poor ( ≤1 pt ) . low-grade inflammation be estimate use infla-score , composite index inflammatory biomarker . mean follow-up 8 . 9 y , brain age be estimate use machine learning model base 1079 brain mri phenotype and use to calculate brain age gap ( bag ; i.e. , brain age minus chronological age ) . datum be analyse use linear regression and generalise structural equation model . finding : baseline , 898 ( 3 . 3 % ) participant have poor sleep , 15 , 283 ( 55 . 6 % ) have intermediate sleep , and 11 , 319 ( 41 . 2 % ) have healthy sleep . compare healthy sleep , intermediate ( β = 0 . 25 [ 0 . 11 , 0 . 40 ] , p = 0 . 010 ) and poor ( β = 0 . 46 [ 0 . 05 , 0 . 87 ] , p < 0 . 001 ) sleep be associate significantly high bag . mediation analysis , infla-score mediate 6 . 81 % and 10 . 42 % association intermediate and poor sleep and high bag . interpretation : poor sleep health may accelerate brain ageing . may be drive high level systemic inflammation . funding : alzheimerfonden ; demensfonden ; loo and hans osterman foundation medical research ; knowledge foundation ; swedish research council .",EBioMedicine,30/09/2025
10.1016/j.ejvs.2025.09.045,international expert consensus management acute aortic type b,"Squizzato F, D'Oria M, Antonello M, Trimarchi S, Mani K, Holden A, Kölbel T, Haulon S, Verhoeven E, Böckler D, Resch T, Azizzadeh A, Lombardi J, Piazza M","objective : aim study be to achieve international expert consensus manage acute type b penetrate aortic ulcer ( paus ) and intramural haematomas ( imhs ) . methods : modify delphi consensus process be employ to develop recommendation management acute type b pau and imh . survey be send international expert practice high volume aortic centre worldwide . statement be vote use four point likert scale three round delphi process . statement achieve grade a ( full agreement 75 % ) or b ( overall agreement 80 % , full disagreement < 5 % ) be include expert recommendation . consistency response be measure use cohen 's κ and intraclass correlation coefficient . result : eighty three expert be include final analysis : 25 statement achieve consensus , 18 ( 72 % ) receive grade b strength and 7 ( 28 % ) grade strength . most statement ( 97 % ) have high consistency classify grade i or ii . expert panel agree indication thoracic endovascular aortic repair ( tevar ) complicated imh/pau , define rupture or refractory pain/hypertension . uncomplicated imh/pau should be manage conservatively and follow serial computed tomography image acute phase . high risk uncomplicated imh be identify increase haematoma thickness , new onset or increase size ulcer projection , or transition aortic dissection ; high risk uncomplicated pau be define new associate haematoma , pau increase , or total aortic diameter increase . uncomplicated high risk imh/paus may be consider tevar . perform tevar , proximal sealing length > 20 mm site free haematoma should be achieve , eventually extend zone 2 , 0 - 10 % oversize . patency left subclavian artery should be maintain . conclusion : agreement international expert be achieve assessment , management , and follow acute type b imh and pau , address area inconsistency or knowledge gap exist guideline .",European journal of vascular and endovascular surgery : the official journal of,30/09/2025
10.1016/S1470-2045(25)00399-7,genetic modification ajcc classification papillary thyroid cancer :,"Xing M, Lin S, Mathur A, Li Y, Bendlova B, Kuklikova V, Melo M, Jesus TT, Soares P, Colombo C, Fugazzola L, Mitsutake N, Matsuse M, Sako A, Estrada-Florez AP, Carvajal-Carmona LG, Bohórquez ME, Mian C, Vianello F, O'Neill CJ, Clifton-Bligh R, Czarniecka A, Jarzab B, Jung CK, Brahma B, Ladenson PW, Park YJ","background : four-stage american joint committee cancer ( ajcc ) staging system have be use almost 50 year assess risk multiple cancer ; ajcc classification papillary thyroid cancer be solely base clinical parameter , and update edition accuracy remain suboptimal . aim to evaluate performance ajcc system could be improve integrate tumour genetic status braf and tert gene . method : retrospective multicentre cohort study use patient medical record 15 medical centre ten country patient ( age ) papillary thyroid cancer have be surgically treat total thyroidectomy or hemithyroidectomy or neck dissection , follow postoperative radioiodine ablation and appropriate thyroid-stimulate hormone level target . test braf(v600e ) and tert promotor ( tertp ) mutation be perform genomic dna isolate surgical or cytological specimen primary papillary thyroid cancer tumour centre . datum medical centre be pool aggregated analysis relationship genetic status and papillary thyroid cancer-specific mortality four classical stage 7th and 8th edition ajcc system ( ajcc7e and ajcc8e ) . primary endpoint be papillary thyroid cancer-specific mortality , characterise mortality rate 1000 person-year . finding : use patient be treat papillary thyroid cancer january 1979 , july 2023 15 centre , cohort comprise 4746 patient ( 3612 [ 76·1 % ] female and 1134 23·9 % ] male ) , median age 48 year ( iqr 37-59 ; 89 [ 1·9 % ] patient age ≤18 year ) . 4400 patient available ethnicity datum , majority be asian ( 2140 [ 48·6 % ] ) and 2096 ( 47·6 % ) be white . ajcc7e , compare original stage , genetic duet braf(v600e ) and tertp mutation be associate increase mortality stage correspond original stage , hr stage do not reach statistical significance . wildtype braf(v600e ) and tertp have flat survival curve stage i-iii ajcc7e and stage i-ii ajcc8e . patient dual mutation have reduction survival stage ajcc7e ( stage hr 5·96 [ 95 % ci 0·73-48·66 ] ; p=0·10 ; stage ii 5·94 [ 95 % ci 1·42-24·91 ] ; p=0·015 ; stage iii 4·04 [ 95 % ci 1·87-8·70 ] ; p=0·00037 ; and stage iv 1·79 [ 95 % ci 1·15-2·76 ] ; p=0·0092 ) . tertp mutation alone be also significantly associate significant increase mortality stage iv ( 3·57 [ 2·01-6·37 ] ; p<0·0001 ) . ajcc8e , observe similar pattern increase mortality mutation be present compare mortality original staging , significant difference hr stage and ii ( stage adjust hr 10·30 [ 95 % ci 3·43-30·93 ] , p<0·0001 ; stage ii hr 3·95 [ 95 % ci 1·92-8·15 ] ; p=0·00020 ) . stage iii also show increase mortality dual mutation , but increase be not statistically significant ( hr 1·77 [ 0·95-3·31 ] ; p=0·072 ) . contrast ajcc7e , dual mutation do not increase mortality compare original stage iv ( hr 0·95 [ 0·47-1·92 ] , p=0·89 ) , but tertp mutation do significantly increase mortality stage iv papillary thyroid cancer ( hr 2·75 [ 1·36-5·58 ] , p=0·0049 ) . interpretation : integrate genetic status braf and tertp ajcc system change original risk stage ajcc system and significantly improve accuracy mortality risk classification papillary thyroid cancer . funding : national institute aging , auburn community cancer endowed chair basic research , heart , breast , and brain health equity research program , national institutes health , and american association cancer research fellowship 21-40-69-estr ( usa ) ; ministry health ( czech republic ) ; prémio francisco augusto da fonseca dias e maria josé melenas da fonseca para jovens investigadores ( portugal ) ; italian ministry health-ricerca corrente ( italy ) ; jsps kakenhi ( japan ) ; minciencias , l ' oreal-unesco-icetex-colciencias , universidad del tolima ( colombia ) ; strategmed2/267398/4/ncbr/2015 , national centre research and development ( poland ) ; risbin iptekdok 2014 , ministry health ( indonesia ) ; and information and communications technology and future planning basic science research program national research foundation korea ( nrf ) fund ministry science ( korea ) .",The Lancet. Oncology,01/10/2025
10.1186/s12933-025-02932-0,association metabolic score insulin resistance and future stroke risk,"Wu H, Zhou Y, Lai X, Ma B, Ding L, Zhu X, Chen Z, Liu Z","background : metabolic disorder , cardiovascular disease , and chronic kidney disease be closely interrelated , and proposal cardiovascular-kidney-metabolic ( ckm ) syndrome concept have receive extensive attention . disease burden ckm be heavy , stroke be significant contributor , and ckm staging be bidirectional . large body evidence have demonstrate insulin resistance be closely associate disease such stroke , obesity and chronic kidney disease . metabolic score insulin resistance ( mets-ir ) serve important indicator evaluate insulin resistance , relationship mets-ir and stroke incidence remain unclear population define ckm syndrome stage 0-3 . method : study , datum individual ckm syndrome stage 0-3 stroke baseline be collect china health and retirement longitudinal study ( charls) . self-reported stroke be use primary outcome , mets-ir baseline exposure factor . logistic regression be perform to analyze effect mets-ir incidence stroke participant ckm , and restrict cubic spline ( rcs ) regression be utilize to explore potential nonlinear relationship . to evaluate predictive value mets-ir stroke risk individual ckm syndrome stage 0-3 , apply receiver operating characteristic ( roc ) analysis . result : total 5009 participant be include study , mean age 60 . 48 ± 8 . 81 year . 5-year follow-up , 339 participant study develop incident stroke . participant be stratify mets-ir quartile ( q1-q4 ) . fully adjust model , compare q1 ( low quartile ) , odd ratio ( or ) q3 be 1 . 88 ( 95 % ci : 1 . 25-2 . 81 ; p = 0 . 002 ) , and or q4 be 1 . 72 ( 95 % ci : 1 . 08-2 . 76 ; p = 0 . 02 ) . rcs analysis reveal nonlinear relationship mets-ir and stroke risk participant ckm syndrome stage 0-3 ( p-overall < 0 . 05 ; p-nonlinearity < 0 . 05 ) . roc analysis show area curve ( auc ) 0 . 726 ( 95 % ci : 0 . 699-0 . 752 ) , optimal mets-ir cutoff value 29 . 58 . conclusion : individual ckm syndrome stage 0-3 , elevated mets-ir level may be associate increase stroke risk . furthermore , mets-ir demonstrate moderate predictive value stroke risk population . monitoring mets-ir may therefore aid early identification .",Cardiovascular diabetology,01/10/2025
10.1038/s41596-025-01259-0,report approval transcranial electrical stimulation ( rate ): expert,"Nejati V, Vaziri Z, Antal A, Antonenko D, Behroozmand R, Bestmann S, Brunelin J, Brunoni AR, Carvalho S, Davis NJ, Enticott PG, Fallgatter AJ, Ferrucci R, Fitzgerald PB, Hamada M, Hamilton RH, Hoy KE, Jaberzadeh S, Jamil A, Cohen Kadosh R, Krekelberg B, Laureys S, Romero Lauro LJ, Loo CK, Martin D, Martinotti G, Mondino M, Oliviero A, Pellicciari MC, Plewnia C, Pobric G, De Raedt R, Razza LB, Rocchi L, Salehinejad MA, Khorrami AS, Schecklmann M, Siebner HR, Taylor SF, Vanderhasselt MA, Vanneste S, Vicario CM, Woods AJ, Ziemann U, Nitsche MA","transcranial electrical stimulation ( tes ) have gain substantial momentum research and therapeutic tool ; however , suffer challenge relate reproducibility and quality assessment absence standardized reporting practice . here aim to develop comprehensive and consensus-based checklist conduct and report tes study to enhance quality research and report . consensus statement , use delphi approach conduct three round and involve 38 expert to identify crucial element require to report tes study . consensus-driven approach include evaluation interquartile deviation ( > 1 . 00 ) , percentage positive response ( 60 % ) and mean importance rating ( <3 ) , hence ensure creation robust and well-balanced checklist . metric be utilize to assess consensus reach and importance rating item . consensus be reach , lead retention 66 initial 70 item . item be categorize five group : participant ( 12 item ) , stimulation device ( 9 item ) , electrode ( 12 item ) , current ( 12 item ) and procedure ( 25 item ) . then distil short version checklist , include 26 item deem essential . report approval transcranial electrical stimulation ( rate ) checklist be relevant carry and assess tes study , provide structured framework researcher to consider and report . reviewer , can serve tool to assess completeness , comprehensiveness and transparency report . addition , rate checklist aim to promote deep understanding tes and facilitate comparison study field . overall , rate checklist provide share reference point may improve research quality , foster harmonization reporting and , ultimately , enhance interpretability and reproducibility finding both research and clinical contexts .",Nature protocols,03/10/2025
10.1038/s43587-025-00962-7,genome-wide analysis brain age identify 59 associate loci and unveil,"Jawinski P, Forstbach H, Kirsten H, Beyer F, Villringer A, Witte AV, Scholz M, Ripke S, Markett S","neuroimage and machine learning be advance research mechanism biological aging . field , ' brain age gap ' have emerge promising magnetic resonance imaging-based biomarker quantify deviation individual 's biological and chronological age brain . here conduct in-depth genomic analysis brain age gap and relationship 1 , 000 health trait . genome-wide analyse to 56 , 348 individual unveil heritability 23-29 % attributable common genetic variant and highlight 59 associate loci ( 39 novel ) . lead locus encompass mapt , encode tau protein central alzheimer 's disease . genetic correlation reveal relationship mental health , physical health , lifestyle and socioeconomic trait , include depressed mood , diabetes , alcohol intake and income . mendelian randomization indicate causal role high blood pressure and type 2 diabetes accelerated brain aging . study highlight key gene and pathway relate to neurogenesis , immune-system-related process and small gtpase binding , lay foundation further mechanistic exploration .",Nature aging,03/10/2025
10.1016/S2215-0366(25)00268-8,"disease relapse , all-cause mortality , and adverse event associate","Wei Y, Yan VKC, Castle DJ, Huang C, Deng EK, Leung SM, Yiu HHE, Lee KJ, Lui SSY, Ng VWS, Hayes JF, Lai FTT, Wang H, Yan EWC, Chan EW","background : old individual ( aged ≥65 year ) schizophrenia be increase risk treatment non-adherence cognitive decline and complex polypharmacy . use long-acting injectable ( lai ) antipsychotic population have not be systematically investigate . aim to compare risk disease relapse , all-cause mortality , and adverse event associate lai oral antipsychotic old people schizophrenia . method : population-based within-subject analysis , use territory-wide electronic health record clinical database analysis and reporting system hong kong hospital authority . individual diagnose schizophrenia ( icd-9-cm code 295 ) inpatient , outpatient , or emergency department setting jan 1 , 1993 , and dec 31 , 2023 , be identify , and people age 65 year and old be prescribe lai or oral antipsychotic jan 1 , 2004 , and dec 31 , 2023 , be consider inclusion . individual incomplete demographic information be exclude . primary outcome be disease relapse , define hospital admission schizophrenia . secondary outcome comprise all-cause mortality and adverse event , include cardiovascular hospital admission , extrapyramidal symptom , acute liver injury , and acute kidney injury , be identify use icd-9-cm code or laboratory test . self-controlled case series study use poisson regression be conduct to compare risk disease relapse and adverse event treatment period lai and oral antipsychotic . individual-stratified cox regression be perform all-cause mortality . time-varying confounder , include age , season , class antipsychotic , covid-19 stringency index , and concomitant treatment antidepressant , benzodiazepine or z-drugs , mood stabiliser , and antiparkinsonian drug , be adjust . people live experience schizophrenia be not involve design or conduct study . finding : 24 985 old individual schizophrenia , 4696 ( 18·8 % ) be prescribe lai or oral antipsychotic . 10 655 ( 42·6 % ) 24 985 individual be male and 14 330 ( 57·4 % ) be female . datum ethnicity be not available . compare oral antipsychotic , lai antipsychotic be associate statistically significantly low risk hospital admission schizophrenia ( incidence rate ratio [ irr ] 0·71 [ 95 % ci 0·64-0·78 ] , p<0·0001 ) and all-cause mortality ( hazard ratio [ hr ] 0·23 [ 95 % ci 0·12-0·44 ] , p<0·0001 ) . statistically significant difference be find cardiovascular hospital admission , acute liver injury , and acute kidney injury . lai antipsychotic be associate increase risk extrapyramidal symptom ( irr 2·17 [ 1·24-3·80 ] , p=0·0068 ) , but only first-generation ( 2·86 [ 1·41-5·84 ] , p=0·0038 ) not second-generation lai antipsychotic . interpretation : old individual schizophrenia , lai antipsychotic be associate low risk disease relapse and mortality , increase risk adverse event , oral antipsychotic , elevated risk extrapyramidal symptom specifically relate first-generation lai antipsychotic . overall , lai antipsychotic , especially second-generation medication , could be more broadly consider long-term use population , particularly early stage disease . funding : national natural science foundation china .",The lancet. Psychiatry,30/09/2025
10.23736/S2784-8671.25.08243-X,clinical management pigment purpuric dermatosis : evidence survey,"Paganelli A, Michelerio A, Collina MC, Pilla MA, Spadafora M, Longo C, Dattola A, Richetta AG, Pellacani G, Pezzini C, Mandel VD, DI Tullio F, Conti A, Motolese A, Marani A, DE Pace B, Megna A, Condorelli AG, Arginelli F, Persechino F, Garbarino F, Ambrosio L, Scala E, Vassallo C, Motolese A","background : pigment purpuric dermatosis ( ppd ) be group chronic , benign skin condition limited evidence-based datum regard diagnosis and management . aim work be to evaluate clinical practice dermatologist manage ppd , focus patient presentation , treatment preference , and need further diagnostic evaluation . method : utilize survey-based design present study . survey be distribute study group cutaneous vascular diseases and skin ulcers italian society dermatology and venereology . survey collect datum number patient evaluate weekly , proportion patient request treatment , preferred therapeutic approach , and indication additional diagnostic test . result : twenty-four clinician 11 center participate . respondent report manage average 5 ppd case week , treatment require approximately 50 % case , remainder be incidental finding evaluation other dermatological condition . skin moisturizer and topical corticosteroid ( tcs ) be universally recommend first-line treatment . additional therapy include zinc oxide cream , compression stocking , and flavonoid-based oral supplement . further diagnostic workup , such leg doppler ultrasound , skin biopsy , and blood test , be consider necessary only select patient base clinical presentation and comorbiditie . conclusion : moisturizer and tcs be cornerstone ppd treatment , supplement tailor therapy and diagnostic evaluation . finding highlight need standardized , evidence-based guideline to optimize management ppd .",Italian journal of dermatology and venereology,01/10/2025
10.1111/jcmm.16698,increase glycolysis skeletal muscle coordinate adipose tissue,"Xiang C, Zhang Y, Chen Q, Sun A, Peng Y, Zhang G, Zhou D, Xie Y, Hou X, Zheng F, Wang F, Gan Z, Chen S, Liu G","insulin-independent glucose metabolism , include anaerobic glycolysis be promote resistance training , play critical role glucose disposal and systemic metabolic regulation . however , underlie mechanism be not completely understand . study , genetically manipulate glycolytic process overexpresse human glucose transporter 1 ( glut1 ) , hexokinase 2 ( hk2 ) and 6-phosphofructo-2-kinase-fructose-2 , 6-biphosphatase 3 ( pfkfb3 ) mouse skeletal muscle , examine impact enhance glycolysis metabolic homeostasis . enhance glycolysis skeletal muscle promote accelerate glucose disposal , lean phenotype and high metabolic rate mouse attenuate lipid metabolism muscle , even high-fat diet ( hfd ) . further study reveal glucose metabolite sensor carbohydrate-response element-binding protein ( chrebp ) be activate highly glycolytic muscle and stimulate elevation plasma fibroblast growth factor 21 ( fgf21 ) , possibly mediate enhance lipid oxidation adipose tissue and contribute systemic effect . pfkfb3 be critically involve promote glucose-sensing mechanism myocyte . thus , high level glycolysis skeletal muscle may be intrinsically couple distal lipid metabolism intracellular glucose sensing . study provide novel insight benefit resistance training and manipulate insulin-independent glucose metabolism .",Journal of cellular and molecular medicine,01/08/2021
10.2147/IJWH.S410489,magnitude and factors associated teenage pregnancy somaliland : evidence,"Gensa Geta T, Ahmed Abdiwali S, Farah MM","purpose : teenage pregnancy be estimate to be common somaliland . be link adverse perinatal outcome . however , study have be conduct country subject . therefore , study intend to assess magnitude and factor associate teenage pregnancy somaliland . patient and method : datum 2020 somaliland health and demographic survey ( slhds ) ; be use current analysis . total sample 3 , 786 woman reproductive age group be involve participant . survey use two-level cluster sampling design , include initial selection enumeration area follow selection household . to identify associated factor , binary logistic regression analysis be apply . result : magnitude teenage pregnancy be 47 . 2 % ( 95%ci : 45 . 5-48 . 9 % ) . be nomadic resident ( aor : 1 . 26 ; 95%ci : 1 . 12-1 . 71 ) , be low wealth quintile ( aor : 1 . 34 ; 95%ci : 1 . 01-1 . 77 ) , be sanaag region ( aor : 1 . 95 ; 95%ci : 1 . 54-2 . 46 ) and have low educational attainment ( aor : 2 . 29 ; 95%ci : 1 . 08-4 . 83 ) be significantly associate teenage pregnancy . conclusion : teenage pregnancy be highly prevalent somaliland and associate low educational level , low wealth quintile and nomadic residence . hence , governmental and non-governmental organization should work educate and financially empower woman give particular focus nomadic people .",International journal of women's health,01/01/2023
10.7150/ijbs.70172,covid-19 receptor and malignant cancer : association ctsl expression,"Zhang L, Wei C, Li D, He J, Liu S, Deng H, Cheng J, Du J, Liu X, Chen H, Sun S, Yu H, Fu J","ctsl be express cancerous tissue and encode lysosomal cysteine proteinase regulate cancer progression and sars-cov-2 entry . therefore , be critical to predict susceptibility cancer patient sars-cov-2 and evaluate correlation disease outcome and expression ctsl malignant cancer tissue . current study , analyze ctsl expression , mutation rate , survival and covid-19 disease outcome cancer and normal tissue , use online database . also perform immunohistochemistry ( ihc ) to test ctsl expression and western blot to monitor regulation cordycepin ( cd ) , and n6 , n6-dimethyladenosine ( m(6)(2)a ) , respectively . find ctsl be conserve different specie , and highly express both normal and cancer tissue human , compare ace2 or other proteinases/protease . additionally , expression ctsl protein be high lung tissue . show mrna expression ctsl be 66 . 4-fold higher normal lung and 54 . 8-fold higher cancer tissue , compare ace2 mrna expression respective tissue . compare other proteases/proteinases/convertase such tmprss2 and furin , expression ctsl be high normal lung and lung cancer sample . datum indicate ctsl might play important role covid-19 pathogenesis normal and cancer tissue lung . additionally , ctsl-002 isoform contain both inhibitor_i29 and peptidase_c1 domain be highly prevalent cancer , suggest potential role tumor progression and sars-cov-2 entry multiple type cancer . further analysis expression ctsl mutant show correlation furin and tmprss2 , suggest potential role ctsl mutation modulate sars-cov-2 entry cancer . moreover , high expression ctsl significantly correlate short overall survival ( os ) lung cancer and glioma . thus , ctsl might play major role susceptibility lung cancer and glioma patient to sars-cov-2 uptake and covid-19 severity . furthermore , cd or m(6)(2)a inhibited ctsl expression cancer cell line a549 , mda-mb-231 , and/or pc3 dose dependent manner . conclusion , show ctsl be highly express normal tissue and increase most cancer , and cd or m(6)(2)a could inhibit expression , suggest therapeutic potential target ctsl cancer and covid-19 treatment .",International journal of biological sciences,01/01/2022
10.1080/09546634.2025.2563657,predictive factor early super response bimekizumab 341 patient,"Çetinarslan T, Mergen MA, Türel Ermertcan A, Bülbül Başkan E, Yazıcı S, An İ, Gürel G, Adışen E, Demirbaş A, Dursun R, Aslancan B, Topkarcı Z, Esen M, Türkoğlu Z, Canat D, Kandiş S, Kılıç A, Ertam Sağduyu İ, Yazıcı EI, Gökyayla E, Demirel Öğüt N, Karstarlı Bakay ÖS, Temiz SA, Erdemir VA, Hapa FA, Aydin Ö, Hızlı P, Solak B, Bütüner M, Aytekin S, Albayrak H, Daye M, Türsen Ü, Sarıbaş Yıldırım AN, Cengiz Özyurt B","purpose/aim study : efficacy bimekizumab be show moderate to severe plaque psoriasis . aim study be to investigate early super responder ( esr ) profile ( week 4 ) bimekizumab . materials and method : perform multicenter retrospective study 20 dermatology outpatient clinic turkey . adult patient moderate-to-severe psoriasis be bimekizumab at least 12 week be enrol . result : total 341 adult patient be include . 136 have nail psoriasis ( 39 . 9 % ) , 148 have psoriatic arthritis ( psa ) ( 43 . 4 % ) , 223 ( 65 . 4 % ) have at least one difficult-to-treat area involvement , 155 ( 45 . 5 % ) be bio-naïve , 110 ( 32 . 5 % ) have ≥ 2 biologic history . week 4 , pasi75 be achieve 144 patient ( 49 . 8 % ) , pasi90 be achieve 88 patient ( 30 . 4 % ) , pasi100 be achieve 51 patient ( 17 . 6 % ) . family history ( p = 0 . 041 ) , palmoplantar involvement ( p = 0 . 008 ) , psa ( p = 0 . 097 ) , and bio-experienced status ( p = 0 . 060 ) be associate low odd be esr , 1-point increase baseline pasi be associate significantly low odd esr ( p < 0 . 001 ) . gender , age , disease duration , history conventional systemic treatment , and presence comorbidity be not significantly associate likelihood be esr ( all p > 0 . 05 ) . conclusion : bimekizumab be effective treatment bio-naïve and bio-experienced patient ; however , may have more rapid onset action bionaive patient . further study be need long-term efficacy and safety datum bimekizumab .",The Journal of dermatological treatment,01/12/2025
10.1038/s41467-025-63454-7,induction experimental cell division to generate cell reduce chromosome,"Marti Gutierrez N, Mikhalchenko A, Shishimorova M, Frana D, Van Dyken C, Li Y, Ma H, Koski A, Liang D, Lee SG, Eyberg D, Safaei Z, Kang E, Lee Y, O'Leary T, Lee D, Krieg S, Wu D, Rubin E, Amato P, Mitalipov S","somatic cell nuclear transfer ( scnt ) enable direct reprogramming somatic cell functional oocyte , diploid genome . to address ploidy reduction , investigate experimental reductive cell division process , term mitomeiosis , non-replicated ( 2n2c ) somatic genome be prematurely force to divide follow transplantation metaphase cytoplasm enucleate human oocyte . however , fertilization sperm , scnt oocyte remained arrest metaphase stage , indicate activation failure . artificial activation use selective cyclin-dependent kinase inhibitor successfully bypass arrest , induce segregation somatic chromosome zygotic pronucleus and polar body . comprehensive chromosome trace sequence reveal homologous chromosome segregation occur randomly and crossover recombination . nonetheless , average 23 somatic chromosome be retain zygote , demonstrate feasibility experimentally halve diploid chromosome set . fertilized human scnt oocyte progress normal embryonic cell division , ultimately develop embryo integrate somatic and sperm-derived chromosome . study demonstrate potential mitomeiosis vitro gametogenesis , stage remain just proof concept and further research be require to ensure efficacy and safety future clinical application .",Nature communications,30/09/2025
10.1016/j.cell.2025.08.037,decoding alzheimer 's disease cellular level reveal promise combination,"Coleman K, Tatonetti NP","alzheimer 's disease ( ad ) have long resist effective treatment pathological heterogeneity and cell-type-specific regulatory change . issue cell , li et al . leverage single-cell rna sequencing and drug repurpose to propose promising combination therapy , validate real-world evidence and mouse model , target multiple ad-relevant cell type .",Cell,02/10/2025
10.1038/s41564-025-02142-0,discovery and artificial intelligence-guide mechanistic elucidation,"Catacutan DB, Tran V, Arnold A, Alexander J, Corso G, Yousefi Y, Tu MM, McLellan S, Tertigas D, Magolan J, Surette MG, Brown ED, Coombes BK, Barzilay R, Stokes JM","current clinical antibiotic be largely broad-spectrum agent can alter gut microbiome and promote colonization enterobacteriaceae , be often drug resistant . include adherent-invasive escherichia coli ( aiec ) , particularly patient inflammatory bowel disease , dysbiosis create niche pathogen to colonize . be urgent and unmet need novel narrow-spectrum and microbiome-sparing antibiotic . here screen 10 , 747 bioactive small molecule antibacterial activity aiec and discover enterololin , antibacterial compound target activity enterobacteriaceae specie . enterololin could overcome intrinsic and acquire resistance mechanism clinical isolate combine subinhibitory concentration spr741 , polymyxin b analogue use here to increase outer membrane permeability gram-negative bacteria . molecular substructure- and deep learning-guided mechanism-of-action investigation reveal enterololin perturb lipoprotein traffic mechanism involve lolcde complex , laboratory-evolved resistant mutant predominantly map lolc and lole , in vitro frequency resistance ~10(-8 ) 10(-7 ) . enterololin show low mammalian cytotoxicity ( hek293 half-maximal inhibitory concentration ~100 µg ml(-1 ) ) and suppress aiec infection mouse model administer combination spr741 , largely preserve overall microbiome composition . study highlight utility deep learning method predict molecular interaction and identify promising enterobacteriaceae-specific antibacterial candidate further development .",Nature microbiology,03/10/2025
10.1186/s12974-025-03561-w,nlrp3 inflammasome and hear loss : mechanism therapy .,"Murillo-Cuesta S, Seoane E, Cervantes B, Zubeldia JM, Varela-Nieto I","nlrp3 inflammasome , key component innate immune system , have emerge central mediator inflammation-driven sensorineural hearing loss ( snhl ) . review synthesize current evidence involvement wide spectrum auditory pathology , include genetic syndrome such caps and autosomal dominant deafness ( dfna ) 34 , as well noise-induced , age-related , drug-induced , and viral hearing loss . dysregulate activation nlrp3 cochlea lead release proinflammatory cytokine ( il-1b and il-18 ) and pyroptotic cell death , contribute irreversible cochlear damage . experimental study have demonstrate pharmacological inhibition nlrp3 agent such mcc950 , oridonin and tranylcypromine can preserve auditory function . gain-of-function mutation nlrp3 gene be frequently associate both syndromic and nonsyndromic hearing loss , and animal model express mutation replicate cochlear inflammation and hear deficit , validate pathogenic role . clinically , il-1b signal blocker such anakinra and canakinumab have show efficacy caps patient , stabilize or improve hearing outcome . emerge selective nlrp3 inhibitor , include dapansutrilo and mcc950 , be progress early-phase clinical trial . additionally , natural compound such piceatannol and oridonin have demonstrate otoprotective effect preclinical model noise- and drug-induced hearing loss . collectively , finding position nlrp3 inflammasome promising therapeutic target snhl . future translational research should focus validate nlrp3-targeting compound human trial , identify biomarker early diagnosis , and explore combination therapy integrate anti-inflammatory , antioxidant , and regenerative strategy . target nlrp3 may ultimately redefine treatment paradigm prevent or halt progressive hearing loss .",Journal of neuroinflammation,04/10/2025
10.1016/S1470-2045(25)00429-2,long-term overall survival dual ctla-4 and pd-l1 or pd-1 blockade and,"Di Federico A, Stumpo S, Mantuano F, De Giglio A, Lo Bianco F, Pecci F, Alessi JV, Wang X, Sperandi F, Melotti B, Gelsomino F, Skoulidis F, Garassino MC, Peters S, Awad MM, Ardizzoni A, Ricciuti B","background : immune checkpoint inhibitor target pd-l1 or pd-1 monotherapy or combine ctla-4 inhibitor or chemotherapy ( or ) be standard care patient advanced non-small-cell lung cancer ( nsclc ) . however , remain unclear patient benefit addition ctla-4 inhibitor . aim to evaluate dual checkpoint blockade ctla-4 and pd-l1 or pd-1 inhibitor provide similar efficacy pd-l1 or pd-1 inhibitor monotherapy , or strategy produce distinct outcome nsclc subpopulation . method : conduct search pubmed , medline , and embase randomised phase 3 trial publish database inception nov 21 , 2024 , investigate pd-l1 or pd-1 inhibitor , or ctla-4 inhibitor , patient advanced nsclc . focus study report kaplan-mei survival datum 5 year or biomarker analysis base pd-l1 , kras , and stk11 mutational status . individual patient datum be extract kaplan-mei curve webplotdigitizer version 5 and reconstruct ipdfromkm method . primary endpoint study be 5-year overall survival overall population and subpopulation base pd-l1 tumour proportion score ( tps ) , tumour histology , and mutational status ( mutant wild-type ) kras and stk11 . study be register prospero , crd420251081707 . finding : initial search yield 1026 result , and six randomise clinical trial meet eligibility criterion and be include . 2881 patient eligible analysis ( 838 [ 29·1 % ] female and 2043 [ 70·9 % ] male ) , 1282 receive dual ctla-4 and pd-l1 or pd-1 blockade and 1599 receive single pd-l1 or pd-1 blockade . patient treat dual ctla-4 and pd-l1 or pd-1 blockade have similar median overall survival compare treat single pd-l1 or pd-1 inhibition ( 16·1 month [ 95 % ci 15·0-17·8 ] 16·9 month [ 15·5-18·3 ] ; hr 0·95 [ 95 % ci 0·87-1·03 ] , p=0·19 ) . median overall survival be significantly long dual",The Lancet. Oncology,29/09/2025
10.1016/j.jchf.2025.102660,semaglutide and exercise function obesity-related hfpef : insight,"Borlaug BA, Kitzman DW, Patel S, Chinnakondepalli KM, Butler J, Davies MJ, Petrie MC, Shah SJ, Verma S, Núñez J, Einfeldt MN, Liisberg K, Salsali A, Kosiborod MN",background : exercise function quantify 6-minute walk distance ( 6mwd ) be severely impaired patient heart failure preserve ejection fraction ( hfpef ) . objectives : prespecifie secondary analysis pool datum,JACC. Heart failure,03/10/2025
10.1016/j.immuni.2025.09.012,inflammation atherosclerosis : lesson and therapeutic implication .,"Libby P, Soehnlein O","inflammatory pathway operate stage atherosclerosis . process be drive risk factor and other stimulus can spark inflammation elicit misdirect response intrinsic vascular cell and leukocyte , culminate lesion initiation , progression , and complication . continue dissection key underlie inflammatory mechanism increasingly sophisticated tool have inspire successful clinical trial and enable translation clinic . here , review mechanistic understanding etiology and progression atherosclerosis . discuss cardiovascular risk factor converge level bone marrow perturb hematopoiesis , yield output pro-inflammatory slant . far consider circulate myeloid cell enter , propagate , and persist atherosclerotic lesion and intimal macrophage take center stage regulate inflammatory milieu . context , delineate emerge therapeutic strategy aim mitigate inflammation atherosclerosis and add exist measure reduce global cardiovascular disease burden .",Immunity,03/10/2025
10.1200/JCO-25-01957,mosunetuzumab plus polatuzumab vedotin transplant-ineligible,"Budde LE, Zhang H, Kim WS, Maruyama D, Rego EM, Norasetthada L, Hong H, Ozcan M, Jeon YW, Cordeiro de Farias DL, Fogliatto LM, Pavlovsky A, Goto H, Olszewski AJ, Shah N, Hu B, Yin S, Wu H, To I, Ead WS, Ashby J, Janousek M, Pham S, Wang J, Kwan A, Batlevi CL, Wei MC, Westin J","purpose : prognosis patient refractory/relapse large b-cell lymphoma ( lbcl ) consider ineligible curative-intent therapy be poor . combination mosunetuzumab , t-cell-engage bispecific antibody , and polatuzumab vedotin , antibody-drug conjugate , ( mosun-pola ) , represent novel fixed-duration outpatient therapy . method : phase 3 sunmo trial , patient refractory/relapse lbcl be ineligible autologous stem cell transplant be randomize ( 2 :1 ) to receive mosun-pola or rituximab , gemcitabine , and oxaliplatin ( r-gemox ) . dual primary endpoint be centrally-assessed overall response rate and progression-free survival . overall survival be key secondary endpoint . result : total 208 patient be randomize to receive mosun-pola ( n=138 ) or r-gemox ( n=70 ) . median follow-up 23 . 2 month , primary analysis sunmo demonstrate median progression-free survival be significantly long mosun-pola r-gemox(11 . 5 month [ 95 % confidence interval ( ci ) , 5 . 6-18 ] 3 . 8 month [ 95 % ci , 2 . 9-4 . 1 ] ; hazard ratio progression or death , 0 . 41 [ 95 % ci , 0 . 3-0 . 6 ] ; p<0 . 0001 ) . overall response rate be significantly great mosun-pola r-gemox ( 70 % 40 % ; p<0 . 0001 ) , complete response rate 51 % and 24 % , respectively . mosun-pola group , rate grade ≥2 cytokine release syndrome and usage tocilizumab occur less 5 % patient , and patient-reported outcome be improve compare r-gemox . conclusion : mosun-pola demonstrate superior efficacy verus r-gemox , significant improvement overall response rate and progression-free survival , and infrequent cytokine release syndrome event manageable safety profile . (funded f . hoffmann-la roche ltd ; clinicaltrials.gov , nct05171647 ) .",Journal of clinical oncology : official journal of the American Society of,02/10/2025
10.1016/S2213-2600(25)00287-5,dupilumab omalizumab patient chronic rhinosinusitis nasal,"De Corso E, Canonica GW, Heffler E, Springer M, Grzegorzek T, Viana M, Horváth Z, Mullol J, Gevaert P, Michel J, Peters AT, Wagenmann M, Zaghloul S, Zhang M, Corbett M, Nash S, Angello JT, Radwan A, Deniz Y, Martin A, Hellings PW","background : chronic rhinosinusitis nasal polyp ( crswnp ) be predominantly drive type 2 inflammation . biologic dupilumab and omalizumab , target driver and mediator type 2 inflammation ( interleukin [ il]-4/il-13 signal and immunoglobulin e [ ige ] , respectively ) , be efficacious treat crswnp but direct comparison be few . everest ( evaluate treatment response dupilumab omalizumab ) , first head-to-head trial respiratory biologic , aim to compare efficacy and safety dupilumab and omalizumab patient severe crswnp have mild , moderate , or severe asthma . methods : everest be international , randomised , double-blind , phase 4 trial , conduct 100 hospital or clinical centre 17 country . site be select otolaryngology , pneumologist , allergist , and immunologist practice ; need to have previously conduct double-blind study ; and be require have nasal endoscopy and electrocardiogram machine . eligible patient age 18 year or old severe uncontrolled crswnp ( nasal polyp score 5 or more [ and ≥2 nostril ] ) , symptom nasal congestion and loss smell at least 8 week screening , and physician-diagnosed asthma . patient be randomly assign ( 1 :1 ) subcutaneous dupilumab 300 mg 2 week or weight-tiered and ige-tiere dose 2 week or 4 week 24 week , background mometasone furoate nasal spray . patient and investigator be mask study drug . primary endpoint be change baseline endoscopic nasal polyp score and university pennsylvania smell identification test ( upsit ) 24 week . efficacy be assess intention-to-treat population and safety be assess patient receive at least one dose study medication . trial be register clinicaltrials.gov , nct04998604 . finding : sept 27 , 2021 , and dec 27 , 2024 , 819 individual be screen study inclusion , 459 be exclude ( most common screen failure be : 167 do not meet nasal polyp score or do not have ongoing symptom nasal congestion and loss smell , 114 do not meet pre-bronchodilator fev(1 ) ≤85 % predict normal , and 99 do not meet eligibility drug-dosing ) , and 360 participant be randomly assign ( 181 assign dupilumab group and 179 assign omalizumab group ) . 360 participant , 198 ( 55 % ) participant be male , 162 ( 45 % ) be female , and mean age total population sample be 52 year ( sd 13·1 ) . improvement be significantly great dupilumab omalizumab primary and secondary efficacy endpoint week 24 . least square mean difference change baseline dupilumab omalizumab be : nasal polyp score -1·60 ( 95 % ci -1·96 to -1·25 ; p<0·0001 ) and upsit 8·0 ( 6·3 9·7 ; p<0·0001 ) . 115 ( 64 % ) 179 participant dupilumab group and 116 ( 67 % ) 173 participant omalizumab group report treatment-emergent adverse event , most common be nasopharyngitis , accidental overdose , headache , upper respiratory tract infection , and cough . be death study . interpretation : dupilumab be superior to omalizumab patient severe crswnp and coexist asthma . finding support efficacy dupilumab patient type 2 respiratory disease active biologic comparator , know safety profile dupilumab and omalizumab , and could enable well treatment target patient crswnp and asthma clinical practice . funding : sanofi and regeneron pharmaceuticals .",The Lancet. Respiratory medicine,28/09/2025
10.1038/srep46971,retraction : murine hypothalamic destruction vascular cell apoptosis,"Aratani S, Fujita H, Kuroiwa Y, Usui C, Yokota S, Nakamura I, Nishioka K, Nakajima T",correct article doi : 10 . 1038/srep36943 .,Scientific reports,11/05/2018
10.1002/advs.202509695,dcaf12 ubiquitin ligase promotes lung cancer metastasis modulating,"Wang Z, Huang H, Huang K, Cui X, Wu L, Lin R, Zhao Z, Chen H, Zheng C, Jin W, Chen S, Chen J, Xu Y, Wei D","metastasis be primary challenge lung cancer treatment . proteostasis support tumor growth , mechanism ubiquitin ligase reprogram chaperone network to drive metastasis be poorly understand . study , be reveal ddb1-cul4-associate factor ( dcaf12 ) , substrate receptor cul4-ring ubiquitin ligase , regulate metastatic progression ubiquitin-mediated proteostatic reprogramme . dcaf12 depletion suppresse tumor cell migration and stemness vitro and reduce pulmonary/hepatic metastasis vivo . mechanistically , dcaf12 catalyze non-degradative ubiquitination tric/cct subunit , enhance chaperonin assembly and folding cytoskeletal effector ( β-actin/tubulin ) and oncogenic client ( stat3/raptor/mlst8 ) , thereby activate yap , stat3 , and mtor pathway . genetic knockdown and pharmacological blockade ( hsf1a ) axis potently inhibit metastasis . clinically , dcaf12 overexpression be correlate yap/stat3 activation , advanced metastasis , and poor survival . three key insight be reveal : 1 ) ubiquitination-mediated tric/cct regulation metastatic switch , 2 ) dcaf12 oncogenic proteostasis hub , and 3 ) therapeutic potential validate multimodal targeting . finding establish dcaf12-tric/cct axis mechanistically novel target simultaneously disrupt cytoskeletal dynamic and oncogenic signaling , make promising therapeutic strategy metastatic lung cancer .","Advanced science (Weinheim, Baden-Wurttemberg, Germany)",05/10/2025
10.1002/cnr2.70357,acinic cell carcinoma breast : population-based clinicopathologic study .,"Skenderi F, Babu GR, Glamoclija U, Veledar E, Gatalica Z, Lamovec J, Vranic S","purpose : acinic cell carcinoma ( acc ) breast be very rare , primary salivary gland-type breast malignancy , ~100 report case literature . limited information clinical feature and outcome patient acc be available . method : utilize surveillance , epidemiology , and end result ( seer ) database to identify acc patient . comparison , also examine cohort invasive breast carcinoma special type ( nst ) . result : thirty acc patient be identify more 248 000 invasive breast carcinoma nst patient . acc be predominantly grade 3 carcinoma ( 44 % ) and be diagnose early stage ( 67 % ) . hormone receptor ( hr ) and her2 status datum be available only 13 patient , reveal molecular heterogeneity : hr-/her2- ( four patient ) , hr-/her2 + ( two patient ) , hr+/her2- ( four patient ) , and hr+/her2 + ( three patient ) . median survival time acc patient be 19 month 48 month nst patient ( p < 0 . 001 ) . complete-case approach be utilize adjusted analysis , restrict sample 46 257 patient miss datum relevant covariate . adjusted kaplan-mei analysis indicate more pronounced decline survival probability patient acc compare nst , number risk acc group diminish four patient 30-month mark . contrast , nst patient exhibit more gradual decrease . multivariable cox regression , adjust age , tnm stage , hr/her2 , and chemotherapy , acc histology be correlate 1 . 69-fold increase hazard death ( hr : 1 . 69 ; 95 % ci : 0 . 63-4 . 56 ) , result be not statistically significant . age and advanced stage continue to be strong predictor poor survival , and inclusion age-time interaction enhance model fit . conclusion : acinic cell carcinoma breast be very rare primary breast malignancy . study indicate potentially aggressive clinical behavior mammary acc ; however , finding must be interpret cautiously give inherent seer limitation , especially regard histologic and molecular subtyping accuracy . far centralized study be urgently need accurate characterization rare entity .","Cancer reports (Hoboken, N.J.)",01/10/2025
10.1186/s12974-025-03546-9,microglial glycolytic reprogramme alzheimer 's disease : association,"Lu N, Jin Z, Liu N, Zhu C, Wei H, Xu Q","background : alzheimer 's disease ( ad ) be characterize chronic neuroinflammation amyloid-beta plaque and phosphorylate tau ( p-tau ) tangle accumulation . microglia , resident immune cell , undergo glycolytic reprogramming may exacerbate inflammation and impede toxic protein clearance . specifically , glycolytic enzyme pyruvate kinase m2 ( pkm2 ) drive proinflammatory microglial phenotype link neurodegeneration . study investigate pkm2-mediate microglial glycolytic reprogramme and inflammatory response aβ/p-tau clearance human ad brain . methods and result : hippocampal-entorhinal cortex ( hp-ec ) tissue 8 ad patient and 8 match control undergo multiplex immunohistochemistry and high-resolution spatial analysis . pkm2(+)iba1(+ ) microglia density significantly increase ad control ( p < 0 . 001 ) , predominantly display disease-associated microglial ( ham-like ) phenotype ( abca7(+ ) ) concurrent lipid-droplet accumulation ( plin3(+ ) ; ldam phenotype ) . spatially , glycolytic pkm2(+)iba1(+ ) microglia accumulate aβ plaque , p-tau tangle , and cerebral vasculature . notably , distribution plaques/tau show anomalous increase density distance ( p < 0 . 001 ) , suggest impair chemotaxis . perivascular localization lack clear chemotactic gradient . functionally , overall phagocytic activity ( cd68(+ ) ) decrease significantly ad ( p = 0 . 001 ) , primarily attribute pkm2- subset , pkm2(+)iba1(+ ) microglia exhibit pronounce phagocytic exhaustion ( plin2(+ ) ; p < 0 . 001 ) , consistent aβ and p-tau lesion ( p < 0 . 001 ) . conclusion : study establish microglial glycolytic reprogramme pkm2 promote proinflammatory ham-like phenotype , phagocytic exhaustion , and peri-pathological accumulation aggregate and cerebral vessel . target glycolytic pathway represent viable therapeutic strategy alleviate microglial dysfunction and neuroinflammation ad .",Journal of neuroinflammation,02/10/2025
10.1186/s12943-025-02447-y,hsa_circ_0038737 promote parpi resistance castration-resistant prostate,"Wang Z, Ge Q, Anwaier A, Liu S, Tian X, Zhang Z, Feng T, Hong Z, Ye D, Xu W, Qin X","background : resistance poly ( adp-ribose ) polymerase inhibitor ( parpi ) pose major challenge therapeutic efficacy castration-resistant prostate cancer ( crpc ) . circular rnas ( circrnas ) have emerge critical regulator cancer biology , involvement parpi resistance remain largely uncharacterized . objective : study aim to elucidate molecular mechanism hsa_circ_0038737 modulate parpi resistance crpc post-transcriptional regulatory pathway . method : employ comprehensive set vitro and vivo approach , include qrt-pcr , rna sequence ,",Molecular cancer,02/10/2025
10.1212/WNL.0000000000214214,anti-inflammatory therapies atherosclerotic stroke prevention .,"Georgakis MK, Melton P, Živković L, Kopczak A, Katsanos AH","ischemic stroke cause atherosclerosis be associate high risk recurrence stroke etiology , highlight residual risk current secondary prevention strategy fail to address . multiple line research implicate inflammation pathogenesis atherosclerosis , include recent large cardiovascular outcome trial demonstrate anti-inflammatory therapy can lower residual vascular risk patient coronary artery disease . notably , low-dose colchicine , long-used anti-inflammatory drug , have receive approval cardiovascular risk reduction patient atherosclerosis . however , translation anti-inflammatory treatment patient ischemic stroke have be challenge , first colchicine trial show neutral or conflict result . study , review preclinical , genetic , and epidemiologic literature link inflammation atherosclerotic stroke ; examine key finding cardiovascular outcome trial stroke prevention ; and summarize complete and ongoing stroke-specific trial . discuss etiologic heterogeneity ischemic stroke may obscure anti-inflammatory treatment effect , highlight need precision medicine approach target patient establish atherosclerosis and vascular inflammation . finally , provide overview emerge anti-inflammatory therapeutic be development atheroprotection and outline translational roadmap to accelerate clinical impact stroke prevention .",Neurology,11/11/2025
10.1016/j.neuron.2025.09.001,treg-microglia partnership injure spinal cord preserve treg cell,"Qin T, Jiang T, Zhou Z, Wu M, Zhang Y, Yang Z, Zheng Z, Yi J, Wang X, Luo M, Gao P, Liu J, Huang Y, Liu H, Li Q, Zhou W, Zhang S, Guo X, He B, Wang Y, Fan J, Zhao S, Chen J, Yin G","spatiotemporal dynamic and specific role regulatory t ( treg ) cell spinal cord injury ( sci ) remain unclear . use single-cell rna sequencing , flow cytometry , and immunofluorescence , find thymus-derived treg cell infiltrate injure spinal cord peripheral blood 3 day post-sci . treg cell depletion worsen sci and impaired long-term recovery . transcriptomic profiling reveal strong anti-inflammatory function treg cell and potential to regulate cholesterol metabolism neighboring microglia . far single-cell rna sequence uncover clonality sci-associate treg cell . major histocompatibility complex class ii ( mhc ii ) expression microglia , not macrophage , be crucial sustain treg cell number and neuroprotective function , myelin-phagocytose microglia-activated treg cell show significant neuroprotective effect . treg cell mitigate microglial inflammation ctla-4 and upregulate atp-binde cassette transporter g1 ( ) receptor microglia , help to manage myelin load and reduce lipid droplet formation . finding offer mechanistic insight sci-associated treg cell and lie groundwork future treg-based therapy sci treatment .",Neuron,29/09/2025
10.1084/jem.20080340,point mutation murine hem1 gene reveal essential role,"Park H, Staehling-Hampton K, Appleby MW, Brunkow ME, Habib T, Zhang Y, Ramsdell F, Liggitt HD, Freie B, Tsang M, Carlson G, Friend S, Frevert C, Iritani BM","hem1 ( hematopoietic protein 1 ) be hematopoietic cell-specific member hem family cytoplasmic adaptor protein . orthologue hem1 dictyostelium discoideum , drosophila melanogaster , and caenorhabditis elegan be essential cytoskeletal reorganization , embryonic cell migration , and morphogenesis . however , vivo function mammalian hem1 be not know . use chemical mutagenesis strategy mouse to identify novel gene involve immune cell function , positionally clone nonsense mutation hem1 gene . hem1 deficiency result defective f-actin polymerization and actin capping lymphocyte and neutrophil cause loss rac-controlled actin-regulatory wave protein complex . t cell development be disrupt hem1-deficient mouse cd4(-)cd8(- ) ( double negative ) cd4(+)cd8(+ ) ( double positive ) cell stage , t cell activation and adhesion be impaired . hem1-deficient neutrophil fail to migrate response chemotactic agent and be deficient ability to phagocytose bacteria . remarkably , rac-dependent function , such th1 differentiation and nuclear factor kappab ( nf-kappab)-dependent transcription proinflammatory cytokine proceed normally hem1-deficient mouse , production th17 cell be enhance . result demonstrate hem1 be essential hematopoietic cell development , function , and homeostasis control distinct pathway lead cytoskeletal reorganization , nf-kappab-dependent transcription proceed independently hem1 and f-actin polymerization .",The Journal of experimental medicine,24/11/2008
10.1038/s41551-025-01509-2,solid tumour car-t cell engineer fusion protein target pd-l1,"Murad JP, Christian L, Rosa R, Ren Y, Buckley AJ, Lee EHJ, Lopez LS, Park AK, Yang J, Yamaguchi Y, Trac C, Adkins LN, Chang WC, Martinez C, June CH, Forman SJ, Ishihara J, Lee JK, Stern LA, Priceman SJ","chimeric antigen receptor ( car)-t cell efficacy solid tumour be limit due part immunosuppressive tumour microenvironment ( tme ) . to improve antitumour response , hypothesize enable car-t cell to secrete bifunctional fusion protein consist cytokine modifier such tgfβ(trap ) , il-15 or il-12 , combine immune checkpoint inhibitor such αpd-l1 , would provide tumour-localized immunomodulation to improve car-t cell functionality . here engineer car-t cell to secrete tgfβ(trap ) , il-15 or il-12 molecule fuse αpd-l1 scfv and assess vitro functionality and vivo safety and efficacy prostate and ovarian cancer model . car-t cell engineer αpd-l1-il-12 be superior safety and efficacy compare car-t cell alone and engineer αpd-l1 fuse tgfβ(trap ) or il-15 . far , αpd-l1-il-12 engineer car-t cell improve t cell trafficking and tumour infiltration , and localize ifnγ production , tme modulation and antitumour response , reduce systemic inflammation-associated toxicity . believe αpd-l1-il-12 engineering strategy present opportunity to improve car-t cell clinical efficacy and safety multiple solid tumour type .",Nature biomedical engineering,01/10/2025
10.1038/s44161-025-00717-y,spatial multiomic acute myocardial infarction reveal immune cell,"Wünnemann F, Sicklinger F, Bestak K, Nimo J, Thiemann T, Amrute JM, Nordbeck M, Hartmann N, Ibarra-Arellano MA, Tanevski J, Chazotte M, Heine C, Frey N, Lavine KJ, Coscia F, Saez-Rodriguez J, Leuschner F, Schapiro D","myocardial infarction ( mi ) continue to be lead cause death worldwide . even be well establish complex interplay different cell type determine overall heal response mi , precise change tissue architecture be still poorly understand . study , generate integrative cellular map acute phase murine mi use combination imaging-based transcriptomic ( molecular cartography ) and antibody-based highly multiplexed imaging ( sequential immunofluorescence ) . enable to evaluate cell type composition and change subcellular resolution time . observe recruitment leukocyte infarcted heart endocardium and perform unbiased spatial proteomic analysis use deep visual proteomics ( dvp ) to investigate underlie mechanism . dvp identify von willebrand factor ( vwf ) upregulated mediator inflammation 24 hour mi , and functional blocking vwf reduce infiltration c-c chemokine receptor 2 ( ccr2)-positive monocyte and worsen cardiac function mi .",Nature cardiovascular research,03/10/2025
10.1038/s43018-025-01054-6,aberrant expression slamf6 constitute targetable immune escape mechanism,"Sandén C, Landberg N, Peña-Martínez P, Thorsson H, Daga S, Puente-Moncada N, Rodriguez-Zabala M, von Palffy S, Rissler M, Lazarevic V, Juliusson G, Ohlin M, Hyrenius-Wittsten A, Orsmark-Pietras C, Lilljebjörn H, Ågerstam H, Fioretos T","immunotherapy have show limited success acute myeloid leukemia ( aml ) , indicate incomplete understanding underlie immunoregulatory mechanism . here identify immune evasion mechanism present 60 % aml case , primitive aml cell aberrantly express lymphoid surface protein slamf6 ( signal lymphocyte activation molecule family member 6 ) . knockout slamf6 aml cell enable t cell activation and highly efficient killing leukemia cell coculture system , demonstrate slamf6 protect aml cell recognition and elimination immune system mode analogous program cell death protein-ligand ( pdl1/pd1 ) axis . target slamf6 antibody slamf6 dimerization site inhibit slamf6-slamf6 interaction and induce t cell activation and killing aml cell both vitro and humanize vivo model . conclusion , show aberrant expression slamf6 be common and targetable immune escape mechanism could pave way immunotherapy aml .",Nature cancer,03/10/2025
10.1016/j.jacc.2025.07.061,fibrinolytic therapy thromboembolic diseases : approved indications and future,"Rashedi S, Leyva H, Hamade N, Pfeferman MB, Ortega-Paz L, Sadeghipour P, Talasaz AH, O'Donoghue ML, Jimenez D, Monrea M, Anderson CD, Elkind MSV, Lang IM, Weitz JI, Goldhaber SZ, De Caterina R, Konstantinides SV, Piazza G, Krumholz HM, Braunwald E, Bikdeli B","fibrinolytic therapy play pivotal role management thromboembolic disease promote plasmin-mediated fibrin degradation and vessel recanalization , frequently come cost increase risk hemorrhagic event , include intracranial bleeding . discovery streptokinase 1933 , several additional fibrinolytic agent have be develop . two plasminogen activators-urokinase and tissue plasminogen activator ( tpa)-were identify human sample . recombinant dna technology , be clone and modify to produce alteplase . subsequent effort to prolong plasma half-life lead development mutant derivative such tenecteplase and reteplase . fibrinolytic therapy patient",Journal of the American College of Cardiology,07/10/2025
10.1038/s41467-025-63885-2,sfpq-tfe3 reciprocally regulate mtorc1 and induce lineage plasticity mouse,"Asrani K, Amaral A, Woo J, Abadchi SN, Vidotto T, Imada E, Skaist A, Feng K, Liu HB, Kasbe M, Satou Y, Baba M, Oike Y, Outeda P, Watnick T, Rosenberg AZ, Schmidt LS, Linehan WM, Argani P, Lotan TL","mit/tfe gene fusion sfpq-tfe3 drive both epithelial ( translocation rcc ) and mesenchymal ( pecomas ) neoplasm . however , mouse model sfpq-tfe3-related tumor exist and underlie mechanism lineage plasticity remain unclear . here , demonstrate constitutive murine renal expression sfpq-tfe3 disrupt kidney development early neonatal renal failure and death , post-natal induction induce infiltrative epithelioid tumor , morphologically and transcriptionally resemble human pecomas , strong activation mtorc1 signal increase v-atpase expression . remarkably ,",Nature communications,03/10/2025
10.1186/s13099-025-00757-6,fusobacterium nucleatum and non-code rnas : orchestrate oncogenic pathway,"Sadeghloo Z, Ebrahimi S, Hakemi-Vala M, Totonchi M, Sadeghi A, Fatemi N","colorectal cancer ( crc ) remain lead cause cancer-related mortality worldwide , mount evidence implicate gut microbiome pathogenesis . microbial agent , fusobacterium nucleatum have emerge prominent contributor , frequently detect crc tissue and associate advanced disease stage and poor prognosis . review highlight complex interplay f . nucleatum and host non-code rnas ( ncrnas ) , include micrornas ( mirnas ) , long non-coding rnas ( lncrnas ) , and circular rnas ( circrnas ) , modulate crc biology . f . nucleatum influence expression several ncrnas , turn regulate key signal pathway such wnt/β-catenin ( e.g. , mir-1246 , mir-135b ) , pi3k/akt ( e.g. , mir-22 , mir-135b ) , and tlr4/nf-κb ( e.g. , mir-31 , lnc-neat1 ) . mechanism , f . nucleatum contribute tumor cell proliferation , immune evasion , metastasis , and chemoresistance . additionally , impact ncrna expression be implicate reduce efficacy standard chemotherapy . emerge microbiota-based therapy , include probiotic and fecal microbiota transplantation , show promise modulate gut flora and potentially reverse ncrna dysregulation ; however , mechanistic effect f . nucleatum-ncrna axis require further investigation . review underscore critical role f . nucleatum-regulated ncrnas crc and present new opportunity biomarker discovery and targeted therapeutic .",Gut pathogens,04/10/2025
10.1016/j.lanhl.2025.100764,aspirin and healthy lifespan old people : main outcome aspree-xt,"Shah RC, Ryan J, Webb KL, Wolfe R, Chan A, Chong TT, Ernst ME, Espinoza SE, Flynn O, Lee SY, McNeil J, Nelson MR, Orchard SG, Reid CM, Sheets K, Stocks NP, Weerasinghe NS, Wilson ME, Woods RL, Murray AM","background : aspirin reduce event elderly ( aspree ) clinical trial , low-dose aspirin be not associate survival free dementia and persistent physical disability ( measure healthy lifespan ) ; however , be small increase risk death . give long pre-clinical phase many age condition , aim to examine legacy effect ( post-trial ) and longer-term effect aspirin placebo extend follow-up aspree-xt observational study . methods : march 10 , 2010 , and dec 24 , 2014 , 19 114 community-dwelling people australia and usa , age predominantly 70 year and old , be randomly assign low-dose aspirin or placebo median 4·7 year part aspree trial . post-trial observational follow-up continue median 4·3 year ( iqr 4·1-4·6 ) . component primary endpoint ( ie , incident dementia , persistent physical disability , and death ) be adjudicate mask expert panel . analysis use cox proportional hazard model intention-to-treat . finding : 15 633 participant ( 8836 [ 56·5 % ] be woman , 6797 [ 43·5 % ] be man ; 981 [ 6·3 % ] be not white ) be eligible and agree to observational follow-up . be effect randomisation aspirin ( 34·37 event 1000 person-year ) placebo ( 33·68 1000 person-year ) primary endpoint ( hazard ratio [ hr ] 1·02 ; 95 % ci 0·94-1·11 ; p=0·63 ) aspree-xt period . similarly , period aspree and aspree-xt , long-term effect aspirin placebo be observe composite outcome death , dementia , or persistent physical disability almost decade follow-up ( hr 1·01 ; 95 % ci 0·95-1·08 ; p=0·65 ) , include long-term effect death ( 1·06 ; 0·99-1·14 ; p=0·10 ) . effect aspirin incident major haemorrhagic event compare placebo be find aspree-xt ; however , aspirin be associate increase hazard incident major haemorrhagic event aspree and aspree-xt ( 1·24 ; 1·10-1·39 ) . interpretation : low-dose aspirin do not appear to be effective promote healthy lifespan initially healthy , community-dwelling old people . funding : national institute aging and national cancer institute ( usa ) .",The lancet. Healthy longevity,27/08/2026
10.1158/0008-5472.CAN-25-0349,flt3-itd induces cmtm6 and enhances immune escape acute myeloid leukemia .,"Zwick M, Zinkel B, Spohr C, Rückert T, Halbach S, Shoumariyeh K, Scheid J, Baur AS, Braun LM, Angel M, Michaeli E, Todkar A, Nelde A, Märklin M, Holzmayer SJ, Dicks S, Boerries M, Duquesne S, Schlaak AE, Otto-Mora P, Bengsch B, Schiff M, Kissel S, Selle M, Follo M, Altmann H, Kunadt D, Illert AL, Walz JS, Walz G, Duyster J, Schetelig J, Brummer T, Zeiser R, Köhler N","fms-like tyrosine kinase-3 internal tandem duplication ( flt3-itd ) mutation be frequent acute myeloid leukemia ( aml ) and be associate high risk relapse . cklf-like marvel transmembrane domain contain member 6 ( cmtm6 ) stabilize pd-l1 surface expression and modulate tumor immunity solid cancer . study , find role flt3-induced cmtm6 hematological malignancy . flt3 drive cmtm6 and pd-l1 expression aml cell , flt3 inhibition reduce expression cmtm6 and pd-l1 . three distinct allogeneic hematopoietic cell transplantation mouse model , transplantation cmtm6 deficient flt3-itd+ leukemia cell result prolonged survival , reduce leukemia burden , enhanced t cell effector function , and decrease expression t cell exhaustion marker compare cmtm6 proficient flt3-itd+ leukemia cell . furthermore , combination therapy anti-pd-l1 and tandutinib significantly improve survival , suppress leukemia cell expansion , and augment anti-leukemia t cell response mouse bear flt3-itd+ leukemia . mechanistically , protein-protein interaction flt3 and cmtm6 transmembrane domain , be not phosphorylation dependent , enhance cmtm6 stability leukemia cell , flt3-itd do not increase cmtm6 and pd-l1 expression rna level . furthermore , cmtm6 upregulation and protein interaction flt3 be validate primary leukemia cell two independent cohort patient flt3-itd+ aml . collectively , finding uncover flt3-mediate stabilization cmtm6 aml cell , result enhanced pd-l1 cell surface expression and leukemia immune escape .",Cancer research,03/10/2025
10.1038/s41467-025-63750-2,platelet activation play pro-inflammatory role myasthenia gravis .,"Wen Q, Zhang S, Wang Y, Liu H, Wang J, Su S, Xie N, Lu Y, Di L, Xu M, Wang M, Chen H, Wang S, Zhu W, Wen X, Han J, Wan D, Zhao S, Lu W, Tao Z, Duo J, Huang Y, Chai G, Duan R, Li X, Hao J, Da Y","myasthenia gravis ( mg ) be autoimmune disorder disrupt neuromuscular junction function autoantibody . platelet be emerge key player pathogenesis mg , bridging innate and adaptive immunity . analyze platelet transcriptome signature and interaction immune system achr+ immunotherapy-naïve mg ( nmg ) patient use bulk and single-cell rna sequence peripheral blood mononuclear cell ( pbmc ) . nmg patient exhibit upregulation gene relate activation , inflammation , and cytoskeletal regulation . increase platelet count , activation , altered morphology , enhance cd62p expression , and elevated plasma cd40l level be observe pbmc , diminish minimal clinical status ( mms ) . functionally , platelet show heighten interaction leukocyte , form aggregate correlate disease severity . feature return baseline intravenous immunoglobulin or prolong immunosuppressive therapy . study underscore platelet activation 's critical role mg and support platelet-targeted therapy .",Nature communications,02/10/2025
10.1038/s41586-025-09571-1,human-specific regulatory mechanism reveal pre-implantation model .,"Fueyo R, Wang S, Crocker OJ, Swigut T, Nakauchi H, Wysocka J","stem cell-based human embryo model offer unique opportunity functional study human-specific feature development . here genetically and epigenetically manipulate human blastoid , 3d embryo model blastocyst(1 ) , to investigate functional effect hervk ltr5hs , hominoid-specific endogenous retrovirus , pre-implantation development . uncover pervasive cis-regulatory contribution ltr5hs element hominoid-specific diversification epiblast transcriptome blastoid . many ltr5hs genomic insertion human genome be unique own specie . show at least one such human-specific ltr5hs element be essential blastoid-forming potential enhance expression primate-specific znf729 gene , encode krab zinc-finger protein . znf729 bind gc-rich sequence , abundant gene promoter associate basic cellular function , such cell proliferation and metabolism . mediate recruitment trim28 , many promoter znf729 act transcriptional activator . together , result illustrate recently emerge transposable element and gene can confer developmentally essential function human .",Nature,01/10/2025
10.1016/j.neuron.2025.09.006,segregate supramammillary-dentate gyrus circuit modulate cognitive and,"Luo YJ, Li L, Chen ZK, Dong P, Xie L, Farmer WT, Yu QS, Jiang LX, Su WK, Liu HS, Wang HZ, Jiao ZL, Melville DJ, Penel E, Sheehy RN, Landry T, Wang J, Jiang H, Xu XH, Chen X, Xu NJ, Xue T, Xu TL, Li YD, Song J","progressive cognitive decline be define feature alzheimer 's disease ( ad ) , many patient also develop prominent neuropsychiatric symptom , include anxiety and depression . circuit-level mechanism underlie distinct symptom domain remain poorly understand , and treatment address both cognitive and noncognitive aspect ad be limited . here , identify anatomically , molecularly , and functionally distinct subpopulation supramammillary ( sum ) neuron project either dorsal or ventral dentate gyrus ( ddg or vdg ) . distinct sum neuron and sum-dg subcircuit selectively regulate memory and emotion , respectively . ad model mouse , sum neuron target ddg or vdg display aberrant activity memory or emotional processing , and importantly , target optogenetic activation sum-ddg or sum-vdg pathway selectively restore cognitive or affective function . finding reveal sum-dg subcircuit parallel modulator cognitive and emotional state and highlight potential therapeutic target address multifaceted symptomatology ad .",Neuron,03/10/2025
10.11477/mf.1416202125,[ case coexistent persistent trigeminal and hypoglossal arteries manifested,"Asayama K, Hayashi K, Kanai Y, Tahara N, Kato Y, Abe S, Mitaki S, Nagai A","70-year-old woman visit hospital hypertension , diplopia , and right orbital pain . neurological examination reveal right ophthalmoplegia . ct angiography and mri identify right persistent trigeminal artery ( pta ) , right persistent hypoglossal artery , and bovine aortic arch . right internal carotid artery ( ica ) be displace laterally cavernous sinus bifurcation pta . compression right oculomotor nerve , right trochlear nerve , and first division right trigeminal nerve elongate right ica be note and consider potential cause ophthalmoplegia and orbital pain . symptom improve normalization blood pressure . embryonic development , right posterior communicate artery and bilateral vertebral artery be aplastic or hypoplastic , suggest carotid-basilar anastomosis may have remain supply route to provide sufficient blood flow posterior cerebral circulation . be extremely rare case embryological implication manifest neurovascular compression syndrome . ( receive 6 january , 2022 ; accepted 17 february , 2022 ; publish 1 june , 2022 ) .",Brain and nerve = Shinkei kenkyu no shinpo,01/06/2022
10.1016/S1473-3099(25)00476-1,long covid associate sars-cov-2 reinfection child and adolescent,"Zhang B, Wu Q, Jhaveri R, Zhou T, Becich MJ, Bisyuk Y, Blanceró F, Chrischilles EA, Chuang CH, Cowell LG, Fort D, Horowitz CR, Kim S, Ladino N, Liebovitz DM, Liu M, Mosa ASM, Schwenk HT, Suresh S, Taylor BW, Williams DA, Morris JS, Forrest CB, Chen Y","background : post-acute sequelae sars-cov-2 infection ( pasc ) remain major public health challenge . previous study have focus characterise pasc child and adolescent initial infection , risk pasc reinfection omicron variant remain unclear . aim to assess risk pasc diagnosis ( u09 . 9 ) and symptom and condition potentially relate pasc child and adolescent sars-cov-2 reinfection omicron period . method : retrospective cohort study use datum 40 child 's hospital and health institution usa participate research covid enhance recovery ( recover ) initiative . include patient young 21 year time cohort entry ; document sars-cov-2 infection jan 1 , 2022 ; and have at least one health-care visit 24 month 7 day first infection . second sars-cov-2 infection be confirm positive pcr , antigen test , or diagnosis covid-19 occur least 60 day first infection . primary endpoint be clinician-documented diagnosis pasc ( u09 . 9 ) . secondary endpoint be 24 symptom and condition previously identify be potentially relate pasc . use modify poisson regression model to estimate relative risk ( rr ) second and first infection episode , adjust demographic , clinical , and health-care utilisation factor use exact and propensity-score matching . finding : identify 407 300 ( 87·5 % ) 465 717 eligible child and adolescent first infection episode and 58 417 ( 12·5 % ) second infection episode jan 1 , 2022 , oct 13 , 2023 , recover database . 233 842 ( 50·2 % ) patient be male and 231 875 ( 49·8 % ) be female . mean age be 8·17 year ( sd 6·58 ) . incident rate pasc diagnosis ( u09 . 9 ) million people 6 month be 903·7 ( 95 % ci 780·9-1026·5 ) first infection group and 1883·7 ( 1565·1-2202·3 ) second infection group . reinfection be associate significantly increase risk overall pasc diagnosis ( u09 . 9 ) ( rr 2·08 [ 1·68-2·59 ] ) and range symptom and condition potentially relate pasc ( rr range 1·15-3·60 ) , include myocarditis , change taste and smell , thrombophlebitis and thromboembolism , heart disease , acute kidney injury , fluid and electrolyte disturbance , generalise pain , arrhythmias , abnormal liver enzyme , chest pain , fatigue and malaise , headache , musculoskeletal pain , abdominal pain , mental ill health , pots or dysautonomia , cognitive impairment , skin condition , fever and chill , respiratory sign and symptom , and cardiovascular sign and symptom . interpretation : child and adolescent face significantly high risk various pasc outcome reinfection",The Lancet. Infectious diseases,30/09/2025
10.1186/s11658-025-00789-5,program cell death triple-negative breast cancer .,"Liu Y, He J, Chen J, Chen T, Li W, Yang Z, Zeng F","triple-negative breast cancer ( tnbc ) be particularly aggressive and therapeutically challenging subtype breast cancer , define lack estrogen receptor , progesterone receptor , and human epidermal growth factor receptor 2 expression . absence actionable molecular target contribute resistance conventional treatment . review provide overview mechanistic function , interrelated process , and therapeutic implication several program cell death ( pcd ) pathways-including apoptosis , pyroptosis , necroptosis , autophagy , and ferroptosis-in context tnbc pathogenesis and treatment . conceptual framework be propose leverage interconnect cell death pathway basis novel target intervention . give complex interplay various pcd form characterize share feature such inflammation , mitochondrial dysfunction , and overlap molecular mediator , integrated network offer promising opportunity combinatorial therapeutic strategy . modulation one cell death pathway may influence other , potentially amplify therapeutic efficacy . furthermore , pcd pathway be highly relevant immunotherapy outcome , offer foundation synergistic treatment modality . review provide in-depth analysis crosstalk immune-based therapy and pcd , comprehensive discussion derive therapeutic approach . however , tumor diversity , resistance mechanism , and discrepancy preclinical model and human physiology pose major challenge apply finding clinically . overarching goal be to present innovative insight and strategy to enhance clinical management tnbc and ultimately improve patient outcome .",Cellular & molecular biology letters,02/10/2025
10.1016/j.cell.2025.09.006,sequencing-free whole-genome spatial transcriptomic single-molecule,"Cheng Y, Dang S, Zhang Y, Chen Y, Yu R, Liu M, Jin S, Han A, Katz S, Wang S","recent breakthrough spatial transcriptomic technology have enhance understanding diverse cellular identity , spatial organization , and function . yet exist spatial transcriptomic tool be still limited transcriptomic coverage or spatial resolution , hinder unbiased , hypothesis-free transcriptomic analysis high spatial resolution . here , develop reverse-padlock amplicon-encoding fluorescence situ hybridization ( raefish ) , image-based spatial transcriptomic method whole-genome coverage and single-molecule resolution intact tissue . demonstrate spatial profiling transcript 23 , 000 human or 22 , 000 mouse gene single cell and tissue section . analysis reveal transcript-specific subcellular localization , cell-type-specific and cell-type-invariant zonation-dependent transcriptome , and gene program underlie preferential cell-cell interaction . finally , far develop technology direct spatial readout guide rnas ( grnas ) image-based , high-content crispr screen . overall , development offer broadly applicable technology enable high-coverage , high-resolution spatial profiling long and short , native and engineer rnas many biomedical contexts .",Cell,01/10/2025
10.1002/advs.202503277,discovery potent and selective tead degrader durable degradation,"Cao L, Yang J, Liu Y, Chen X, Shi Y, Zhao Y, Zhang Y, Chen J, Li B, Wen W, Chen L, Peng B, Huang L, Sun Y, Zhou L, Rees MG, Ronan MM, Roth JA, Guo Z, Xing J, Zhu G, Wang Y, Jiang B, Lu J, Zhao K, Lu W","tea/atss ( tead ) family transcription factor be key effector hippo pathway , exert function interaction coactivator yap and taz . past five year , development yap-tead disruptor have emerge central focus both academic and industrial effort aim target hippo pathway cancer therapy . study , discovery and comprehensive characterization kg-fp-003 , potent , selective , and durable tead degrader be report . kg-fp-003 exhibit superior activity compare lipid-binding pocket ( lbp ) inhibitor myf-03-176 and tead-yap protein-protein interaction ( ppi ) inhibitor iag933 , efficiently degrade tead isoform low nanomolar concentration ubiquitin-proteasome system ( ups)-dependent manner . degradation translate more robust and sustain therapeutic response both vitro and vivo . furthermore , barcode cell line screening reveal elevated sensitivity several cancer type , include endometrial carcinoma , glioblastoma , ovarian epithelial tumor , and osteosarcoma . finding position kg-fp-003 compelling lead candidate tead isoform-selective therapy and underscore potential utility hippo-dysregulated mesothelioma .","Advanced science (Weinheim, Baden-Wurttemberg, Germany)",05/10/2025
10.2337/db25-0215,regulatory roles igf2r insulin secretion and adaptive β-cell proliferation .,"Shirakawa J, De Jesus DF, Tsuno T, Basile G, Inoue R, Takatani T, Nishiyama A, Okawa ER, Tamura T, Terauchi Y, Kulkarni RN","growth factor-2 receptor ( igf2r ) , also know cation-independent mannose-6-phosphate receptor , be localize cytosolic vesicle and be unique ability to transport enzyme lysosome and to clear igf2 cell surface act scavenger receptor . to evaluate direct role igf2r β-cell biology , undertake complementary vitro knockdown and vivo knockout approach . β-cell line stable knockdown igf2r ( igf2rkd ) exhibit decrease glucose-induced insulin secretion and enhance cell proliferation . tamoxifen-inducible β-cell-specific igf2r knockout mouse exhibit impair glucose tolerance and blunt insulin secretion high-fat-diet load be likely secondary reduced β-cell mass attenuate proliferation . β-cell igf2rkd have few autophagosome starvation and reduced expression p62 , lc3b , and ulk1 . aged mouse also have impair autophagy βigf2r-deficient β-cell . reduce igf2r function and n6-methyladenosine ( m6a ) mrna methylation be observe islet both mouse and human type 2 diabetes . take together , datum point igf2r important regulator insulin secretion , cell proliferation , and autophagy mammalian β-cell . article highlight : significance insulin-like growth factor-2 receptor ( igf2r ) β-cell remain unclear . to assess physiological role igf2r β-cell , effect igf2r deficiency vivo and vitro be investigate . igf2r modulate insulin secretion , cell proliferation , and autophagy β-cell . igf2r play role regulation β-cell biology .",Diabetes,03/10/2025
10.1186/s12943-025-02449-w,brd9-p53-e2f1 circuit orchestrate cell growth and dna damage repair gastric,"Zhou Q, Wang Q, Duan Y, Zhang C, Liu T, Liu H, Zhao M, Hu Z","background : brd9 be involve multiple physiological and pathological pathway , yet functional role and molecular mechanism gastric cancer ( gc ) remain largely unexplored . address knowledge gap be critical give persistent global mortality burden gc and limited efficacy current therapeutic strategy . method : brd9 expression gc patient be systematically analyze use immunohistochemical ( ihc ) assay and transcriptomic dataset . comprehensive functional validation , employ cellular and murine tumor model , elucidate brd9 's role gc progression . molecular pathway underlie brd9-mediated gastric carcinogenesis be delineate integrated approach , include rna sequencing , co-immunoprecipitation ( co-ip ) , subcellular fractionation , and luciferase reporter assay . result : brd9 be significantly overexpresse gc and associate poor patient prognosis . functionally , brd9 promote gc cell proliferation and enhance dna damage repair capacity . mechanistically , elevate brd9 expression inhibit p53 nuclear translocation direct binding , subsequently activate e2f transcription factor family . notably , identify e2f1 directly bind and transactivate brd9 promoter , establish positive feedback loop sustain brd9 expression . additionally , brd9 knockdown sensitize gc cell cisplatin and oxaliplatin treatment . conclusion : finding highlight critical role brd9 gc progression and therapeutic potential . brd9-p53-e2f1 axis act crucial regulator gc cell proliferation and dna damage response . target brd9 pharmacologically could be novel therapeutic approach to enhance chemotherapy efficacy and improve treatment outcome gc patient .",Molecular cancer,02/10/2025
10.1186/s13062-016-0107-8,paneukaryotic genomic analysis small gtpase rabl2 underscore,"Eliáš M, Klimeš V, Derelle R, Petrželková R, Tachezy J","background : cilium ( flagellum ) be complex cellular structure inherit last eukaryotic common ancestor ( leca ) . large number ciliary protein have be characterize few model organism , but evolutionary history often remain unexplored . one such protein be small gtpase rabl2 , recently implicate assembly sperm tail mammal . result : use wealth currently available genome and transcriptome sequence , include datum on-going sequence project , systematically analyze phylogenetic distribution and evolutionary history rabl2 ortholog . dense taxonomic sampling reveal presence rabl2 gene nearly major eukaryotic lineage , include small "" obscure "" taxa such breviate , ancyromonad , malawimonad , jakobid , picozoan , or palpitomonad . phyletic pattern rabl2 gene indicate be present already leca . however , organism lack rabl2 result secondary loss and present sampling predict well 30 such independent event eukaryote evolution . distribution rabl2 gene correlate presence/absence cilia : not single well-established cilium-lacking specie have retain rabl2 ortholog . however , several ciliated taxa , most notably nematode , arthropod and platyhelminth , diplomonad , and ciliate subgroup apicomplexans and embryophyte , lack rabl2 as well , suggest simplification cilium-associated function . other hand , several algae currently unknown to form cilia , e.g. , "" prasinophyte "" genus prasinoderma or ochrophyte pelagococcus subviridis and pinguiococcus pyrenoidosus , turn to encode not only rabl2 , but also homolog hallmark ciliary protein , suggest existence cryptic flagellate stage life cycle . additionally obtain insight evolution rabl2 gene architecture , seem to have ancestrally consist eight exon subsequently modify not only lineage-specific intron loss and gain , but also recurrent loss terminal exon encode poorly conserve c-terminal extension . conclusion : comparative analysis support notion rabl2 be ancestral component eukaryotic cilium and underscore still underappreciated magnitude recurrent gene loss , or reductive evolution general , history eukaryotic genome and cell .",Biology direct,02/02/2016
10.1038/s41565-025-02017-9,spatiotemporal-adaptive nanotherapeutic promote post-injury regeneration,"Liang K, Zhao L, Zhang S, Zheng L, Zhang Z, Wang S, Chen J, Xu W, Wang W, Yang H, Song C, Qiu P, Zhao C, Fang W, Zhu J, Fan S, Liu Z, Tang R, Zhao Y, Fang X","elderly population , dysregulate cellular behaviour healing process impact tissue regeneration injury . early regeneration process , pro-inflammatory macrophage contribute immune imbalance , late stage , senescent stem cell reduce regenerative capacity . here demonstrate nicotinamide adenine dinucleotide ( nad(+ ) ) can reprogramme type dysfunctional cell . develop spatiotemporal-adaptive nanotherapeutic system delivery nad(+ ) select cell different phase tissue repair . replenish intracellular nad(+ ) pool , system reshape multicellular regeneration niche , metabolically rewire pro-inflammatory macrophage pro-repair phenotype early phase , and enhance differentiation capacity senescent stem cell later stage . strategy effectively restore impaired bone regeneration osteoporotic mouse and accelerate skin wound healing . work present spatiotemporal-adaptive nanomedicine platform bridge cell metabolism , nanomedicine and regeneration therapy .",Nature nanotechnology,01/10/2025
10.1093/braincomms/fcaf337,systemic increase ampa receptor associate cognitive impairment long,"Fujimoto Y, Abe H, Eiro T, Tsugawa S, Tanaka M, Hatano M, Nakajima W, Ichijo S, Arisawa T, Takada Y, Kimura K, Sano A, Hirahata K, Sasaki N, Kimura Y, Takahashi T","long covid primarily present persistent cognitive impairment ( cog-lc ) , impose substantial and lasting global burden . even pandemic , remain critical global need diagnostic and therapeutic strategy target cog-lc . nevertheless , underlying neural mechanism remain poorly understand . give central role synapsis brain function , investigation synaptic molecular change may provide vital insight cog-lc pathophysiology . study , use [ ( 11)c]k-2 pet to characterize density ampa receptor ( ampar ) post-synaptic cell surface , be crucial synaptic component brain signal . statistical parametrical mapping be use to spatially normalize and apply independent t-test voxel-based comparison . select patient cog-lc ( n = 30 ) base repeatable battery assessment neuropsychological status assess persistent cognitive impairment and healthy control ( n = 80 ) diagnose neuropsychiatric disorder . primary objective be to compare [ ( 11)c]k-2 standardized uptake value ratio white matter ( suvr(wm ) ) reference region patient cog-lc and healthy control , and to define regional extent difference . secondary objective be to examine association [ ( 11)c]k-2 suvr(wm ) and plasma concentration cytokine or chemokine . exploratory objective , test [ ( 11)c]k-2 pet datum could distinguish cog-lc healthy control use partial least square base classification algorithm . voxel-based comparison ( p < 0 . 05 , t > 1 . 66 , one-tailed , false discovery rate control ) and volume interest analysis ( p < 0 . 05 , bonferroni multiple comparison ) demonstrate increase index ampar density large part brain patient cog-lc compare healthy control . voxel-based correlation analysis also show brain region [ ( 11)c]k-2 suvr(wm ) correlate positively plasma tnfsf12 and negatively plasma ccl2 concentration . partial least square model train index ampar density datum demonstrate high diagnostic accuracy , achieve 100 % sensitivity and 91 . 2 % specificity . [ ( 11)c]k-2 pet signal represent index ampar density post-synaptic neural cell surface , not glial cell surface . systemic increase synaptic ampar brain may drive abnormal information processing cog-lc and , excessive excitatory signalling , pose risk excitotoxic neuronal damage . derive hypothesis [ ( 11)c]k-2 pet would be helpful establish diagnostic framework cog-lc and antagonist cell surface ampar , such perampanel , would be potential therapeutic target . hypothesis should be investigate future large-scale clinical study .",Brain communications,01/01/2025
10.1186/s12933-025-02920-4,dual modulation lipid and glucose metabolism nutraceutical combination,"Pacella D, Lembo M, Trimarco V, Izzo A, Manzi MV, Jankauskas SS, Forzano I, Gallo P, Spinelli A, Morisco C, Cristiano S, Rozza PI, Esposito E, Rozza F, Esposito L, Bear SKB, Giugliano G, Santulli G","background : recent evidence suggest inhibit 3-hydroxy-3-methylglutaryl coenzyme reductase ( hmgcr ) , key enzyme cholesterol biosynthesis , have beneficial effect lipid metabolism and blood pressure ( bp ) , but detrimental consequence glycemia . nutraceutical ( nut ) contain monacolin k ( mk ) and morus alba have be show to be more effective lower lipid compare nut formulation contain only mk . however , effect nut glucose homeostasis have not be fully determine . method : to evaluate association ldl-c-lowering therapy and glycemia patient receive nut combination or morus alba , analyze datum prospective , randomize , active-treatment control trial ( nct02898805 ) , enrol 359 patient to compare effect nut combination contain mk alone ( formulation 1 , f1 ; n = 170 ) one contain mk and morus alba ( formulation 1 , f2 ; n = 189 ) . result : participant two treatment arm ( f1 f2 ) be comparable term sex , age , metabolic parameter , and bp . 3 month , group experience significant reduction ldl-c , fast plasma glucose , hba1c , and homa index . f2 treatment lead significantly great reduction glycemic level compare f1 treatment ( b = - 16 , p < 0 . 001 ) . notably , divergent trend emerge time : inverse relationship ldl-c and glycemic level be observe f1 group , significant direct association ldl-c and glycemic level be detect f2 group ( b = 0 . 06 , p = 0 . 002 ) . conclusion : take together , finding indicate treatment nut combination contain morus alba simultaneously reduce plasma level ldl-c and glucose .",Cardiovascular diabetology,03/10/2025
10.1038/s41598-025-17956-5,"development cognitive , motor , metabolic , and mutant huntingtin aggregation","McLean FH, Monteiro O, Lelos MJ, Ekkunagul T, Spicer RM, Rybnicek J, Lambert JJ, Langston RF","huntington 's disease ( hd ) be inherit neurodegenerative disease . human , clinical diagnosis be often dependent emergence motor symptom . however , cognitive impairment and metabolic change can be early indicator . hd mouse model be useful tool to understand disease progression , however , relatively few study have monitor timeline emergence cognitive index motor and metabolic phenotype parallel . study , cognitive , motor , and metabolic phenotype be investigate different age zq175 knock-in mouse immunohistochemical and long-term potentiation ( ltp ) study . demonstrate zq175 mouse develop impair hippocampal ltp 3-month and cognitive deficit visuospatial attention be evident 4-month . long-term and spatial memory impairment emerge 12-month , motor impairment . additionally , anxiolytic-like phenotype emerge 6-month . difference body weight be also detect 6-month onwards , primarily drive reduction fat mass . additionally , reduce brain weight and presence huntingtin aggregate hippocampus , striatum and hypothalamus be observe 12-month . datum support zq175 mouse model hd , recapitulate many aspect disease progression human and can be use to understand mechanism underlie disease .",Scientific reports,03/10/2025
10.1016/j.amjcard.2022.01.027,usefulness empagliflozin versus oral semaglutide prevention,"Hammerman A, Moore CM, Aboalhasan E, Azuri J, Arbel R","empagliflozin and oral semaglutide reduce incidence cardiovascular mortality ( cvm ) patient type 2 diabete mellitus . however , therapy impose significant financial burden healthcare system . therefore , compare value money empagliflozin oral semaglutide to prevent cvm . calculate cost need to treat to prevent 1 case cvm use drug multiply annualize number need to treat to prevent 1 event annual cost therapy . efficacy estimate be extract publish randomize control trial datum . perform scenario analysis to mitigate primary difference population randomize control trial . drug cost be calculate 75 % united states national average drug acquisition cost list . annualize number need to treat empagliflozin empa-reg-outcome be 141 ( 95 % confidence interval [ ci ] 104 to 230 ) and 141 ( 95 % ci 96 to 879 ) oral semaglutide pioneer 6 . annual treatment cost be $ 4 , 797 empagliflozin $ 7 , 133 oral semaglutide . therefore , corresponding cost need to treat be $ 676 , 385 ( $ 498 , 894-$1 , 101 , 039 ) and $ 1 , 005 , 855 ( 95 % ci $ 684 , 837-$6 , 270 , 544 ) respectively . conclusion , finding suggest empagliflozin provide well value money oral semaglutide to prevent cvm patient type 2 diabete mellitus current united states price intervention .",The American journal of cardiology,01/05/2022
10.1186/s12889-025-24746-1,association sarcopenic obesity and risk fall : population-based,"Yu C, Meng Z, Wang X, Xiao J","objective : previous research have establish strong link sarcopenia and fall risk middle-aged and old adult , effect sarcopenic obesity and possible sarcopenic obesity fall risk remain underexplored large-scale study . longitudinal analysis aim to examine association use nationally representative cohort datum . method : analyze datum china health and retirement longitudinal study ( charls ) , include 9 , 996 participant age 45 and old available body composition measurement . participant be categorize four group base asian working group sarcopenia ( awgs ) criterion and median waist circumference ( wc ): ( 1 ) normal wc sarcopenia ( control group ) , ( 2 ) normal wc sarcopenia , ( 3 ) obesity sarcopenia , and ( 4 ) obesity sarcopenia . cox proportional hazards model be use to estimate adjusted hazard ratio ( hrs ) , 95 % confidence interval ( ci ) , and p-values , control group reference . model be sequentially adjust demographic ( age , sex , residence ) , socioeconomic ( education ) , and behavioral ( smoking , alcohol ) variable . result : compare participant normal wc and sarcopenia ( reference group ) , sarcopenic obesity have significantly high risk fall ( hr = 1 . 25 ; 95 % ci : 1 . 00-1 . 56 ; p = 0 . 048 ) , even adjust demographic , socioeconomic , and behavioral factor . similarly , possible sarcopenic obesity be link modest but statistically significant increase fall risk ( hr = 1 . 12 ; 95 % ci : 1 . 02-1 . 24 ; p = 0 . 021 ) . subgroup analysis reveal fourth quartile show trend high fall risk subgroup , especially individual age ≥ 60 year and male . however , most subgroups , 95 % cis cross 1 , suggest limited statistical significance strata . conclusion : sarcopenic obesity and possible sarcopenic obesity be associate elevated risk fall . middle-aged and old adult should adopt preventive strategy , such maintain regular physical activity , to preserve muscle mass and reduce risk fall .",BMC public health,03/10/2025
10.1371/journal.pone.0071955,"smoking , radiotherapy , diabete and osteoporosis risk factor dental","Chen H, Liu N, Xu X, Qu X, Lu E","background : be conflicting report association smoking , radiotherapy , diabete and osteoporosis and risk dental implant failure . undertake meta-analysis to evaluate association smoking , radiotherapy , diabete and osteoporosis and risk dental implant failure . method : comprehensive research medline and embase , up january 2013 , be conduct to identify potential study . reference relevant study be also search . screening , datum extraction and quality assessment be conduct independently and duplicate . random-effect meta-analysis be use to pool estimate relative risk ( rrs ) 95 % confidence interval ( ci ) . result : total 51 study be identify meta-analysis , more 40 , 000 dental implant place risk-threatening condition . pooled rr show direct association smoking ( n = 33 ; rr = 1 . 92 ; 95 % ci , 1 . 67-2 . 21 ) and radiotherapy ( n = 16 ; rr = 2 . 28 ; 95 % ci , 1 . 49-3 . 51 ) and risk dental implant failure , inverse impact diabetes ( n = 5 ; rr = 0 . 90 ; 95 % ci , 0 . 62-1 . 32 ) risk dental implant failure be find . influence osteoporosis risk dental implant failure be direct but not significant ( n = 4 ; rr = 1 . 09 ; 95 % ci , 0 . 79-1 . 52 ) . subgroup analysis indicate influence study design , geographical location , length follow-up , sample size , or mean age recruit patient . conclusion : smoking and radiotherapy be associate increase risk dental implant failure . relationship diabete and osteoporosis and risk implant failure warrant further study .",PloS one,01/01/2013
10.1016/S1470-2045(25)00280-3,safety and efficacy dexamethasone-sparing regimen daratumumab and,"Manier S, Lambert J, Hulin C, Macro M, Laribi K, Araujo C, Pica GM, Touzeau C, Godmer P, Slama B, Karlin L, Orsini Piocelle F, Dib M, Sanhes L, Morel P, El Yamani A, Tiab M, Tabrizi R, Richez V, Garderet L, Royer B, Bareau B, Mariette C, Fleck E, Robu D, Calmettes C, Rigaudeau S, Demarquette H, Frenzel L, Decaux O, Mohty M, Arnulf B, Bigot N, Perrot A, Corre J, Mary JY, Avet-Loiseau H, Moreau P, Leleu X, Facon T","background : patient frailty and newly diagnose multiple myeloma have bad outcome high rate adverse event ( aes ) and treatment discontinuation . study evaluate dexamethasone-sparing regimen daratumumab plus lenalidomide lenalidomide plus dexamethasone frail patient newly diagnose multiple myeloma . method : prospective , randomise , open-label trial , conduct 61 active intergroup francophone myeloma centre , patient age 65 year or old newly diagnose multiple myeloma and eastern cooperative oncology group proxy frailty score 2 or more be randomly assign 2 :1 to receive daratumumab ( 1800 mg subcutaneously ) plus oral lenalidomide ( 25 mg daily 21 day 28 day cycle ) and dexamethasone ( 20 mg weekly ) two cycle ( dexamethasone-sparing group ) or lenalidomide ( 25 mg daily ) and oral dexamethasone ( 20 mg weekly ; control group ) , stratification international staging system , age , and centre . primary endpoint be progression-free survival . efficacy be assess intention-to-treat population and safety be assess patient expose at least one dose randomised intervention . trial be register clinicaltrials.gov , nct03993912 , and be complete . finding : oct 18 , 2019 july 20 , 2021 , 335 patient be screen , 295 patient be randomly assign ( 200 to lenalidomide plus daratumumab , 95 to lenalidomide plus dexamethasone ) . median age be 81 year ( iqr 77-84 ) , 180 ( 61 % ) aged old 80 year , and 151 ( 51 % ) patient be female and 144 ( 49 % ) be male . median follow-up be 46·3 month ( iqr 46·0-52·7 ) . median progression-free survival be 53·4 month ( 95 % ci 35·3-not reach ) dexamethasone-sparing group 22·5 month ( 16·5-39·0 ) control group ( hazard ratio [ hr ] 0·51 , 95 % ci 0·37-0·70 , p<0·0001 ) . most common grade 3-5 aes be neutropenia ( 110 [ 55 % ] 200 patient dexamethasone-sparing group 23 [ 24 % ] 95 patient control group ) , and infection ( 38 [ 19 % ] 20 [ 21 % ] ) . serious adverse event occur 126 patient ( 63 % ) dexamethasone-sparing group and 66 patient ( 69 % ) control group . lead death occur 23 patient ( 12 % ) dexamethasone-sparing group and 12 patient ( 13 % ) control group , 4 ( 2 % ) and 2 ( 2 % ) grade 5 treatment-emergent adverse event , respectively . interpretation : ifm2017-03 trial , use lenalidomide plus daratumumab , dexamethasone limit first 2 treatment cycle , reduce risk progression or death compare lenalidomide plus dexamethasone , additional safety concern . lenalidomide plus daratumumab could therefore be consider treatment option old patient frailty and newly diagnose multiple myeloma . funding : study be fund johnson & johnson .",The Lancet. Oncology,01/10/2025
10.1371/journal.pone.0048639,neural correlate identity fake and concealment : fmri study .,"Ding XP, Du X, Lei D, Hu CS, Fu G, Chen G","neural basis self and identity have receive extensive research . however , most exist study have focus situation internal representation self be consistent external one . present study use fmri methodology to examine neural correlate two different type identity conflict : identity fake and concealment . participant be present sequence name and ask to either conceal own identity or fake one . result reveal right insular cortex and bilaterally inferior frontal gyrus be more active identity concealment compare control condition , identity fake elicit significantly large percentage signal increase control condition right superior frontal gyrus , left calcarine , and right caudate . result suggest different neural system associate identity processing and deception be involve identity concealment and faking .",PloS one,01/01/2012
10.1016/j.stemcr.2025.102649,"integrated profiling ipsc-derived motor neuron carry c9orf72 , fus , tardbp ,","Ma GM, Xia CC, Lyu BY, Liu J, Luo F, Guan MF, Wang JY, Sun L, Zhang L, Chen Y, Mao YW, Yu GQ, Wang WY","here , conduct temporal rna sequence ( rna-seq ) profiling human induce pluripotent stem cell ( hipscs ) and induce pluripotent stem cell ( ipsc)-derive motor neuron ( imns ) carry c9orf72 , fus , tardbp , or sod1 mutation patient amyotrophic lateral sclerosis ( als ) and healthy individual . discover dysregulate gene expression and alternative splicing ( as ) imn development and maturation , and imns mutation als-associate gene display enrichment cytoskeletal defect and synaptic alteration premature stage to mature imns . finding indicate synaptic gene dysfunction be common molecular hallmark familial als , may result neuronal susceptibility and progressive motor neuron degeneration . analysis upstream splicing factor reveal differentially express rna-binding protein ( rbps ) imns patient als may cause abnormal event . overall , research provide comprehensive and valuable resource gain insight share mechanism familial als pathogenesis motor neuron development and maturation imn model .",Stem cell reports,02/10/2025
10.1248/bpb.b15-00842,mechanism underlying induction hyperglycemia rat single administration,"Nagata M, Nakajima M, Ishiwata Y, Takahashi Y, Takahashi H, Negishi K, Yasuhara M","acute administration olanzapine rapidly elevate blood glucose level . however , mechanism underlie rapid development hyperglycemia administration olanzapine remain unclear . aim present study be to clarify mechanism underlie olanzapine-induced acute hyperglycemia . male wistar rat receive intravenous infusion saline ( control ) or olanzapine 2 . 5 , 5 , or 10 mg/kg . blood sample be obtain periodically olanzapine infusion to determine serum concentration glucose , olanzapine , and several endogenous substance . separate experiment , rat receive intravenous injection propranolol ( 2 mg/kg ) 30 min infusion olanzapine ( 10 mg/kg ) . intravenous infusion olanzapine induce dose-dependent increase serum concentration glucose , epinephrine , and insulin . pretreatment propranolol suppress olanzapine-induced elevation serum concentration glucose , but do not affect serum concentration olanzapine or olanzapine-induced increase serum concentration epinephrine . serum concentration corticosterone increase administration olanzapine , significant difference be observe olanzapine dose group . furthermore , administration olanzapine do not affect serum concentration glucagon or histamine . develop pharmacokinetic-pharmacodynamic model assume olanzapine-induced secretion epinephrine lead elevated serum glucose concentration . model appear to satisfactorily characterize olanzapine-induced hyperglycemia . conclusion , single intravenous dose olanzapine dose-dependently increase serum concentration glucose rat , and epinephrine play role olanzapine-induced acute hyperglycemia .",Biological & pharmaceutical bulletin,01/01/2016
10.1016/j.lanmic.2025.101174,rapid pan-microbial metagenomic pathogen detection and personalised therapy,"Alcolea-Medina A, Snell LB, Humayun G, Al-Yaakoubi N, Ward D, Alder C, Patel V, Vivian F, Meadows CIS, Wyncoll D, Paul R, Barratt N, Batra R, Edgeworth J, Nebbia G, Whitehorn J","background : most clinical metagenomic study do not provide rapid result , detect pathogen microbial kingdom , or measure clinical impact . aim to evaluate feasibility , performance , and clinical impact rapid pan-microbial respiratory metagenomic service patient admit intensive care unit ( icu ) . methods : be single-centre observational study rapid metagenomics service test respiratory sample icu patient guy 's and st thomas ' hospital , london , uk , dec 5 , 2023 , and april 12 , 2024 . testing use previously publish pan-microbial metagenomics workflow , simultaneously detect bacteria , fungus , and dna and rna virus ; provide same-day preliminary result 2 h ; and provide final result 24 h. patients be include be age 18 year or old , admit icu , have confirm respiratory failure require supplemental oxygen or advanced airway support , and have at least one following : ( 1 ) clinical suspicion low respiratory tract infection base clinical , biochemical , or radiological finding , ( 2 ) sepsis unknown origin , and ( 3 ) concern intensive care physician regard inflammatory pathology . patient suspect or confirmed containment level three organism be exclude . outcome be performance characteristic metagenomic test compare routine diagnostic testing , detection additional pathogen metagenomic , change antimicrobial prescribing 24 h testing , and initiation immunomodulation . finding : process 114 sample ( 1-5 day ) 74 patient ( 39 [ 53 % ] female and 35 [ 47 % ] male ) . 107 ( 94 % ) 114 sample pass quality control , 101 ( 94 % ) provide same-day preliminary result . bacteria be detect 45 ( 43 % ) 104 test specimen , fungal organism 17 ( 16 % ) 104 test specimen , and virus 28 ( 34 % ) 83 test specimen . sensitivity low respiratory tract sample 24 h be 97 % ( 95 % ci 87-100 ) bacteria , 89 % ( 65-99 ) fungus , and 89 % ( 71-98 ) virus , only one false positive bacteria . metagenomic identify 42 pathogen not detect other test 32 ( 30 % ) 107 sample . antimicrobial therapy be change metagenomic result 30 ( 28 % ) 107 sample : 22 ( 21 % ) be de-escalate and eight ( 7 % ) be escalate . metagenomic contribute initiation immunomodulation 15 ( 20 % ) 74 patient range inflammatory condition . pathogen clinical significance local infection control or national public health be find ten ( 14 % ) 74 patient , include three invasive group a streptococci , two parvovirus b19 , and one hiv-1 , measle virus , mycobacterium tuberculosis , neisseria meningitidis , and mycoplasma pneumoniae . interpretation : respiratory metagenomic icu patient show good performance and turnaround time , and diverse clinical and public health benefit . ability to inform personalise patient therapy and infectious disease surveillance need evaluation multicentre study . funding : none .",The Lancet. Microbe,01/10/2025
10.1016/j.xcrm.2025.102408,4-1bb(+ ) treg and inhibitory progenitor exhausted t cell confer resistance,"Cha J, Kim CG, Sim NS, Kim G, Son W, Kim D, Jung Y, Hong HJ, Lee HB, Kim J, Kim J, Yoon SO, Go S, Kim J, Seong E, Baek S, Kim KH, Hong MH, Koh YW, Lee I, Kim HR","predictor immune checkpoint inhibitor response cancer remain elusive . previous phase 2 neoadjuvant immunotherapy window-of-opportunity study , present single-cell rna and t cell receptor ( tcr ) sequence analysis 57 pre- and post-treatment tumor biopsy head and neck cancer patient treat durvalumab ( anti-pd-l1 ) alone or tremelimumab ( anti-ctla-4 ) , identify key cellular and molecular predictor immune checkpoint inhibitor ( ici ) response . malignant cell and neutrophil senescence promote ici response . cxcl13(+ ) exhausted t ( tex ) cell enhance response 4-1bb signal , anti-ctla-4 induce 4-1bb(+ ) regulatory t cell ( tregs ) restrict ici efficacy . oppose role 4-1bb different cellular context may explain limited benefit combinatorial immunotherapy observe clinical trial . identify two subset tumor-reactive progenitor tex ( tpex ): ici-responsive tpex1 and ici-resistant tpex2 , subset characterize klrb1 and il17r . balance tpex1 and tpex2 associate ici response multiple cancer , offer insight sustain response . study be register clinicaltrials.gov ( nct03737968 ) .",Cell reports. Medicine,03/10/2025
10.1016/S1470-2045(25)00409-7,first-line immunotherapy or chemotherapy braf plus mek,"Di Federico A, Wang K, Chen MF, Barsouk AA, Pagliaro A, Chen LN, Ogliari FR, Stockhammer P, Thawani R, Raslan S, Gariazzo E, Fusco F, Hambelton GM, Citarella F, Meyer D, Aldea M, De Giglio A, Alessi JV, Pecci F, Gelsomino F, Corassa M, Vokes NI, Wang X, de Biase D, Abu Rous F, Areesawangkit P, Elghawy O, Cortellini A, Metro G, Ferrara R, Awad MM, Pabani A, Murray JC, Cappuzzo F, Garassino MC, Dagogo-Jack I, Riely G, Grant M, Herzberg BO, Ardizzoni A, Planchard D, Johnson BE, Langer CJ, Offin M, Negrao MV, Ricciuti B","background : patient braf(v600e ) ( ie , val600glu)-mutate non-small-cell lung cancer ( nsclc ) can be treat braf and mitogen-activated protein kinase ( mek ) inhibitor , or immune checkpoint inhibitor ( ici ) or chemotherapy . aim to investigate initial systemic treatment should be prioritise population . method : retrospective cohort study conduct 17 centre usa , italy , france , and brazil , clinicopathological datum be collect participant age 18 year and old stage iv , treatment-naive , metastatic braf(v600e)-mutated nsclc and eastern cooperative oncology group performance status 0-3 , start first-line treatment ici or chemotherapy ( pd-1 or pd-l1 inhibitor or platinum-based chemotherapy ) or braf and mek inhibitor ( dabrafenib and trametinib or encorafenib and binimetinib ) jan 2 , 2015 , and july 11 , 2024 . primary endpoint be overall survival first-line ici or chemotherapy braf and mek inhibitor . finding : 284 participant be identify study , 88 ( 31 % ) receive ici or chemotherapy and 196 ( 69 % ) receive braf and mek inhibitor . median age participant be 68 year ( iqr 61-74 ) , and 148 ( 52 % ) participant be female and 136 ( 48 % ) male . participant ici or chemotherapy group have high history smoking ( 73 [ 83 % ] 118 [ 60 % ] ; p=0·0002 ) and high pd-l1 expression ( ≥50 % 58 [ 66 % ] 76 [ 39 % ] , 1-49 % 16 [ 18 % ] 67 [ 34 % ] , and < 1 % eight [ 9 % ] 31 [ 16 % ] ; p=0·0003 ) braf and mek inhibitor group . median follow-up time 45·0 month ( 95 % ci 39·0-55·7 ) , ici or chemotherapy be associate improved median overall survival compare braf and mek inhibitor ( 40·9 month [ 95 % ci 33·3-not reach ] 25·2 month [ 19·9-31·1 ] ; hazard ratio [ hr ] 0·69 [ 0·49-0·98 ] , p=0·039 ) . subgroup analysis , ici or chemotherapy , compare braf and mek inhibitor , be associate long median overall survival participant history smoking ( hr 0·60 [ 0·40-0·90 ] , p=0·013 ) , pd-l1 tumour proportion score ≥1 % or high ( hr 0·66 [ 0·45-0·98 ] , p=0·039 ) , age 70 year or old ( hr 0·54 [ 0·31-0·94 ] , p=0·029 ) , tp53 co-mutation ( hr 0·46 [ 0·27-0·79 ] , p=0·0048 ) , and brain metastasis ( hr 0·66 [ 0·45-0·99 ] , ) . braf and mek inhibitor , frequency adverse event grade and grade 3 and high be similar administer first-line therapy or second-line therapy follow ici or chemotherapy . interpretation : first-line ici or chemotherapy be associate improve overall survival compare braf and mek inhibitor participant metastatic braf(v600e)-mutated nsclc , particularly specific subpopulation . finding , suggest potential clinical relevance , remain exploratory and require confirmation prospective study . funding : nextgenerationeu .",The Lancet. Oncology,01/10/2025
10.1186/s12974-025-03552-x,cytokine expression profile human brain old adult .,"Godoy JB, Vialle RA, Dos Santos L, Raittz RT, Wang Y, Menon V, De Jager PL, Schneider JA, Tasaki S, Bennett DA, Guizelini D, de Paiva Lopes K","alzheimer 's disease ( ad ) be complex neurodegenerative condition link chronic neuroinflammation . study investigate cytokine gene expression profile cortical tissue sample elderly individual and ad to identify potential biomarker and enhance understanding disease pathogenesis . utilize high-depth rna sequence datum , identify set cytokine expression significantly associate different aspect ad phenotype , include measure neurofibrillary tangle , amyloid-β deposition , and person-specific rate cognitive decline . single-nucleus transcriptomic datum facilitate identification specific cell type , such microglia and astrocyte , significantly contribute inflammatory response ad . additionally , observe correlation expression certain cytokine and genetic risk disease . finding indicate cytokine-mediated neuroinflammation may play important role neurodegeneration and modulate immune response may offer promising strategy develop new therapy .",Journal of neuroinflammation,03/10/2025
10.2337/db25-0282,trem2 + macrophages alleviate renal tubule lipid accumulation and ferroptosis,"Wang X, Wan J, Wang C, Tong Y, Chen Y, Wang X, Liu J, Li Q, Dong Z, Hong Q, Sun X, Cai G, Ouyang Q, Chen X","presence macrophage surround lipotoxic tubular epithelial cell ( tecs ) be hallmark diabetic nephropathy ( dn ) . nevertheless , mechanism communication cell type be not well understand . previous study have reveal unique subset macrophage express trigger receptor express myeloid cell 2 ( trem2 ) kidney human patient and mouse dn . here , explore characteristic and function trem2 + macrophage progress dn . rna-sequencing macrophage kidney trem2 knockout ( ko ) mouse feed high-fat diet plus streptozotocin ( hfd/stz ) reveal functional enrichment metabolic process , cytokine production , positive regulation extracellular signal-regulated kinase ( erk ) cascade , and regulation phagocytosis . vivo study demonstrate trem2 + macrophage reduce lipid accumulation and mitigated ferroptosis tec diabetic mouse . mechanistically , trem2-deficient macrophage amplify production interleukin-1β ( il-1β ) activate erk signal pathway . furthermore , il-1β trigger cd36 expression transcription factor nf-κb . bioinformatics and functional assay show nf-κb bind cd36 promoter , directly bind promoter cd36 to facilitate transcription . inhibition nf-κb block",Diabetes,03/10/2025
10.52225/narra.v2i2.78,hepatitis e virus pig and environment : update review public health,"Ahmad T, Jin H, Dhama K, Yatoo MI, Tiwari R, Bilal M, Dhawan M, Emran TB, Alestad JH, Alhani HM, BinKhalaf HK, Rabaan AA","hepatitis e virus ( hev ) be important public health problem and be responsible both acute and chronic viral hepatitis . public health implication hev be derive transmission route , either water-borne or food-borne , and zoonotic potential . not only develop country , but hev case be also find high number develop country . spread hev environment might pollute surface water , could act source infection human and animal . identification virus animal product suggest circulation hev water and food chain . high seroprevalence and circulation hev livestock , particular pig , as well environmental sample warrant further investigation pig market . hev virulence different environment and meat supply chain could shed light possible source infection human and degree occupational risk . purpose review be to discuss hev infection emphasis livestock- and environment-related risk factor , and food-borne , water-borne , and zoonotic transmission .",Narra J,01/08/2022
10.1186/s12943-025-02458-9,microbiome-metabolome interplay pancreatic cancer progression : insight,"Luo D, Chen Q, Li Y, Yang J, Tao Y, Ji L, Gong X","background : recent study suggest intratumoral microbiome and alter metabolic network play crucial role pancreatic cancer ( pc ) progression . however , precise interplay microbial community and tumor metabolism pc remains poorly understand . study aim to investigate impact intratumoral microbiome , metabolic landscape , and interaction pc development . methods : 16s rdna sequence and untargeted metabolomic profiling be perform 47 pair pancreatic cancer and adjacent normal tissue to analyze intratumoral microbiome and metabolic landscape . bioinformatics tool be use to conduct differential microbiome abundance analysis and pathway enrichment . correlation analysis be perform to identify key microbiota-metabolite interaction . result : 16s rdna sequence reveal significant difference abundance and diversity ( α-diversity and β-diversity ) intratumoral microbiome pc . predominant specie pancreatic cancer be pseudomonas . enrichment analysis show amino acid metabolic pathway , include arginine and proline metabolism , arginine biosynthesis , be significantly enrich pc . untargeted metabolomic identify 298 metabolite be significantly alter pc ( fold change > 1 . 5 , p-value < 0 . 05 ) . include amino acid metabolite such lys-leu , pro-leu , arg-leu , lys-val , his-lys , and other . functional enrichment analysis highlight several metabolic pathway play important role pancreatic cancer , include glycine , serine , and threonine metabolism , amino acid biosynthesis , metabolic pathways and cysteine and methionine metabolism . correlation analysis microbiome and metabolic datum reveal significant association pseudomonas and several metabolite , include alpha-ketoisovaleric acid , 16-hydroxyhexadecanoic acid , myristic acid , nonanoic acid ( spearman correlation coefficient r , 0 . 5 ≤|r|≤ 1 and p-value < 0 . 05 ) . conclusion : study suggest relationship microbiome and metabolism pancreatic cancer . observe pseudomonas contribute alter amino acid metabolism , but interaction be causal and mechanism underlie remain unclear . far experimental validation be require consider microbiome-targeted metabolic intervention viable therapeutic strategy .",Molecular cancer,02/10/2025
10.1093/eurheartj/ehaf766,taurochenodeoxycholic acid alleviate obesity-induced endothelial dysfunction .,"Lu H, Wu Z, Wan M, Xiong S, Huang X, Liu T, Jiang X, He L, Ma C, Cui H, Yue X, Li J, Qin X, Wang Y, Zhang C, Yang J, Liu S, Zhang W","background and aims : obesity be global health challenge significantly increase cardiovascular disease ( cvd ) burden . effective prevention and treatment necessitate target early pathological change , particularly obesity-induced endothelial dysfunction ( ed ) . study aim to characterize ed heterogeneity non-hypertensive obese ( nho ) individual , investigate association serum metabolite obesity-induced ed , and identify potentially predictive and therapeutic metabolite . methods : utilize wire myograph , study assess ed ex vivo arteriole omental adipose tissue 213 nho patient , categorize metabolically healthy obesity ( mho ) and metabolically unhealthy obesity ( muo ) . targeted metabolomic profiling identify association serum metabolite and ed . result : obesity-induced ed nho patient lack correlation many traditional cardiovascular risk factor . mho and muo individual exhibit similar ed and metabolomic profile characteristic . serum metabolomic identify bile acid ( bas ) , particularly chenodeoxycholic acid ( cdca ) , negatively correlate ed nho patient . taurochenodeoxycholic acid ( tcdca ) , taurine-conjugated derivative cdca , protect obesity-induced ed and hypertension . mechanistically , endothelial farnesoid x receptor ( fxr ) deletion aggravate obesity-induced ed and hypertension , negate beneficial effect bariatric surgery or tcdca treatment . tcdca-fxr activation endothelial cell upregulate atf4 transcription , be suppress phb1 , thereby enhance serine and one-carbon metabolism . conclusion : study suggest cdca promising biomarker identification obesity-induced ed . taurochenodeoxycholic acid demonstrate significant therapeutic potential alleviate various form obesity-induced ed . effect be mediate endothelial tcdca-fxr-phb1-atf4 axis , upregulate serine and one-carbon metabolism , thereby offer novel strategy to delay onset hypertension and other cvd .",European heart journal,03/10/2025
10.1038/s41746-025-01976-6,current status and solution ai ethic ophthalmology : bibliometric,"Chen X, Yang Y, Yun D, Wang R, Lin Y, Luo M, Zhang W, Yu-Wai-Man P, Burton M, Liang L, Lin H","ophthalmology , early adopter medical artificial intelligence ( ai ) , have make significant advancement , but ethical discussion limit . bibliometric analysis review 498 publication web science and scopus ( 2000-2023 ) to explore evolution , status , thematic trend , data modality and ethical focus , and solution ophthalmic ai ethic . ophthalmology rank second medical ai ethic , major contributor united states ( us ) , china , united kingdom ( uk ) , singapore and india . ethical concern focus privacy , fairness , and transparency . ethical priority differ modality fundus imaging ( 59 . 4 % ) and optical coherence tomography ( oct ) ( 30 . 9 % ) most common . most study ( 78 . 3 % ) address ethic diagnostic algorithm development , only 11 . 5 % directly target ethical concern , focus be increase . study highlight need ai technology and guideline to address ethical challenge ophthalmology , offer future direction research and innovation medical ai governance .",NPJ digital medicine,02/10/2025
10.1016/j.redox.2025.103869,park7-driven igf2bp3-k76 lactylation mediate ferroptosis and haic resistance,"Zhu Z, Xia X, Lu Y, Li D, He X, Zhang B, Xiong G, Zhang W, Liang H, Zhu H","oxaliplatin/5-fluorouracil ( oxa/5-fu)-base hepatic artery infusion chemotherapy ( haic ) represent promising strategy advanced hepatocellular carcinoma ( hcc ) , yet acquire resistance frequently impede efficacy . here , identify lactylation igf2bp3 lysine 76 ( igf2bp3-k76lac ) key driver haic resistance . igf2bp3-k76lac overexpression enhance chemoresistance vitro and vivo . mechanistically , lactylation igf2bp3 k76 strengthen affinity m6a-modifie fsp1 mrna , upregulate fsp1 and confer ferroptosis resistance . block igf2bp3-k76lac bolster oxa/5-fu-induce ferroptosis , disrupt antioxidant defense , and curb tumor growth . moreover , park7 function lactyltransferase to facilitate igf2bp3-k76lac increase binding lactate igf2bp3-k76 site . finally , block antibody target igf2bp3-k76lac be show to work synergistically oxa/5-fu to restore chemosensitivity . take together , finding reveal critical role park7-igf2bp3-k76lac-fsp1 axis haic resistance , highlight igf2bp3-k76lac potential therapeutic target hcc .",Redox biology,26/09/2025
10.1126/sciimmunol.adu6730,vaccination-induced t cell response maintain polyclonality high antigen,"Kocher K, Drost F, Tesfaye AM, Moosmann C, Schülein C, Grotz M, D'Ippolito E, Graw F, Spriewald B, Busch DH, Bogdan C, Tenbusch M, Schubert B, Schober K","clonal expansion be hallmark adaptive immunity and have be challenge to investigate human standardized manner compare animal model . study cohort 29 healthy individual receive three mrna vaccination sars-cov-2 breakthrough infection . characterize magnitude , phenotype , and clonal composition cd8 t cell response 16 epitope specificity elispot ; flow cytometry ; and single-cell rna , protein , and t cell receptor ( tcr ) sequence . one hundred six tcr five epitope-specific repertoire be reexpresse and test peptide sensitivity . vaccination-recruited t cell repertoire be enrich high-avidity tcr , differential clonal expansion be not link fine avidity difference . instead , maintenance polyclonality ensure robustness counteract viral mutational escape altered epitope . decipher functionality human antigen-specific t cell repertoire instruct understanding human t cell biology and may guide development vaccine and other immunotherapy .",Science immunology,03/10/2025
10.3389/fnagi.2025.1617106,understanding parkinson 's disease : current trend and multifaceted,"Chaudhary SA, Chaudhary S, Rawat S","background : parkinson 's disease ( pd ) be multifactorial , progressive neurodegenerative disorder primarily affect dopaminergic neuron substantia nigra . addition hallmark motor symptom , manifest wide range nonmotor complication , include cognitive decline , neuropsychiatric symptom , autonomic dysfunction , and comorbid metabolic and infectious disease . objective : review aim to elucidate molecular and cellular mechanism underlie pd , explore influence genetic and environmental factor , evaluate current treatment limitation , and assess clinical and socioeconomic burden globally . emphasis be place emerge therapeutic avenue and innovative research direction . method : structured literature review be conduct use pubmed , scopus , and web science database . search include article publish 2010 and 2025 , use keyword : "" parkinson 's disease , "" "" α-synuclein , "" "" dopaminergic degeneration , "" "" ferroptosis , "" "" deep brain stimulation , "" "" stem cell therapy , "" and "" ai pd diagnosis . "" result : review highlight multifactorial etiology involve α-synuclein pathology , oxidative stress , mitochondrial dysfunction , genetic mutation ( snca , lrrk2 , vps35 ) , environmental toxin , and gut dysbiosis . comorbiditie such hiv , diabetes , and cardiovascular disorder exacerbate disease burden . levodopa remain gold standard , limitation necessitate combination therapy and adjunct modality such deep brain stimulation and nanocarrier-based drug delivery . emerge approaches-stem cell therapy , crispr-cas9 , and ai-enhance diagnostics-show promise . conclusion : pd management require paradigm shift precision medicine . advance research biomarker , immunotherapy , and system biology , couple equitable access care and early diagnosis tool , be critical mitigate global impact pd .",Frontiers in aging neuroscience,01/01/2025
10.1186/s12889-025-24558-3,association social isolation and loneliness incident cancer,"Liu X, Chen P, Wang J, Li Z, Zhu Y, Yang J, Wang L, He S, Sun X, Li J, Yang H","background : social isolation and loneliness pose significant public health challenge globally . study aim to examine association social isolation , loneliness and combined effect incident cancer . methods : study utilize datum uk biobank ( ukb ) , be population-based prospective cohort . social isolation and loneliness be assess self-reported questionnaire . cancer case be identify link cancer registry . result : total 430 , 376 participant be include , mean follow-up 14 . 32 year , 45 , 131 participant be diagnose cancer . compare participant least isolate group , most isolated group have significantly high risk cancer lip , oral cavity and pharynx ( hr 1 . 32 , 95 % ci 1 . 11-1 . 58 ) , cancer digestive organ ( hr 1 . 10 , 95 % ci 1 . 03-1 . 16 ) , cancer respiratory and intrathoracic organ ( hr 1 . 17 , 95 % ci 1 . 07-1 . 28 ) , breast cancer ( hr 1 . 11 , 95 % ci 1 . 04-1 . 18 ) , cancer female genital organ ( hr 1 . 23 , 95 % ci 1 . 09-1 . 38 ) , and cancer urinary tract ( hr 1 . 31 , 95 % ci 1 . 17-1 . 46 ) . however , most isolated group have low risk cancer mesothelial and soft tissue ( hr 0 . 80 , 95 % ci 0 . 64-0 . 99 ) , prostate cancer ( hr 0 . 88 , 95 % ci 0 . 83-0 . 94 ) . individual loneliness have significantly increase risk cancer urinary tract ( hr 1 . 19 , 95 % ci 1 . 01-1 . 40 ) , but reduced risk cancer skin ( hr 0 . 76 , 95 % ci 0 . 61-0 . 93 ) . conclusion : social isolation and loneliness be independently associate incident cancer , implication early effective cancer prevention .",BMC public health,01/10/2025
10.1038/s41586-025-09569-9,miniature crispr-cas10 enzyme confer immunity inhibitory signal .,"Doherty EE, Adler BA, Yoon PH, Hsieh K, Loi K, Armbruster EG, Lahiri A, Bolling CS, Wilcox XE, Akkati A, Iavarone AT, Pogliano J, Doudna JA","microbial and viral co-evolution have create immunity mechanism involve oligonucleotide signal share mechanistic feature human antiviral systems(1 ) . pathway , include cyclic oligonucleotide-based antiphage signal system ( cbass ) and type iii crispr system bacteria and cyclic",Nature,01/10/2025
10.1002/ijgo.70577,paracetamol ( acetaminophen ) use pregnancy and autism risk : evidence do,"Louwen F, Deuster E, McAuliffe FM, Jacobsson B, Geary M, Fleischman S, Kihara AB","recent political statement link paracetamol ( acetaminophen ) use pregnancy autism spectrum disorder have create concern patient and healthcare provider worldwide . editorial critically examine scientific evidence , highlight large and most methodologically rigorous population-based study employ sible control analysis demonstrate causal association prenatal paracetamol exposure and neurodevelopmental disorder . observational study have suggest potential weak association , finding likely reflect confound indication and familial genetic factor rather actual causal relationship . most robust evidence come swedish population-based study 2 . 48 million child , find increase risk control familial confounding . major international medical organization include acog , rcog , and figo , and regulatory agency include european medicines agency continue to recommend paracetamol safe analgesic option pregnancy clinically indicate . establish risk untreated pain and fever pregnancy significantly outweigh theoretical concern base methodologically limit study . healthcare provider should continue evidence-based counseling avoid unnecessary anxiety essential medication obstetric practice .",International journal of gynaecology and obstetrics: the official organ of the,30/09/2025
10.1038/s41591-025-03972-5,varicella-zoster virus reactivation and risk dementia .,"Polisky V, Littmann M, Triastcyn A, Horn M, Georgiou A, Widenmaier R, Anspach B, Tahrat H, Kumar S, Buser-Doepner C, Geldsetzer P, Van Duijn CM, Schwab P","varicella-zoster virus ( vzv ) be neurotropic virus establish lifelong latency human . vzv reactivation be associate wide range symptom , include herpe zoster ( hz ; also know shingle ) , and have be implicate development dementia , unknown extent . here present large-scale longitudinal analysis health record more 100 million individual united states demonstrate consistent relationship vzv reactivation dementia control nearly 400 measure characteristic ( cover demographic , socioeconomic factor , comorbiditie , medication , proxy healthcare-seeking behavior , shift clinical guideline and completeness record ) . find recurrent hz be associate increase risk dementia compare single hz episode . additionally , exposure hz vaccine be associate reduce risk dementia compare control 23-valent pneumococcal polysaccharide vaccine . furthermore , reduced risk dementia administration live-attenuated zoster vaccine wane time and be highly correlate waning vaccine-mediated protection hz . dementia risk reduction 3 and 5 year postexposure be also strong individual receive multiple oppose only one dose recombinant hz vaccine and great risk hz . finding strongly implicate vzv reactivation modifiable risk factor dementia .",Nature medicine,06/10/2025
10.1001/jamanetworkopen.2025.33512,use ai identification sexually transmitted infections and anogenital,"Soe NN, Kusnandar II, Latt PM, Fairley CK, Chow EPF, Maatouk I, Johnson CC, Shah P, Peters RPH, Subissi L, Zhang L, Ong JJ","importance : artificial intelligence ( ai ) excel dermatology . however , application sexually transmit infection ( sti ) remain unclear . objective : to assess performance ai algorithm and application detect sti and anogenital dermatosis clinical image sexual health . data source : six database ( ieee xplore , embase , scopus , medline , web science , and cinahl ) be search study publish january 1 , 2010 , april 12 , 2024 , use 3 main concept : artificial intelligence , diagnosis , and sexually transmit infection . study selection : study use ai to identify anogenital skin condition clinical image be include . study use non-ai approach or nonanogenital condition , as well review and study lack performance metric , be exclude . data extraction and synthesis : follow preferred reporting items systematic reviews and meta-analyses ( prisma ) guideline , 2 reviewer independently assess full-text article and extract datum use standardized spreadsheet . 2 reviewer resolve disagreement . modify quality assessment diagnostic accuracy studies ( quadas-2 ) critical appraisal tool and checklist evaluation image-based ai reports dermatology ( clear derm ) be use quality assessment . main outcomes and measures : pool sensitivity and specificity ai application detect anogenital skin condition . bivariate random-effect meta-analysis be conduct condition more 3 study . result : 5381 study screen and 258 full text select , 140 meet inclusion criterion . most study report mpox ( 110 [ 78 . 6 % ] ) , other anogenital condition , include genital herpe ( 7 [ 5 . 0 % ] ) , genital wart ( 8 [ 5 . 7 % ] ) , scabie ( 8 [ 5 . 7 % ] ) , and molluscum contagiosum ( 6 [ 4 . 3 % ] ) , receive less attention . meta-analyse show high performance ai identification mpox ( pool sensitivity : 0 . 96 [ 95 % ci , 0 . 93-0 . 97 ] ; pool specificity : 0 . 98 [ 95 % ci , 0 . 97-0 . 99 ] ) , herpe simplex ( sensitivity : 0 . 91 [ 95 % ci , 0 . 71-0 . 98 ] ; specificity : 0 . 97 [ 95 % ci , 0 . 94-0 . 98 ] ) , genital wart ( sensitivity : 0 . 87 [ 95 % ci , 0 . 67-0 . 96 ] ; specificity : 0 . 98 [ 95 % ci , 0 . 95-0 . 99 ] ) , psoriasis ( sensitivity : 0 . 90 [ 95 % ci , 0 . 78-0 . 95 ] ; specificity : 0 . 98 [ 95 % ci , 0 . 96-0 . 99 ] ) , and scabie ( sensitivity : 0 . 89 [ 95 % ci , 0 . 84-0 . 93 ] ; specificity : 0 . 98 [ 95 % ci , 0 . 95-0 . 99 ] ) . study quality be variable , and assessment identify high risk bias population selection ( 76 . 1 % ) , reference standard ( 76 . 1 % ) , and index test ( 20 . 0 % ) . most study rely open-source dataset ( 121 [ 86 . 4 % ] ) ; only 17 ( 12 . 1 % ) use external validation . but 1 study ( 0 . 7 % ) remain proof-of-concept stage , and model be not publicly available external evaluation . conclusion and relevance : finding suggest ai show promise identify sti and anogenital dermatosis but significant research gap exist . future work should prioritize understudied sti and differential condition improve datum quality , conduct external validation , and validate finding clinical setting .",JAMA network open,01/10/2025
10.1038/s41582-025-01142-2,parkinson disease be fatty acidopathy .,"Fanning S, Selkoe D","basis extensive mechanistic research three decade , parkinson disease ( pd ) and related synucleinopathie have be propose to be combine proteinopathie and lipidopathie . evidence strongly support physiological and pathogenic interplay disease-associated protein α-synuclein and lipid , demonstrable role lipid modulate pd phenotype brain . here , refine hypothesis propose pd to be disease specifically involve metabolic dysregulation fatty acid , ' fatty acidopathy ' . review extensive finding many laboratory support perspective pd centre fatty acid dyshomeostasis - alteration fatty acid-ome - critical feature lipid aberration pd and other α-synucleinopathie . construct place transient α-synuclein bind fatty acid side chain cytoplasmic vesicle principal contributor biology pd-relevant α-synuclein-membrane interaction . propose α-synuclein-fatty acid interaction fatty acid-rich brain be interdependent determinant gradual progression neuronal health to pd , attendant therapeutic implication .",Nature reviews. Neurology,01/10/2025
10.1016/j.xcrm.2025.102396,"update efficacy and predictive biomarker ql1706 , bifunctional pd-1/ctla-4","Ma Y, Lin S, Chen Q, Xue J, Yang Y, Zang A, Cheng Y, Zhang Y, Wang X, Chen Z, Qu S, He J, Chen C, Jin C, Zhu D, Li Q, Liu X, Su W, Ba Y, Li W, Li Q, Zhu C, Huang Z, Kang X, Xue S, Li H, Wang C, Luo F, Huang Y, Zhang L, Zhao H","ql1706 have show promise efficacy solid tumor phase 1/1b study . here , report update long-term survival outcome and biomarker analysis . 468 patient treat ql1706 ( 5 mg/kg ) , median progression-free survival ( mpfs ) and overall survival ( mos ) be 1 . 5 and 14 . 2 month non-small cell lung cancer ( nsclc ) , 1 . 9 and 20 . 2 month nasopharyngeal carcinoma ( npc ) , and 4 . 2 and 18 . 6 month cervical cancer ( cc ) , respectively . liver metastasis be correlate poor progression-free survival ( pfs ) and overall survival ( os ) nsclc and poor os cc , elevated lactate dehydrogenase be link short pfs and os npc . cdk4/11q13 diploid or expression gzmk(high ) & myc(low ) distinguish npc most favorable pfs . nsclc , pd-l1(+)/til(+ ) or low arg1 : cxcl13 ratio indicate well outcome . ql1706 offer long-term survival benefit solid tumor , identify molecular marker aid select suitable candidate . study have be register clinicaltrials.gov ( nct04296994 and nct05171790 ) .",Cell reports. Medicine,03/10/2025
10.1016/j.neuron.2025.09.007,"identification peptide vulnusin , wound signal mediate","Guo Y, Li T, Tuomivaara ST, Teo CF, Feng S, Chalkley RJ, Zhu R, Cheng T, Li KH, Chen W, Simon A, Jin P, Younger S, Yong AJH, Li K, Li K, Burlingame AL, Jan LY, Jan YN","animal can acutely sense puncture or cut skin nociceptor . however , molecular identity such "" wound signal "" and receptor nociceptor remain unknown . drosophila larvae , class iv dendritic arborization neuron be multimodal nociceptor detect harsh touch , heat , and uv light to initiate nociceptive behavior . here , identify vulnusin ( vulnus , latin word wound ) , endogenous peptide likely serve wound signal . vulnusin , derive larval epidermis , activate ppk1/ppk26 ion channel express endogenously nociceptor and heterologously drosophila s2 cell . moreover , vulnusin act together ppk1/ppk26 to trigger puncture-induced rolling behavior , response mechanical injury . finding establish vulnusin ligand activate larval nociceptor and mediate mechanical-injury-induced nociception .",Neuron,03/10/2025
10.1038/srep36943,murine hypothalamic destruction vascular cell apoptosis subsequent,"Aratani S, Fujita H, Kuroiwa Y, Usui C, Yokota S, Nakamura I, Nishioka K, Nakajima T","vaccination be most powerful way to prevent human being contract infectious disease include virus . case human papillomavirus ( hpv ) vaccine , unexpectedly novel disease entity , hpv vaccination associate neuro-immunopathetic syndrome ( hans ) , have be report and remain to be carefully verify . to elucidate mechanism hans , apply strategy similar active experimental autoimmune encephalitis ( eae ) model - one most popular animal model use to induce maximum immunological change central nervous system . surprisingly , mouse vaccinate pertussis toxin show neurological phenotype include low responsiveness tail reflex and locomotive mobility . pathological analysis reveal damage hypothalamus and circumventricular region third ventricle , and region contain apoptotic vascular endothelial cell . datum suggest",Scientific reports,11/11/2016
10.1001/jamapediatrics.2025.4091,reevaluate nonoperative management pediatric uncomplicated acute,"Faria I, Cintra ACG, de Oliveira LGAM, Squizzato F, Maia AS, Cunha AG, Radhakrishnan RS","importance : nonoperative management ( nom ) have emerge potential alternative surgery acute uncomplicated appendicitis child ; however , short-term outcome be often favorable , concern remain treatment durability , complication rate , and long-term failure . update meta-analysis randomize clinical trial ( rcts ) may help clarify comparative safety and effectiveness nom appendectomy . objective : to evaluate safety and effectiveness nom compare appendectomy uncomplicated appendicitis child use high level available evidence . data source : systematic review pubmed , embase , scopus , cochrane , and web science be conduct inception march 2025 to identify randomize clinical trial compare nom surgical management pediatric patient . study selection : rct compare nom surgical management pediatric patient young 18 year be include . nonrandomize and quasi-randomized study be exclude . data extraction and synthesis : datum be extract follow preferred reporting items systematic reviews and meta-analyses guideline . meta-analyses be conduct use random-effect model . risk bias be assess independently multiple reviewer . trial sequential analysis be perform to determine evidence be sufficiently robust and conclusive . main outcomes and measures : primary outcome be treatment failure and treatment success 1 year and major complication ( clavien-dindo grade ≥iiib ) . secondary outcome include time to return school and time to return normal activity . result : 1246 study screen , 7 rcts , include 1480 pediatric patient , meet inclusion criterion . treatment failure be significantly high nom group appendectomy group 1 year ( risk ratio [ rr ] , 4 . 97 ; 95 % ci , 3 . 57-6 . 91 ; i2 = 0.0 % ) . treatment success be significantly low nom group 1 year ( rr , 0 . 67 ; 95 % ci , 0 . 60-0 . 75 ; i2 = 31 . 1 % ) . major complication classify clavien-dindo grade iiib or bad be more frequent nom group ( rr , 33 . 37 ; 95 % ci , 7 . 89-141 . 05 ; i2 = 9 . 5 % ) . appendicitis recur rate 18 . 47 events/100 observation ( 95 % ci , 12 . 62-25 . 07 events/100 observation ; i2 = 48 . 5 % ) patient receive nom . nom , compare appendectomy , be associate modestly fast return school ( mean difference , -1 . 36 day ; 95 % ci , -2 . 64 -0 . 08 day ; p = .04 ; i2 = 57 . 7 % ) and return normal activity ( -4 . 93 day ; 95 % ci , -8 . 68 to -1 . 19 day ; p = .01 ; i2 = 87 . 2 % ) , may be offset subsequent readmission or reintervention . trial sequential analysis demonstrate robustness and conclusiveness primary outcome . conclusion and relevance : contrast early study , meta-analysis find significantly high treatment failure and major complication rate year nom child and adolescent . meta-analysis provide pediatrician and pediatric surgeon up-to-date datum to inform share decision-making family and encourage individualized , patient-centered treatment .",JAMA pediatrics,05/10/2025
10.1016/j.phrs.2025.107977,tdp-43 alzheimer 's disease : pathophysiology and therapeutic strategy .,"Zhou X, Lin X, He Y, Huang N, Luo Y","alzheimer 's disease ( ad ) be complex neurodegenerative disorder characterize dysregulation multiple molecular mechanism . recent year , transactive response dna-binde protein 43 kda ( tdp-43 ) have increasingly be recognize critical pathological protein and have become prominent focus ad research .",Pharmacological research,04/10/2025
10.1038/s41409-025-02729-5,comparison single-unit umbilical cord blood transplantation and haploidentical,"Yanada M, Yamasaki S, Mizuno S, Sugita J, Fujino T, Misaki Y, Tanaka M, Uchida N, Onizuka M, Doki N, Ota S, Sawa M, Kawakita T, Hasegawa Y, Nakamae H, Ishiwata K, Hiramoto N, Ishimaru F, Kanda J, Ohbiki M, Atsuta Y, Nakasone H, Konuma T","choose optimal alternative donor be important clinical concern allogeneic hematopoietic cell transplantation ( hct ) . japan , single-unit umbilical cord blood transplantation ( ucbt ) have be widely use last two decade , hct hla-haploidentical relate donor ( haplo-hct ) have be increasingly use follow advent posttransplant cyclophosphamide ( ptcy ) graft-versus-host disease ( gvhd ) prophylaxis . registry-based study aim to compare outcome single-unit ucbt ( n = 848 ) and ptcy-base haplo-hct ( n = 241 ) perform first complete remission patient acute myeloid leukemia . ucbt be associate low likelihood engraftment ( p < 0 . 001 ) , high risk grade 2-4 and grade 3-4 acute gvhd ( p = 0 . 003 ) , and low risk extensive chronic gvhd ( p = 0 . 048 ) . ucbt and haplo-hct group do not significantly differ 3-year probability overall survival ( 68 % 69 % , p = 0 . 686 ) , gvhd/relapse-free survival ( 55 % 54 % , p = 0 . 866 ) , relapse ( 14 % 16 % , p = 0 . 463 ) , and non-relapse mortality ( 21 % 19 % , p = 0 . 403 ) , respectively , be confirm multivariate analysis . result indicate procedure should be consider viable option patient lack match donor .",Bone marrow transplantation,05/10/2025
10.1001/jamaoncol.2025.3760,definition cure colon cancer : pooled analysis 15 randomized,"Pastorino A, Liu H, Pederson L, Martelli V, Iveson T, de Gramont A, Alberts SR, George TJ, Yothers G, Harkin A, Labianca R, Taieb J, Schmoll HJ, Twelves C, Wolmark N, Saltz LB, Souglakos I, Goldberg RM, Kerr R, Lonardi S, Yoshino T, Puccini A, André T, Shi Q, Sobrero A","importance : definition cure stage ii iii colon cancer ( cc ) remain unclear limitation conventional end point , include death and second primary tumor event . can complicate communication patient regard long-term outcome . objective : to distinguish relapse compete health-related event to classify long-term outcome year surgery and explore incidence true relapse initial cc approach 0 % to define cure disease . design , setting , and participant : pool analysis individual patient-level datum 15 phase 3 randomize clinical trial assess time cc-relate relapse use kaplan-mei and aalen-johansen method , death and second primary tumor treat compete risk . cox regression model evaluate prognostic association , stratify sex , stage , and tumor . patient stage ii iii cc undergo adjuvant chemotherapy be include . patient have undergo radical surgery cc and receive adjuvant chemotherapy median follow-up at least 6 year . adjuvant colon cancer endpoints ( accent ) and international duration evaluation adjuvant chemotherapy ( idea ) database include adjuvant study conduct 1996 and 2015 . datum be analyze february 2022 june 2025 . exposures : adjuvant chemotherapy regimen varied trial , include fluoropyrimidine alone or combination oxaliplatin or biologic agent . main outcomes and measures : primary outcome be time cc-relate recurrence . predefine threshold cure be recurrence risk 0 . 5 % . result : 35 213 include patient , 19 346 ( 54 . 9 % ) be male , and mean ( sd ) age be 60 . 2 ( 10 . 8) year . incidence rate recurrence peak 6 . 4 % ( 1993 31 373 ) month 6 and month 12 and decrease continuously year 10 follow-up never exceed 0 . 5 % . recurrence rate appear to increase again year 10 and peak 2 . 0 % year 12 . 5 to year 13 , pattern observe exclusively mosaic trial . competing-event analysis reveal death and second primary tumor inflate apparent recurrence rate , especially old patient . overall cumulative incidence relapse death compete risk be low female patient ( hazard ratio , 0 . 58 ; 95 % ci , 0 . 45-0 . 76 ; p < .001 ) . conclusions and relevance : pool analysis phase 3 randomize clinical trial , recurrence rate less 0 . 5 % occur 6 year surgery , support practical definition cure . recognize milestone may improve patient communication , guide follow-up duration , and reduce unnecessary long-term surveillance .",JAMA oncology,02/10/2025
10.1038/s43587-025-00968-1,zdhhc11-mediated palmitoylation alleviate chondrocyte senescence and serve,"Wang K, He W, Gong Z, Gao J, Gao T, Pan N, Wu D, Yang Y, Li Z, Zhao X, Ji M, Shen S","osteoarthritis ( oa ) be whole-joint disorder interfere quality life old individual . here report zdhhc11 be highly express articular chondrocyte but be downregulate degenerated cartilage aged mouse and patient oa . zdhhc11 prevent chondrocyte senescence and promote cartilage anabolism , culminate improved oa phenotype . deletion zdhhc11 mouse ( zdhhc11(fl/fl ) ) exacerbate oa progression destabilized medial meniscus model . specifically , identify zdhhc11 key palmitoyltransferase depletion lead gnb2-dependent e3 ubiquitin ligase-mediated proteasomal degradation apod . mechanistically , zdhhc11-mediated palmitoylation alleviate oa progression deactivate gata4-p65 signal pathway . also propose original lipid nanoparticle-based platform zdhhc11 mrna delivery to rejuvenate impair cartilage specifically target chondrocyte vivo . collectively , zdhhc11-dependent palmitoylation be essential ameliorate oa , and target delivery zdhhc11 may serve promising strategy future oa treatment .",Nature aging,30/09/2025
10.1155/2024/9526283,assessment meat content and foreign object detection cattle meatballs use,"Ulum MF, Maryani, Rahminiwati M, Choridah L, Setyawan NH, Ain K, Mukhaiyar U, Pamungkas FA, Jakaria, Garnadi AD","meat content and physically hazardous contaminant internal section meatball can not be detect naked eye or surface detector . study be aim analyze meat content cattle meatball and detect foreign object use ultrasonography ( usg ) , digital radiography ( dr ) , and electrical impedance tomography ( eit ) . meatball be produce use four different meat formulation ( 0 % , 25 % , 50 % , and 75 % meat ) and three treatment ( preservative ( control ) , borax , and formalin preservative ) . cast iron and plastic bead be use model foreign object embed sample . echogenicity , opacity , and resistivity value sample be evaluate and compare group . result show shelf life control meatball be short meatball preservative . echogenicity and opacity value different meat formulation be hypoechoic usg and grey dr . usg be able to distinguish control and preservative-treated meatball but could not differentiate meat content and detect foreign object . conversely , dr effectively assess meat content and detect iron-based foreign object , eit show high resistivity value iron and plastic bead compare meatball body .",International journal of food science,01/01/2024
10.1126/scitranslmed.adp3378,genetic and structural aspect amyloid disease .,"Rosenberg GM, Murray KA, Sawaya MR, Jiang YX, Geschwind DH, Eisenberg DS","conversion protein insoluble fibrillar aggregate know amyloid occur wide variety disease , e.g. , alzheimer 's disease , amyotrophic lateral sclerosis , systemic transthyretin amyloidosis , and multisystem atrophy . be more 60 disease-associated amyloid-forming protein , and amyloid formation can occur sporadically or can be induce or accelerate genetic mutation . review discuss structural mechanism genetic change promote amyloid formation and thereby influence disease outcome . divide amyloid-forming protein six type accord genetic mutation carry and analyze mutation-induced structural change amyloid fibril , well understanding inheritance pattern amyloid disease ( amyloidose ) can be obtain .",Science translational medicine,01/10/2025
10.1016/j.bcp.2025.117376,cancer-associated transporter : molecular driver and drug delivery gateway .,"Khan A, Biswas S, Garg M, Sengupta S","membrane transporter be critical regulator cellular homeostasis , mediate uptake and efflux nutrient , ion , and drug . cancer , expression be frequently reprogramme to support enhanced growth , survival , metabolic rewiring , invasiveness , and therapy resistance . several solute carrier ( slc ) transporter such glucose transporter ( glut ) , monocarboxylate transporter ( mcts ) , and sodium/iodine symporter ( nis ) also facilitate selective delivery radiopharmaceutical , make attractive therapeutic target . tumor suppressor p53 know central role genome stability and apoptosis , also regulate broad spectrum membrane transporter . however , oncogenic mutation or structural conversion amyloid can disrupt regulatory network , lead alter transporter expression and multidrug resistance . grow interest , transcriptional and post-transcriptional control transporter wt , mutant , and amyloid form p53 remain underexplored . review , systematically characterize p53-mediate regulation diverse transporter class involve transport sugar , amino acid , metal ion , lipid abc transporter function and multidrug resistance . highlight cancer cell exploit transporter such p-glycoprotein ( p-gp ) , lat1 , glut1 , mcts , and nis metabolic advantage and survival . also examine therapeutic strategy aim modulate transporter function use crispr/cas9 , small-molecule inhibitor , sirna , and nanoparticle-based co-delivery system . particular , lat1 inhibition demonstrate potential to starve tumor essential nutrient . ultimately , propose dual targeting p53 aberration and membrane transporter synthetic biology and precision delivery approach could restore chemosensitivity and suppress tumor progression , offer promise avenue personalized cancer therapy .",Biochemical pharmacology,02/10/2025
10.1038/s41586-025-09580-0,track clonal evolution treatment ovarian cancer use cell-free dna .,"Williams MJ, Vázquez-García I, Tam G, Wu M, Varice N, Havasov E, Shi H, Al-Rawi DH, Satas G, Lees HJ, Lee JJ, Myers MA, Zatzman M, Rusk N, Ali E, Shah RH, Berger MF, Mohibullah N, Lakhman Y, Chi DS, Abu-Rustum NR, Aghajanian C, McPherson A, Zamarin D, Loomis B, Weigelt B, Friedman CF, Shah SP","emergence drug resistance be main cause therapeutic failure patient high-grade serous ovarian cancer ( hgsoc)(1 ) . to study drug resistance patient , develop cloneseq-sv , combine single-cell whole-genome sequencing(2 ) target deep sequencing clone-specific genomic structural variant time-series cell-free dna . cloneseq-sv exploit tumour clone-specific structural variant highly sensitive endogenous cell-free dna marker , enable relative abundance measurement and evolutionary analysis co-existe clonal population therapeutic time course . here , use approach , study 18 patient hgsoc multi-year period diagnosis to recurrence and show drug resistance typically arise selective expansion single or small subset clone present diagnosis . drug-resistant clone frequently show interpretable and distinctive genomic feature , include chromothripsis , whole-genome doubling , and high-level amplification oncogene such ccne1 , rab25 , myc and notch3 . phenotypic analysis match single-cell rna sequence data(3 ) indicate pre-existing and clone-specific transcriptional state such upregulation epithelial-to-mesenchymal transition and vegf pathway , link drug resistance . one notable case , clone-specific erbb2 amplification affect efficacy secondary target therapy positive patient outcome . together , finding indicate drug-resistant state hgsoc pre-exist diagnosis , lead positive selection and reduce clonal complexity relapse . suggest finding motivate investigation evolution-informed adaptive treatment regimen to ablate drug resistance future hgsoc study .",Nature,01/10/2025
10.1186/s12943-025-02439-y,p23 act negative regulator ferroptosis nsclc block gpx4,"Chen J, Peng Y, Zhou M, Che Y, Zhao S, He C, Zhang W, Tian X, Zhang W, Liu Z, Zhou M, Liang G, Huo X, Wang Y, Yu Z, Ma X","ferroptosis have be identify tumor-inhibiting event variety cancer ; however , molecular basis non-small cell lung cancer ( nsclc ) have not be completely elucidated . notably , glutathione peroxidase 4 ( gpx4 ) play crucial role ferroptosis . previous research reveal prostaglandin e synthase 3 ( p23 ) , potential transcription factor , play crucial role promote cancer progression and metastasis succinylation . study reveal previously unknown antiferroptotic function p23 . mechanistically , p23 stabilize gpx4 competitively bind heat shock cognate 71 kda protein ( hsc70 ) to suppress chaperone-mediated autophagy ( cma ) activity , subsequently inhibit ferroptosis and accelerate tumor growth . notably , impair p23 succinylation disrupt interaction hsc70 , restore",Molecular cancer,02/10/2025
10.1016/j.ccell.2025.09.005,distinct t cell function enable efficient immunoediting and prevent tumor,"Cheung JF, Hunt BG, Wahed S, Cheng E, Connolly KA, Venkatesan S, Loza JL, Bansal I, Fagerberg E, Kessler EA, Riffard C, Buck J, Attanasio J, Borr ER, Wei W, William I, Fitzgerald B, Joshi NS","t cell edit tumor eliminate neoantigen-expressing tumor cell . yet , and be achieve remain uncertain . use murine sarcoma model fluorescent neoantigen , find tumor develop later and few t cell-sufficient mouse ( ∼53 % penetrance ) t cell-deficient mouse ( ∼100 % ) . t cell , emergent tumor cell have silence neoantigen , but neoantigen-negative tumor cell be also present t cell-deficient mouse . suggest silence be necessary but not sufficient outgrowth . genetic removal neoantigen restore tumor penetrance implement day 5 post-tumor initiation , but not day 10 , cd8(+ ) and cd4(+ ) t cell infiltrate tissue and eliminate most neoantigen-positive and -negative tumor cell 8 day . single-cell analysis day-7 tumor show oncogenic change include increase proliferation and t cell-dependent upregulation ifnγ-response gene cd274 ( pd-l1 ) . t cell-depletion rescue neoantigen-positive and -negative cell , ifnγ blockade rescue only negative cell . show t cell efficiently edit sarcoma neoantigen and prevent early tumor ifnγ-independent and ifnγ-dependent ( bystander ) mechanism .",Cancer cell,02/10/2025
10.1158/2159-8290.CD-25-0947,epigenetic regulation chromosomal instability ezh2 methyltransferase .,"Bai Y, Agustinus AS, Yomtoubian S, Meydan C, McNally DR, Yoffe L, Hubisz MJ, Tranquille M, Pramod S, Hong C, Plasilova ML, Kapoor AR, Singh A, Withers H, Dow LE, Laughney AM, Bhinder B, Elemento O, Melnick AM, Bakhoum SF, Mittal V","chromosomal instability ( cin ) and epigenetic reprogramming be central driver breast cancer progression , yet mechanism connect remain elusive . uncover direct role ezh2 histone methyltransferase promote cin triple-negative breast cancer ( tnbc ) . breast cancer , ezh2 expression correlate copy number alteration , and catalytic activity be associate increase cin metastasis-initiating cell . pharmacological ezh2 inhibition suppress cin , reveal unexpected vulnerability . integrate chromatin and transcriptome profiling identify tankyrase ( tnks ) , poly(adp-ribose ) polymerase , direct transcriptional target ezh2 . mechanistically , ezh2-mediated tnks suppression disrupt cpap ( centrosomal p4 . 1-associated protein ) , drive centrosome overduplication , multipolar mitosis and exacerbate cin . vivo , cin suppression be critical mechanism underlie anti-metastatic effect ezh2 inhibition . finding delineate previously unrecognized epigenetic mechanism govern cin and establish ezh2 inhibitor first therapeutic agent capable directly suppress cin , underscore need trial metastasis-focused endpoint .",Cancer discovery,02/10/2025
10.1186/s13098-025-01947-7,c-reactive protein-triglyceride glucose index predict mortality,"Ying Q, He F, Wu L, Wei Q, Xu J","background : cardiovascular-kidney-metabolic ( ckm ) syndrome be define interplay metabolic risk factor , chronic kidney disease , and cardiovascular disease . c-reactive protein-triglyceride glucose index ( cti ) be composite biomarker reflect inflammation and insulin resistance , but be associate mortality person early-stage ckm syndrome be unknown . method : analyze datum national health and nutrition examination survey 1999 2010 . use multivariable cox proportional-hazards model to assess association cti score and risk all-cause mortality and cardiovascular disease ( cvd ) mortality , vital status ascertain linkage national death index december 31 , 2019 . result : 10 , 718 participant , total 1783 death ( 491 cvd ) occur mean follow-up 14 . 0 year . fully adjust model , high cti score be associate great risk all-cause mortality ( hr unit increase , 1 . 56 ; 95 % ci , 1 . 36 to 1 . 78 ) and cvd mortality ( hr unit increase , 2 . 03 ; 95 % ci , 1 . 49 to 2 . 77 ) . association all-cause mortality be strong participant age 60 60 year old ( p < 0 . 001 interaction ) . conclusion : study find patient early-stage ckm syndrome , high cti be independently associate increase risk all-cause mortality and cvd mortality . association be more significant young participant .",Diabetology & metabolic syndrome,03/10/2025
10.1186/s12985-025-02928-y,human endogenous retrovirus ervk3-1 characterize metabolically active and,"Wen X, Weng S, Chen M, Lin D, Xue W, Zeng D, Shen J","background : human endogenous retrovirus ( herv ) , particularly herv-k family , be increasingly recognize role cancer biology , yet function ervk3-1 ( hervk_3p21 . 31 ) liver hepatocellular carcinoma ( lihc ) remain largely unexplored . method : analyze transcriptomic datum",Virology journal,01/10/2025
10.1016/j.jhep.2025.08.020,multicenter phase ii trial lenvatinib patient advanced hepatocellular,"Kim HD, Sym SJ, Chon HJ, Kim M, Kang JH, Ryoo BY, Lee CK, Hong J, Ryu H, Bae WK, Kim H, Kim H, Kim JW, Kim TY, Yoo C","background & aims : atezolizumab plus bevacizumab ( atezo-bev ) be global standard first-line therapy unresectable hepatocellular carcinoma ( uhcc ) . however , most patient eventually experience disease progression and optimal second-line strategy atezo-bev failure remain unclear . prospective evidence support multikinase inhibitor context be limited . method : investigator-initiated , multicenter , single-arm study ( kcsg hb23-04 ) enrol 50 patient uhcc progress first-line atezo-bev 13 site august 2023 and may 2024 . patient receive second-line lenvatinib 12 mg or 8 mg daily , depend body weight , disease progression or unacceptable toxicity . primary endpoint be progression-free survival . secondary endpoint be overall survival , objective response rate , disease control rate , duration response , and safety . result : 50 patient enrol , median age be 66 year , and 72 % have viral etiology . median time progression atezo-bev be 6 . 5 month . median follow-up 12 . 6 month , median progression-free survival be 5 . 4 month ( 95 % ci 4 . 2-7 . 1 ) ( > 4 . 5 month ) , meet prespecified primary endpoint . median overall survival be 9 . 8 month ( 95 % ci 8 . 1-nr ) . objective response rate be 14 . 0 % , and disease control rate be 82 . 0 % . median duration response be 9 . 4 month . survival outcome be different accord objective response lenvatinib , but not time progression atezo-bev or hcc etiology . most common adverse event be diarrhea ( 42 . 0 % ) , hypothyroidism ( 32 . 0 % ) , and anorexia ( 30 . 0 % ) . grade ≥3 adverse event occur 46 . 0 % patient . conclusion : lenvatinib demonstrate promise efficacy and manageable safety profile second-line treatment patient hcc progressing atezo-bev . finding offer prospective evidence support lenvatinib viable treatment option post-atezo-bev context . impact and implication : study provide first prospective evidence use lenvatinib second-line therapy patient unresectable hepatocellular carcinoma have progress first-line atezo-bev treatment . finding highlight potential lenvatinib viable therapeutic option clinical setting few alternative be available . result be particularly important healthcare professional manage unresectable hepatocellular carcinoma , provide robust framework consider lenvatinib second-line treatment protocol . give manageable safety profile , finding could be translate practical recommendation clinical practice , offer physician treatment strategy to improve patient outcome follow atezo-bev failure guide future research combination therapy and broad patient population . clinical trial number : nct06138769 .",Journal of hepatology,04/09/2025
10.1007/s13577-025-01294-9,elucidate risk factor and oncogene driver acute myeloid leukemia .,"Sanya DRA, Onésime D","hematopoietic system be critical maintain physiological homeostasis but be also implicate various pathology . magnitude hematopoietic response perturbation or disease exhibit significant inter-individual variability , underscore need to identify predictor and determinant blood responsiveness human . reaction be shape not only genetic factor but also epigenetic modification and environmental effect . elucidate baseline predictor hematopoietic response and molecular underpinning be particular interest acute myeloid leukemia ( aml ) , give potential to inform malignancy immunotherapy . limited understanding cellular and molecular mechanism drive diverse aml subtype pediatric and adult patient , couple increase prevalence refractory or relapse hematological malignancy , review highlight underexplored prognostic biomarker , molecular mechanism , and potential clinical utility optimize therapeutic strategy improved patient survival . examine recent advance aml research and vaccine development , focus effort to address highly aggressive and rare aml subtype drive aberrantly activate transcription factor . review also address clinical implication overall survival and treatment response , as well promising vaccine candidate . additionally , highlight newly identify mutation and high-risk molecular marker could enhance risk stratification early disease progression , identify patient may benefit allogeneic stem cell transplantation or enrollment clinical trial .",Human cell,04/10/2025
10.1016/S1470-2045(25)00345-6,assess pathological response neoadjuvant therapy renal cell carcinoma :,"Blackmur JP, van der Mijn JCK, Warren AY, Browning L, Burgers F, Hirsch MS, Kapur P, Mehra R, Rao P, Signoretti S, Bex A, Stewart GD, van Montfoort ML, Jones JO","pathological response be surrogate marker efficacy neoadjuvant therapy various tumour type , but be consensus report pathological response renal cell carcinoma . aim to assess status pathological response report renal cell carcinoma and develop recommendation tissue preparation and response report neoadjuvant treatment . conduct systematic review publication pubmed and web science database to identify manuscript reporting response pre-surgical therapy renal cell carcinoma . 119 eligible paper be identify . only five ( 4 % ) study include detail pathological response have be assess . qualitative statement residual tumour be common ( 55 [ 46 % ] study ) , but only eight ( 7 % ) study use quantitative assessment pathological response . guideline tissue preparation and pathological response reporting be review international workshop hold netherlands cancer institute october , 2024 , and far develop expert discussion . to assess neoadjuvant pathological response , nephrectomy specimen should be sample use standardise baseline approach consideration more extensive sampling . microscopic assessment should quantify residual viable tumour 10 % interval and great linear extent . clinical detail , include neoadjuvant therapy receive , should accompany pathological assessment . systematic review , describe standardised method assessment and report pathological response , initially intend use clinical trial or research setting . guideline will help investigator to assess degree pathological response be link survival outcome and will inform future standard reporting practice .",The Lancet. Oncology,01/10/2025
10.1038/s41571-025-01075-1,optimize car t cell therapy solid tumour : clinical perspective .,"Li J, Liu C, Zhang P, Shen L, Qi C","chimeric antigen receptor ( car ) t cell therapy be revolutionize management haematological malignancy but face particular hurdle treatment solid tumour . review , discuss important advance refine car t cell therapy to provide practical clinical insight to address challenge . describe key strategy , include target antigen selection to enhance efficacy minimize on-target , off-tumour toxicity ; early apheresis , rapid manufacturing and frontline application to preserve t cell fitness and ensure timely treatment ; lymphodepletion to augment car t cell expansion ; locoregional delivery to maximize local therapeutic concentration and reduce systemic toxicity ; and repeat infusion to prolong therapeutic effect . furthermore , discuss advanced response evaluation framework will be essential accurate assessment efficacy car t cell therapy , and highlight need robust toxicity management approach to mitigate severe adverse event . systematically address multifaceted challenge , review provide comprehensive guide optimization car t cell therapy solid tumour to enhance efficacy and safety .",Nature reviews. Clinical oncology,02/10/2025
10.1002/ajh.70099,"clinical characteristics , treatment responses and outcome light chain","Bolarinwa A, Zanwar S, Abdallah N, Buadi FK, Hayman SR, Gertz MA, Dispenzieri A, Muchtar E, Kapoor P, Gonsalves W, Kourelis T, Dingli D, Warsame R, Leung N, Cook J, Binder M, Lin Y, Hwa Y, Rogers MG, Hobbs M, Fonder A, Jevremovic D, Rajkumar SV, Kumar SK","light chain multiple myeloma ( lcmm ) be subtype multiple myeloma ( mm ) characterize exclusive production immunoglobulin light chain and account 15%-20 % newly diagnose mm . comprehensive comparison lcmm mm produce intact immunoglobulin ( non-lcmm ) remain limited . retrospective study , describe distinct clinical and cytogenetic feature and assess long-term outcome 852 lcmm patient diagnose 01/01/2004 and 12/31/2022 , compare non-lcmm control match age , sex , and year diagnosis . univariable analysis , lcmm patient be more likely to present elevated creatinine ( > 2 mg/dl ) , beta-2-microglobulin ≥ 5 . 5 mg/l , elevated ldh , hypercalcemia , t(11 ; 14 ) , del(13q ) , and t(6 ; 14 ) . conversely , ims-imwg high-risk disease , hyperdiploidy , t(4 ; 14 ) , and serum albumin < 3 . 5 g/dl be less common . multivariable analysis , elevated creatinine ( or : 5 . 1 , 95 % ci : 1 . 2-27 , p = 0 . 04 ) , t(11 ; 14 ) ( or : 2 . 6 , 95 % ci : 1 . 3-5 . 2 , p = 0 . 006 ) , and del(13q ) ( or : 4 . 1 , 95 % ci : 2 . 1-8 . 2 , p < 0 . 001 ) be independently associate lcmm ,",American journal of hematology,04/10/2025
10.1038/s41467-025-63865-6,pathogenic variant reveal candidate gene prostate cancer germline testing,"Gheybi K, Soh PXY, Jiang J, Mbeki TMN, Louw M, Burns D, Mundra P, Kiriy D, Hasan MM, Jaratlerdsiri W, Lebelo MT, Campbell RA, Radzuma MB, Nenzhelele M, Obida M, Obida M, Ombuki WM, Oyaro MO, Patrick SM, Loda M, Wedge DC, Bristow RG, Brewer DS, Cooper CS, Reimand J, Cancel-Tassin G, Cussenot O, Hovens CM, Cocoran NM, Stricker PD, Schlomm T, Prins GS, Sørensen KD, Weischenfeldt J, Mutambirwa SBA, Ngugi PM, Thomas DM, Kote-Jarai Z, Eeles RA, Bornman MSR, Hayes VM","prostate cancer ( pca ) germline testing , gain momentum , be ancestry restrictive and african exclusive . whole genome sequence 217 african ancestral case ( 186 southern african , 31 pan representative ) , identify 172 potentially pathogenic variant 78 dna damage repair or pca related gene . prevalence report ( 13/217 , 5 . 99 % ) and cumulative predict ( 24/217 , 11 . 06 % ) variant significance ( 11 gene ) fall report non-african . conversely , brca1 , hoxb13 , cdk12 , mlh1 , msh2 , and brip1 remain unimpacted . pathogenic ranking base variant frequency and functionality , clinical presentation and tumour-matched biallelic inactivation , top-ranked candidate include prex2 , pole , fat1 , brca2 , polq , lrp1b and atm . notable impact dna polymerase , include polg , fanconi anaemia gene include fancd2 , fanca , fancg , ercc4 , fance and fanci , dna mismatch repair gene msh3 and pms1 outrank know namesake msh6 and pms2 . study provide insight spectrum african-relevant potentially pathogenic pca variant , highlight much-needed gene candidate ancestry-inclusive germline testing .",Nature communications,02/10/2025
10.1038/s41380-025-03273-w,"classification major depressive disorder use vertex-wise brain sulcal depth ,","Goya-Maldonado R, Erwin-Grabner T, Zeng LL, Ching CRK, Aleman A, Amod AR, Basgoze Z, Benedetti F, Besteher B, Brosch K, Bülow R, Colle R, Connolly CG, Corruble E, Couvy-Duchesne B, Cullen K, Dannlowski U, Davey CG, Dols A, Ernsting J, Evans JW, Fisch L, Fuentes-Claramonte P, Gonul AS, Gotlib IH, Grabe HJ, Groenewold NA, Grotegerd D, Hahn T, Hamilton JP, Han LKM, Harrison BJ, Ho TC, Jahanshad N, Jamieson AJ, Karuk A, Kircher T, Klimes-Dougan B, Koopowitz SM, Lancaster T, Leenings R, Li M, Linden DEJ, MacMaster FP, Mehler DMA, Meinert S, Melloni E, Mueller BA, Mwangi B, Nenadić I, Ojha A, Okamoto Y, Oudega ML, Penninx BWJH, Poletti S, Pomarol-Clotet E, Portella MJ, Radua J, Rodríguez-Cano E, Sacchet MD, Salvador R, Schrantee A, Sim K, Soares JC, Solanes A, Stein DJ, Stein F, Stolicyn A, Thomopoulos SI, Toenders YJ, Uyar-Demir A, Vieta E, Vives-Gilabert Y, Völzke H, Walter M, Whalley HC, Whittle S, Winter N, Wittfeld K, Wright MJ, Wu MJ, Yang TT, Zarate C, Veltman DJ, Schmaal L, Thompson PM","major depressive disorder ( mdd ) be complex psychiatric disorder affect life hundred million individual globe . even today , researcher debate morphological alteration brain be link mdd , likely heterogeneity disorder . application deep learning tool neuroimage datum , capable capture complex non-linear pattern , have potential to provide diagnostic and predictive biomarker mdd . however , previous attempt to demarcate mdd patient and healthy control ( hc ) base segment cortical feature linear machine learning approach have report low accuracy . study , use globally representative datum enigma-mdd working group contain 7012 participant 31 site ( n = 2772 mdd and n = 4240 hc ) , allow comprehensive analysis generalizable result . base hypothesis integration vertex-wise cortical feature can improve classification performance , evaluate classification densenet and support vector machine ( svm ) , expectation former would outperform latter . analyze multi-site sample , additionally apply combat harmonization tool to remove potential nuisance effect site . find classifier exhibit close chance performance ( balanced accuracy densenet : 51 % ; svm : 53 % ) , estimate unseen site . slightly high classification performance ( balanced accuracy densenet : 58 % ; svm : 55 % ) be find cross-validation fold contain subject site , indicate site effect . conclusion , integration vertex-wise morphometric feature and use non-linear classifier do not lead differentiability mdd and hc . result support notion mdd classification combination feature and classifier be unfeasible . future study be need to determine more sophisticated integration information other mri modality such fmri and dwi will lead high performance diagnostic task .",Molecular psychiatry,03/10/2025
10.1186/s12933-025-02915-1,real-world cardiovascular effectiveness sustained glucagon-like peptide 1,"Sørensen KK, Yazdanfard PDW, Zareini B, Pedersen-Bjergaard U, Kosjerina V, Andersen MP, Munch A, Ohlendorff JS, Schmid S, Lanzinger S, Choudhary P, Gillies C, Gharibzadeh S, Lind M, Tasselius V, Michelsen J, Gerds TA, Torp-Pedersen C","background : cardiovascular outcome trial have show glucagon-like peptide 1 receptor agonist ( glp1-ras ) reduce cardiovascular event rate more effectively placebo and patient type 2 diabete increase cardiovascular risk . however , generalizability finding real-world setting remain uncertain . aim : study aim to evaluate real-world cardiovascular effectiveness sustained glp1-ra use compare dipeptidyl peptidase 4 inhibitor ( dpp-4i ) 3 . 5 year . methods : use danish nationwide registry , emulate target trial to assess real-world effectiveness glp1-ras population individual type 2 diabete mirror inclusion and exclusion criterion liraglutide effect and action diabetes : evaluation cardiovascular outcome result ( leader ) trial . study period be 2012-2022 . outcomes include composite myocardial infarction , stroke , and cardiovascular mortality ( 3p-mace ) , as well component individually , all-cause mortality , heart failure , angina pectoris , and revascularization . longitudinal target minimum loss-based estimation , method adjust baseline and time-varying confounding , be use to estimate absolute risk cardiovascular outcome sustained use glp1-ra and dpp 4i ( active comparator ) , adjust baseline and time-varying confound . result : include 6 , 681 people initiate glp1-ra and 19 , 072 initiate",Cardiovascular diabetology,06/10/2025
10.1016/j.tibs.2025.09.001,mitochondrial dynamic and pore formation regulate cell death pathway .,"Hohorst L, Ros U, Garcia-Saez AJ","mitochondria act central hub cell death signal . apoptosis and regulated necrosis ( pyroptosis , necroptosis , and ferroptosis ) , mitochondria undergo drastic change include membrane permeabilization , fragmentation , and loss membrane potential . however , dissection mechanism underlie process be challenging involve remodel mitochondrial membrane couple assembly protein complex dynamic be difficult to capture . discuss progress understanding mitochondrial alteration cell death and highlight state-of-the-art experimental approach to study . focus advanced single-molecule and correlative microscopy method have recently provide unprecedented detail dynamic and structure protein complex mitochondria and impact membrane organization .",Trends in biochemical sciences,02/10/2025
10.1371/journal.pone.0127045,alternate hemiplegia childhood : retrospective genetic study and,"Viollet L, Glusman G, Murphy KJ, Newcomb TM, Reyna SP, Sweney M, Nelson B, Andermann F, Andermann E, Acsadi G, Barbano RL, Brown C, Brunkow ME, Chugani HT, Cheyette SR, Collins A, DeBrosse SD, Galas D, Friedman J, Hood L, Huff C, Jorde LB, King MD, LaSalle B, Leventer RJ, Lewelt AJ, Massart MB, Mérida MR 2nd, Ptáček LJ, Roach JC, Rust RS, Renault F, Sanger TD, Sotero de Menezes MA, Tennyson R, Uldall P, Zhang Y, Zupanc M, Xin W, Silver K, Swoboda KJ","mutation atp1a3 alternate hemiplegia childhood ( ahc ) disrupt function neuronal na+/k+ atpase . publish study date indicate 2 recurrent mutation , d801n and e815 k , and more severe phenotype e815 k cohort . perform mutation analysis and retrospective genotype-phenotype correlation eligible patient ahc enrol us ahc foundation registry 1997-2012 . clinical datum be abstract standardized caregiver ' questionnaire and medical record and confirm expert clinician . identify atp1a3 mutation sanger and whole genome sequencing , and compare phenotype and 4 group subject , d801n , e815 k , other atp1a3 or atp1a3 mutation . identify heterozygous atp1a3 mutation 154 187 ( 82 % ) ahc patient . 34 unique mutation , 31 ( 91 % ) be missense , and 16 ( 47 % ) have not be previously report . concordant prior study , more 2/3 mutation be clusteredin exon 17 and 18 . 143 simplex occurrence , 58 have d801n ( 40 % ) , 38 have e815k(26 % ) and 11 have g947r ( 8 % ) mutation [ corrected] . patient e815 k mutation demonstrate early age onset , more severe motor impairment and high prevalence status epilepticus . study far expand number and spectrum atp1a3 mutation associate ahc and confirm more deleterious effect e815 k mutation select neurologic outcome . however , complexity disorder and extensive phenotypic variability subgroup merit caution and emphasize need further study .",PloS one,01/01/2015
10.1038/s41591-025-03918-x,genomically match therapy advanced solid tumor : randomized phase 2 rome,"Marchetti P, Curigliano G, Biffoni M, Lonardi S, Scagnoli S, Fornaro L, Guarneri V, De Giorgi U, Ascierto PA, Blandino G, D'Amati G, Aglietta M, Cremolini C, Conte P, Crimini E, Ceracchi M, Pisegna S, Verkhovskaia S, Bordonaro R, Bracarda S, Butturini G, Del Mastro L, DeCensi A, Fabbri A, Fenocchio E, Gori S, Metro G, Pessino A, Pozzessere D, Puglisi F, Tamberi S, Zambelli A, Marino D, Capoluongo E, Cappuzzo F, Cerbelli B, Giannini G, Malapelle U, Mazzuca F, Nuti M, Pruneri G, Simmaco M, Strigari L, Tonini G, Martini N, Botticelli A","recent advancement demonstrate potential tumor-agnostic biomarker to guide effective therapy , randomize evidence support clinical superiority precision oncology approach compare standard therapy remain limited . rome trial be multicenter , randomize , open-label phase 2 study compare tailor treatment ( tt ) standard care ( soc ) patient advanced solid tumor progress one or two line therapy . comprehensive genomic profiling tissue and blood be perform to identify actionable alteration . overall response rate ( orr ) be primary endpoint , and progression-free survival ( pfs ) , overall survival ( os ) , time treatment failure ( ttf ) , time next treatment ( ttnt ) and safety be secondary endpoint . november 2020 and august 2023 , 1 , 794 patient be screen , 897 be evaluate molecular tumor board ( mtb ) and 400 be randomize tt or soc . tt achieve significantly high orr ( 17 . 5 % 10 % ; p = 0 . 0294 ) and improve median pfs ( 3 . 5 month 2 . 8 month ; hazard ratio = 0 . 66 ( 0 . 53-0 . 82 ) , p = 0 . 0002 ) . tt also show superior 12-month pfs rate ( 22 . 0 % 8 . 3 % ) . median os be similar , 52 % crossover rate . grade 3/4 adverse event be also similar ( 40 % tt 52 % soc ) . result highlight potential tt to improve outcome patient diverse actionable genomic alteration . result also provide relevant evidence support tumor-agnostic precision oncology strategy and highlight potential tts , guide genomic profiling and mtb recommendation , to significantly improve outcome patient diverse actionable genomic alteration . clinicaltrials.gov identifier : nct04591431 .",Nature medicine,29/09/2025
10.1186/s12943-025-02467-8,non-code rnas gastric cancer : mechanism and therapeutic prospect .,"Han Z, Liu W, Zhu Y, Sun Y, Sun D, Jia R, Yang Y, Qi H, Zhang L, Huo Y, Zhang N, Chai J, Yang M","gastric cancer be fifth most common cancer and third lead cause cancer-related death worldwide . be associate high molecular and phenotypic heterogeneity . early-stage gastric cancer can be treat endoscopic resection and surgery , advanced stage , sequential chemotherapy present only treatment option , start first-line platinum and fluoropyrimidine-based dual drug , support median survival period less one year . targeted monoclonal antibody approve treatment gastric cancer be effective limited subset patient . furthermore , painless and precise marker early detection gastric cancer and new target treatment be unavailable . interestingly , many non-coding rnas ( ncrnas ) , such micrornas ( mirnas ) , long non-coding rnas ( lncrnas ) , and circular rnas ( circrnas ) , play key role development gastric cancer . multiple piece evidence suggest ncrnas play crucial role treatment gastric cancer use chemotherapy and target therapy drug . article , systematically review important role ncrnas chemotherapy resistance , immune escape , metabolism , and angiogenesis gastric cancer , and systematically elucidate relevant molecular mechanism . addition , also propose potential clinical significance ncrna new therapeutic target and prognostic biomarker gastric cancer .",Molecular cancer,03/10/2025
10.1016/j.jhep.2025.08.038,reversal aclf and alf use whole blood extracorporeal system combine,"Yamaguchi H, Yoneyama Y, Ichimura K, Ohtsu K, Soen M, Moriya C, Kumagai M, Myers RP, Subramanian GM, Takebe T","background & aims : acute-on-chronic liver failure ( aclf ) be characterize catastrophic loss liver function patient advanced chronic liver disease , 28-day mortality rate reach to 80 % . advance intensive care , high mortality primarily stem absence therapeutic modality simultaneously address both profound systemic inflammatory response and severe hepatic synthetic dysfunction . methods : design integrate extracorporeal circuit , term utopia system , combine granulocyte and monocyte apheresis ( gma ) human induce pluripotent stem cell-derived hepatocyte-like cell ( ihlc ) organoid engineer hla-a ,",Journal of hepatology,02/10/2025
10.1001/jamanetworkopen.2025.35343,cost-utility analysis accelerated and standard strategies renal,"Round J, Akpinar I, Yan C, Patel N, van Katwyk S, Montgomery C, Wald R, Bagshaw SM","importance : little be know long-term cost and outcome relate strategy timing initiation kidney replacement therapy ( krt ) critically ill patient severe acute kidney injury ( aki ) . objective : to estimate cost-utility and cost-effectiveness accelerated krt initiation compare standard krt initiation critically ill patient aki . design , setting , and participant : economic evaluation , state-transition model be develop use datum standard accelerated initiation renal replacement therapy aki ( starrt-aki ) trial , multicenter , multinational randomize clinical trial critically ill patient severe aki conduct october 2015 and september 2019 . trial datum be link administrative health database alberta , canada , to estimate cost and long-term clinical outcome . model include 4 health state : chronic kidney disease , severe chronic kidney disease , krt dependent , and dead . cost be report 2024 canadian dollar . datum be analyze february 2022 november 2024 . exposure : initiation krt . main outcomes and measures : primary outcome economic evaluation be cost quality-adjusted life-year ( qaly ) gain . qaly be combine measure patient quality life and length life . expected cost , qaly , incremental cost-effectiveness ratio ( icer ) , and incremental net monetary benefit ( inmb ) be estimate basis 5000 monte carlo simulation . result : total 146 patient starrt-aki trial be include analysis , 73 patient ( mean [ sd ] age , 59 . 67 [ 14 . 5 ] year ; 52 man [ 71 . 3 % ] ) randomize to receive accelerate initiation and 73 patient ( mean [ sd ] age , 61 . 88 [ 12 . 9 ] year ; 48 man [ 65 . 8 % ] ) randomize to receive standard initiation . standard initiation be more costly patient accelerate initiation ( mean [ sd ] , $ 251 370 $ 155 801 ] $ 231 518 [ $ 183 302 ] ) but generate more qaly ( mean [ sd ] 7 . 49 [ 2 . 03 ] qaly 6 . 64 [ 1 . 76 ] qaly ) . icer standard initiation compare accelerated initiation be $ 23 208 , inmb $ 22 648 ( 95 % credible interval , $ 15 980-$29 316 ) assume willingness to pay qaly $ 50 000 . conclusion and relevance : finding economic evaluation suggest standard krt initiation may be cost-effective canadian setting , but finding be sensitive postdischarge cost trajectory and regional variation krt dependence .",JAMA network open,01/10/2025
10.1136/gutjnl-2025-335412,current and emerge concept systemic treatment metastatic colorectal,"Steup C, Kennel K, Neurath MF, Fichtner-Feigl S, Greten F","colorectal cancer ( crc ) be one most common malignant cancer and incidence be steadily rise particularly young patient . screen measure and widespread availability surgical treatment have lead impressive improvement prognosis overall crc population , patient metastatic crc still face 5-year survival rate 10-25 % . continuous development new systemic treatment strategy include cytotoxic chemotherapy and target therapy , most patient metastatic crc eventually progress . however , small proportion patient mismatch repair-deficient or microsatellite unstable crc respond exceptionally well treatment immune checkpoint inhibitor , thereby prove crc be principle amenable immunotherapy and show long-term disease stabilisation can be achieve even metastasised stage . however , reason lack response immunotherapy vast majority crc case remain to be elucidate . yet , recent evidence suggest tumour stroma , include non-immune cell colorectal tumour microenvironment , mediate immunosuppressive mechanism prevent effective immunotherapy . finding open new avenue development advanced immunotherapy crc . review , summarise major development systemic therapy crc last couple decade , provide overview emerge and soon-to-be implement therapeutic strategy and present concept clinical and preclinical research to manipulate tumour cell and tumour stroma to sensitise microsatellite stable colorectal tumour immunotherapy .",Gut,05/10/2025
10.1016/j.semarthrit.2017.08.010,t-regulatory cells-triumph perseverance : crafoord prize polyarthritis,Wollheim FA,"crafoord prize polyarthritis rank one most prestigious prize and can be award only royal swedish academy sciences decide likelihood prize worthy progress field , and most 4th year . have happen only four time 1982 . year 5th laureates be shimon sakaguchi , fred ramsdell , and alexander rudensky motivation "" discovery relate regulatory t cell , counteract harmful immune reaction arthritis and other autoimmune disease "" . here review history contribution and impact rheumatology .",Seminars in arthritis and rheumatism,01/02/2018
10.1093/jnci/djaf272,stratify lung adenocarcinoma risk multi-ancestry polygenic risk score,"Blechter B, Wang X, Dai J, Karsonaki C, Shi J, Shiraishi K, Choi J, Matsuo K, Chen TY, Hung RJ, Chen K, Shu XO, Kim YT, Choudhury PP, Williams J, Landi MT, Lin D, Zheng W, Yin Z, Zhou B, Wang J, Seow WJ, Song L, Chang IS, Hu W, Chien LH, Cai Q, Hong YC, Kim HN, Wu YL, Wong MP, Richardson BD, Li S, Zhang T, Breeze C, Wang Z, Bassig BA, Kim JH, Albanes D, Wong Sm JY, Shin MH, Chung LP, Yang Y, Zheng H, Dai H, Yatabe Y, Zhang XC, Kim YC, Caporaso NE, Chang J, Ho JCM, Daigo Y, Momozawa Y, Kamatani Y, Kobayashi M, Okubo K, Honda T, Hosgood HD, Kunitoh H, Watanabe SI, Miyagi Y, Matsumoto S, Horinouchi H, Tsuboi M, Hamamoto R, Goto K, Takahashi A, Goto A, Minamiya Y, Hara M, Nishida Y, Takeuchi K, Wakai K, Matsuda K, Murakami Y, Shimizu K, Suzuki H, Saito M, Ohtaki Y, Tanaka K, Wu T, Wei F, Machiela MJ, Kim YH, Oh IJ, Lee VHF, Chang GC, Chen KY, Su WC, Chen YM, Seow A, Park JY, Kweon SS, Gao YT, Liu J, Schwartz AG, Houlston R, Gorlov IP, Wu X, Yang P, Lam S, Tardon A, Chen C, Bojesen SE, Johansson M, Risch A, Bickeböller H, Ji BT, Wichmann HE, Christiani DC, Rennert G, Arnold SM, Brennan P, McKay J, Field JK, Davies MPA, Shete SS, Le Marchand L, Liu G, Andrew AS, Kiemeney LA, Zienolddiny-Narui S, Grankvist K, Cox A, Taylor F, Yuan JM, Lazarus P, Schabath MB, Aldrich MC, Jeon HS, Jiang SS, Chen CH, Hsiao CF, Hu Z, Burdett L, Yeager M, Hutchinson A, Hicks B, Liu J, Berndt SI, Wu W, Wang J, Li Y, Choi JE, Park KH, Sung SW, Kang CH, Wang WC, Xu J, Guan P, Tan W, Yu CJ, Yang G, Sihoe ADL, Choi YY, Park IK, Hung HH, Vermeulen RCH, Cheng I, Wu J, Tsai FY, Chan JKC, Li J, Lin HC, Liu J, Song B, Sawada N, Yamaji T, Wyatt K, Ma H, Zhu M, Wang Y, Qi T, Li X, Ren Y, Chao A, Iwasaki M, Zhu J, Wu G, Chen CY, ScD CC, Yang PC, Stevens VL, Fraumeni JF Jr, Lin K, Walters RG, Chen Z, Chatterjee N, Gorlova OY, Amos CI, Shen H, Hsiung CA, Chanock SJ, Rothman N, Kohno T, Lan Q, Zhang H","background : lung adenocarcinoma ( luad ) never-smoker be major public health burden , especially east asian woman . polygenic risk score ( prs ) be promise risk stratification but be primarily develop european-ancestry population . aim to develop and validate single- and multi-ancestry prs east asian never-smoker to improve luad risk prediction . methods : prs be develop use genome-wide association study summary statistic east asian ( 8 , 002 case ; 20 , 782 control ) and european ( 2 , 058 case ; 5 , 575 control ) population . single-ancestry model include prs-25 ,",Journal of the National Cancer Institute,01/10/2025
10.1053/j.seminhematol.2025.08.003,immunotherapy landscape aml : define knowledge gap rational,"Subklewe M, Rutella S, Curti A","immunotherapy have dramatically improve outcome lymphoid malignancy . b cell cancer , cd19-directed car t cell and t-cell engager have produce high remission rate and durable response , now form cornerstone treatment many relapsed or refractory setting . contrast , acute myeloid leukemia ( aml ) have not experience comparable breakthrough . date , only antibody-drug conjugate have reach regulatory approval , gemtuzumab ozogamicin approve combination intensive induction and consolidation therapy newly diagnose cd33-positive aml . divergence be root biological and immunologic complexity aml . b-cell malignancy lineage-restricted surface marker such cd19 , aml lack leukemia-specific antigen . most target be share normal hematopoietic progenitor , lead on-target/off-leukemia toxicity . moreover , aml exert local and systemic immunosuppression tumor-intrinsic and microenvironmental mechanism , limit t-cell persistence and function . review will introduce current immunotherapy platform investigation aml , start antibody-based approach , follow t-cell redirect therapy , and culminate overview immune resistance , bone marrow microenvironment , and strategy personalized combinatorial immunotherapy . synthesize recent clinical datum and mechanistic insight , include early car and t-cell engager trial , aim to provide translational framework immunotherapy might still reshape aml care-through integration immune contexture bone marrow environment aim rational combinatorial approach .",Seminars in hematology,29/08/2025
10.1002/adma.202508072,engineered apoptotic extracellular vesicles programmable regulation,"Kang Y, Han X, Zhou S, Wang X, Wang Y, Song P, Su X, Qin M, Qian D, Meng H, Yan J, Pu F, Zhang H","rheumatoid arthritis microenvironment ( ram ) contain complex pathogenic mediator interact dynamically to drive progression rheumatoid arthritis ( ra ) . however , most current ra treatment be single-target intervention , exert limited impact ram . herein , apoptotic extracellular vesicle ( apoev ) be construct programmable regulation neutrophil-macrophage-ros pathogenic axis , aim to reconstruct ram and improve ra therapy . mesenchymal stem cell ( mscs ) be pretreate dexamethasone ( dex ) and induce apoptosis to produce dex-loaded and fasl-overexpresse apoev ( d@apoev(fasl ) ) , be far modify low-molecular-weight heparin ( lmwh )","Advanced materials (Deerfield Beach, Fla.)",03/10/2025
10.1016/j.canlet.2025.218072,target fbxo5-dok6 axis to overcome temozolomide resistance glioblastoma,"Wang C, Wang M, Zhu Z, Tan H, Su D, Qiao M, Jiang M, Che F","development resistance temozolomide ( tmz ) represent critical challenge management glioblastoma ( gbm ) , yet molecular basis resistance be still not fully elucidate . study , utilize custom-designed crispr/cas9 sgrna library target 1 , 117 gene associate ubiquitination , combine positive-negative dual screening strategy , to identify pivotal factor tmz resistance . approach reveal f-box protein 5 ( fbxo5 ) , e3 ligase subunit , major contributor tmz resistance . correlation analysis indicate high level fbxo5 be associate poor treatment response and reduced survival gbm patient . further investigation show fbxo5 promote k48-linke polyubiquitination and subsequent proteasomal breakdown dok6 , protein depletion enhance mechanical rigidity tumor cell and initiate survival signal . additionally , virtual screening natural product library contain 4 , 500 compound , identify theaflavin 3 , 3 ' -digallate ( tf3 ) selective inhibitor fbxo5 . compound be find to synergistically improve tmz sensitivity both vitro and vivo . result highlight critical proteasome-cytomechanic pathway gbm chemoresistance and suggest target fbxo5 could be effective therapeutic strategy treat patient gbm .",Cancer letters,02/10/2025
10.1016/j.jacc.2025.07.014,very high prevalence nonoptimally controlled traditional risk factors,"Lee H, Huang X, Khan SS, Son D, Lee HH, Kim EJ, Lloyd-Jones DM, Kim HC, Greenland P","background : recent study suggest coronary heart disease ( chd ) may frequently occur absence traditional cardiovascular disease ( cvd ) risk factor . however , be unclear could reflect miss clinical diagnosis or subthreshold nonoptimal risk factor exposure precede chd , and similar pattern be observe heart failure ( hf ) or stroke . objective : purpose study be to determine antecedent occurrence nonoptimal level 4 traditional risk factor ( blood pressure [ bp ] , cholesterol , glucose , and tobacco smoking ) first chd , hf , or stroke . method : analyze 2 population-based prospective cohort : knhis ( korean national health insurance service ) ( n = 9 , 341 , 100 ; baseline age ≥20 year ; follow-up , 2009-2022 ) and mesa ( multi-ethnic study atherosclerosis ) ( n = 6 , 803 ; baseline age 45-84 year ; follow-up , 2000-2019 ) . individual develop incident chd , hf , or stroke follow-up , determine prevalence ≥1 traditional risk factor optimal level-systolic bp ≥120 mm hg or diastolic bp ≥80 mm hg or bp-lowere treatment ; total cholesterol ≥200 mg/dl or lipid-lowere treatment ; fast glucose ≥100 mg/dl or diagnosis diabete or glucose-lowering treatment ; or past or current smoking-at visit cvd . result : analysis be base 601 , 025 and 1 , 188 cvd event knhis and mesa , respectively . prevalence ≥1 nonoptimal risk factor be high ( 99 . 7 % and 99 . 6 % ) chd , similar pattern hf ( 99 . 4 % and 99 . 5 % ) and stroke ( 99 . 3 % and 99 . 5 % ) knhis and mesa , respectively . prevalence ≥1 risk factor cvd be consistently high ( > 99 % ) age group man and woman , low proportion observe hf and stroke ( > 95 % ) occur age < 60 year woman . prevalence ≥2 risk factor be also common ( 93 . 2 % 97 . 2 % ) cvd event . conclusion : binational study 2 prospective cohort , presence nonoptimal level ≥1 traditional risk factor be nearly universal cvd . result not only challenge claim chd event frequently occur antecedent major risk factor but also demonstrate other cvd event , include hf or stroke , rarely occur absence nonoptimal traditional risk factor , highlight importance primordial prevention effort .",Journal of the American College of Cardiology,07/10/2025
10.1038/s41467-025-63987-x,bacterial rna promote proteostasis inter-tissue communication c .,"Kyriakakis E, Medde C, Ritz D, Fucile G, Schmidt A, Spang A","life expectancy have be increase last decade , be not match increase healthspan . genetic composition , environmental and nutritional factor influence both health- and lifespan . diet be think to be major factor healthy ageing . here , show dietary rna specie improve proteostasis c . elegan . inherent bacterial-derived double strand rna reduce protein aggregation c . elegan muscle proteostasis model . beneficial effect depend low level systemic selective autophagy , rnai machinery germline , even rna be deliver ingestion intestine and integrity muscle cell . datum suggest requirement inter-organ communication intestine , germline and muscle . result demonstrate bacterial-derived rnas elicit systemic response c . elegan , protect animal protein aggregation ageing , might extend healthspan .",Nature communications,01/10/2025
10.1016/j.ecoenv.2025.119155,decipher carcinogenic role benzo[a]pyrene glioblastoma : insight,"Yi L, Wang W, Sun Z, Chen Y, Xiong Z, Ma L, Ye W, Li X","background : benzo[a]pyrene ( bap ) be known environmental carcinogen link multiple tumor , but role glioblastoma ( gbm ) remain poorly understand . study aim to explore bap 's tumorigenic mechanism gbm integrated approach combine network toxicology , single-cell transcriptomic , mendelian randomization , and bibliometric analysis . methods : bap target gene be predict use chembl , sea , and pharmmapper , and gbm-relate gene be retrieve genecards , omim , and ttd . overlapping gene be use to construct protein-protein interaction network cytoscape . molecular docking and molecular dynamic simulation be perform to assess bap-target interaction . single-cell rna-seq data ( gse131928 ) be analyze to profile gene expression gbm subpopulation . mendelian randomization assess causal relationship core gene and gbm risk , and finding be validate vitro . bibliometric analysis track research trend gene . result : 31 overlap gene be identify . tp53 be highly express mes-like and ac-like malignant cell as well cd8⁺ tex cell . mr reveal significant inverse association tp53 expression and gbm risk ( or = 0 . 13 , 95 % ci : 0 . 04-0 . 47 , p = 0 . 002 ) . docking and simulation show strong bap-tp53 binding , confirm vitro experiment . bibliometrics indicate tp53 research gbm have shift basic mechanism clinical translation . conclusion : bap may drive gbm target tp53 , offer insight gbm prevention and therapy .",Ecotoxicology and environmental safety,01/10/2025
10.1038/s41397-025-00384-z,serine-arginine protein kinase 1 ( srpk1 ) be under-expressed mucinous,"Duggan WP, Azimi M, Flanagan L, Sullivan GP, Reynolds IS, Fay J, Dussmann H, Ní Chonghaile T, Sheehan KM, Jirström K, Prehn JHM, Burke JP","5-15 % colorectal cancer ( crcs ) be mucinous . mucinous crc be associate inhibited response standard adjuvant and neoadjuvant therapy . serine-arginine protein kinase 1 ( srpk1 ) be enzyme , modulate activity multiple splicing factor . srpk1 under-expression be associate resistance platinum-based chemotherapeutic agent multiple tumor type . objective study be to evaluate srpk1 expression mucinous crc and to explore potential relationship differential srpk1 expression and oxaliplatin resistance mucinous crc . rectal cancer and crc tissue microarrays ( tma ) be stain srpk1 to compare expression mucinous and non-mucinous tumor . expression be analyze mucinous and non-mucinous crc cell line . cell be treat oxaliplatin to explore difference treatment response . mucinous cell be transfecte srpk1 crispr/cas9 lentiviral activation plasmid to investigate relationship srpk1 expression and oxaliplatin resistance . tma cohort include 117 patient mucinous and 441 patient non-mucinous crc . be find to be under-expressed both mucinous rectal cancer ( p < 0 . 001 ) and crc cohort ( p = 0 . 003 ) . univariate analysis , srpk1 under-expression be find to be associate bad 5-year os ( p = 0 . 001 ) . treatment mucinous crc cell oxaliplatin do not result significant increase cell death ( p = 0 . 149 ) . however overexpression srpk1 follow transfection crispr/cas9 activation plasmid result significant increase sensitivity cell oxaliplatin treatment ( p = 0 . 029 ) . be under-expressed mucinous crc , and under-expression be associate bad os . may be due positive effect srpk1 oxaliplatin sensitivity .",The pharmacogenomics journal,03/10/2025
10.1016/j.cell.2025.08.038,multiscale proteomic modeling reveal protein network drive alzheimer 's,"Wang E, Yu K, Cao J, Wang M, Katsel P, Song WM, Wang Z, Li Y, Wang X, Wang Q, Xu P, Yu G, Zhu L, Geng J, Habibi P, Qian L, Tuck T, Li A, Tcw J, Roussos P, Brennand KJ, Haroutunian V, Johnson ECB, Seyfried NT, Levey AI, Bennett DA, Peng J, Cai D, Zhang B","molecular mechanism underlie pathogenesis alzheimer 's disease ( ad ) , most common form dementia , remain poorly understand . proteomic offer crucial approach elucidate ad pathogenesis , alteration protein expression be more directly link phenotypic outcome change genetic or transcriptomic level . study , develop multiscale proteomic network model ad integrate large-scale match proteomic and genetic datum brain region vulnerable disease . model reveal detailed protein interaction structure and identify putative key driver protein ( kdp ) involve ad progression . notably , network analysis uncover",Cell,25/09/2025
10.1002/1878-0261.70132,characterize epithelial-mesenchymal transition-linked heterogeneity breast,"Topa J, Richert J, Stokowy T, Staśczak A, Szajewski M, Ciesielski M, Grešner PM, Tomasik B, Arcimowicz Ł, Stankiewicz A, Suchodolska G, Senkus E, Kruszewski W, Żaczek AJ, Markiewicz A","epithelial-mesenchymal transition ( emt ) generate heterogeneity circulate tumor cell ( ctc ) , affect biological property and hamper detection . limit understanding mechanism underlie hematogenous dissemination , especially early breast cancer ( bc ) , ctc be rare . here , aim to detect ctc different emt status bc patient . ctc blood sample 107 bc patient be evaluate use immunomagnetic depletion and multi-marker immunofluorescence ( epcam , e-cadherin , mcam , cell surface vimentin , cd31 , cd45 ) , follow single-cell transcriptomic . ctc be detect 51 . 9 % therapy-naïve early bc case , 3 . 8 % show only epithelial ctc ( ectcs ) , 5 . 8 % epithelial-mesenchymal ( emctc ) , 26 . 0 % mesenchymal ( mctcs ) , and 16 . 3 % mixed phenotype . ctc heterogeneity be more frequent triple-negative ( 86 % ) luminal bc ( 17 % , p = 0 . 008 ) . lymph node involvement strongly predict dissemination ctc phenotype , tumor size correlate mctc abundance . single-cell rna sequence reveal downregulation ribosomal gene and translation inhibition ctc mesenchymal feature , link mtorc1 signal . finding be also validate independent dataset , highlight vulnerability ctc dissemination .",Molecular oncology,05/10/2025
10.1186/s13148-025-01976-z,explore causal relationship epigenetic age acceleration and,"Liu H, Yin Z, Chen X, Wang Z","background : alzheimer 's disease ( ad ) be identify distinct progression aging-associated cognitive and functional impairment . recent advance recognize dna methylation-based epigenetic clock precise predictor aging process and relate health outcome . however , observational study explore link be often compromise confound factor and reverse causality bias . to address question , study employ bidirectional mendelian randomization ( mr ) analysis to explore causal relationship epigenetic age acceleration ( eaa ) and ad . methods : genome-wide association study ( gwas ) statistic epigenetic clock ( grimage , phenoage , horvathage , and hannumage ) be source edinburgh datashare and alzheimer disease genetics consortium ( adgc ) . dataset comprise 63 , 926 participant , and , 21 , 982 case be ad patient and 41 , 944 be control . primary analytical method mr be inverse variance weight ( ivw ) . potential pleiotropy and heterogeneity instrumental variable be evaluate additional sensitivity analysis . result : employ random-effect ivw approach , find , indicate grimage , eaa be associate increase risk ad ( odd ratio [ or ] = 1 . 025 , 95 % confidence interval [ ci ] : 1 . 006-1 . 044 , p = 0 . 009 ) . quality control assessment confirm reliability and robustness finding . however , evidence do not support causal relationship ad and epigenetic aging reverse direction . conclusion : mr study indicate positive causal relationship eaa and ad . further research be necessary to explore underlie physiological mechanism .",Clinical epigenetics,03/10/2025
10.1038/hgv.2015.60,genomic architecture inflammatory bowel disease five family multiple,"Stittrich AB, Ashworth J, Shi M, Robinson M, Mauldin D, Brunkow ME, Biswas S, Kim JM, Kwon KS, Jung JU, Galas D, Serikawa K, Duerr RH, Guthery SL, Peschon J, Hood L, Roach JC, Glusman G","currently , good clinical predictor inflammatory bowel disease ( ibd ) be family history . 163 sequence variant have be associate ibd genome-wide association study , but have weak effect and explain only fraction observed heritability . be expect additional variant contribute genomic architecture ibd , possibly include rare variant effect size large identify common variant . here apply family study design and sequence 38 individual five family , hypothesis family multiple ibd-affected individual harbor one or more risk variant ( i ) be share affect family member , ( ii ) be rare and ( iii ) have substantial effect disease development . analysis reveal not only novel candidate risk variant but also high polygenic risk score common know risk variant four five family . functional analysis top novel variant remain family , rare missense mutation ubiquitin ligase trim11 , suggest lead increase nuclear factor kappa light chain enhancer b-cells ( nf-κb ) signal . conclude accumulation common weak-effect variant account high incidence ibd most , but not family analyze and family study design can identify novel rare variant confer risk ibd potentially large effect size , such trim11 p. h414y mutation .",Human genome variation,01/01/2016
10.1038/s41467-025-63876-3,inner nuclear membrane protein lemd3 organize 3d chromatin architecture,"Li W, Liao Y, Liu Z, Niu L, Huang J, Jia Y, Xu R, Guan S, Liang Z, Li Y, Wu H, Zhu S, Tan L, Yu F, Wang Z, Sun L, Zhao D, Kong W, Fu Y","maintain contractile phenotype vascular smooth muscle cell ( vsmc ) be critical vascular homeostasis . however , role 3d chromatin architecture regulate vsmc identity remain elusive . genome-scale crispr screen identifie lemd3 potential regulator to maintain vsmc identity . lemd3 deficiency vsmcs result loss contractile phenotype and exacerbate intimal hyperplasia mouse . protein interactome analysis reveal lemd3 interact cbx3 , principal reader h3k9me2/3 , subsequently anchor heterochromatin nuclear periphery . employ dna polymer model base hi-c datum , whole-chromosome simulation demonstrate lemd3 depletion disturb chromatin structure . multi-omic analysis far reveal lemd3 depletion alter genome conformation increase inter-tad ( topologically associate domain ) interaction boundary a and b compartment , correlate decrease chromatin accessibility and repress expression vsmc contractile gene . study reveal lemd3 organize 3d chromatin architecture anchor heterochromatin nuclear periphery to maintain vsmc contractile identity .",Nature communications,03/10/2025
10.1038/s41556-025-01773-z,microtubule architecture connect amot stability yap/taz mechanotransduction,"Vanni G, Citron A, Suli A, Contessotto P, Caire R, Gandin A, Mantovan G, Zanconato F, Brusatin G, Di Palma M, Peirano E, Pozzer LS, Albanese C Jr, Steiner RA, Cordenonsi M, Panciera T, Piccolo S","cellular mechanotransduction be key informational system , yet mechanism remain elusive . here unveil role microtubule mechanosignalling , operate downstream subnuclear f-actin and nuclear envelope mechanic . mechanical activation , microtubule reorganize perinuclear cage radial array nucleate centrosome . structural rearrangement trigger degradation amot protein , identify key mechanical rheostat sequester yap/taz cytoplasm . amot be stable mechano-off but degrade mechano-on cell state , microtubule allow amot rapid transport pericentrosomal proteasome complex dynein/dynactin . process ensure swift control yap/taz function response change cell mechanic , experimental loss amot protein render cell insensitive mechanical modulation . ras/rtk oncogene promote yap/taz-dependent tumorigenesis corrupt amot-centred mechanical checkpoint . notably , hippo pathway fine-tune mechanotransduction : lats kinase phosphorylate amot , shield degradation , thereby indirectly restrain yap/taz . thus , amot protein stability serve hub link cytoskeletal reorganization and hippo signal yap/taz mechanosignalling .",Nature cell biology,01/10/2025
e315,influence pokémon go physical activity : study and implications .,"Althoff T, White RW, Horvitz E","background : physical activity help people maintain healthy weight and reduce risk several chronic disease . knowledge be widely recognize , adult and child many country world do not get recommend amount physical activity . many intervention be find to be ineffective increase physical activity or reach inactive population , have be anecdotal report increase physical activity novel mobile game embed game play physical world . most recent and salient example game be pokémon go , have reportedly reach ten million user united states and worldwide . objective : objective study be to quantify impact pokémon go physical activity . method : study effect pokémon go physical activity combination signal large-scale corpora wearable sensor datum and search engine log 32 , 000 microsoft band user period 3 month . pokémon go player be identify search engine query and physical activity be measure accelerometer . result : find pokémon go lead significant increase physical activity period 30 day , particularly engage user ( ie , make multiple search query detail game usage ) increase activity 1473 step day average , more 25 % increase compare prior activity level ( p< . 001 ) . short time span study , estimate pokémon go have add total 144 billion step us physical activity . furthermore , pokémon go have be able to increase physical activity man and woman age , weight status , and prior activity level show form game lead increase physical activity significant implication public health . particular , find pokémon go be able to reach low activity population , 4 lead mobile health app study work largely draw already very active population . conclusion : mobile app combine game play physical activity lead substantial short-term activity increase and , contrast many exist intervention and mobile health app , have potential to reach activity-poor population . future study be need to investigate potential long-term effect application .",Journal of medical Internet research,06/12/2016
10.1016/j.str.2025.09.006,structural basis dcaf2 novel e3 ligase protac-mediated target,"McMahon EJ, Cioffi AG, Visperas PR, Lin Y, Shaghafi M, Daczkowski CM, Hermann JC, Everley RA, Neve RM, Erlanson DA, Webster KR, Narayan V, Wang W","targeted protein degradation ( tpd ) leverage ubiquitin-proteasome system to eliminate disease-causing protein e3 ligase . date , field be limit utilize few 600 human e3 ligase . to expand repertoire , conduct structural and functional validation ddb1 ( damage-specific dna bind protein 1 ) and cullin-associate factor ( dcaf)2 ( dtl/cdt2 ) , cullin4-ring ligase substrate adaptor implicate dna damage response and cancer , novel e3 tpd . cryoelectron microscopy ( cryo-em ) structure dcaf2 : ddb1 : dda1 complex ( 3 . 3 å ) , ligand bind complex ( 3 . 1 å ) , and ternary complex covalent proteolysis-targeting chimera ( protac ) and brd4 ( 3 . 4 å ) reveal protac-mediate substrate recruitment . use covalent bifunctional tool compound engage residue c141 wd40 domain , demonstrate robust ubiquitination biochemical assay and cellular tpd use coffee ( covalent functionalization follow e3 electroporation ) method . finding position dcaf2 promising e3 adaptor protac strategy and identify c141 relevant site future protac discovery .","Structure (London, England : 1993)",03/10/2025
10.1016/j.ccell.2025.09.003,sensory neuron drive pancreatic cancer progression glutamatergic,"Ren L, Liu C, Çifcibaşı K, Ballmann M, Rammes G, Mota Reyes C, Tokalov S, Klingl A, Grünert J, Goyal K, Neckel PH, Mattheus U, Schoeps B, Yıldızhan SE, Sezerman OU, Cevik NC, Sever EA, Karakas D, Safak O, Steiger K, Muckenhuber A, Görgülü K, Chen Z, Zhang J, Ye L, Maula Ali MI, Tiwari VK, Romanyuk N, Giesert F, Saur D, Rad R, Schmid RM, Algül H, Krüger A, Friess H, Ceyhan GO, Istvanffy R, Demir IE","cancer thrive neuronal input . here , demonstrate presence pseudo-synaptic connection sensory nerve ending and cancer cell extracerebral cancer , i.e. , pancreatic ductal adenocarcinoma ( pdac ) . synaptic site exhibit selective enrichment glutamatergic n-methyl-d-aspartate receptor ( nmda ) receptor subunit nmdar2d ( grin2d ) cancer cell , turn pdac cell responsive neuron-derived glutamate and promote tumor growth and spread . intriguingly , neuron transform subset co-culture pdac cell calcium-responsive cell grin2d-type glutamate receptor neuron-cancer pseudo-synapse . find expression subunit be due increase glutamate availability provide sensory innervation neurotrophic feedforward loop . moreover , interference glutamate-grin2d signal neuron-cancer pseudo-synapse markedly improve survival vivo . discovery peripheral cancer-neuron pseudo-synapse may provide opportunity cancer-neuroscience-instructed oncological therapy .",Cancer cell,25/09/2025
10.2967/jnumed.125.270190,multicentric matched-pair analysis long-term hematotoxicity peptide,"Steinhelfer L, Jungmann F, Endroes L, Lanzafame H, Hermann K, Pfob CH, Lapa C, Hartrampf PE, Dörrler AL, Buck AK, Götze K, Wenzel P, Geisler F, Walter R, Haneder E, Lohöfer F, Haller B, Braren R, Eiber M","peptide receptor radionuclide therapy ( prrt ) ( 177)lu-dotatate be approve treatment metastatic neuroendocrine tumor ( net ) . therapy be effective , hematologic toxicity , particularly leukopenia , remain significant concern . spleen , accumulates radiolabele somatostatin analog , may play critical role modulate toxicity . study investigate patient undergo prrt splenectomy exhibit low hematologic toxicity . method : multicenter retrospective study include 68 patient metastatic net treat prrt 2009 and 2022 . splenectomized patient ( n = 34 ) be match nonsplenectomize patient basis age , sex , tumor location , grading , metastatic pattern , and treatment cycle . hematologic parameter ( leukocyte , lymphocyte , neutrophil , hemoglobin , and platelet ) be assess baseline and 12 and 24 mo prrt . hematotoxicity be grade use common terminology criteria adverse event . statistical analysis include t test , mann-whitney u test , and fisher exact test , α 0 . 05 and bonferroni adjustment apply . result : splenectomize patient have significantly low rate leukopenia , mean decline 12 . 8 % leukocyte count 24 mo 47 . 2 % nonsplenectomize patient ( p < 0 . 001 ) , and high median absolute leukocyte count ( 7 . 2 4 . 2 × 10³/mm³ , p < 0 . 001 ) . leukopenia occur 2 splenectomize patient compare 20 control group ( p < 0 . 001 ) . lymphocyte decline be also less pronounced , high absolute count 24 mo . platelet count be consistently high postsplenectomy , relative change time be not significant . neutrophil count and hemoglobin level remain comparable group . conclusion : splenectomy appear to reduce leukopenia and improve hematologic tolerability net patient undergo prrt , highlight spleen 's role leukocyte regulation . patient may well tolerate intensify prrt regimen , include additional cycle or reinduction , minimal toxicity . be particularly relevant patient pancreatic net , frequently undergo splenectomy and face poor prognosis . prospective study be need to far clarify spleen 's impact prrt-related hematotoxicity and guide treatment optimization .","Journal of nuclear medicine : official publication, Society of Nuclear Medicine",03/10/2025
10.1016/S2213-2600(25)00240-1,"durvalumab , carboplatin , and etoposide patient be treatment-naive","Asao T, Saida Y, Watanabe S, Kisohara A, Kishi K, Morita R, Nakagawa T, Tsukita Y, Furuya N, Miyawaki T, Ishikawa N, Yamada T, Tanaka T, Morita S, Kikuchi T, Maemondo M, Kobayashi K","background : treat patient extensive-stage small-cell lung cancer ( sclc ) poor performance status pose considerable challenge . aim to evaluate combination immune checkpoint inhibitor platinum-based therapy population . methods : open-label , single-arm phase 2 nej045a trial enrol untreated patient extensive-stage sclc performance status 2 or 3 . participant receive four cycle durvalumab , carboplatin , and etoposide , follow durvalumab maintenance . dose adjustment strategy be use , initial reduction carboplatin-etoposide dosage , subsequently adjust base adverse event , allow potential escalation . primary endpoint be tolerability , assess proportion patient complete induction therapy . key secondary endpoint be 1-year survival rate . trial be register japan registry clinical trials ( jrcts031200319 ) and have be complete . finding : april 8 , 2021 , and oct 3 , 2023 , 57 patient ( performance status 2 n=43 and performance status 3 n=14 ) be enrol median age 73·5 year ( iqr 69·0-77·5 ) , 44 ( 79 % ) 56 be male . 26 ( 67 % ; 80 % ci 55·2-76·7 ; p<0·0001 ) 39 patient performance status 2 and five ( 50 % ; 26·7-73·3 ; p=0·0088 ) ten performance status 3 complete induction therapy , exceed pre-specified threshold . grade 3 or high adverse event occur 52 ( 93 % ) 56 patient , and 12 ( 21 % ) 56 discontinue adverse event . 1-year survival rate be 43·4 % ( 80 % ci 34·1-53·1 ) overall ( p<0·0001 ) , 50·0 % ( 39·1-60·9 ) performance status 2 ( p<0·0001 ) , and 18·2 % ( 5·0-41·5 ) performance status 3 . interpretation : durvalumab , carboplatin , and etoposide show tolerability and promising efficacy first-line treatment patient untreated extensive-stage sclc poor performance status , support integration immune checkpoint inhibitor therapeutically challenging population . funding : astrazeneca kk .",The Lancet. Respiratory medicine,28/09/2025
10.1016/j.chom.2025.09.009,immunometabolic reprogramme macrophage gut microbiota-derived cadaverine,"de Oliveira Formiga R, Li Q, Zhao Y, Campos Ribeiro MA, Guarino-Vignon P, Fatouh R, Dubois L, Creusot L, Puchois V, Amouyal S, Alonso Salgueiro I, Bredon M, Chollet L, Ledent T, Scandola C, Auger JP, Danne C, Krönke G, Tkacz E, Emond P, Chevreux G, Pham HP, Pontoizeau C, Lamaziere A, Argüello RJ, Rolhion N, Michel ML, Wai T, Sokol H","cadaverine be polyamine produce gut microbiota link health and disease , notably inflammatory bowel disease ( ibd ) . here , show cadaverine shape monocyte-macrophage immunometabolism context- and concentration-dependent fashion to impact macrophage functionality . baseline , cadaverine be take l-lysine transporter and activate thioredoxin system , inflammation , cadaverine signal aconitate decarboxylase 1 ( acod1)-itaconate . pathway induce activation transcription factor , nuclear factor erythroid 2-related factor 2 ( nrf2 ) , support mitochondrial respiration and promote immunoregulatory macrophage polarization . conversely , high concentration , cadaverine act histamine 4 receptor , lead glycolysis-driven inflammation and pro-inflammatory function macrophage . likewise , cadaverine exhibit paradoxical effect experimental colitis , either protective or detrimental , evoke opposite fate macrophage depend level dictate enterobacteriaceae . ibd patient , elevated cadaverine correlate high flare risk . finding implicate cadaverine microbiota-derived metabolite manipulate macrophage energy metabolism consequence intestinal inflammation and implication ibd pathogenesis .",Cell host & microbe,30/09/2025
10.3389/fimmu.2025.1666884,neutrophil-to-albumin ratio : novel predictor osteoporosis rheumatoid,"Zhang Y, He Z, Li K, Wu Q, Wang S, Liu M, Liu Q, Xu Q, Kong X, Lin C","background : osteoporosis ( op ) frequently coexist rheumatoid arthritis ( ra ) , but validate predictor early risk be not extensively study . study seek to examine relationship neutrophil percentage-to-albumin ratio ( npar ) and likelihood develop ra-related op(ra-op ) . methods : investigate relationship npar and ra-op clinical retrospective study , far validate association use datum national health and nutrition examination survey ( nhanes ) database ( 2005-2020 cycle ) . retrospective study enrol 718 ra patient rheumatology department first affiliated hospital guangzhou university chinese medicine january 2020 and december 2024 . patient be categorize low-npar ( < 1 . 7598 ) and high-npar ( ≥1 . 7598 ) group base median npar . extract clinical datum encompass demographic characteristic , comorbiditie , serological marker , and other laboratory parameter . preliminary univariate and multivariate logistic regression analyse assess potential association npar and ra-op , multi-model adjust logistic regression be subsequently apply to evaluate independent association , subgroup analysis examine consistency demographic and clinical strata , receiver operate characteristic ( roc ) curve analysis assess npar 's diagnostic performance , and then restrict cubic spline ( rcs ) visualize potential non-linear relationship . finally use identical statistical framework , validate finding nhanes cohort . result : high-npar group exhibit significantly high op incidence low-npar group ( 39 . 0 % 26 . 5 % ; p<0 . 001 ) . full adjustment ( model 4 ) , npar remained independently associate increase ra-op risk categorical variable ( high vs. low npar : adjust or = 1 . 70 ( 95%ci : 1 . 01 ~ 2 . 88 ) ; p = 0 . 049 ) . subgroup analysis demonstrate significant interaction effect ( p-interaction>0 . 05 ) disease duration . roc curve show area curve(auc ) 0 . 58 ( 95%ci : 0 . 53 ~ 0 . 63 ) and npar cut-off 1 . 886 . covariate-adjusted rcs indicate linear dose-response relationship ( p overall=0 . 033 ; p . 168 ) . nhanes cohort analysis independently validate both npar-ra-op association and linear characteristic . conclusion : npar , serve novel composite biomarker integrate neutrophil-mediated inflammation and nutritional status ( albumin ) , independently predict op risk ra . derivation routine clinical parameter render npar readily deployable , cost-effective tool op risk stratification clinical practice .",Frontiers in immunology,01/01/2025
10.1038/s41551-025-01525-2,targeted clearance extracellular tau use aptamer-armed monocyte alleviate,"Zhuo Y, Lu Y, Zhu Y, Wen N, Zou G, Lu H, Pei X, Zhang Y, Zhang Q, Wang X, Zhang W, Zhang Q, Wang Z, Xie S, Li CQ, Tan W, Qiu L","extracellular tau determine progression alzheimer 's disease , yet therapeutic strategy target be hinder poor brain delivery and limited clearance . here develop tau-clearing cell therapy base monocyte functionalize high-affinity tau-specific aptamer . aptamer be covalently conjugate surface monocyte ( derive bone marrow leucocyte and cultured monocyte-inducing condition ) bioorthogonal chemistry affect viability or function . intravenous administration mouse express mutant and disease-relevant human tau , engineer monocyte actively cross blood-brain barrier and accumulate tau-rich brain region such hippocampus and striatum . efficiently phagocytose extracellular tau , lead significant reduction tau burden . result , glial activation be suppress , neuroinflammation be alleviate , and neuronal and mitochondrial integrity be preserve . long-term treatment improve memory and spatial learning , induce toxicity or behavioural side effect . result demonstrate aptamer-guided monocyte can achieve targeted delivery , effective clearance and sustained neuroprotection , offer promising strategy therapeutic intervention alzheimer 's disease .",Nature biomedical engineering,01/10/2025
10.1002/jcsm.70079,resistance exercise intervention restores functional capacity and improve,"Marcos-Perez D, Hernandez-Vicente A, Cruces-Salguero S, Landa J, Bonvini M, Vicente-Rodríguez G, Pueyo E, Rodriguez-Mañas L, Abizanda P, Otaegui D, Garatachea N, Matheu A","background : centenarians comprise age group characterize exceptional longevity and low age-associated pathology . however , still experience physiological decline , and different study have link frailty population . exercise intervention reverse frailty and improve functional capacity , but study have address effect intervention centenarian . study , assess impact 12-week resistance exercise intervention group centenarian and characterize functional capacity as well expression several molecular biomarker associate frailty . method : total 19 centenarian be enrol , but 7 do not complete study . remain 12 centenarian be randomly assign control or intervention group , be 12-week resistance exercise intervention . molecular biomarker be measure qrt-pcr and elisa . result : intervention group improve functional capacity measure short physical performance battery ( sppb ) ( post 5 . 0 2 . 3 pre ) and physical performance and mobility examination ( ppme ) ( 6 . 5 3 . 8) , as well frailty status study fried frailty phenotype ( 3 . 0 3 . 8) and frailty trait scale 5 ( fts5 ) ( post 30 . 7 34 . 0 pre ) scale . ancova reveal resistance training lead significant improvement functional capacity scale sppb ( p = 0 . 01 ) and ppme ( p < 0 . 001 ) , as well fried frailty phenotype ( p = 0 . 001 ) and fts5 ( p = 0 . 05 ) . biomarker relate frailty ( egr1 , mir194-5p , mir125b-5p and mir454-3p ) and inflammation ( il-6 and il-1β ) show different expression pattern centenarian ( n = 19 ) compare old ( n = 44 , average 79 year old ) and young adult ( n = 34 , average 29 year old ) group . notably , intervention be associate improvement frailty and inflammation biomarker expression . finally , correlation analysis show significant association functional and frailty variable , sppb correlate mir454-3p ( ρ = 0 . 73 ) and fts5 correlate mir454-3p ( ρ = -0 . 83 ) , il-6 ( ρ = 0 . 60 ) and mir125b-5p ( ρ = -0 . 55 ) . conclusion : result reveal resistance exercise intervention enhance functional status and reduce frailty centenarian , and be associate improvement frailty and inflammation biomarker .","Journal of cachexia, sarcopenia and muscle",01/10/2025
10.1002/oby.70058,reason discontinuation obesity pharmacotherapy semaglutide or,"Gasoyan H, Butsch WS, Casacchia NJ, Schulte R, Criswell V, Fox J, Renner H, Le P, Alpert J, Rothberg MB","objective : study aim to characterize reason treatment discontinuation injectable semaglutide or tirzepatide obesity regular clinical practice . method : cross-sectional study use electronic health record datum january 2022 and december 2024 single integrate health system ohio and florida . primary reason treatment discontinuation be examine randomly select sample adult overweight or obesity and type 2 diabete initiate injectable semaglutide or tirzepatide and discontinue treatment first year . result : randomly select 288 patient ; 145 receive semaglutide and 143 tirzepatide . overall , 137 patient ( 47 . 6 % ) discontinue medication to cost or insurance-related issue , 42 ( 14 . 6 % ) inability to tolerate side effect , 34 ( 11 . 8 % ) be unable to fill medication shortage , 7 ( 2 . 4 % ) switch compound medication , and 5 ( 1 . 7 % ) unsatisfactory weight loss ; 31 ( 10 . 8 % ) discontinue other reason , and 32 ( 11 . 1 % ) patient discontinuation reason be not specify electronic health record . conclusion : high cost or insurance-related issue be most common reason treatment discontinuation semaglutide or tirzepatide obesity . finding highlight need policy to address cost and could inform discussion healthcare provider and patient concern cost and side effect .","Obesity (Silver Spring, Md.)",02/10/2025
10.1038/s41467-025-63942-w,mitotic dna repair tmej suppresse replication stress-induced nuclear envelope,"Ye G, He Y, Zhang Y, Li D, Liu F, Li Y, Ge Q, Guo Q, Han S, Song C, Chang W, Zhang H, Peng Q, Sun K, Ji W, Deng L","replication stress ( rs ) , not effectively and timely address , could result dna damage mitosis . however , relationship rs and other mitotic event , such nuclear envelope ( ne ) breakdown and reassembly , remains poorly understand . here report rs can lead ne defect . importantly , rather de novo ne rupture , defect se be result nuclear envelope reassembly defect ( nerd ) mitosis . interestingly , nerd be associate mitotic dna damage , and repair damage dna polymerase theta ( polθ)-mediate end join ( tmej ) ameliorate nerd . genomic mapping lamina associated domain ( lad ) cleavage target and tagmentation ( cut&tag ) identify population replication stress-sensitive lad ( resslads ) . strikingly , substantial portion resslad reside common fragile site ( cfs ) . loss resslads-ne interaction rs might be attribute sustained phosphorylation lamin a/c site nerd . addition , prominent ne defect be observe multiple condition synthetic lethality . altogether , finding establish link genome instability and nuclear vulnerability replication stress .",Nature communications,03/10/2025
10.1016/j.ajcnut.2025.06.019,"ultraprocessed food consumption , inflammatory index level , and risk suicide","Wu Y, Sun M, Yuan Y, Zhang S, Zhu L, Lou Z, Shi Y, Li J, Sun Z, Yang L, Li L, Shen Y","background : suicide attempt ( sas ) be major public health issue , many case be preventable . however , impact dietary pattern remain inadequately study . currently , rise consumption ultraprocessed food ( upfs ) have be link various health issue , include mental health disorder may increase risk sa . objectives : study aim to investigate association upf consumption and sa , and explore mediate role sa-relate inflammatory index level . method : study include 208 , 938 participant uk biobank cohort , recruit 2006 2010 . cox proportional hazard model be use to assess association weight proportion upf intake and incident sa . substitution analysis be conduct to evaluate risk sa replace upf unprocessed or minimally process food ( unpf ) . causal mediation analysis be far conduct to estimate mediating effect inflammatory index level association . result : median follow-up 13 . 1 y , 545 sa event be identify . compare participant low quintile upf consumption , high quintile have 1 . 63 time high risk develop sa [ hazard ratio ( hr ): 1 . 63 , 95 % confidence interval ( ci ): 1 . 23 , 2 . 15 ] . additionally , sd increase upf consumption be associate 20 % high risk sa ( hr : 1 . 20 , 95 % ci : 1 . 11 , 1 . 29 ) . notably , replace 20 % upf weight unpf be link 23 % reduction sa risk ( hr : 0 . 77 , 95 % ci : 0 . 69 , 0 . 85 ) . furthermore , causal mediation analysis , inflammatory index level mediate 0 . 7%-1 . 5 % association upf consumption and sa . conclusions : high upf consumption be associate increase risk sa , partially mediate inflammatory index level . replace upf unpf significantly reduce sa incidence , highlight potential benefit transition diet high unpf consumption .",The American journal of clinical nutrition,01/10/2025
10.1016/j.devcel.2025.09.009,tmk-pin1 drive short self-organizing circuit auxin export and signal,"Huang R, Wang J, Chang M, Tang W, Yu Y, Zhang Y, Peng Y, Wang Y, Guo Y, Lu T, Cao Y, Zhou Y, Zhang Q, Huang Y, Wu A, Ren L, Gallei M, Dong J, Chen H, He J, Wen M, Friml J, Sun L, Xiong Y, Yang Z, Xu T","versatile and pivotal role phytohormone auxin regulate plant growth and development be typically link directional transport , rely polarized pin-formed ( pin ) auxin exporter plasma membrane ( pm ) . decade , auxin have be propose to promote pin polarization , generate self-regulatory feedback mediating much plant development , but mechanistic insight regulation be lack . here , uncover auxin-induced protein complex pm , contain auxin co-receptor transmembrane kinase ( tmks ) and pin1 auxin exporter , core machinery underlie feedback regulation . auxin promote pin1 phosphorylation tmk , modulate pin1 polarization and transport activity . also provide evidence pin1-exporte extracellular auxin be crucial tmk activation and cell elongation , thus form simple two-element self-regulatory feedback circuit . thus , finding offer direct mechanistic insight potential self-organizing circuit auxin signal and transport to ensure proper plant development arabidopsis .",Developmental cell,02/10/2025
10.1186/s12885-025-14915-1,impact systemic inflammatory marker egfr-mutant non-small cell lung,"Wangsubtawee S, Thamrongjirapat T, Trachu N, Incharoen P, Jinawath N, Cheyasawan P, Monnamo N, Munthum D, Reungwetwattana N, Amponnavarat S, Sanvarinda P, Chairoungdua A, Ngodngamtaweesuk M, Khiewngam K, Sirachainan E, Chansriwong P, Dejthevaporn T, Reungwetwattana T, Lumjiaktase P","background : high prevalence egfrm lung cancer be find asian population . preclinical datum suggest inflammatory cytokine activate pm2 . 5 affect egfrm clone expansion . here , explore correlation inflammatory marker and egfrm nsclc . methods : resect nsclc patient ( 2016-2023 ) be enrol . tumor tissue and blood serum be retrieve ramathibodi tumor biobank . egfr 19del and l858r mutation be perform rt-pcr cancerous tissue and dpcr normal tissue same patient . nf-kb and stat3 protein signal be measure elisa both cancerous and normal tissue . cytokine ( il-1ß , il-6 , il-8 , il-10 , il-12 and tnf-α ) be explore serum flow cytometry . result : 140 patient , egfrm prevalence be 58 % cancerous tissue but only 5 % normal tissue . nf-kb and stat3 be statistically high cancerous tissue normal tissue [ nf-kb median o . d . =0 . 82 ( iqr ; 0 . 07-2 . 82 ) 0 . 32 ( iqr ; 0 . 05-2 . 48 ) , p < 0 . 001 ; stat3 median o . d . =0 . 32 ( iqr ; 0 . 10-1 . 58 ) 0 . 17 ( iqr ; 0 . 06-1 . 29 , p < 0 . 001 ] . stat3 be significantly increase egfrm compare egfrwt [ median o . d . =0 . 36 ( iqr ; 0 . 234-0 . 592 ) 0 . 23 ( iqr ; 0 . 158-0 . 409 ) , or = 11 . 09 ( 95 % ci ; 2 . 17-56 . 58 ) , p = 0 . 004 ] . tnf-α ,",BMC cancer,04/10/2025
10.1016/j.immuni.2025.09.008,transcriptional repressor blimp1 enforce tcf-1-dependent and -independent,"Murphy MK, McCullen M, Deffenbaugh JL, Chen AY, Pai J, Daniel B, Yousif A, Raju S, Hsiung S, Wang Z, Ghoneim HE, Satpathy AT, Colonna M, Oltz EM, Egawa T","differentiation cd8(+ ) t cell , transcription factor tcf-1 and blimp1 control progenitor and terminally differentiate state , respectively . here , examine hierarchy and functional consequence cross-regulation factor . identify two blimp1-bound cis-regulatory element , tcf7(+22 kb ) and tcf7(+17 kb ) , enforce tcf7 silence context-specific manner both acute and chronic response . deletion element decouple tcf7 repression effector differentiation but do not rewire effector t cell memory state or prevent acquisition phenotypic hallmark exhaustion . however , combined ablation prdm1 and tcf7 preserve memory surface phenotype defect secondary expansion . thus , anti-proliferative and pro-differentiative effect blimp1 effector or exhausted cd8(+ ) t cell represent mechanistically distinct module , repression tcf7 limit proliferative capacity but not memory or progenitor specification .",Immunity,02/10/2025
10.1136/jitc-2025-012717,abscopal effect patient malignant melanoma treat radiotherapy,"Ferdinandus S, Rühle A, Lamrani A, Frei C, Kaufmann J, Mäurer M, Wurschi G, Jiang P, Ehret F, Baehr A, Hardt A, Bodensohn R, Käsmann L, Waltenberger M, Scafa D, Layer JP, Troost EGC, Elkhamisy SA, Jazmati D, Franklin C, Neppl S, Hagemeier A, Trommer M","background : abscopal effect ( abe ) , regression non-irradiated metastatic lesion ( nils ) follow radiotherapy ( rt ) , be relevant patient malignant melanoma ( mm ) progressive disease ( pd ) immune checkpoint inhibition ( ici ) resistance immunotherapy . "" artic "" trial , assess incidence abe patient progressive mm evaluate effect rt nils . methods : artic ( abscopal effect metastasized cancer patient treat radiotherapy and immune checkpoint inhibition ) ( aro ( arbeitsgemeinschaft radiologische onkologie ) 2022-10 , drks00032390 ) retrospectively screen clinical record patient stage iv mm pd ici . patient receive rt metastasis and have ≥1 nil rt field (= control lesion ) . nil be evaluate accord irecist ( immune response evaluation criteria solid tumors ): abscopal response ( ar ): size reduction ≥30 % , abscopal progression ( ap ): size increase ≥20 % , abscopal control ( ac ): other . patient ar and/or ac be categorize abscopal benefit ( ab ) , patient ap and/or mixed response=no ab . rt detail and factor influence ar be analyze . result : screen clinical record 3773 patient stage iv tumor 12 oncological center germany , identify 47 patient mm 115 nils . rt target metastasis brain ( 38 . 3 % ) and lung ( 19 . 1 % ) , primarily use stereotactic rt ( 29 . 8 % ) . mean time interval end ici and rt be 3 . 53±5 . 67 month . ar be achieve 19 . 1 % patient and 29 . 1 % lesion . compare stereotactic rt , normofractionate or other ( non-stereotactic ) rt regimen significantly reduce probability ab ( or=0 . 092 , p=0 . 04 , 95 % ci : ( 0 . 007 0 . 758 ) ) . long",Journal for immunotherapy of cancer,02/10/2025
10.1016/j.eururo.2025.09.4137,cost-effectiveness analysis treatments bacillus,"Myers AA, Talwar R, Duan Z, Hensley P, Lotan Y, Williams SB, Luckenbaugh AN, Li R, Kassouf W, Necchi A, Packiam VT, Shore N, Steinberg GD, Witjes JA, Schmidt B, Porten S, Hahn NM, Bree KK, Toumazis I, Zhao H, Kamat AM","background and objective : treatment option patient "" bacillus calmette-guérin ( bcg)-unresponsive "" disease be ineligible or refuse radical cystectomy ( rc ) be expand . give lack direct comparative datum , conduct cost-effectiveness analysis to guide treatment selection . method : develop markov decision analytic model to assess five treatment : rc , nadofaragene , nogapendekin , pembrolizumab , and gemcitabine/docetaxel . cost effectiveness be evaluate 5-yr period use willingness-to-pay threshold $ 100 000 quality-adjusted life year us medicare perspective . three index patient bcg-unresponsive carcinoma situ ( cis ) be assess . key finding and limitation : index patient 1 , be willing to try one line therapy or proceed directly rc , gemcitabine/docetaxel be most cost-effective option . index patient 2 , open two line therapy or upfront rc , rc be most cost effective . index patient 3 , willing to try two line us food and drug administration ( fda)-approve therapy ( pembrolizumab , nadofaragene , or nogapendekin ) rc , pembrolizumab be most cost-effective option . conclusion and clinical implication : current pricing bladder-spare treatment pose significant financial barrier patient bcg-unresponsive cis . gemcitabine/docetaxel be most cost effective only one therapy line be consider rc , vary clinical scenario . upfront rc be most cost effective patient want to try two line therapy . patient only willing to try fda-approved option and unwilling to undergo upfront rc , pembrolizumab be most cost-effective option . finding highlight need well treatment selection tool and more equitable pricing .",European urology,03/10/2025
10.1016/j.neurot.2025.e00760,prevalence hypogammaglobulinemia non-anti-cd20 therapy and impact,"Perriguey M, Rigollet C, Freeman SA, Graille-Avy L, Lafontaine JC, Lemarchant B, Alberto T, Demortière S, Boutiere C, Rico A, Hilézian F, Durozard P, Pelletier J, Maarouf A, Zéphir H, Audoin B","people multiple sclerosis ( pwms ) exhibit reduce serum immunoglobulin ( ig ) level , potentially due disease-modifying therapy ( dmt ) , raise concern initiate anti-cd20 therapy . assess frequency hypogammaglobulinemia pwms previously receive non-anti-cd20 dmt and evaluate short-term ig level change switch rituximab ( rtx ) or ocrelizumab ( ocr ) . retrospective study include pwms start rtx or ocr , or prior dmt exposure . patient be group treatment-naïve or receive fingolimod ( fing ) , natalizumab ( ntz ) , or moderate-efficacy dmt ( interferon , glatiramer acetate , dimethyl fumarate , or teriflunomide ) switch . 417 include patient , 89 be treatment-naïve , 207 have receive fing , 70 ntz , and 51 moderate-efficacy dmt . switching , hypogammaglobulinemia ( igg level < 7 ​g/l ) be rare treatment-naïve and moderate-efficacy dmt group ( 2 ​% ) but more frequent fing ( 29 ​% ) and ntz ( 14 ​% ) treatment . one year initiate rtx/ocr , igg level slightly decrease treatment-naïve patient ( p ​ < ​0 . 05 ) , remain stable ntz and moderate-efficacy dmt group , and increase significantly fing-treated patient ( 8 . 0-8 . 6 ​g/l , p ​ < ​0 . 0001 ) , decline hypogammaglobulinemia prevalence ( 29 ​%-21 . 5 ​% ) . fing exposure be associate frequent igg hypogammaglobulinemia , but switch rtx/ocr be not link short-term decrease igg level ; instead , lead significant increase level . finding support hypogammaglobulinemia should not be absolute contraindication switch rtx/ocr fing discontinuation give efficacy prevent ms reactivation . secondary de-escalation strategy may be consider base individual risk profile and igg level trajectory .",Neurotherapeutics : the journal of the American Society for Experimental,04/10/2025
10.1016/j.ejphar.2025.178206,statin activate temperature-gated transient receptor potential ion channel .,"Oprita G, Domocos D, Selescu T, Paduraru A, Tunaru S, Leffler A, Babes A, Babes RM","statin be reductase inhibitor administer to decrease level ldl cholesterol and to lower risk cardiovascular disease . statin be relatively well tolerate , adverse effect such myalgia and painful peripheral neuropathy have be report . underlying cause have not be fully elucidate , accumulate evidence show statin have numerous pleiotropic effect include anti-inflammatory and analgesic action several animal pain model . here report most extensively use statin activate member temperature-gated transient receptor potential ( trp ) ion channel subfamily express heterologous system . test statin ( simvastatin , atorvastatin and rosuvastatin ) activate human trpa1 and , addition , simvastatin activate human trpv1 and rosuvastatin activate human trpm8 . activation trpv1 simvastatin be abolish capsaicin-insensitive mutant . furthermore , sensitivity trpv1 and trpa1 to simvastatin be diminish triple cysteine mutant know to exhibit reduce sensitivity to reactive oxygen specie . rosuvastatin-induce activation trpm8 seem to involve aspartate residue be essential sensitivity synthetic trpm8-agonist icilin . mouse dorsal root ganglion ( drg ) neuron , simvastatin activate subpopulation neuron also respond trpv1-agonist capsaicin or trpa1-agonist allyl isothiocyanate . addition , trpm8 play important role activation small population drg neuron rosuvastatin . take together , result indicate statin activate thermo-sensitive trp channel express nociceptive sensory neuron . property may explain pleiotropic effect widely use drug .",European journal of pharmacology,01/10/2025
10.1038/s41467-025-63842-z,cross-ancestral gwas identify 29 variant head and neck cancer subsite .,"Ebrahimi E, Sangphukieo A, Park HA, Gaborieau V, Ferreiro-Iglesias A, Diergaarde B, Ahrens W, Alemany L, Arantes LM, Betka J, Bratman SV, Canova C, Conlon MS, Conway DI, Cuello M, Curado MP, de Carvalho AC, de Oliviera JC, Gormley M, Hadji M, Hargreaves S, Healy CM, Holcatova I, Hung RJ, Kowalski LP, Lagiou P, Lagiou A, Liu G, Macfarlane GJ, Olshan AF, Perdomo S, Pinto LFR, Podesta JRV, Polesel J, Pring M, Rashidian H, Gama RR, Richiardi L, Robinson M, Rodriguez-Urrego PA, Santi SA, Saunders DP, Soares-Lima SC, Timpson N, Vilensky M, von Zeidler SV, Waterboer T, Zendehdel K, Znaor A, Brennan P, McKay J, Virani S, Dudding T","head and neck squamous cell carcinoma ( hnscc ) include diverse cancer arise oral cavity , oropharynx , and larynx , main risk factor be environmental exposure such tobacco , alcohol , and human papillomavirus ( hpv ) infection . genetic factor contribute susceptibility different population and tumour subsite remain incompletely understood . here show , genome-wide association and fine mapping study 19 , 000 hnscc case and 38 , 000 control multiple ancestry , 18 genetic risk variant and 11 signal fine mapping human leukocyte antigen ( hla ) region , previously unreporte . rs78378222 , regulatory variant tp53 be associate 40 % reduction overall hnscc risk . also identify gene-environment interaction , brca2 and adh1b variant show effect modify smoking and alcohol use . subsite-specific analysis hla region reveal distinct immune-related association hpv-positive and hpv-negative tumour . finding refine genetic architecture hnscc and highlight mechanism link inherit variation , immunity , and environmental exposure .",Nature communications,02/10/2025
10.1016/j.cell.2025.09.005,evolution mycobacterium tuberculosis transcription regulation be associate,"Culviner PH, Frey AM, Liu Q, Ha DTM, Thai PVK, Thu DDA, Quang NL, Calderon R, Lecca L, Caws M, Dunstan SJ, Murray MB, Thuong NTT, Fortune SM","mycobacterium tuberculosis ( mtb ) have co-evolve human thousand year and be characterize variation virulence , transmissibility , and disease phenotype . to identify bacterial contributor to phenotypic diversity , develop new rna sequence ( rna-seq ) and phylogenomic tool to capture hundred mtb isolate transcriptome , link transcriptional and genetic variation , and find association variant and epidemiologic trait . 274 mtb clinical isolate , uncover unexpected diversity virulence gene expression , link known and unknown regulator . surprisingly , find many isolate harbor variant associate decrease expression esxa ( esat6 ) and esxb ( cfp10 ) , be virulence effector , dominant t cell antigen , and immunodiagnostic target . > 55 , 000 isolate , variant associate increase transmissibility , especially drug-resistant mtb strain . datum suggest expression mtb virulence gene be evolve response drug-linked pressure , raise concern use target immunodiagnostic and next-generation vaccine .",Cell,30/09/2025
10.1038/s41598-025-17908-z,dynamic detergent-resistant membrane plasmodium falciparum blood,"Sferra G, Fratini F, Birago C, Megliorini L, Mochi S, Lalle M, Paone S, Olivieri A, Ferreri C, Sansone A, Ponzi M, Currà C, Pizzi E","membrane microdomain , also know detergent-resistant membrane ( drm ) , be tightly pack assembly enrich cholesterol and sphingolipid , various membrane-associated process occur . many intracellular pathogen , include plasmodium , exploit raft-like structure to recognize and invade host cell . particular , plasmodium depend host cholesterol to build own membrane , be unable to perform sterol synthesis . use quantitative proteomic , lipid analysis , and bioinformatics , study define composition and dynamic plasmodium drm key developmental stage : schizont , give rise invasive merozoite , and gametocyte , be responsible transmission mosquito vector . comparative analysis flotation property drm-associate protein and lipid reveal conserve and stage-specific feature structural organization membrane microdomain . follow parasite invasion , host drm be also remodel internalization component erythrocyte junctional complex and repositioning newly generate parasitophorous vacuole membrane . prediction and analysis drm interactome reveal core protein involve fundamental biological process maintain schizont and gametocyte stage . common core form highly interconnect subnetwork occupy central position interactome , stage-specific function occupy peripheral position network .",Scientific reports,03/10/2025
10.1038/s41586-025-09557-z,panoptes system use decoy cyclic nucleotide to defend phage .,"Sullivan AE, Nabhani A, Izrailevsky DS, Schinkel K, Hoffman CRK, Robbins LK, Nagy TA, Duncan ML, Ledvina HE, Erbse AH, Kibby EM, Tak U, Dinh DM, Ednacot EMQ, Nguyen CM, Burroughs AM, Aravind L, Whiteley AT, Morehouse BR","bacteria combat phage infection use antiphage system and many system generate nucleotide-derived second messenger infection activate effector protein to mediate immunity(1 ) . phage respond counter-defence deplete second messenger , lead escalate arm race host . here outline antiphage system call panoptes indirectly detect phage infection phage protein antagonize nucleotide-derived second-messenger pool . panoptes be two-gene operon , optse , be predict to synthesize nucleotide-derived second messenger and opte be predict to bind signal and drive effector-mediated defence . crystal structure show opts be minimal crispr polymerase ( mcpol ) domain , version polymerase domain find type iii crispr system ( cas10 ) . opts orthologue two distinct panoptes system generate cyclic dinucleotide product , include 2 ' , 3 ' -cyclic diadenosine monophosphate ( 2 ' , 3 ' -c-di-amp ) , show be able to bind soluble domain opte transmembrane effector . panoptes potently restrict phage replication , but phage have loss-of-function mutation anti-cyclic oligonucleotide-based antiphage signal system ( cbass ) protein 2 ( acb2 ) escape defence . finding be unexpected acb2 be nucleotide ' sponge ' antagonize second-messenger signal . datum support idea cyclic nucleotide sequestration acb2 release opte toxicity , thereby initiate inner membrane disruption , lead phage defence . datum demonstrate sophisticated immune strategy bacteria use to guard second-messenger pool and turn immune evasion virus .",Nature,01/10/2025
10.1016/j.jaci.2025.09.020,lifestyle-associate metabolite signature and risk late-onset asthma .,"Chang Q, Chen L, Zhu Y, Liu B, Zhou X, Liang H, Lin F, Li D, Zhu Z, Pan Z, Chen X, Liu H, Sun D, Lv J, Li L, Pan P, Yu C, Zhang Y","background : unhealthy lifestyle behavior , lead systemic metabolic disturbance , be significantly link risk late-onset asthma . however , underlie metabolism-related mechanism remain unclear . objective : study aim to identify lifestyle-related metabolite and assess predictive value incident asthma . methods : use nmr metabolomic datum uk biobank population ( aged 40-69 ) , plasma metabolite associate healthy lifestyle score be identify multiple linear regression . cox proportional hazard regression be use to far screen metabolite link late-onset asthma risk . elastic net regularization select critical metabolite develop asthma risk prediction model , incorporate conventional clinical characteristic and lifestyle factor . metabolic score base non-zero regularization coefficient be derive , and association asthma risk be evaluate survival analysis . model and metabolic score performance be validate unused internal uk biobank participant and external china kadoorie biobank cohort . result : 198 , 607 participant ( mean age 56 . 4 year ) , 159 plasma metabolite be significantly relate healthy lifestyle score , 103 be associate incident asthma risk . nine metabolite be select and incorporate asthma risk prediction model , significantly improve predictive performance ( area curve : 0 . 812 0 . 758 ) . individual unfavorable metabolic signature exhibit 77 . 0 % increase risk ( hazard ratio [ hr ] 1 . 770 , 95 % confidence interval [ ci ] 1 . 634-1 . 918 ) develop asthma compare favorable metabolic signature , strong effect observe female ( hr 1 . 914 , 95 % ci 1 . 729-2 . 118 ) . result predictive model and metabolic score be confirm both internal and external validation . conclusion : multiple lifestyle-related metabolite be associate late-onset asthma risk and can help stratify asthma risk , particularly female .",The Journal of allergy and clinical immunology,03/10/2025
10.1111/dom.70172,weight loss people type 1 diabete 12 month : real-world datum,"Al Ozairi E, Irshad M, Alkandari J, Sojan L, Alroudhan D, Alotaibi N, le Roux CW","aim : study aim to compare effect tirzepatide , semaglutide , and liraglutide body weight and metabolic risk marker 12 month people body mass index ≥27 kg/m(2 ) and type 1 diabetes ( t1d ) . methods : real-world study include 250 people obesity and t1d ( female = 54 . 8 % ) , treat tirzepatide ( n = 35 ) , semaglutide ( n = 36 ) , liraglutide ( n = 97 ) or usual care ( n = 82 ) . secondary outcome include change lipid profile , renal and liver marker , blood pressure , and hba1c . result : three agent lead significant weight loss . tirzepatide show great reduction weight loss ( 10 . 9 % ; p < 0 . 001 ) , follow semaglutide ( 9 . 9 % ; p < 0 . 001 ) and liraglutide ( 7 . 1 % ; p < 0 . 001 ) . dose-dependent reduction be observe tirzepatide and semaglutide . tirzepatide , semaglutide and liraglutide modestly reduce hba1c 0 . 65 % ( p = 0 . 004 ) , 0 . 33 % ( p = 0 . 034 ) and 0 . 23 % ( p = 0 . 017 ) , respectively . ldl-cholesterol be reduce semaglutide ( p = 0 . 05 ) and liraglutide ( p = 0 . 02 ) , and liraglutide also lower urine albumin-to-creatinine ratio ( p = 0 . 007 ) . be change body weight and hba1c usual care group . severe hypoglycaemia or diabetic ketoacidosis ( dka ) event be report group . conclusion : tirzepatide , semaglutide , and liraglutide reduce bodyweight and improve select metabolic risk marker 12 month increase risk hypoglycaemia or dka . weight loss appear less compare patient diabetes . tirzepatide , semaglutide and liraglutide modestly improve glycaemic control adult t1d and obesity . finding support potential adjunctive role glp-1 receptor agonist people obesity and t1d and underscore need further validation randomize control trial .","Diabetes, obesity & metabolism",06/10/2025
10.3892/ijmm.2025.5651,gut‑skin axis : emerge insight understanding and treat skin disease,"Zhao Y, Yu C, Zhang J, Yao Q, Zhu X, Zhou X","emerge evidence indicate significant association composition and functionality gut microbiome and various skin disorder , include psoriasis , atopic dermatitis , acne and several dermatological condition . gut‑skin axis theory describe complex bidirectional communication network gut and skin , provide mechanistic insight pathogenesis certain cutaneous disease . specifically , gut microbiome influence skin health regulation systemic immunity , inflammatory response and metabolic pathway . advance high‑throughput sequence and bioinformatics technology have substantially enhance understanding role gut microbiome skin pathology . clinical and preclinical study have demonstrate restore gut microbial homeostasis intervention such faecal microbiota transplantation , probiotic and prebiotic can ameliorate symptom skin disease . furthermore , personalize microbiome‑based therapy , next‑generation probiotic and dietary modification hold promise refine gut‑skin interaction and advance precision medicine dermatology . therapeutic strategy target gut‑skin axis offer novel avenue innovative dermatological treatment , future breakthrough potentially involve microbial community engineering , postbiotic and artificial intelligence microbiome‑related diagnostic . narrative review summarize recent advance gut‑skin axis research , explore potential prevention and management select dermatosis and discuss future trend and scientific development field .",International journal of molecular medicine,01/12/2025
10.1172/JCI190017,target specific kinase substrate rescue increase colitis severity induce,"Heaton GR, Li X, Li X, Zhou X, Zhang Y, Vu DT, Oeller M, Karayel O, Hoang QQ, Kars ME, Kamath N, Wang M, Tarassishin L, Mann M, Peter I, Yue Z","lrrk2 contain kinase domain crohn 's disease ( cd ) risk and g2019s parkinson 's disease ( pd ) pathogenic variant be locate . be not clear variant increase cd risk or adjacent mutation give rise distinct disorder . to investigate pathophysiology cd-linke lrrk2 n2081d variant , generate knock-in ( ki ) mouse model and compare effect lrrk2-g2019s mutation . lrrk2n2081d ki mouse demonstrate heighten sensitivity induced colitis , result more severe intestinal damage lrrk2g2019s ki and wt mouse . analysis colon tissue reveal distinct mutation-dependent lrrk2 rab substrate phosphorylation , significantly elevated phosphorylate rab10 level lrrk2n2081d mouse . cell , demonstrate mutation activate lrrk2 mechanism distinct lrrk2-g2019s . also find proinflammatory stimulation enhance lrrk2 kinase activity , lead mutation-dependent difference rab phosphorylation and inflammatory response dendritic cell ( dcs ) . finally , show knockout rab12 , but not pharmacological lrrk2 kinase inhibition , significantly reduced colitis severity lrrk2n2081d mouse . study characterize pathogenic mechanism lrrk2-linked cd , highlight structural and functional difference disease-associated lrrk2 variant , and suggest rab protein promise therapeutic target modulate lrrk2 activity cd treatment .",The Journal of clinical investigation,01/10/2025
10.1002/adma.202512531,environmental response temporal release injectable hydrogel controlled growth,"Qiu P, Ouyang Y, Liu S, Dai J, Wang R, Zhao W, Xu C, Fan Z","regeneration periodontal bone defect inflammatory microenvironment remain challenge oxidative stress and excessive bone resorption . various biomaterial have be develop , current strategy often fail to address combine obstacle immune dysregulation , oxidative damage , and bone loss . injectable multifunctional hydrogel ( htf@ha ) dynamic borate ester cross-linked network be design to provide environmental responsiveness and temporal release bioactive factor . acidic and oxidative condition , hydrogel degrade more rapidly and preferentially release antioxidative and anti-inflammatory component , facilitate macrophage polarization m2 phenotype and alleviate inflammation . subsequent repair phase , calcium-phosphate interaction mediate sustained release concentrated growth factor ( cgf ) and low-dose bone morphogenetic protein-2 ( bmp-2 ) , support osteogenic differentiation and angiogenesis . vitro , htf@ha exhibit high biocompatibility , antioxidative capacity , anti-inflammatory effect , and significant enhancement periodontal ligament stem cell osteogenesis and endothelial cell angiogenesis inflammatory condition . animal study confirm hydrogel promote new bone and vessel formation ( p < 0 . 001 ) , and bmp-2 dose 50 µg/l , achieve bone regeneration comparable high-dose","Advanced materials (Deerfield Beach, Fla.)",04/10/2025
10.3389/fimmu.2025.1635757,efficacy and safety immune checkpoint inhibitor advanced squamous,"Liu N, Zhang B, He J, Li S","objective : significant efficacy heterogeneity exist first- and second-line immunotherapy regimen advanced squamous non-small cell lung cancer ( sqnsclc ) , but most regimen lack directly comparable clinical trial evidence , result unclear prioritization . analysis identify optimal treatment strategy evaluate difference efficacy immune checkpoint inhibitor ( ici ) . methods : search comprehensive database , include pubmed , embase , cochrane library and clinical trials database . traditional meta-analysis be do use stata 15 . 0 , bayesian-framework network meta-analysis be implement r 's gemtc package markov chain monte carlo simulation . subgroup analysis be perform different pd-l1 expression level , number treatment , ethnic group , and smoke history . result : include 25 randomize control trial . immune-relate therapy can provide significant benefit relative chemotherapy alone advanced sqnsclc . compare chemotherapy , ipilimumab+chemo [ hr = 0 . 92 , 95%ci : ( 0 . 59-1 . 40 ) ] , atezolizumab+chemo [ hr = 0 . 88 , 95%ci : ( 0 . 56-1 . 40 ) ] , and durvalumab+chemo [ hr = 0 . 84 , 95 % ci : ( 0 . 52-1 . 40 ) ] , durvalumab+ tremelimumab+chemo [ hr = 0 . 88 , 95 % ci : ( 0 . 54-1 . 40 ) ] , significantly improve overall survival(os ) . cemiplimab [ hr = 0 . 48 , 95 % ci : ( 0 . 34-0 . 67 ) ] show good os benefit . compare chemotherapy , immunotherapy significantly improve progression-free survival ( pfs ) ipilimumab+chemo [ hr = 0 . 87 , 95 % ci : ( 0 . 75-1 . 00 ) ] . sugemalimab+chemo provide good survival benefit [ hr = 0 . 34 , 95 % ci : ( 0 . 24-0 . 48 ) ] . pd-l1≥50 % tumor , penpulimab show excellent os and pfs ; pd-l1 1-49 % tumor , pembrolizumab+chemo and camrelizumab+chemo achieve good os and pfs , respectively ; pd-l1≥1 % tumor , tislelizumab+chemo and camrelizumab+chemo show good os and pfs result , tumor",Frontiers in immunology,01/01/2025
10.1126/sciadv.adv2283,meiotic cohesin rad21l shape 3d genome structure and transcription male,"Marín-Gual L, Vara C, Sainz-Urruela R, Cuartero Y, Álvarez-González L, Felipe-Medina N, Garcia F, Llano E, Marti-Renom MA, Pendás AM, Ruiz-Herrera A","distinctive three-dimensional ( 3d ) chromatin architecture adopt chromosome meiosis be essential fertility , yet functional implication fine-scale spatial organization remain poorly understand . here , investigate impact rad21l deletion , meiosis-specific cohesin subunit , 3d genome architecture and gene expression male germ line . use fluorescence-activated cell sorting , high-throughput chromosome conformation capture , and single-cell rna sequencing , demonstrate rad21l deficiency impairs meiotic chromatin organization and inter/intrachromosomal interaction . conspicuous 3d genome reorganization also disrupt bouquet formation , result increase telomeric interaction heterologous chromosome primary spermatocyte . genome reorganization be accompany detectable transcriptional dysregulation spermatogonia and primary spermatocyte , mainly affect sex chromosome . collectively , finding establish cohesin rad21l germline-specific critical regulator genome-wide 3d genome reorganization spermatogenesis and modulator male germline transcriptional landscape .",Science advances,03/10/2025
10.1016/j.cell.2025.09.004,functional rna splitting drive evolutionary emergence type v crispr-cas,"Jin S, Zhu Z, Li Y, Zhang S, Liu Y, Li D, Li Y, Luo Y, Cheng Z, Zhao KT, Gao Q, Yang G, Li H, Liang R, Zhang R, Qiu JL, Zhang YE, Liu JG, Gao C","transposon-encode tnpb nuclease give rise to type v crispr-cas12 effector multiple independent domestication event . system use different rna molecule guide dna targeting : transposon-derived right-end rnas ( rernas or omega rnas ) tnpb and crispr rnas type v crispr-cas system . however , molecular mechanism bridge transposon activity and crispr immunity remain unclear . identify trancs ( transposon-crispr intermediate ) derive distinct is605- or is607-tnpb lineage . trancs utilize crispr rnas and rernas direct dna cleavage . cryoelectron microscopy ( cryo-em ) structure latranc lawsonibacter sp . closely resemble isdra2 tnpb complex ; however , single-molecule rerna , latranc guide rna be functionally split tracrrna and crrna . engineered rna split isdra2 tnpb enable activity crispr array . finding indicate functional rna splitting be primary molecular event drive emergence diverse type v crispr-cas system transposon .",Cell,29/09/2025
10.1007/s40259-025-00744-y,biological therapies chronic obstructive pulmonary disease : new directions,"Mappin-Kasirer B, Pavord ID","chronic obstructive pulmonary disease ( copd ) , lead cause global morbidity and mortality , be complex and heterogeneous respiratory condition characterise incompletely reversible airflow obstruction spirometry . aetiology and pathological pattern copd be varied , have long be view hindrance target treatment . yet inflammation be central diverse mechanism copd pathogenesis , and type 2 inflammation have emerge measurable , modifiable and clinically meaningful therapeutic target patient be identify . approval first biological therapy type 2 inflammation copd build understanding immunological mechanism airways disease , be inform decade randomised trial and make possible fundamental shift approach common condition . review will ( 1 ) assess aspect pathological inflammation copd , namely type 1 , 2 and 3 inflammation , and role epithelial alarmin ; ( 2 ) examine datum randomised trial efficacy and safety monoclonal antibody inflammatory mediator copd ; and ( 3 ) discuss future direction biological therapy copd , include new patient population , new agent and new approach focus high-risk disease and open door prevention .","BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy",04/10/2025
10.1038/s41586-025-09560-4,efferocytic remodelling pancreatic islet macrophage limited β-cell death .,"Zakharov PN, Chowdhury CS, Peterson OJ, Barron B, Vomund AN, Gorvel L, Unanue ER, Klechevsky E, Wan X, Ravichandran KS","primary driver type diabete be autoimmune t cell destroy insulin-produce β-cell islet langerhans pancreas(1 ) . pancreatic islet macrophage have also be variably link to disease onset and progression . macrophage-mediated removal die cell efferocytosis regulate tissue homeostasis and immune responses(2 ) , here investigate efferocytosis intra-islet macrophage influence immune environment pancreatic islet . use series complementary omics-based and functional approach , identify subset anti-inflammatory intra-islet efferocytic macrophage ( e-mac ) pancrea mouse and human . limited β-cell apoptosis be induce vivo wild-type c57bl/6 mouse and diabetic-prone nod mouse , islet macrophage adopt e-mac phenotype apparent increase total number intra-islet macrophage . such limited β-cell apoptosis and increase e-mac number lead long-term suppression autoimmune diabete nod mouse . e-mac phenotype could also be recapitulate ex vivo co-culture macrophage apoptotic β-cell . mechanistically , e-mac-enriched population impart anergic-like state cd4(+ ) t cell ex vivo and promote accumulation such anergic-like cd4(+ ) t cell vivo islet . analyse macrophage-t cell interaction pancreatic islet use nichenet and target experimental validation , identify igf-1-igf1r axis contributor anergic-like t cell phenotype islet . collectively , datum advance concept efferocytosis-associated reprogramme islet macrophage and subsequent influence adaptive immune response could be beneficial modulate diabetic autoimmunity .",Nature,01/10/2025
10.1016/S0140-6736(25)01148-1,"oral iptacopan therapy patient c3 glomerulopathy : randomised ,","Kavanagh D, Bomback AS, Vivarelli M, Nester CM, Remuzzi G, Zhao MH, Wong EKS, Wang Y, Krishnan I, Schuhmann I, Trapani AJ, Webb NJA, Meier M, Israni RK, Smith RJH","background : c3 glomerulopathy be ultra-rare , severe form glomerulonephritis cause overactivation alternative complement pathway . aim to assess efficacy and safety iptacopan ( lnp023 ) , oral , proximal complement inhibitor target factor b to selectively inhibit alternative pathway complement cascade . methods : appear-c3 g be multicentre , randomise , double-blind , placebo-controlle , phase 3 study iptacopan placebo ( addition supportive care [ renin-angiotensin-aldosterone system ( raas ) inhibitor ] and immunosuppression ) . adult participant ( aged 18-60 year ) biopsy-confirmed c3 glomerulopathy be enrol 35 hospital or medical centre 18 country . inclusion criterion include reduce serum c3 concentration ( ie , < 77 mg/dl [ define < 0·85 × low limit central laboratory normal range ] ) screening , urine protein-creatinine ratio ( upcr ) 1·0 g/g or high day -75 and day -15 randomisation , estimate glomerular filtration rate ( egfr ) 30 ml/min 1·73 m(2 ) or high screening and day -15 , and vaccination neisseria meningitidi and streptococcus pneumoniae . eligible participant be randomise 1 :1 interactive response technology either iptacopan or placebo group , stratify treatment corticosteroid , mycophenolic acid , or ( yes or no ) . 6-month double-blind period , participant orally receive either iptacopan 200 mg twice daily or placebo ; be follow 6-month open-label period participant receive iptacopan 200 mg twice daily . primary endpoint be relative reduction proteinuria ( measure log-transformed ratio baseline upcr sample 24-h urine collection ) 6 month . primary analysis be do full analysis set ( ie , participant to study treatment be assign randomisation ) ; participant receive at least one dose study treatment be include safety analysis . trial be register ( nct04817618 ) and adult cohort have be complete . finding : july 28 , 2021 , and feb 15 , 2023 , 132 participant be screen , 58 do not complete screening period and 74 ( 64 % male ; 69 % white ) be randomise 1 :1 to receive either iptacopan ( n=38 ) or placebo ( n=36 ) . one participant placebo group discontinue treatment open-label period . 24-h upcr percentage change relative baseline 6 month be -30·2 % ( 95 % ci -42·8 -14·8 ) iptacopan group and 7·6 % ( -11·9 31·3 ) placebo group . iptacopan group , geometric mean 24-h upcr be 3·33 g/g ( 95 % ci 2·79 3·97 ) baseline and 2·17 g/g ( 1·62 2·91 ) 6 month ; placebo group , be 2·58 g/g ( 2·18 3·05 ) baseline and 2·80 g/g ( 2·37 3·30 ) 6 month . primary endpoint be meet relative reduction 24-h upcr 6 month iptacopan placebo 35·1 % ( 13·8 51·1 ; p=0·0014 ) . 30 ( 79 % ) 38 participant iptacopan group have treatment-emergent adverse event , compare 24 ( 67 % ) 36 participant placebo group ; most be mild or moderate severity . be death , treatment discontinuation due treatment-emergent adverse event , and meningococcal infection . serious adverse event be report three ( 8 % ) participant iptacopan group and one ( 3 % ) participant placebo group . interpretation : iptacopan show statistically significant , clinically meaningful proteinuria reduction addition raas inhibitor and immunosuppression 6 month . iptacopan be well tolerate acceptable safety profile patient c3 glomerulopathy . funding : novartis pharma .","Lancet (London, England)",25/09/2025
10.1038/s41392-025-02415-4,multiple sclerosis : molecular pathogenesis and therapeutic intervention .,"Boutitah-Benyaich I, Eixarch H, Villacieros-Álvarez J, Hervera A, Cobo-Calvo Á, Montalban X, Espejo C","multiple sclerosis be chronic immune-mediated disorder central nervous system characterize demyelination , axonal loss , and neuroinflammation , culminate progressive neurological disability . significant advance understand immunopathogenesis , current immunotherapy remain limited ability to halt disease progression , make multiple sclerosis incurable and highlight critical need novel therapeutic strategy . antigen-specific immunotherapy represent groundbreake approach aim to restore immune tolerance myelin-derived antigen preserve protective function immune system . broad immunosuppressive strategy , antigen-specific immunotherapy offer potential highly target modulation pathogenic immune response , reduce off-target effect and enhance safety profile . last two decade , preclinical study and clinical trial have explore diverse antigen-specific immunotherapy modality , range peptide-based vaccine nanoparticle platform , aim achieve durable tolerance multiple sclerosis . review provide comprehensive overview multiple sclerosis , cover etiology , clinical feature , pathogenesis , pathology , and current therapeutic approach . thus , delve current state antigen-specific immunotherapy research , critically examine success and limitation address translational challenge must be overcome to realize therapeutic potential . integrate insight immunology , biotechnology , and translational medicine , propose direction advance antigen-specific approach quest transformative multiple sclerosis therapy .",Signal transduction and targeted therapy,02/10/2025
10.1016/j.landig.2025.100900,can artificial intelligence transform training medical student and,"Ning Y, Ong JCL, Cheng H, Wang H, Ting DSW, Tham YC, Wong TY, Liu N","advance artificial intelligence ( ai ) , particularly generative ai , hold promise transform medical education and physician training response increase health-care demand and shortage global health-care workforce . meanwhile , challenge remain effective and equitable integration ai technology medical education and physician training worldwide . viewpoint explore opportunity and challenge integration . study evolve role ai medical education , potential to enhance high-fidelity clinical training , and contribution to research training use real-world example . also highlight ethical concern , particularly unclear boundary appropriate use ai and call clear guideline to govern integration ai medical education and physician training . furthermore , viewpoint discuss practical constraint , include human , financial , and resource constraint , ai integration , and emphasise need comprehensive cost evaluation and collaborative funding model to support sustainable implementation ai integration . tight collaborative network health-care institution and system , medical school and university , industry partner , and education and health-care regulatory agency could lead ai-transforme medical education and physician training scheme ultimately support adoption and integration ai clinical medicine and potentially bring tangible improvement global health-care delivery .",The Lancet. Digital health,04/10/2025
10.1002/ajh.70074,"teg and rotem : technology and clinical applications , 2026 update .","Longacre MM, Ibla JC","viscoelastic testing ( vet ) have evolve significantly inception mid-20th century , be first develop to guide transfusion strategy trauma and surgical patient . initially , vet technology such teg and rotem assess clot formation measure mechanical resistance pin or piston blood sample . recent advance have introduce automate , cartridge-based system and novel detection methods-including resonance frequency and ultrasound-based sonorheometry-these new system allow more precise , rapid , and user-friendly assessment clot dynamic point care . vet be now indicate wide range clinical scenario complex coagulopathy be anticipate , include trauma , cardiac surgery , liver transplantation , obstetric hemorrhage , and hematologic disorder such dic . use be expand new population , include pediatric cardiac surgery , patient inflammatory bowel disease , and covid-19 . however , vet remain limited ability to reliably detect therapeutic anticoagulant and certain congenital bleed disorder , such von willebrand disease and deficiency protein c , s , and antithrombin . technical limitation , include potential discrepancy vitro and vivo clot formation , and lack fda approval pediatric use have impose implementation barrier center interested pediatric vet . look forward , integration vet datum electronic medical record , development predictive model , artificial intelligence , and continue innovation platelet function assessment and detection technology be poise to enhance clinical utility vet . guideline and evidence continue to evolve , vet be position to become increasingly important tool real-time , individualized management coagulopathy diverse patient population .",American journal of hematology,04/10/2025
10.1002/advs.202503691,single cell and spatial transcriptomics define proinflammatory and profibrotic,"Li L, Liao J, Zhang Y, Yao Z, Huang J, Wu K, Li L, Peng Y, Zhu H, Hong X, Liu X, Zhou L, Hou FF, Fu H, Liu Y","kidney fibrosis be common outcome chronic kidney disease ( ckd ) . often instigate focal site form fibrogenic niche injury . study , use single-cell rna sequence ( scrna-seq ) and spatial transcriptomic ( st ) approach , cellular heterogeneity , spatial organization , and molecular interaction be delineate fibrotic kidney . analysis scrna-seq and st datum normal and fibrotic kidney mouse subject unilateral ischemia-reperfusion injury , tenascin c ( tnc)-enriched , proinflammatory , and profibrotic microenvironment be identify facilitate macrophage activation and promote renal inflammation and fibrosis .","Advanced science (Weinheim, Baden-Wurttemberg, Germany)",03/10/2025
10.1186/s13063-025-09038-8,early implantation transjugular intrahepatic portosystemic shunt ( tips ),"Bettinger D, Janoschke M, Jenkner C, Kaufmann M, van Gessel J, Otter HH, Schultheiss M, Thimme R","background : portal hypertension be major complication patient liver cirrhosis , lead severe outcome such variceal bleeding and ascite . transjugular intrahepatic portosystemic shunt ( tips ) have emerge effective interventional treatment recurrent ascite and variceal bleeding . however , to 30 % patient recurrent ascite show tips refractory ascite , and prior datum have show frequency paracentese tips implantation predict ascite clearance indicate tips implantation may be too late patient . especially , patient grade 2 ascite and meld score ≥ 15 , or grade 3 ascite irrespective meld score first decompensation ascite face high risk further decompensation and mortality . therefore , patient may benefit early tips implantation order to improve post-tip mortality . hypothesise early tips implantation select patient time first decompensation may improve transplantation-free survival compare standard medical treatment ( smt ) . methods : etips study be prospective , randomised , open , multicenter interventional , superiority trial . patient will be randomise 1 :1 intervention group tips implantation and smt group . primary endpoint be transplantation-free survival . secondary endpoint include time ascite need paracentesis and quality life assess six and 12 month randomisation . discussion : expand concept early tips implantation ascites management may offer significant survival benefit and may significantly change treatment algorithm patient ascite . trial registration : german registry clinical studies drks00034545 . register 20/02/2025 . clinical trial nct06576934 . register 04/12/2024 .",Trials,02/10/2025
10.1001/jamanetworkopen.2025.35200,acute surgery conservative treatment traumatic acute subdural hematoma .,"Van Essen TA, Yue JK, Barber J, Lingsma HF, Pisica D, den Boogert HF, van Dijck JT, Moojen WA, Hutchinson P, Markowitz AJ, Steyerberg EW, Okonkwo DO, Bodien YG, Valadka AB, Diaz-Arrastia R, Robertson CS, Foreman B, Wang VY, McCrea MA, Giacino JT, Yuh EL, de Ruiter GCW, Temkin NR, Maas AIR, Peul WC, Manley GT","importance : be unclear perform surgery most patient acute subdural hematoma ( asdh ) and traumatic brain injury ( tbi ) be superior conservative treatment . objective : to compare effectiveness strategy prefer acute surgical asdh evacuation one prefer initial conservative treatment . design , setting , and participant : comparative effectiveness study use datum february 1 , 2014 , july 31 , 2018 , prospective observational transforming research and clinical knowledge traumatic brain injury study , conduct 18 level 1 trauma center us . study include patient nonpenetrate tbi present emergency department and admit 24 hour injury asdh detect acute head computed tomography scan . statistical analysis be perform december 1 , 2022 , december 20 , 2024 . exposures : acute surgical hematoma evacuation initial conservative treatment , compare outcome center accord treatment preference , measure case mix-adjusted probability undergo acute surgery ( conservative treatment ) center . main outcomes and measures : functional disability 6 month be assess glasgow outcome scale-extende 6 month , analyze ordinal logistic regression adjust prespecifie confounder , quantify common odd ratio ( or ) . variation center preference be quantify median or ( mor ) . result : 2697 include patient , 711 ( mean [ sd ] age , 46 . 5 [ 19 . 4 ] year ; 539 man [ 76 % ] ) have asdh , 148 ( 21 % ) undergo acute cranial surgery and 563 ( 79 % ) underwent initial conservative treatment . acute surgery cohort have low mean ( sd ) glasgow coma scale score ( 6 . 8 [ 4 . 4 ] 11 . 4 [ 4 . 6 ] ) , more pupil abnormality ( both pupil unreacting : 43 133 [ 32 % ] 41 477 [ 9 % ] ) , and few isolated asdh ( eg , more concurrent intracranial lesion ; 92 133 [ 69 % ] 297 563 53%% ] ) compare conservative treatment cohort . surgical cohort , 129 148 patient ( 87 % ) undergo decompressive craniectomy ( dc ) , and 17 148 ( 11 % ) underwent craniotomy . conservative treatment cohort , 67 563 patient ( 12 % ) underwent delay cranial surgery ( dc or craniotomy ) . proportion patient undergo acute surgery range 0 % to 86 % ( median , 17 % [ iqr , 5%-27 % ] ) center , 3-fold high probability prognostically similar patient receive acute surgery one center compare random center ( mor , 2 . 95 [ 95 % ci , 1 . 79-7 . 47 ] ; p = .06 ) . center preference acute surgery initial conservative treatment be not associate well outcome ( or , 1 . 05 [ 95 % ci , 0 . 88-1 . 26 ] 22 % [ iqr , 5%-27 % ] increase acute surgery give trauma center ) . conclusion and relevance : comparative effectiveness study , similar patient traumatic asdh be treat differently center-specific treatment preference . outcomes be similar center prefer surgical evacuation and prefer initial conservative treatment . study suggest , patient asdh neurosurgeon experience clinical equipoise acute surgery ( initial ) conservative treatment , conservative treatment may be consider .",JAMA network open,01/10/2025
10.1038/s41388-025-03588-6,target srebp-dependent lipogenesis potentiate anti-tumor activity,"Chen J, Wang ME, Bawcom AR, Lu Y, Asara JM, Li L, Chen M","lipid metabolism be most frequently dysregulate metabolic process human cancer , yet cellular lipid , end product lipogenesis , and composition be alter to support various aspect cancer remain poorly understand . here , show target srebp-dependent lipogenesis fgh10019 , orally available srebp inhibitor , enhance docetaxel-induced cytotoxicity human prostate cancer cell vitro and vivo . mechanistically , suppression lipid biosynthesis lead shift cellular lipid composition polyunsaturate lipid , result increase membrane permeability and intracellular docetaxel accumulation . thus , finding reveal critical role de novo lipogenesis protect cancer cell chemotherapeutic and suggest treatment lipogenesis inhibitor could improve efficacy chemotherapy human prostate cancer .",Oncogene,04/10/2025
10.1016/j.ccell.2025.09.006,cell-free dna fragmentomic cancer .,"Tsui WHA, Jiang P, Lo YMD","analysis cell-free dna ( cfdna ) fragmentation pattern , know "" fragmentomic , "" have open new opportunity noninvasive cancer diagnostic . close relationship genomic organization and cell death , cfdna fragmentomic lie intersection many aspect cancer biology , include epigenetic dysregulation , transcriptomic alteration , and aberrant cellular turnover pattern . recent advance library preparation , sequence technology , and integrative epigenomic-fragmentomic analysis have uncover novel fragmentomic feature reveal specific cellular dysfunction cancer . additionally , cutting-edge artificial intelligence algorithm now harness high-dimensional fragmentomic feature , boost precision and power cancer detection . promise result recent clinical trial evaluate utility fragmentomic analysis real-world setting support potential . review , explore exciting frontier cfdna fragmentomic , discuss critical unanswered question , and highlight future direction to unlock promise fragmentomics-based liquid biopsy cancer care .",Cancer cell,02/10/2025
10.1242/dmm.052376,truncated cd19 selection marker isolation stem cell derive,"Ting Helen Huang L, Gao RJ, Zhang D, Nian C, Martzke W, Shapiro AMJ, Kin T, Tahamtani Y, Lynn FC","stem cell-derived β-cell ( scβ-cell ) be renewable and scalable alternative to cadaveric islet cell replacement therapy type 1 diabetes ( t1d ) . however , heterogeneity scβ-cell culture remain problematic graft safety and function . magnetic selection scβ-cells express unique cell surface marker may help deplete undesirable cell type and facilitate functional maturation . here , explore cd19 potential cell surface marker enrichment insulin-expressing scβ-cell . use crispr/cas9 technology , create knock-in add-on cd19-mscarlet downstream insulin code sequence human embryonic stem cell ( hescs ) . develop and optimize magnetic sort protocol cd19-mscarlet-expressing cell , form enrich scβ-cell cluster improve glucose-stimulated c-peptide secretion . strategy hold promise to facilitate large-scale production functional scβ-cell disease modeling and cell replacement therapy .",Disease models & mechanisms,06/10/2025
10.1016/j.eururo.2025.09.4148,development and validation novel plasma metabolomic signature,"Huang C, Wang G, Yuan Y, Zou Y, Tang X, Guo H, Song H, Gao W, Wang A, Yu Y, Tian Y, Chi C, Dong A, Li H, Li X, He S, Yin Y, Zhou L","background and objective : early diagnosis be critical improve survival renal cell carcinoma ( rcc ) ; yet , effective laboratory test remain lacking . aim to characterise metabolic reprogramme rcc and develop artificial intelligence ( ai)-enabled plasma metabolic model rcc detection . method : multicentre diagnostic model development and validation study , plasma sample rcc patient and healthy control ( hcs ) be collect five hospital december 2019 and october 2023 . eligible patient have pathologically confirm rcc prior treatment ; hcs be recruit routine physical examination . participant history malignancy be exclude . untargeted plasma metabolomic be conduct to identify candidate metabolite support vector machine , far confirm high-resolution target metabolic analysis . ai-aide diagnostic model , renal cell carcinoma artificial intelligence detector ( rcaid ) , be develop use select metabolite and validate six independent validation cohort . multiomic analysis be perform to elucidate underlie metabolic mechanism . key finding and limitation : study enrol 1680 participant , comprise 920 rcc patient and 760 hcs . rcc case , 744 ( 81 % ) have clear cell rcc and 633 ( 69 % ) have stage disease . seven key plasma metabolite , include 2-hydroxyphenylacetic acid , azelaic acid , n , n-dimethylglycine , n-acetyl-l-aspartic acid , n-epsilon-acetyl-l-lysine , proline , and ( z , z)-4-oxo-2 , 5-hetpadienedioic acid , be identify and use to develop rcaid model , demonstrate area receiver operate characteristic curve ( auroc ) 0 . 988 training cohort ( n = 503 ) . model exhibit excellent diagnostic performance , auroc 0 . 977 , 0 . 911 , 0 . 945 , and 0 . 972 internal ( n = 202 ) , external ( n = 158 ) , multicentre ( n = 346 ) , and temporal ( n = 123 ) validation cohort , respectively . additionally , rcaid achieve auroc 0 . 940 late-stage rcc ( n = 179 ) and 0 . 932 non-clear cell rcc ( n = 169 ) validation cohort . multiomic analysis far reveal six rcaid-associate dysregulate metabolic pathway rcc . conclusions and clinical implication : study identify metabolic alteration rcc and develop promising ai-based plasma metabolic model potential clinical application rcc diagnosis .",European urology,04/10/2025
10.1007/s11011-025-01678-8,"epstein-barr virus infection and vitamin d deficiency be "" causal ""","van Rensburg SJ, van Toorn R, Jaftha M, Kemp MC, Engel-Hills P, Kotze MJ","multiple sclerosis ( ms ) be neurological disorder characterize damage myelin sheath surround axon central nervous system , cause decrease axonal signal transmission and disability people ms . epstein-barr virus ( ebv ) infection and vitamin d deficiency have be put forward causal factor development ms , but effect have not be conclusively link disruption myelin maintenance . interestingly , ebv infection and vitamin d deficiency increase level hepcidin , acute-phase peptide hormone inhibit iron absorption . current understanding iron dysregulation ms be iron accumulate deep gray matter brain structure lead disability progression . however , recent study have reveal apparent iron influx may be artefact disease-related brain atrophy , and iron be contrast deplete deep gray matter ms , could cause iron deficiency oligodendrocyte ( cell produce myelin ) , lead demise mitochondrial energy deficit , consequent demyelination . ebv infection , vitamin d deficiency and iron deficiency may converge causal risk factor ms . dismantle current understanding iron excess underpin ms would improve testing and optimization iron parameter and vitamin d part clinical management ms . review additionally explore risk factor lytic reactivation ebv be hypothesize to drive ms disease activity . conversely , ensure ebv remain latent state ameliorate risk factor may prevent ms exacerbation and disease worsen .",Metabolic brain disease,04/10/2025
10.1016/j.ard.2025.07.029,innate immune cell subset be enrich synovial fluid acpa-negative,"Argyriou A, Wadsworth MH 2nd, Fienman J, Gonzalez-Sanchez AC, Ghannoum S, Krishna C, Gerstner C, Horuluoglu B, Sijbranda M, Rönnblom L, Eloranta ML, Wahren-Herlenius M, Hensvold A, Turcinov S, Winkler A, Malmström V, Chemin K","objective : around 30 % patient rheumatoid arthritis ( ra ) lack rheumatoid factor and anti-citrullinated protein antibodie ( acpa ) complicate diagnosis and potentially delay treatment . hypothesise innate immune mechanism might be more prominent acpa- ra . methods : perform single-cell rna sequence mononuclear cell peripheral blood ( pbmc ) and synovial fluid ( sfmc ) patient acpa- and acpa+ ra ( n = 4 group : discovery cohort ; n = 8 group : validation cohort ) . dendritic cell and proinflammatory cytokine production be analyse flow cytometry sfmc patient acpa- ra , acpa+ ra , and psoriatic arthritis . interferon ( ifn ) level synovial fluid ( sf ) and serum be measure group . result : several macrophage subset and cdc2 be enrich acpa- ra sf frequency tph and b cell be increase acpa+ ra sf . type ifn-stimulate gene be detect sfmc , but not pbmc , patient acpa- ra . type ifn signature be also observe synovial tissue two patient acpa- ra independent dataset . ifn level be high sf serum but ifn-α/β production do not differ acpa+ and acpa- ra . conclusion : study identify distinct innate cell composition and type ifn gene response synovial joint , but not peripheral blood , patient acpa- ra . similar ifn level group suggest ifn signature may have be prime cell enter joint . finding provide foundation future research type ifn response acpa- ra .",Annals of the rheumatic diseases,03/10/2025
10.1016/S2213-2600(25)00283-8,assessment role small airway dysfunction relation exacerbation,"Galant SP, Kuks PJM, Kole TM, Kraft M, Siddiqui S, Fabbri LM, Beghé B, Rabe KF, Papi A, Brightling CE, Singh D, Kocks JWH, Franzini L, Vonk JM, Kerstjens HAM, Heijink IH, Pouwels SD, Slebos DJ, van den Berge M","background : recent survey suggest asthma remain inadequately control more 50 % adult asthma guideline-based standard therapy . small airway be often under-recognised major site airway obstruction and inflammation . might be relate lack assessment current tool such impulse oscillometry , and thus under-treatment might explain inadequate control . small airway dysfunction , be common adult well control asthma , might represent important biomarker future risk exacerbation . aim to investigate small airway dysfunction be present patient well control asthma and , so , be risk factor future exacerbation population . methods : observational assessment small airways involvement asthma ( atlantis ) study include 773 extensively characterise patient asthma age 18-65 year 29 primary and specialty clinic nine country june 30 , 2014 , march 3 , 2017 . patient be require to be diagnose asthma at least 6 month inclusion base evidence airway hyper-responsiveness , bronchodilator reversibility , or peak expiratory flow variability . patient be require to have stable asthma , define asthma exacerbation and regular asthma treatment consistent dose 8 week baseline visit . current analysis include patient well control asthma , define asthma control questionnaire ( acq-6 ) score less 0·75 baseline . small airway dysfunction be define , base deviation predict value impulse oscillometry parameter , z score more 1·645 r5-r20 ( resistance 5 hz minus resistance 20 hz ) and ax ( area reactance ) and z score less -1·645 x5 ( reactance 5 hz ) , additional analysis explore severe small airway dysfunction ( z score 3 or -3 ) . atlantis be register clinicaltrials.gov , nct02123667 . finding : 773 patient , acq-6 assessment be available 772 patient . patient , 384 ( 50 % ) be classify have well control asthma , and small airway dysfunction be present 108 ( 36 % [ 95 % ci 30-41 ] ) 304 patient impulse oscillometry datum available r5-r20 , 89 ( 34 % [ 28-42 ] ) 261 patient datum ax , and 79 ( 26 % [ 21-31 ] ) 303 patient datum x5 . multivariable analysis , find r5-r20-define small airway dysfunction be associate increase risk future exacerbation , independent age , sex , smoking status , global initiative asthma step 4-5 , previous exacerbation , percentage predict fev(1 ) , ratio residual volume total lung capacity , and peripheral blood eosinophil count ( hazard ratio [ hr ] 2·26 [ 95 % ci 1·05-4·85 ] ; p=0·038 ) , ax ( 2·07 [ 0·91-4·70 ] ; p=0·082 ) and x5 ( 0·86 [ 0·33-2·21 ] ; p=0·75 ) be not associate exacerbation . severe small airway disease , r5-r20 ( hr 2·80 [ 95 % ci 1·26-6·26 ] ; ) and ax ( 2·51 [ 1·04-6·04 ] ; p=0·041 ) become independent predictor future exacerbation , x5 remain non-significant ( 0·99 [ 0·29-3·32 ] ; p=0·98 ) . interpretation : have address undervalue trait show small airway dysfunction be common , sensitive , early independent risk biomarker future exacerbation adult well control asthma . funding : chiesi pharmaceuticals and dutch ministry health .",The Lancet. Respiratory medicine,29/09/2025
10.1007/s11064-025-04559-9,mitochondrial-astrocyte-neuron triad hypothesis parkinson 's disease : a,"Walecha V, Luthra PM","medical field have spend many year investigate parkinson 's disease ( pd ) , primarily focus main pathogenic feature , dopaminergic neuronal degeneration . recent study indicate pd develop complex pathogenic model link mitochondria astrocyte and neuron , create destructive metabolic loop , protein aggregation cycle , and oxidative stress . review examine mitochondria integrate astrocyte and neuron "" triad hypothesis , "" offer multifaceted perspective pd progression . be previously overlook , have observe astrocytic mitochondria play central role maintain neuroprotection and homeostasis . give , dysfunctional mitochondria astrocyte and neuron lead metabolic failure , compromise glutamate regulation , also enhance α-synuclein aggregation , amplify neuroinflammation , ferroptotic vulnerability and oxidative stress . henceforth , report discuss current insight astrocyte-neuron metabolic coupling , mitochondrial quality control , and lipid redox imbalance , highlight role astrocytic mitochondria strong therapeutic strategy . discuss experimental and translational approach aim to restore triad integrity , include mitophagy enhancement , metabolic reprogramming , mitochondrial transfer , and astrocyte-to-neuron reprogramme . position astrocytic mitochondria core pd pathogenesis , review advocate novel intervention focus glial metabolic resilience . integrated approach address three major pathogenic axis . offer promise potential disease modification and develop effective therapeutic symptomatic dopamine replacement to correct neurodegenerative condition .",Neurochemical research,04/10/2025
10.1038/s41467-025-63718-2,engineer exosome kras(g12d ) specific sirna pancreatic cancer : phase,"Kalluri VS, Smaglo BG, Mahadevan KK, Kirtley ML, McAndrews KM, Mendt M, Yang S, Maldonado AS, Sugimoto H, Salvatierra ME, Solis Soto LM, Haymaker C, Finch R, Gagea M, Fluty AC, Ludtke SJ, Jack Lee J, Jain AK, Varadhachary G, Shroff RT, Maitra A, Shpall E, Pant S, Kalluri R","oncogenic kras be key genetic driver initiation and maintenance pancreatic ductal adenocarcinoma ( pdac ) . here , show engineer exosome kras(g12d ) specific sirna ( iexokras(g12d ) ) reveal biodistribution pancrea negligible toxicity preclinical study mouse and rhesus macaque . clinical testing iexokras(g12d ) iexplore ( iexokras(g12d ) pancreatic cancer ) phase study employ non-randomized single-arm classical 3 + 3 dose escalation design ( phase ia ) , follow accelerated titration design ( phase ib ) ( nct03608631 ) . primary outcome include safety , tolerability and target engagement , and secondary outcome aim to assess disease control . patient advanced metastatic disease be enrol failure multiple line therapy . iexokras(g12d ) therapy be well-tolerate : primary outcome be meet iexokras(g12d ) show dose-limiting toxicity . maximum tolerate dose be not reach even high dose . case , iexokras(g12d ) therapy be associate stable disease response ( secondary outcome ) . downregulation kras(g12d ) dna and suppression phospho-erk be document together increase intratumoral cd8(+ ) t cell follow treatment . cd8(+ ) t cell recruitment priming iexokras(g12d ) inform potential efficacy immune checkpoint therapy and lead validation testing preclinical pdac model . combination therapy iexokras(g12d ) and anti-ctla-4 antibodie , but not anti-pd1 , reveal robust pre-clinical anti-tumor efficacy fas mediate cd8(+ ) t cell anti-tumor activity . first-in-human , precision medicine clinical trial and support preclinical functional study offer new insight priming immunotherapy oncogenic kras inhibitor future opportunistic combination therapy pdac patient .",Nature communications,30/09/2025
10.1016/j.euf.2025.08.005,observational health data analysis cardiovascular adverse events,"Rajwa P, Borkowetz A, Abbott T, Alberti A, Beyer K, Bjartell A, Brash JT, Chilelli A, Davies E, Meulder B, Fazekas T, Golozar A, Hijazy A, Josefsson A, Kasivisvanathan V, Kolde R, Kotik D, Leapman MS, Miszczyk M, Nicoletti R, Prinsen P, Remmers S, Ribal MJ, Rivas JG, Rodriguez-Sanchez L, Roobol MJ, Smith E, Snijder R, Steinbeisser C, Stroomberg HV, Gandaglia G, Cornford P, Evans-Axelsson S, N'Dow J, Willemse PM","background and objective : cardiovascular toxicity modern systemic treatment metastatic hormone-sensitive prostate cancer ( mhspc ) remain concern , real-world datum be limited . aim to characterise patient treat mhspc multiple large cohort and estimate cardiovascular adverse event ( ae ) risk . method : leverage pioneer 's big data platform , database standardise use observational medical outcomes partnership model , define cohort and calculate incidence rate ae 1000 person-year . time first event be assess kaplan-mei analysis , and mean cumulative function ( mcf ) be estimate recurrent event . analysis be stratify therapy and database . key finding and limitation : include 90 087 mhspc patient five database , treat androgen deprivation therapy ( adt ) + androgen receptor pathway inhibitor ( arpi ) + docetaxel ( doc ) ( n = 3743 ) , adt + arpi ( n = 13 588 ) , adt + doc ( n = 16 287 ) , or adt alone ( n = 56 469 ) . distribution age ( 63 . 5-73 . 7 yr ) and comorbiditie vary database ( eg , hypertension 22-79 % ) . diabetes be report to 33 % , heart failure 17 % , obesity 25 % , and kidney impairment 26 % man . high incidence rate aes be follow : 115 case ( adt ) acute cardiac event , 403 ( adt + arpi ) cerebral event , 214 ( adt + arpi ) thromboembolism , 34 ( adt ) chronic heart failure , and 143 ( adt + arpi + doc ) hypertension . 3-yr acute cardiac event-free survival rate range 79 % to 97 % , and 3-yr mcf acute cardiac event be up 0 . 33 . limitation include retrospective nature and lack ae grade . conclusion and clinical implication : study highlight important heterogeneity real-world , observational mhspc datum . include patient demonstrate substantial comorbidity burden , often exceed report clinical trial , high rate cardiovascular ae .",European urology focus,03/10/2025
10.1002/adma.202507012,chimeric glycoprotein nanoparticles elicit robust neutralizing antibodie,"Sun C, Xie C, Fang XY, Hong DC, Zhang H, Wu PH, Liu YN, Bu GL, Cao DH, Si-Tu MY, Peng YJ, Wang J, Feng GK, Zhong Q, Liu Z, Zeng MS","epstein‒barr virus ( ebv ) be ubiquitous gammaherpesvirus link broad spectrum malignancy and autoimmune disease approve therapeutic drug or vaccine . ebv infection rely viral glycoprotein gb and ghgl , , together , function fusion apparatus , mediate viral recognition and membrane fusion both epithelial and b cell . discover potent neutralize antibody target gb and ghgl , heterogeneous antigen structure and distribution multiple glycoprotein virion hinder rational vaccine design target apparatus complex . study , chimeric nanoparticle ( chimeric-nps ) be design co-display ebv fusion apparatus and induce significantly more neutralizing antibody mouse and nonhuman primate cocktail counterpart . be far demonstrate chimeric-nps elicit neutralize antibody predominantly target gb , closely mimic antibody induction pattern whole ebv virion . additionally , single-bcr sequence be use to analyze b cell response chimeric-np , and novel neutralize antibody fab5 target new vulnerable site ebv gb be identify . finding provide novel candidate and vaccine design strategy ebv and reveal underlie mechanism antibody induction and immune response regulation chimera vaccine , potential implication multi-antigen-harbored pathogen .","Advanced materials (Deerfield Beach, Fla.)",04/10/2025
10.1016/j.amjms.2025.07.018,relationship depression and chronic liver disease : potential role,"Nasir AB, Zouridis S, Aspichueta P, Manka P, Syn WK","depression be frequent comorbidity chronic liver disease ( cld ) , include metabolic dysfunction-associate steatotic liver disease ( masld ) , viral hepatitis , autoimmune hepatitis ( aih ) , primary sclerose cholangitis ( psc ) , primary biliary cholangitis ( pbc ) , hemochromatosis , and wilson 's disease . be associate bad outcome , accelerate disease progression , increase hospitalization , and high mortality . antidepressant be commonly prescribe , effect liver disease , particularly liver fibrosis , remain underexplored . narrative review examine relationship depression , cld , and antidepressant literature review study publish 2010 and 2024 . evidence suggest antidepressant may have antifibrotic property , see pulmonary fibrosis , but liver-specific datum be limited . understand potential role both mental health and liver disease management could improve patient outcome . however , significant research gap remain , and further clinical trial be need to determine antidepressant influence liver fibrosis , disease progression , and overall prognosis cld .",The American journal of the medical sciences,01/10/2025
10.1016/j.gim.2025.101595,recurrent missense variant ppib gene encode peptidylprolyl isomerase b,"Valentin K, Kustermann M, Schneider MR, Aminfar H, Vollnhofer K, Wedrich A, Stapf C, Bertich M, Ritter M, Mendrina T, Valcanover D, Berger W, Eckhard M, Sombke A, Lilja SV, Paquay A, Rosensteiner B, Schmidt I, Bittner RE, Georgi TP, Pemp B, Schmidt WM","purpose : hereditary optic atrophy ( oa ) represent one lead cause blindness . relatively large number gene , many be implicate mitochondrial function , be know to be involve oa . many affected individual , however , genetic cause still can not be identify . method : large pedigree and additional family , exome sequence ( es ) be use to identify genetic cause individual so far genetically unresolved oa . subsequently , mitochondrial function be study cultured dermal fibroblast . result : es reveal heterozygous missense variant ppib [ nm_000942 . 5 : c. 538c>t p. (arg180trp ) ] , encode peptidylprolyl isomerase b , segregate clinically isolate oa 19 individual 9 family .",Genetics in medicine : official journal of the American College of Medical,01/10/2025
10.1111/nyas.13853,musical rhythm and read development : do beat processing matter ?,"Ozernov-Palchik O, Patel AD","be mount evidence link musical rhythm processing and reading-related cognitive skill , such phonological awareness . may be music and speech be rhythmic : involve process complex sound sequence systematic pattern timing , accent , and grouping . yet , be salient difference musical and speech rhythm : musical rhythm be often beat-based ( base underlying grid equal time interval ) , speech rhythm be not . thus , role beat-based processing reading-rhythm relationship be not clear . be be distinct relation beat-based processing mechanism and reading-related language skill , or be rhythm-reading link entirely share mechanism process nonbeat-based aspect temporal structure ? discuss recent evidence distinct link beat-based processing and early read ability young child , and suggest experimental design would allow to far methodically investigate relationship . propose beat-based processing tap listener 's ability to use rich contextual regularity to form prediction , skill important read development .",Annals of the New York Academy of Sciences,20/05/2018
10.1186/s12974-025-03545-w,cerebrospinal fluid neuronal pentraxin level be associate tau pathology,"Zhang Z, Chen X, Sheng Z, Jiang N, Zou WQ","background : recent study have report neuronal pentraxin 2 ( nptx2 ) , synapse-associated protein , can significantly predict progression cognitive decline . however , role nptx protein family pathological progression alzheimer 's disease ( ad ) human remain unclear . method : study include 263 participant alzheimer 's disease neuroimaging initiative , include cognitively normal , mild cognitive impairment , and ad individual , mean age 73 . 99 ± 7 . 43 year . cerebrospinal fluid ( csf ) nptx protein and glial fibrillary acidic protein ( gfap ) be quantify mass spectrometry , soluble triggering receptor express myeloid cells 2 ( strem2 ) meso scale discovery-base multiplex immunoassay , and amyloid-beta 42 ( aβ42 ) , phosphorylate tau ( p-tau ) , and total tau ( t-tau ) roche elecsys immunoassay . systematically evaluate association nptx protein and baseline csf ad biomarker , as well relationship longitudinal biomarker change . mediation model be apply to explore gfap and strem2 mediate association nptx protein and t-tau pathology . additionally , subgroup analysis base a/t/(n ) classification be conduct to assess stage-specific effect , and sensitivity analysis be perform use 18 f-fluorodeoxyglucose positron emission tomography place csf ad biomarker . result : find csf nptx protein be significantly associate csf strem2 ( β(nptx1 ) 0 . 293 , p < 0 . 001 ; β(nptx2 ) 0 . 387 , p < 0 . 001 ; β(npr ) 0 . 382 , p < 0 . 001 ) , gfap ( β(nptx1 ) 0 . 274 , p < 0 . 001 ; β(nptx2 ) 0 . 472 , p < 0 . 001 ; β(npr ) 0 . 444 , p < 0 . 001 ) , and core ad biomarker baseline . association nptx2 and t-tau level be significant and independent aβ42 ( β = 0 . 619 , p < 0 . 001 ) . mediation analysis indicate strem2 and gfap , individually or sequentially , partially mediate association nptx and t-tau pathology , strong effect observe suspect non-ad pathology and stage 2 group . pathway analysis suggest nptx may influence tau pathology and cognitive function sequential strem2→gfap→t-tau or p-tau pathway . conclusion : nptx protein be associate tau-related pathology ad , and csf gfap and strem2 may mediate association , role potentially differ stage disease progression .",Journal of neuroinflammation,02/10/2025
10.1080/15548627.2025.2568487,aging-rewired metabolic cue promote autophagy and senescence dram1 .,"Yang J, Sun H, Xu K, Zhang X, Huang M, Jin G, Liu Y, Chen W, Lin S, Shen J, Zhong CQ, Xu Y, Zhang Q, Liu W, Yang Y, Ou J","be major contributor cell senescence and aging , dna damage activate macroautophagy/autophagy , but process be affect aging-rewired metabolism normal biological system remain to be explore . here cultured human umbilical cord-derived mesenchymal stem cell ( hsmscs ) and mouse liver accumulate dna damage aging , find elevation dram1 ( dna damage regulate autophagy modulator 1 ) and dram1-mediate pro-senescent autophagy ( dmpa ) . confirm dram1 activate ampk , seek dmpa-associated metabolic feature and note substantial enrichment n-acetylhistamine ( n-acha ) and phosphatidylethanolamine ( pe ) product age hsmscs and mouse liver . elevate dna damage and senescence , n-acha supplement be sufficient to upregulate dram1 and dmpa primary hepatocyte young mouse but not even pre-senescent hsmscs , hence reflect differential tolerance cell model cytotoxic metabolic cue . effect n-acha be far verify mouse aging and post-hepatectomy liver regeneration model . contrast , accumulate cellular pe content ethanolamine supplement augment autophagy but not dna damage and senescence tend to induce dram1 . combine treatment n-acha and ethanolamine be sufficient to trigger dmpa hsmscs . differential cellular response n-acha and ethanolamine supplement , primary hsmscs and mouse hepatocyte dmpa do not notably downregulate sqstm1/p62 protein , differ general macroautophagy and may constitutively support fusion sqstm1-modified cargo-containing autophagosome lysosome . overall , study reveal",Autophagy,02/10/2025
10.1016/j.celrep.2025.116354,central clock drive metabolic rhythm muscle stem cell .,"Sica V, Smith JG, Deryagin O, Andrés E, Lukesova V, Egg M, Cabezas-Wallscheid N, Benitah SA, Serrano AL, Perdiguero E, Muñoz-Cánoves P","satellite cell ( sc ) , skeletal muscle resident stem cell , maintain state quiescence yet exhibit robust circadian oscillation transcriptional level . sc circadian rhythm be control be not well understand . here , use sc-specific reconstitution essential clock gene bmal1 mouse to elucidate role local sc clock and interplay central clock brain . find 24-h rhythmicity metabolic gene sc depend central clock input , independent sc clock , and identify rhythmic feeding-fasting cycle key brain clock-dependent output control oscillation . functionally , central signal regulate sc metabolic state and",Cell reports,30/09/2025
10.1016/j.jbior.2025.101119,induced pluripotent stem cell-based modelling disease evolution myeloid,Boultwood J,"myelodysplastic syndrome ( mds ) be common myeloid malignancy develop successive acquisition driver mutation hematopoietic stem cell reside bone marrow . third mds patient will develop secondary acute myeloid leukemia ( saml ) and patient high-risk mds or saml have dismal prognosis . study disease progression myeloid malignancy have be enhance recent year use induce pluripotent stem cell ( ipscs ) technology . ipscs offer advantage indefinite expansion and potential genetic modification , reprogramme enable capture full complement genetic lesion find primary patient bone marrow sample . power ipsc and crispr-cas9 gene editing technology have be harness to generate range ipsc-base cellular model mds , reflect genetic and biologic heterogeneity disease . stage-specific patient ipsc line have be produce and sequential gene editing normal human ipscs have be perform to map evolution mds aml . study have increase understanding impact driver mutation , and co-mutation , disease phenotype and reveal mechanism underlie disease stage transition myeloid malignancy . ipsc-base model mds have also prove important tool high throughput drug screening and have empower drug testing and drug discovery , offer new platform to develop personalized therapy .",Advances in biological regulation,26/09/2025
10.1186/s40478-025-02124-7,mglur5 agonist chpg enhance human oligodendrocyte differentiation .,"Huang Y, Geywitz C, Bandaru A, Glass IA, Schirmer L, Nobuta H, Dreyfus CF","previous study adult mouse indicate mglur5 agonist 2-chloro-5-hydroxyphenyl glycine ( chpg ) , reduce cuprizone-elicited loss myelin . effect be partly mediate chpg bind mglur5 receptor reactive astrocyte , trigger release brain derive neurotrophic factor ( bdnf ) , result increase myelin . however , remain unclear chpg have similar beneficial effect human oligodendrocyte . to address issue , examine effect chpg use cultured human induce pluripotent stem cell ( hipsc)-derive oligodendrocyte and primary human fetal oligodendrocyte . show chpg increase proportion mbp(+ ) mature oligodendrocyte affect survival . effect be mediate increase proliferation oligodendrocyte precursor cell ( opc ) and enhance differentiation young oligodendrocyte . contrast observation mouse , mglur5 expression human be localize pdgfrα(+ ) opc and o4(+ ) immature oligodendrocyte , but not astrocyte . use purified human opc culture , show direct effect chpg increase proportion mbp(+ ) mature oligodendrocyte . to identify potential cellular target chpg demyelinate disease , analyze postmortem tissue individual chronic active multiple sclerosis ( ms ) and healthy control . contrast hipscs or primary oligodendrocyte , demyelinate white matter ms patient show elevated mglur5 mrna expression astrocyte . take together , finding suggest chpg enhance differentiation human opc mechanism distinct observe cuprizone-treated mouse . moreover , astrocyte ms pathology upregulate mglur5 , suggest mglur5 expression change dynamically disease condition .",Acta neuropathologica communications,03/10/2025
10.34133/research.0901,cancer-associate fibroblast-derived gdf15 induces oxidative stress and,"Zhao Z, Cai H, Zhao Z, Wang X, Nie W, Zhao F, Chen Y, Ding Y, Luo Z, Lin Z, Ding Y","background : head and neck squamous cell carcinoma ( hnscc ) be malignant tumor oral mucosal epithelium . high incidence recurrence and metastasis present substantial challenge treatment , underscore complex molecular landscape underlie disease . purpose work be to clarify hnscc tumor cell and cancer-associated fibroblast ( cafs ) interact . method : spatial transcriptome sequence and single-cell rna sequencing have be employ to describe biological characteristic cafs hnscc . biological connection cafs and tumor cell be verify molecular interaction experiment . addition , regulatory effect caf oxidative stress tumor cell and phenotypic conversion neutrophil be explore coculture system , knockdown/overexpression method , flow cytometry , and animal experiment . finally , potential small-molecule inhibitor be screen molecular dynamic simulation and validate vitro and vivo assay . result : growth differentiation factor 15 ( gdf15 ) promote tumor cell growth and invasion enhance pcna clamp associate factor ( pclaf ) transcription interferon regulatory factor 5 modulation . interaction receptor gdnf family receptor alpha ( gfral ) trigger chronic inflammatory signal phosphatidylinositol-3 kinase/protein kinase b/signal transducer and activator transcription 3 pathway , lead oxidative stress imbalance and contribute to tumor progression and development drug resistance . moreover , gdf15 activate extracellular signal-regulated kinase 1/2 pathway tumor necrosis factor-α , thereby facilitate neutrophil infiltration and promote lung metastasis hnscc . notably , risperidone ( sm-2 ) emerge potential inhibitory regulator capable disrupt cascade effect mediate gdf15-gfral axis , underscore therapeutic relevance . conclusion : study identify gdf15-gfral signal axis critical regulator oxidative stress and immune evasion hnscc and demonstrate novel small-molecule sm-2 effectively target pathway , highlight potential promising therapeutic strategy .","Research (Washington, D.C.)",01/01/2025
10.1016/j.jhep.2025.09.024,prognostic value liver stiffness measurement biochemical response,"Wong YJ, Lam L, Soret PA, Lemoinne S, Hansen B, Hirschfield G, Gulamhusein A, Lytvyak E, Pares A, Olivas I, Londono MC, Rogriguez-Tajes S, Eaton JE, Osman KT, Schramm C, Sebode M, Lohse AW, Dalekos G, Gatselis N, Nevens F, Cazzagon N, Zago A, Russo FP, Floreani A, Abbas N, Trivedi P, Thorburn D, Saffioti F, Barkai L, Roccarina D, Calvaruso V, Fichera A, Delamarre A, Sobenko N, Villamil AM, Medina-Morales E, Bonder A, Patwardhan V, Rigamonti C, Carbone M, Invernizzi P, Cristoferi L, van der Meer A, de Veer R, Zigmond E, Yehezkel E, Kremer AE, Deibel A, Bruns T, Große K, Wetten A, Dyson JK, Jones D, Levy C, Tanaka A, Dumortier J, Pageaux GP, de Lédinghen V, Carrat F, Chazouillères O, Corpechot C, Montano-Loza AJ","background/aim : liver stiffness measurement ( lsm ) and biochemical response have prognostic significance patient primary biliary cholangitis ( pbc ) . however , frequency and clinical relevance discordant biochemical and lsm change remain unclear . aim to determine performance most recent or current lsm ( lsmc ) predict first hepatic decompensation ( hd ) setting discordant biochemical and lsm response . method : international , multicenter study , include patient at least two reliable lsm perform least six month apart . patient prior hd , liver transplantation ( lt ) or hepatocellular carcinoma be exclude . biochemical response be base paris-2 criterion . lsm response be define stable or reduction lsm . primary outcome be occurrence first hd . secondary outcome be lt and liver-related death . influence lsm hd be estimate use cox regression analysis . result : total 1 , 793 pbc patient be analyze . median follow-up 22 ( iqr : 12-39 ) month , 3 . 3 % develop hd . to 55 % pbc patient exhibit discordance lsm and biochemical response . patient lsm response , achieve paris-2 criterion be associate low risk hd ( hr 0 . 25 , 95%ci : 0 . 06-0 . 97 , p<0 . 044 ) . patient biochemical response , lsm response do not influence risk develop hd ( hr 0 . 64 , 95%ci : 0 . 21-1 . 96 , p=0 . 429 ) . lsmc > 10 kpa strongly predict hd ( hr 14 . 5 , 95 % ci 6 . 9-30 . 6 , p<0 . 001 ) , irrespective biochemical response and prior lsm trajectory . conclusion : discordance lsm and biochemical response be frequent . most recent or current lsm be strong predictor first liver-related event patient pbc , irrespective prior biochemical response or lsm trajectory . impact and implication : liver stiffness measurement ( lsm ) and biochemical response have prognostic significance patient primary biliary cholangitis ( pbc ) . however , clinical relevance and discordant biochemical and lsm change should be well interpret remain unclear . large international multicenter study , demonstrate current lsm ( lsmc ) be know , prior lsm trajectory and biochemical change do not improve prediction liver-related event patient pbc .",Journal of hepatology,03/10/2025
10.1080/15502783.2025.2568048,"randomize , placebo-controlle , crossover clinical trial to evaluate effect","Schönenberger KA, Laval J, Woods T, Truillet R, Naranjo-Modad S, Mettler S, Fança-Berthon P","background : turmeric may alleviate exercise-induced muscle soreness ( delay onset muscle soreness ) and muscular function loss strong anti-inflammatory and antioxidant activity active compound , curcuminoid . primary objective trial be to evaluate effect highly bioavailable turmeric formulation delay onset muscle soreness male adult . method : randomize , double-blind , placebo-controlle , crossover trial ( clinicaltrials.gov nct04946981 ) , 44 moderately active adult ( 34 male , 10 female , mean [ sd ] age = 33 . 7 [ 6 . 4 ] year ) ingest turmeric formulation ( 300 mg/day , thereof 90 mg active curcuminoid ) or placebo five day . second day , muscle damage be induce exercise ( 30 min downhill run 70 % vo₂ max ) . immediately before and 0 , 24 , 48 , and 72 hour post-exercise , muscle soreness squat quadricep ( visual analog scale ) , muscular function ( knee extension dynamometer ) , muscle power ( vertical jump test ) , muscle damage ( serum creatine kinase ) , range motion ( knee flexion ) , and perceive wellness and wellbeing ( questionnaire ) be assess . exercise , exhaustion be assess use borg rating perceived exertion . primary trial population consist male participant , outcome female be consider exploratory . adjust least square mean standard error ( se ) be obtain mixed model repeat measure . result : be significant difference turmeric formulation and placebo muscle soreness area curve pre-exercise 72 hour post-exercise and timepoint , trend observe male 72 hour exercise ( adjust mean [ se ] difference placebo = -4 . 8 [ 2 . 7 ] mm , p = 0 . 0776 ) . muscle soreness recovery ( difference soreness 72 hour and maximal post-exercise soreness ) be significantly great turmeric formulation compare placebo ( adjust mean [ se ] difference placebo = -10 . 7 % [ 4 . 3 % ] , p = 0 . 0184 male participant , and -7 . 9 % [ 3 . 6 % ] , p = 0 . 0346 total sample ) . furthermore , male , decrease pre-exercise 24 hour exercise isokinetic peak torque be significantly low turmeric formulation ( adjust mean [ se ] difference placebo = 11 . 0 [ 4 . 9 ] nm , p = 0 . 0275 ) , be decrease isokinetic max rep work ( adjust mean [ se ] difference placebo = 11 . 6 [ 4 . 9 ] j , p = 0 . 0195 ) , vertical jump peak power 24 hour exercise be high ( median [ interquartile range ] turmeric formulation placebo = 931 . 1 [ 825 . 9 ; 1001 . 1 ] w 916 . 5 [ 824 . 8 ; 989 . 5 ] w , p = 0 . 0445 ) . conclusion : supplementation turmeric formulation can accelerate exercise-induced muscle soreness recovery and could attenuate muscular function loss and improve performance unaccustomed exercise young , moderately active , male adult .",Journal of the International Society of Sports Nutrition,01/12/2025
10.4070/kcj.2025.0001,current therapeutic patterns pulmonary arterial hypertension korea :,"Ha KE, Park S, Chung WJ, Kim GH, Park JH, Choi JH, Kim H, Heo R, Bae DH, Jang Y","background and objective : 2022 revise pulmonary hypertension guideline emphasize risk stratification to enhance outcome , necessitating investigation adherence . study aim to examine treatment pattern patient pulmonary arterial hypertension ( pah ) platform deep phenotyping korean subject ( phoeniks ) study cohort . method : total 321 patient phoeniks cohort be include , consist 101 patient phase 1 ( 2018-2020 ) and 220 phase 2 ( 2021-2023 ) . total 275 patient either idiopathic pah or associate pah be include final analysis . risk assessment be conduct utilize online calculator integrate multiple validate risk stratification model . adherence revise guideline be evaluate , and survival outcome be analyze study period . result : cohort consist primarily middle-aged and female patient ( mean age 51 . 96±15 year , 71 % female ) . total 53 % have idiopathic pah and 47 % have associate pah . intermediate-risk patient comprise 62 % cohort initial diagnosis . proportion low-risk patient increase 34 % to 64 % follow-up period . adherence revise guideline slightly improve study period , only 26 % patient demonstrate compliance . one-year survival rate be 96 % , 3-year survival rate be 87 % . conclusion : current korean pah treatment strategy must be improve to align revise guideline and optimize patient outcome . further effort be need to change health insurance coverage criterion to enhance guideline adherence .",Korean circulation journal,01/08/2025
10.1016/S0140-6736(25)00861-X,budesonide-formoterol salbutamol reliever therapy child mild,"Hatter L, Holliday M, Oldfield K, Kearns C, Barry T, Black M, Bruce P, Colman A, Dickinson E, Eathorne A, Harwood M, Hills T, Lamb R, Kerse K, Krishnamoorthy S, Martindale J, Semprini A, Shortt N, McNamara D, Byrnes CA, Dalziel SR, Bush A, Weatherall M, Beasley R","background : combination inhale corticosteroid-formoterol reliever monotherapy reduce rate asthma attack compare short-acting β(2)-agonist ( saba ) reliever monotherapy adult . comparative efficacy child have not be establish . methods : care be 52-week , open-label , parallel-group , multicentre , superiority , randomise control trial child age 5-15 year asthma use saba reliever monotherapy 15 clinical trial site new zealand . participant be randomly assign ( 1 :1 ) either budesonide 50 μg-formoterol 3 μg , two actuation need , or salbutamol 100 μg , two actuation need . primary outcome be asthma attack rate participant year . trial be register australian new zealand clinical trials registry , actrn12620001091998 . finding : jan 28 , 2021 , june 23 , 2023 , assess 382 participant eligibility . randomly assign 360 ( 94 % ) participant treatment ( 179 [ 50 % ] budesonide-formoterol group and 181 [ 50 % ] salbutamol group ) . annualise rate asthma attack be low budesonide-formoterol group salbutamol group-cluster-adjusted rate 0·23 versus 0·41 participant year ( relative rate 0·55 [ 95 % ci 0·35-0·86 ] ; p=0·012 ) . number participant at least one adverse event be 162 ( 91 % ) budesonide-formoterol group and 167 ( 92 % ) salbutamol group ( odd ratio 0·79 [ 95 % ci 0·35-1·79 ] ) . interpretation : child age 5-15 year mild asthma , budesonide-formoterol reliever monotherapy be superior salbutamol prevent asthma attack , similar safety profile . funding : health research council new zealand , cure kids new zealand , and barbara basham medical charitable trust ( manage perpetual guardian ) .","Lancet (London, England)",04/10/2025
10.1038/s41593-025-02068-0,single-dose psilocybin rapidly and sustainably relieve allodynia and,"Hammo A, Wisser S, Cichon J","chronic pain and mood disorder co-occur , exacerbate one and share neurobiological mechanism , but single intervention could promptly alleviate condition remain unclear . here , two chronic pain model , show single dose psilocybin induce rapid and sustain reversal mechanical allodynia and anxiodepression-like state adult male and female mouse . use local psilocin injection , key active metabolite psilocybin , show engagement prefrontal cortical circuit be critical concurrent alleviation condition . two-photon calcium imaging reveal psilocin rapidly normalize chronic pain-associated hyperactivity anterior cingulate cortex layer 2/3 pyramidal neuron . pharmacologic manipulation full agonist 5-ht(2a ) and 5-ht(1a ) receptor replicate , but not , psilocin 's cellular and behavioral effect , suggest psilocin 's action arise partial agonism receptor share circuit govern pain and mood process .",Nature neuroscience,02/10/2025
10.1186/s12920-025-02222-4,adr pharmaceutical care severe gastrointestinal bleeding rivaroxaban,"Huang Y, Gao H, Chen M, Lin Y, Liu H, Chen M","background : predictable pharmacodynamic and pharmacokinetic , stable blood concentration , and relatively short half-life , rivaroxaban be widely use prevention and treatment thrombosis . nevertheless exhibit certain level inter-individual variability , and safety concern , include bleeding , be also become more noteworthy . case presentation : paper describe elderly patient nonvalvular atrial fibrillation be complicated coronary heart disease , be homozygous mutation carrier abcb1 allele ( rs1045642 c > t , rs1128503 c > t , rs2032582 g > t ) . be develop severe gastrointestinal bleed administration oral rivaroxaban combine aspirin . investigate possible cause bleeding , and potential correlation abcb1 gene polymorphism , combine antiplatelet drug and anemia . conclusion : treatment patient atrial fibrillation , doctor should pay close attention drug interaction antiplatelet agent high-risk group and closely monitor various examination index , include hemoglobin . case , bleeding might be potentially influence homozygous mutation abcb1 , but more clinical datum be need to clarify association abcb1 polymorphism and rivaroxaban pharmacokinetic and bleeding .",BMC medical genomics,03/10/2025
10.1038/s41588-025-02355-3,genetic map human metabolism allele frequency spectrum .,"Zoodsma M, Beuchel C, Yasmeen S, Kohleick L, Nepal A, Koprulu M, Kronenberg F, Mayr M, Williamson A, Pietzner M, Langenberg C","genetic study human metabolism have be limit scale and allelic breadth . here provide data-driven map genetic regulation circulate small molecule and lipoprotein characteristic ( 249 trait ) measure use proton nuclear magnetic resonance spectroscopy allele frequency spectrum , 000 individual . trans-ancestral meta-analyse identify 29 , 824 locus-metabolite association mapping 753 region effect largely consistent man and woman and large ancestral group represent uk biobank . observe and classify extreme genetic pleiotropy , identify regulator lipid metabolism , and assign effector gene > 100 loci rare-to-common allelic series . propose role gene less establish metabolic control ( example , sidt2 ) , gene characterize phenotypic heterogeneity ( example , apoa1 ) and gene specific disease relevance ( example , vegfa ) . study demonstrate value broad , large-scale metabolomic phenotype to identify and characterize regulator human metabolism .",Nature genetics,03/10/2025
10.7150/thno.117582,gpx1-driven selenium nanoplatform reprogram mams-mediate organelle crosstalk,"Tan Y, Zhang F, Cao J, Feng L, Xie B, Gao L, Chen X, Yan Z, Xiong W","background : thyroid eye disease ( ted ) be multifactorial autoimmune disorder limited therapeutic option complexity oxidative , metabolic , and inflammatory network . study aim to develop selenium-based nanoplatform target mitochondria-er interaction to reverse inflammatory adipose expansion ted . method : design dual-responsive selenium nanoparticle ( se@lnt ) modify lentinan , capable ros/ph-triggered release . human primary orbital fibroblast , bioinformatic analysis public dataset , and ted mouse model be use to investigate therapeutic mechanism . result : se@lnt undergoe intracellular metabolic conversion selenocysteine , enhance gpx1 activity and promote redox balance . exert triple regulatory effect stabilize mitochondrial membrane to reduce mtdna leakage , downregulate grp75 to normalize mams contact and calcium flux , and suppress perk-eif2α-atf4 signal to relieve er stress . transcriptomic profiling reveal multi-target modulation immune-stromal interaction . vivo , se@lnt achieve orbital targeting , rapid hepatic-renal clearance , and significant reduction adipose expansion immune remodeling . conclusion : se@lnt offer first mams-targete nanotherapy ted reprogramme organelle crosstalk , restore metabolic-immune homeostasis , and modify disease progression subcellular level .",Theranostics,01/01/2025
10.1186/s12967-025-06818-3,vista express tumor cell be regulate m6a and influence immune,"Xu H, Shen K, Jiang B, Xu Q, Li B, Ke Z, Cheng Q, Zhu S, Wang D, Song Y, Lv T","background : immunotherapy be play increasingly vital role treatment non-small cell lung cancer ( nsclc ) , yet challenge immune evasion remain prevalent . therefore , investigate regulatory mechanism tumor immune microenvironment could yield significant benefit . method : study utilize differential expression analysis , wgcna , and to analyze gse126044 dataset , identify n6-methyladenosine ( m6a)-related molecule play significant role immunotherapy . m6a modification molecule be validate m6a dot blot , merip , rna pull-down and rna stability assay . impact biological behavior tumor cell ( tc ) be evaluate cck-8 assay , wound healing assay , transwell assay , co-culture experiment and flow cytometry . furthermore , rna sequence be conduct to uncover downstream pathway and cytokine , follow subsequent validation . lastly , validation be carry vivo . result : bioinformatics analysis , identify v-domain immunoglobulin suppressor t cell activation ( vista ) serve crucial role immunotherapy and expression be regulate m6a . be subsequently confirm mettl3 enhance m6a modification level vista mrna , be recognize ythdf1 . interaction improve stability vista mrna , lead increase expression vista protein surface tc . elevated expression vista boost cytotoxic response cd8 + t cell tc . rna sequence analysis indicate jak/stat pathway significantly contribute process . overexpression vista tc decrease phosphorylation stat3 , turn reduce expression and release ccl22 . reduction alleviate immune suppression tumor microenvironment , result increase enrichment and activity cd8 + t cell and decrease enrichment regulatory t cell ( tregs ) , ultimately enhance cytotoxic effect tc . conclusion : conduct pioneer systematic study expression , function , and molecular mechanism vista molecule nsclc tc . propose tumor immune microenvironment , vista function both immune checkpoint and regulator cd8 + t cell activation/recruitment and treg recruitment expression tc .",Journal of translational medicine,02/10/2025
10.1001/jamaoncol.2025.3746,prostate-specific membrane antigen pet-guide intensification salvage,"Belliveau C, Saad F, Duplan D, Petit C, Delouya G, Taussky D, Barkati M, Lambert C, Beauchemin MC, Clavel S, Mok G, Igidbashian L, Gauthier-Paré AS, Nguyen TV, McLaughlin PY, Keu KV, DaSilva JN, Juneau D, Ménard C","importance : prostate-specific membrane antigen positron emission tomography ( psma-pet ) offer superior accuracy detect prostate cancer lesion lead intensify radiotherapy ( rt ) , but impact patient outcome be still undefined . objective : to evaluate intensification salvage rt ( srt ) radical prostatectomy ( rp ) guide psma-pet ( psmaisrt ) be associate improved failure-free survival ( ffs ) . design , setting , and participant : psmaisrt be stratified cohort large psma-guide intensification radiotherapy ( psmagrt ) trial , phase 2 , two-center , registry-based randomize clinical trial . patient biochemical recurrence follow rp be eligible standard-of-care ( soc ) srt may 2018 february 2021 , be eligible randomization psmaisrt stratum . total 130 patient be randomize , 2 do not proceed to radiotherapy ( rt ) . cutoff date primary analysis be october 26 , 2023 . intervention : patient be randomize 1 :1 ratio to receive either soc srt prostate bed , or elective pelvic rt , or adjuvant hormonal therapy ( ht ) , or",JAMA oncology,02/10/2025
10.1158/0008-5472.CAN-24-4916,spp1 drives colorectal cancer liver metastasis and immunotherapy resistance,"Liu S, Zhang Z, Wang Z, Liu C, Liang G, Xu T, Li Z, Duan X, Xu G, Feng X, Feng Q, Wang Q, Han D, Zhang C, Li J, Shen L","colorectal cancer ( crc ) remain major cause cancer-related morbidity and mortality globally , 30%-40 % case develop metastasis , mainly liver . immunotherapy have show promise crc treatment , patient crc liver metastasis ( crlm ) experience limit therapeutic benefit , potentially immunosuppressive tumor microenvironment ( tme ) . thus , urgent need exist to identify key player drive crlm and potentiate immunotherapeutic resistance . herein , establish liver metastatic cell continuous passage vivo , allow screening rna expression profile relate crlm . combination spatial transcriptomic sequencing and single-cell analysis reveal substantial upregulation spp1 expression and secretion crlm . spp1 induce immunotherapeutic resistance stimulate cxcl12 production cancer-associated fibroblast ( cafs ) activation β-catenin/hif-1α-related transcription . cxcl12 promote epithelial-mesenchymal transition crc cell but suppress cd8 + t cell infiltration . treatment cxcl12 receptor antagonist or anti-spp1 antibody markedly activate intratumoral cd8 + t cell infiltration and enhance efficacy anti-pd-1 antibody treatment . elevated spp1 and cxcl12 correspond immunotherapy resistance crlm patient . together , study highlight potential spp1/cxcl12 axis target and biomarker precise cancer immunotherapy crlm . intricate interaction tme offer promising avenue improve therapeutic outcome crc patient liver metastasis .",Cancer research,06/10/2025
10.1038/s41386-025-02256-3,preclinical efficacy muscarinic agonist ml-007 psychosis model depend,"Chatterjee S, Soria M, Norville ZC, Thompson KR, Lillie J, Kreitzer AC, Wood MW","muscarinic agonist represent new class treatment psychosis mechanism distinct typical and atypical antipsychotic . muscarinic subtype m(4 ) have be propose primary mediator efficacy but result recent clinical trial m(4)-selective compound have draw hypothesis question . instead , activation m(1 ) and m(4 ) receptor subtype may be require robust treatment effect . here , characterize clinical-stage muscarinic agonist ml-007 preclinical model and explore therapeutic potential treat psychosis schizophrenia and alzheimer 's disease . ml-007 be potent brain-penetrant agonist m(1 ) and m(4 ) muscarinic receptor have demonstrate compelling efficacy range preclinical model psychosis schizophrenia include amphetamine-induced hyperlocomotion , pcp-induce hyperlocomotion , and condition avoidance response . moreover , ml-007 be approximately ten-fold more potent comparator xanomeline animal model . dose-response experiment m(1 ) and m(4 ) knockout mouse reveal efficacy ml-007 be dependent m(1 ) and m(4 ) receptor . take together , datum suggest m(1 ) and m(4 ) receptor contribute potent efficacy ml-007 preclinical rodent model psychosis .",Neuropsychopharmacology : official publication of the American College of,04/10/2025
10.1681/ASN.2021040585,impaired mineral ion metabolism mouse model targeted calcium-sensing,"Schepelmann M, Ranieri M, Lopez-Fernandez I, Webberley TS, Brennan SC, Yarova PL, Graca J, Hanif UK, Müller C, Manhardt T, Salzmann M, Quasnichka H, Price SA, Ward DT, Gilbert T, Matchkov VV, Fenton RA, Herberger A, Hwong J, Santa Maria C, Tu CL, Kallay E, Valenti G, Chang W, Riccardi D","background : impaired mineral ion metabolism be hallmark ckd-metabolic bone disorder . can lead pathologic vascular calcification and be associate increase risk cardiovascular mortality . loss calcium-sensing receptor ( casr ) expression vascular smooth muscle cell exacerbate vascular calcification vitro . conversely , vascular calcification can be reduce calcimimetic , function allosteric activator casr . method : to determine role casr vascular calcification , characterize mouse target casr gene knockout vascular smooth muscle cell ( ( sm22α ) casr ( δflox/δflox ) ) . result : vascular smooth muscle cell culture knockout ( ko ) mouse calcify more readily control ( wild-type ) mouse vitro . however , mouse do not show ectopic calcification vivo but do display profound mineral ion imbalance . specifically , ko mouse exhibit hypercalcemia , hypercalciuria , hyperphosphaturia , and osteopenia , elevated circulate fibroblast growth factor 23 ( fgf23 ) , calcitriol ( 1 , 25-d(3 ) ) , and parathyroid hormone level . renal tubular α-klotho protein expression be increase ko mouse but vascular α-klotho protein expression be not . altered casr expression kidney or parathyroid gland could not account observed phenotype ko mouse . conclusion : result suggest , addition casr 's establish role parathyroid-kidney-bone axis , expression casr vascular smooth muscle cell directly contribute total body mineral ion homeostasis .",Journal of the American Society of Nephrology : JASN,01/07/2022
10.1186/1471-2407-8-221,esophageal cancer risk type alcohol drinking and smoking : case-control,"Vioque J, Barber X, Bolumar F, Porta M, Santibáñez M, de la Hera MG, Moreno-Osset E","background : effect tobacco smoking and alcohol drink esophageal cancer ( ec ) have never be explore spain black tobacco and wine consumption be quite prevalent . estimate independent effect different alcoholic beverage and type tobacco smoking risk ec and main histological cell type ( squamous cell carcinoma ) hospital-based case-control study mediterranean area spain . methods : only include incident case histologically confirm ec ( n = 202 ) . control be frequency-matched case age , sex and province ( n = 455 ) . information risk factor be elicit train interviewer use structured questionnaire . multiple logistic regression be use to estimate adjusted odd ratio and 95 % confidence interval ( ci ) . result : alcohol drinking and tobacco smoking be strong and independent risk factor esophageal cancer . alcohol be potent risk factor clear dose-response relationship , particularly esophageal squamous-cell cancer . compare never-drinker , risk heavy drinker ( > or = 75 g/day pure ethanol ) be 7 . 65 ( 95%ci , 3 . 16-18 . 49 ) ; and compare never-smoker , risk heavy smoker ( > or = 30 cigarettes/day ) be 5 . 07 ( 95%ci , 2 . 06-12 . 47 ) . low consumption only wine and/or beer ( 1-24 g/d ) do not increase risk strong positive trend be observe type alcoholic beverage include combination hard liquor beer and/or wine ( p-trend<0 . 00001 ) . significant increase ec risk be only observe black-tobacco smoking ( 2 . 5-fold increase ) , not blond tobacco . effect alcohol drinking be much strong analysis be limit esophageal squamous cell carcinoma ( n = 160 ) , lack effect adenocarcinoma be evidence . smoking cessation show beneficial effect ten year drinking cessation do not . conclusion : study show risk ec , and particularly squamous cell type , be strongly associate alcohol drinking . consumption combination hard liquor seem to be harmful low consumption only wine may not . may relate presence certain antioxidant compound find wine but practically lack liquor . tobacco smoking be also clear risk factor , black more blond .",BMC cancer,01/08/2008
10.1002/prp2.70176,preclinical evaluation novel molecule target nucleoside homeostasis to,"Wu KC, Lin CY, Tran T, Lin JH, Yeh HH, Ho CJ, Chern Y, Lin CJ","alzheimer 's disease ( ad ) be most prevalent cause dementia , characterize progressive cognitive decline and cerebral metabolic impairment . yet , therapeutic option address disease pathogenesis be limited . here , report approach target brain nucleoside homeostasis and energy metabolism to alleviate ad-associate cognitive deficit . compound , j4 , be design to modulate nucleoside homeostasis interact equilibrative nucleoside transporter-1 ( ent1 ) . effect j4 brain nucleoside homeostasis and energy metabolism be examine mouse . two ad animal model ,",Pharmacology research & perspectives,01/10/2025
10.1111/ijd.12562,evaluation candidal colonization and specific humoral response,"Taheri Sarvtin M, Shokohi T, Hajheydari Z, Yazdani J, Hedayati MT","background : psoriasis be inflammatory skin disease can considerably affect patient 's quality life . environmental and genetic factor , as well superantigen and toxin candida specie , may play various role exacerbation and persistence psoriasis . present study , evaluate candidal colonization and specific humoral response candida albican patient psoriasis . method : total 100 patient psoriasis vulgaris and 50 healthy control individual be enrol study . skin and oral specimen participant be cultured chromagar candida medium . isolated yeast-like fungus be identify use sequence d1/d2 domain 26s rrna gene . enzyme-linked immunosorbent assay ( elisa ) be use to detect immunoglobulin m ( igm ) , iga , and igg antibodie c . albican sera patient and healthy individual . result : candida specie be isolate skin 15 % patient and 4 % control and oral specimen 60 % patient and 20 % control . be significant difference candidal colonization patient and control ( p < 0 . 05 ) . serum igm , iga , and igg level c . albican be significantly low patient psoriasis control ( p < 0 . 05 ) . be significant association serum level specific antibody c . albican or frequency candidal colonization clinical severity disease ( p > 0 . 05 ) . conclusion : result present study show high rate candidal colonization patient psoriasis comparison control and reduction humoral immune response patient .",International journal of dermatology,01/12/2014
10.3389/fimmu.2025.1614702,integrate bioinformatic and experimental validation to reveal novel vrk,"Fu Z, Liu D, Chen M, Zhong G, Zhao Z, Gong J, Dai X, Hu J, Jia D, Cheng L, Cai D, Gong J","background : vaccinia-related kinase ( vrk ) family gene play multifunctional role tumor development . however , role vrk family gene hepatocellular carcinoma ( hcc ) require further research . moreover , clinical potential vrk-related model remain unclear . aim study be to construct vrk-related model to predict hcc prognosis and therapeutic efficacy . methods : datum hcc patient be extract cancer genome atlas ( tcga ) , international cancer genome consortium ( icgc ) , and gene expression omnibus ( geo ) database . single-sample gene set enrichment analysis ( ssgsea ) algorithm be use to calculate vrk score sample . tumor immune estimation resource 2 . 0 ( timer 2 . 0 ) and tumor immune dysfunction and exclusion ( tide ) be use to evaluate immune cell infiltration and immune checkpoint response . prrophetic be use predict drug sensitivity . cck-8 , colony formation , wound healing , transwell and xenograft assay be use to experimentally validate biofunction vrk2 hcc . result : find vrk family gene be highly express hcc . compare patient low vrk score , patient high vrk1 or vrk2 expression tcga , icgc , and gse14520 cohort have poor outcome . moreover , patient high vrk score tcga , icgc , and gse14520 cohort also have poor outcome . importantly , cox analysis reveal vrk score be potential independent risk factor hcc . notably , timer2 . 0 and tide suggest patient high vrk score have high immune checkpoint response rate . similarly , drug sensitivity analysis suggest patient high vrk score be more resistant sorafenib , paclitaxel , cisplatin , and gemcitabine . finally , experimental validation reveal vrk2 knockdown inhibit hcc development vitro and vivo . conclusion : vrk score be find to be reliable indicator predict hcc prognosis and therapeutic efficacy . vrk2 be potential therapeutic target hcc .",Frontiers in immunology,01/01/2025
10.1186/s12986-025-01011-1,vitamin d and bone health : physiological function to disease association .,"Liu Y, Wang W, Yang Y, Deng J, Zhang Z","vitamin d ( vd ) be pleiotropic secosteroid hormone well-established role calcium homeostasis , bone metabolism , and emerge function immune regulation , inflammation , and chronic disease modulation . paper , provide comprehensive summary current research significance vd bone health , emphasis mechanism action and clinical significance bone health . review start overview vd metabolism , emphasis enzyme transformation vitamin d3 ( vd3 ) and vitamin d2 ( vd2 ) active 1 , 25-dihydroxyvitamin d ( 1α , 25(oh)(2)d ) and genomic and non-genomic signal pathway vitamin d receptor ( vdr ) . then , discuss vdr polymorphism affect disease susceptibility and dual role vd promote innate immunity as well inhibit over-adaptive immunity . main focus be place vd 's involvement bone destruction disease , include osteoarthritis ( oa ) , osteoporosis ( op ) , rheumatoid arthritis ( ra ) , and bone tuberculosis . oa , be conflicting evidence vd supplementation reduce cartilage degradation or pain . op , vitamin d deficiency aggravate bone loss , but effectiveness supplementation be dependent baseline and calcium supplementation . ra , immunomodulatory effect vd may decrease activity disease , tuberculosis , vd increase clearance macrophage-mediated mycobacterial clearance , clinical study datum be still inconclusive . review underscore vd critical mediator bone-immune crosstalk call rigorous translational research to clarify therapeutic potential diverse disease .",Nutrition & metabolism,02/10/2025
10.1126/science.aec7429,"first , gene therapy seem to slow huntington disease .",Kaiser J,small study suggest uniqure drug could be first successful treatment devastate brain disorder .,"Science (New York, N.Y.)",02/10/2025
10.1073/pnas.2502841122,mitochondrial ros trigger mitophagy activate dna damage response,"Guo QQ, Wang SS, Jiang XY, Xie XC, Zou Y, Liu JW, Guo Y, Li YH, Liu XY, Hao S, Zhang XY, Wu XX, Lu SM, Xu HD, Guo WD, Feng YL, Wang CG, Zhang SP, Li JB, Liu C, Song XY, Finkel T, Cao L","homeostatic link production mitochondrial ros ( mtros ) and mitophagy play significant role cell respond various physiological and pathological condition . however , remain unclear cell translate oxidative stress signal adaptive mitophagy response . here , show mtros act signal molecule activate ataxia-telangiectasia mutate ( atm)-cell cycle checkpoint kinase 2 ( chk2 ) , dna damage response ( ddr ) pathway . activate , chk2 regulate three critical step mitophagy . first , chk2 phosphorylate mitochondrial membrane protein atad3a ser371 , inhibit transport pink1 inner mitochondrial membrane and lead accumulation pink1 and commencement mitophagy . second , activate chk2 target autophagy adaptor optn ser177 and ser473 , thereby enhance targeting ubiquitinated mitochondria autophagosome . finally , chk2 phosphorylate beclin 1 ser90 and ser93 , hence promote formation autophagosomal membrane . consistent effect , chk2(-/- ) mouse show impair mitophagic induction and impaired recovery ros-dependent model renal ischemia-reperfusion . study reveal mtros-triggered adaptive pathway coordinate mitophagic induction , order to protect cell and tissue expose pathophysiological stress-induced damage .",Proceedings of the National Academy of Sciences of the United States of America,07/10/2025
10.1096/fj.202502040R,impact dietary patterns human gut microbiome and health,"Muigano MN, Liu J, Liu X, Luo P, Li Z, Li J","gut microbiome constitute dynamic and complex ecosystem human body , play crucial role maintain metabolic homeostasis , immune regulation , and disease prevention . various factor shape ecosystem , dietary pattern represent major determinant microbial composition and function . recent study have identify dietary pattern one primary factor influence composition and function gut microbiome . review summarize effect various dietary pattern , include mediterranean diet , vegetarianism , low-carbohydrate high-fat diet , and high-protein diet , gut microbiome dynamic . furthermore , explore mechanism gut microbiome contribute pathophysiology multiple chronic disease , such obesity , diabetes , inflammatory bowel disease , osteoporosis , and neurodegenerative disorder . potential dietary intervention to improve health modulate gut microbiome be also evaluate , emphasize recent finding unveil intricate network dietary microbiome-host interaction . review aim to provide scientific basis development future dietary strategy leverage gut microbiome modulation , ultimately contribute personalized nutrition and precision medicine .",FASEB journal : official publication of the Federation of American Societies for,15/10/2025
10.1016/j.ajpath.2020.01.007,identification lacrimal gland postganglionic innervation and regulation,"Jin K, Imada T, Hisamura R, Ito M, Toriumi H, Tanaka KF, Nakamura S, Tsubota K","tear fluid secrete exocrine lacrimal gland ( lg ) have essential role maintain homeostatic environment healthy ocular surface . tear secretion be regulate sympathetic and parasympathetic component autonomic nervous system , contribution component be not fully understand . to investigate lg innervation , identify sympathetic and parasympathetic postganglionic nerve , specifically innervate mouse lg , inject retrograde neuronal tracer lg . interruption neural stimulus lg denervation postganglionic nerve immediately and chronically decrease tear secretion , lead lg atrophy destruction lobular structure . investigation also find parasympathetic , but not sympathetic , innervation be involve alteration .",The American journal of pathology,01/05/2020
10.1038/s41590-025-02289-2,chemotherapy-induce ca-repeat dna fragment breast cancer trigger antitumor,"Zhang X, Huang P, Chen H, Yang C, Yang X, Liu Y, Wu B, Zeng W, Saw PE, Ye S, Li J, Wang J, Wu Z, Wang J, Li H, Huang JD, Zeng M, Li M, Liu Q, Su S, Song E, Chen J","damage-associate molecular pattern generate cancer treatment can modulate antitumor immunity , but underlie mechanism effect be unclear . here show ca-enriche dna fragment result dna-damage chemotherapy msh2-low tumor preferentially bind cga strong affinity and form biomolecular condensate phase separation cytoplasm , result antitumor immunity . however , classical ca-poor dna release msh2-high tumor cell engage aim2 , result immunosuppression upregulate pd-l1 and ido . intratumoral administration ca-rich dna fragment enhance antitumor immunity syngrafte pymt tumor . clinically , ca-rich dna abundance breast cancer follow chemotherapy be associate increased tumor-antigen-reactive t cell and well chemotherapeutic response . therefore , different tumor dna fragment can trigger oppose immune response depend preference differential sensor . study highlight mechanistic link genome instability and immune modulation and therapeutic potential ca-rich dna to enhance antitumor immunity .",Nature immunology,29/09/2025
10.1016/j.ccell.2025.09.002,ketogenic diet inhibit glioma progression promote gut microbiota-derived,"Chen ML, He Y, Dong XH, Liu HF, Yan ZX, Lu XL, Miao QQ, Zhao QN, Zhang H, Luo L, Wang S, Li JY, Xiang DF, Lin Y, Li TR, Zhou XY, Zhou YY, Mao M, Zhang X, Wei H, Shi Y, Liu XD, Ping YF, Bian XW","ketogenic diet ( kd ) be potential therapeutic strategy glioma ; however , underlie mechanism remain unclear . herein , first identify glioma patient exhibit distinct gut microbial profile characterize reduce butyrate-producing bacteria abundance , particularly r . faecis , decrease butyrate level . notably , kd reshape gut microbiota especially enrich a . muciniphila mucin-2-dependent manner , elevate butyrate production , and activate caspase-3 microglia . change promote anti-tumor microglial phenotype , ultimately suppress glioma progression mouse . crucially , kd 's anti-glioma effect be notably abolish antibiotic treatment ; germ-free condition ; or specific depletion mucin-2 , microglia , or microglial caspase-3 . furthermore , butyrate , a . muciniphila , r . faecis , or a . muciniphila plus r . faecis restore kd-induce microglial caspase-3 activation and anti-tumor phenotype microglia antibiotics-treated or germ-free mouse . finding highlight target gut microbiota kd or supplement butyrate could be effective strategy glioma therapy .",Cancer cell,25/09/2025
10.1007/s10265-015-0705-z,molecular and physiological mechanism regulate tissue reunion incise plant,"Asahina M, Satoh S","interaction functionally specialized organ high plant ensure plant body develop and function properly response change environmental condition . incision or graft procedure interrupt original organ or tissue connection , cell division be induce and tissue reunion occur to restore physiological connection . such activity have long be observe graft technique , be advantageous not only agriculture and horticulture but also basic research . to understand healing process be control and process be initiate and regulate molecular level , physiological and molecular analysis tissue reunion have be perform use incise hypocotyls cucumber ( cucumis sativus ) and tomato ( solanum lycopersicum ) and incise flower stem arabidopsis thaliana . result suggest leaf gibberellin and microelement root be require tissue reunion cortex cucumber and tomato incise hypocotyls . addition , wound-inducible hormone ethylene and jasmonic acid contribute regulation tissue reunion process upper and low part , respectively , incise arabidopsis stem . ethylene and jasmonic acid modulate expression anac071 and rap2 . 6l , respectively , and auxin signal arf6/8 be essential expression transcription factor . report , discuss recent finding regard molecular and physiological mechanism graft union and tissue reunion process wound tissue plant .",Journal of plant research,01/05/2015
10.1016/j.molmet.2025.102262,tert expression attenuate metabolic disorder obese mouse promote adipose,"Braud L, Bernabe M, Vernerey J, Miranda AMA, Dominguez A, Churikov D, Richaud M, Jourquin F, Allan LM, Lachaud C, Gil J, Scott W, Géli V","background and aim : adipose tissue ( at ) senescence , induce obesity or aging , lead reduce capacity tissue remodeling and chronic pro-inflammatory state , lead onset metabolic pathology . cellular senescence be trigger various stress , particular excessive shortening telomere , activate p21 pathway and lead arrest cell cycle . use mouse model p21(+/tert ) express tert cdkn1a locus to investigate counteract telomere shorten telomerase ( tert ) specifically pre-senescent cell could improve obesity-induced metabolic disorder . result : study demonstrate conditional expression tert reduce insulin-resistance and glucose intolerance associate obesity . at , be accompany decrease number senescent p21-positive cell , very short telomere , and oxidative dna damage . single nucleus rna-seq datum reveal tert expression attenuate senescence induce hfd particular adipose stem and progenitor cell ( aspc ) . demonstrate aspc expansion and differentiation be promote p21(+/tert ) obese mouse , thereby improve at plasticity . furthermore , show tert expression enhance mitochondrial function and alleviate oxidative stress aspc . process contribute at hyperplasia increase number adipocyte have be show to have protective effect obesity-associated metabolic disorder conclusion : result underscore tert 's role mitigate obesity-related metabolic dysfunction . conditional tert expression may therefore represent promising therapeutic strategy obesity-associated metabolic disorder .",Molecular metabolism,03/10/2025
10.1038/s41418-025-01592-7,k11- and k29-ubiquitination-mediated nuclear translocation glycolytic enzyme,"Zhou S, Li Y, Wang C, Zhao Y, Zheng X","function cytosolic aldolase a ( aldoa ) glycolysis be well recognize . however , cytosol-to-nucleus redistribution aldoa and nuclear function be poorly understand . here , uncover inflammatory factor-stimulated nuclear function aldoa augment pancreatic carcinogenesis activate signal ubiquitination-dependent manner . tnf-α-triggere k11- and k29-linke ubiquitination aldoa lys200 promote interaction rela/p65 and facilitate importin-β-dependent nuclear translocation , establish positive feedback regulation tumor microenvironment elevate",Cell death and differentiation,04/10/2025
10.1148/radiol.233057,amplifying research : potential podcasts to boost radiology journal,"Wang M, Le T, Leswick DA","background podcasts have become increasingly popular method communicate information medicine , include radiology . however , effect podcast reach journal article remain unclear . purpose to evaluate influence radiology podcast performance metric , include download , citation , and altmetric attention score ( aas ) , radiology article . material and method be retrospective study . article publish print version radiology january 2021 december 2022 be review ; editorial and case report be exclude . article feature radiology podcast be include podcast group . article publish same journal issue and category be nonpodcast group . download , google scholar citation , dimension citation , and aas metric be record . mann-whitney u test be use to compare medians and evaluate difference old and more recently publish article . result podcast group , compose 88 article , exhibit significantly high median value download ( pg , 4521 . 0 ; nonpodcast group , 2123 . 0 ; p < .001 ) , google scholar citation ( podcast group , 14 . 5 ; nonpodcast group , 10 . 0 ; p = .01 ) , dimension citation ( podcast group , 12 . 0 ; nonpodcast group , 9 . 0 ; p = .01 ) , and aas ( podcast group , 43 . 0 ; nonpodcast group , 10 . 0 ; p < .001 ) compare nonpodcast group 378 article . group , article publish early nonpodcast group ( january june 2021 ) have high download ( podcast group , p = .08 ; nonpodcast group , p < .001 ) , google scholar citation ( podcast group and nonpodcast group , p < .001 ) , and dimension citation ( podcast group and nonpodcast group , p < .001 ) article later period ( july december 2022 ) . aas markedly increase recent podcast article ( p = .03 ) , but aas nonpodcast article significantly decrease time ( p = .01 ) . conclusion radiology article feature radiology podcast have great median metric , include download , google scholar citation , dimension citation , and aas , compare nonpodcast article , suggest podcast can be effective method disseminate and amplifying research field radiology . © rsna , 2024 see also editorial chu and nicola issue .",Radiology,01/09/2024
10.1186/s13073-025-01527-4,genome sequence diagnosis intellectual disability paradigm,"El Chehadeh S, Heide S, Quélin C, Rio M, Margot H, Geneviève D, Isidor B, Goldenberg A, Guégan C, Lesca G, Willems M, Ormières C, Caumes R, Busa T, Bonneau D, Guerrot AM, Marey I, Vera G, Marzin P, Philippe A, Garde A, Coubes C, Vincent M, Michaud V, Mignot C, Charles P, Sigaudy S, Edery P, Lacombe D, Boland A, Nowak F, Bouctot M, Humbert-Asensio ML, Simon A, Chennen K, Sabour N, Delmas C, Nicolas G, Saugier-Veber P, Lecoquierre F, Cassinari K, Keren B, Courtin T, De Sainte Agathe JM, Malan V, Barcia G, Tran Mau-Them F, Safraou H, Philippe C, Thévenon J, Chatron N, Januel L, Piton A, Haushalter V, Gérard B, Lejeune C, Faivre L, Sanlaville D, Héron D, Odent S, Nitschké P, Schluth-Bolard C, Lyonnet S, Deleuze JF, Binquet C, Dollfus H","background : intellectual disability ( id ) be lead cause patient referral medical genetic department french academic hospital . whole genome sequencing ( wgs ) first diagnostic approach be expect to achieve high diagnostic yield french national reference strategy ( refstrategy ) ( fragile x expansion testing , chromosomal microarray analysis , and 44 id gene panel ) , give broad and more homogeneous coverage , ability to identify copy number , structural and intergenic/deep intronic event . method : defidiag be national , prospective pilot investigation , carry framework french initiative genomic medicine ( plan france médecine génomique 2025 ) , aim compare diagnostic yield wgs trio analysis ( wgs-trio ) ( index case , father , mother ) refstrategy real-life condition clinical and laboratory workflow . strategy be apply blinded fashion 1239 id proband ( 50 % be already-tested , 50 % be never-tested ) definitive genetic diagnosis . , subgroup 187 patient be randomize to undergo wgs-solo ( proband only ) addition wgs-trio and refstrategy . result : four hundred forty two likely pathogenic/pathogenic single-nucleotide variant be identify ( 231 gene ) as well 171 variant uncertain significance warrant clinical or functional reassessment potential reclassification ( vus + ) ( 142 gene ) , 79 likely pathogenic/pathogenic copy number variant and 10 likely pathogenic/pathogenic structural variant . diagnostic yield likely pathogenic/pathogenic variant increase 17 . 3 % refstrategy 41 . 9 % wgs-trio never-tested patient cohort . increase 13 . 9 % be observe category add vus + , thus raise yield 56 % wgs-trio . overall ,",Genome medicine,03/10/2025
10.1038/s41584-025-01302-0,glucagon-like peptide-1 receptor agonist arthritis : current insight and,"Karacabeyli D, Lacaille D","obesity affect nearly one six adult worldwide . excess adiposity be pro-inflammatory state associate increase risk several type arthritis , increase arthritis disease activity and/or severity , and poor response certain treatment . obesity be major risk factor cardiovascular disease , lead cause death people common arthritide such osteoarthritis ( oa ) , gout , rheumatoid arthritis , psoriatic arthritis and axial spondyloarthritis . glucagon-like peptide-1 receptor agonist ( glp-1ras ) be promising therapeutic option people arthritis and obesity or type 2 diabetes mellitus owe pleiotropic effect , include weight loss , improved survival and reduce risk major cardiovascular and renal event . vitro and preclinical vivo experiment arthritis have uncover weight-loss-independent anti-inflammatory and chondroprotective property",Nature reviews. Rheumatology,01/10/2025
10.1111/cas.70200,"impdh and gtp metabolism cancer : mechanisms , regulation , and translational","Ogawa-Iio A, Takeuchi K, Shigemi K, Genoveso MJ, Niitsu H, Koh I, Ota Y, Yamane K, Hinoi T, Osaka N, Oshima M, Ishikawa T, Mizuno T, Natsumeda M, Tateishi K, Hashizume R, Osuka S, Goyama S, Yasuda T, Senda T, Sasaki AT","guanosine triphosphate ( gtp ) be increasingly recognize critical actor cancer cell proliferation , yet regulatory mechanism remain incompletely define . key contributor elevated gtp level tumor be inosine monophosphate dehydrogenase 2 ( impdh2 ) , rate-limiting enzyme de novo guanine nucleotide biosynthetic pathway . impdh inhibitor , mycophenolic acid ( mpa ) and mycophenolate mofetil ( mmf ) , have show potential cancer therapy , success have be limit immunosuppressive side effect and several unresolved regulatory mechanism , include paradoxical control impdh activity gtp . review provide systematic summary current understanding impdh biology , emphasize complex regulation and therapeutic relevance cancer . will outline key unresolved question , include isozyme-specific role and mechanism escape regulation , and propose mechanistic and translational strategy to design impdh-targeted cancer therapy .",Cancer science,03/10/2025
10.1186/s12929-025-01188-w,impact different dietary restriction regimen aging and longevity :,"Ching TT, Hsu AL","dietary restriction ( dr ) refer broad set intervention limit intake specific nutrient or overall food consumption , either quantity or timing , cause malnutrition . dr have long be consider most robust intervention increase healthspan and lifespan . include , not exhaustively , caloric restriction ( cr ) , protein restriction ( pr ) , amino acid restriction ( aar ) , intermittent fasting ( if ) , and time-restricted fasting ( trf ) , overlapping but distinct metabolic and physiological effect . brief review examine current scientific understanding most commonly employ dr regimen may impact metabolism , lifespan , and healthspan . particular attention be give underlie biological mechanism and support evidence derive human clinical study and fundamental biological research conduct model organism range yeast non-human primate .",Journal of biomedical science,03/10/2025
10.1126/science.aeb2962,hidden network brain .,"Budinger D, Heneka MT",dendritic nanotube extend brain connectivity synapsis .,"Science (New York, N.Y.)",02/10/2025
10.1080/13685538.2025.2568142,genetic evidence correlation relative nutrient intake and male,"Li S, Wang S, Jing Z, Guo J, Cao X, Guo Q","background : relationship composition dietary macronutrient intake and male reproductive health ( mrh ) have be topic interest public health . study aim to evaluate causal effect dietary macronutrient composition mrh . methods : datum four relative macronutrient intake and seven mrh outcome be obtain large genome-wide association study ( gwas ) and finngen biobank . multiple mr ( mendelian randomization ) method be utilize study , include inverse variance weight ( ivw ) , mr-egger , weight median ( wm ) , and mr-pleiotropy residual sum and outlier ( mr-presso ) . result : result reveal high relative intake carbohydrate ( rc ) be associate reduce risk erectile dysfunction [ or = 0 . 43 ; ci = 0 . 18-1 . 00 ; p = 0 . 0049 ] . additionally , high relative intake fat be observe to be risk factor abnormal spermatozoa [ or = 19 . 98 ; ci = 1 . 16-345 . 25 ; p = 0 . 039 ] . relative intake sugar ( rs ) be positively correlate level bioavailable testosterone [ or = 1 . 23 ; ci = 1 . 03-1 . 47 ; p = 0 . 022 ] . conclusion : finding contribute evidence causal relationship four relative macronutrient intake and mrh . however , further confirmation causal effect clinical trial be warrant .",The aging male : the official journal of the International Society for the Study,01/12/2025
10.1155/crp/9292002,relationship fibrinogen-to-albumin ratio and short-term mortality,"Guo LL, Liu P, Cai LN, Hu L, Zhou YS","background : recent study have identify association fibrinogen-to-albumin ratio ( far ) and prognosis coronary heart disease ; however , evidence regard significance heart failure patient remain limited . study aim to examine relationship far and short-term mortality individual heart failure . method : retrospective cohort study , conduct analysis clinical datum patient heart failure be hospitalize zigong fourth people 's hospital december 2016 june 2019 . primary exposure variable be far , outcome interest be mortality rate 28 day and 3 month . multivariate logistic regression evaluate far 's independent association short-term mortality , predictive accuracy assess roc curve and subgroup consistency stratified analysis . furthermore , smooth curve fitting be utilize to investigate linear relationship , and series sensitivity analysis be conduct to validate robustness finding . result : analysis include 1880 participant , 58 . 1 % be female and 54 . 1 % be age 60-80 year . study show one standard deviation rise far be link 45 % increase 28-day mortality ( or = 1 . 45 , 95 % ci = 1 . 02-2 . 06 , p=0 . 04 ) adjust potential confounding factor . 28-day mortality rate be markedly elevated high far group ( far > 0 . 126 ) compare low far group ( or = 4 . 01 , 95 % ci = 1 . 17-13 . 82 , p=0 . 028 ) . comparable finding be note 3-month mark . be significant interaction find subgroup analysis . linear association be identify far and short-term mortality . optimal far cutoff value predict 28-day mortality be 0 . 156 ( sensitivity 68 . 0 % , specificity 59 . 4 % , auc = 0 . 654 ) , 3-month mortality , be 0 . 156 ( sensitivity 68 . 0 % , specificity 58 . 3 % , auc = 0 . 647 ) . sensitivity analysis corroborate robustness finding . conclusion : positive correlation exist far and short-term mortality chinese patient heart failure . finding underscore necessity further investigation underlie pathophysiological mechanism and potential therapeutic intervention associate far context heart failure .",Cardiology research and practice,01/01/2025
10.1038/s41569-025-01211-5,takotsubo syndrome : pathophysiological insight and innovation patient care .,"Omerovic E, Redfors B","takotsubo syndrome , also know broken heart syndrome , be first describe japan 1990 and present acute heart failure cause transient contractile dysfunction mimic acute coronary syndrome but be not cause acute coronary obstruction . takotsubo syndrome account as much 2-3 % suspect coronary syndrome and be considerably more common woman man . review , discuss historical background and clinical feature takotsubo syndrome and evolve understanding pathophysiology . hallmark feature takotsubo syndrome be transient left ventricular dysfunction link emotional or physical stressor . advance understanding clinical presentation and possible pathophysiological mechanism takotsubo syndrome , condition continue to challenge fundamental understanding human anatomy and physiology , particularly regard acute emotional and physical stressor can trigger such profound cardiovascular dysfunction . definitive mechanism remain elusive , current hypothesis largely centre catecholamine surge and sympathetic nervous system hyperactivation . diagnostic criterion have be develop mayo clinic and european society cardiology work group but , absence randomize control clinical trial , specific treatment takotsubo syndrome be available . review , highlight complex pathophysiology takotsubo syndrome , emphasis interplay emotional stress and cardiac health , and call development evidence-based management protocol .",Nature reviews. Cardiology,02/10/2025
10.1038/s41380-025-03292-7,transcranial temporal interference stimulation treat bipolar disorder,"Zhou H, Wang M, Qi S, Chen Q, Lai J, Wu Z, Liu R, Wang L, Zhou H, Zhang S, Hu S","bipolar depression ( bd-d ) be significant clinical challenge associate high disease burden . transcranial temporal interference stimulation ( ttis ) , novel and noninvasive approach target deep brain structure , be investigate efficacy and safety bd-d patient trial . thirty-six patient be recruit single-arm , open-label trial , and 25 complete 5-day intervention consist 10 ttis session target left nucleus accumben . session last 20 min , maximum current intensity 2 ma and envelope stimulation frequency 40 hz . significant symptom reduction be observe follow treatment , mean hamd-17 score decrease 23 . 36 to 16 . 16 ( p < 0 . 0001 ) , madrs score 39 . 12 31 . 28 ( p < 0 . 01 ) , hama score 19 . 68 15 . 44 ( p < 0 . 05 ) , and qids score 13 . 52to 9 . 68 ( p < 0 . 001 ) . eleven participant ( 44 . 0 % ) meet improvement criterion and seven ( 28 . 0 % ) achieve response . cognitive assessment indicate improvement memory and executive function , and change reward-related brain activity correlate positively symptom reduction . adverse event be mild , mainly transient scalp discomfort . finding provide preliminary evidence support efficacy and safety ttis alleviate depressive symptom and cognitive impairment bd-d .",Molecular psychiatry,02/10/2025
10.1002/mds.70070,biomarker-based classification corticobasal syndrome .,"Palleis C, Bernhardt AM, Weidinger E, Fietzek UM, Jäck A, Katzdobler S, Gnörich J, Bauer T, Franzmeier N, Perneczky R, Brendel M, Levin J, Höglinger GU","background : corticobasal syndrome ( cbs ) be clinically define syndrome progressive movement and cortical dysfunction , cause various underlie pathology , most commonly tau-predominant pathology such progressive supranuclear palsy and corticobasal degeneration , or alzheimer 's disease ( ad ) . lewy-type α-synucleinopathie ( lts ) , tdp-43 proteinopathie , and mixed pathology may also underlie cbs . clinical impact pathology remain poorly understand . objective : to subclassify cbs patient vivo use biomarker amyloid-β ( aβ ) , tau , and α-synuclein ( αsyn ) , and assess clinical relevance stratification . method : conduct prospective cohort study 50 cbs patient lmu university hospital munich . biomarker analysis include cerebrospinal fluid ( csf ) aβ42 and aβ42/40 , [ ( 18)f]flutemetamol aβ-pet , [ ( 18)f]pi-2620 tau-pet , and αsyn seed amplification assay csf . csf neurofilament light chain ( nfl ) serve marker neurodegeneration . patient be stratify six group base biomarker positivity . result : tau positivity be find 90 % cbs case , aβ 28 % , and αsyn 24 % . stratification identify : 52 % consistent tau-predominant pathology , 18 % ad , 10 % ad+lts , 10 % tau-predominant+lts , 4 % isolated lts , and 6 % unclassified . αsyn positivity be more frequent ad-cbs ( 36 % ) tau-predominant-cbs ( 16 % ) . aβ-positive case show great cognitive impairment ; tau positivity correlate bad motor symptom ; αsyn-positive patient have milder motor symptom , slow progression , and low nfl level . conclusion : cbs be molecularly heterogeneous . biomarker-base classification may enhance diagnostic precision and support personalize therapeutic strategy . © 2025 author(s ) . movement disorders publish wiley periodicals llc behalf international parkinson and movement disorder society .",Movement disorders : official journal of the Movement Disorder Society,06/10/2025
10.1186/s12967-025-07097-8,mnda promote immunosuppression microsatellite instability-high colorectal,"Zhang X, Wang WB, Cai XY, Chen XQ, Feng Q, Yang Q, Li JB, Xiong W, Wu T","background : immune checkpoint inhibitor ( ici ) target program death-1 ( pd-1 ) have demonstrate significant clinical benefit colorectal cancer ( crc ) microsatellite instability-high ( msi-h ) status , yet substantial subset patient remain resistant therapy . understand mechanism resistance and identify new therapeutic target be urgently need . method : establish murine mc38-based msi-h crc model to investigate variability",Journal of translational medicine,03/10/2025
10.4168/aair.2025.17.5.531,"overview chronic spontaneous urticaria : diagnosis , management , and","Tbakhi B, Ware K, Park HS, Bernstein JS, Bernstein JA","chronic spontaneous urticaria ( csu ) be complex mast cell-driven disorder characterize recurrent pruritic wheal and/or angioedema last 6 week . condition affect woman more frequently man , particularly age 20 and 40 , and impose considerable physical , psychological , and economic burden , annual healthcare cost u . s exceed $ 200 million . current management strategy emphasize stepwise approach , initiate escalate dose second-generation antihistamine , follow biologic such omalizumab or now dupilumab , and prescribe cyclosporine refractory case . emerge therapy target specific endotype csu , include bruton 's tyrosine kinase inhibitor and mast cell deplete agent , present new avenue personalized treatment . furthermore , validate patient-reported outcome measure and digital tool cruse application enhance symptom tracking and facilitate patient-physician communication . therapeutic landscape csu evolve , focus individualized , evidence-based care approach be critical optimize patient outcome . future research priority include identify biomarker predictive treatment response , conduct long-term outcome study , and evaluate treatment tapering strategy to achieve sustained remission . address cost-effectiveness and accessibility new therapy will be pivotal ensure equitable management csu diverse population . ultimately , be goal comprehensive understanding csu 's heterogeneity , tailor therapeutic strategy , will significantly improve patient quality life and outcome .","Allergy, asthma & immunology research",01/09/2025
10.1186/s12967-025-07075-0,macrophage polarization diabetic vascular complication : mechanistic insight,"Cao L, Ding L, Xia Q, Zhang Z, Li M, Song S, Yin K, Li Z, Li X, Wang Z, Zhao D, Li X, Wang Z","diabetes mellitus , particularly type 2 diabete mellitus , be widespread chronic metabolic disorder characterize persistent hyperglycemia and low-grade chronic inflammation . sustain inflammatory state be major driver macrovascular and microvascular complication . immune cell , macrophage play central role effector and regulator chronic inflammation . diabetic milieu , respond to diverse microenvironmental cue and polarize distinct functional phenotype , thereby contribute both progression and potential resolution diabetes-associated vascular damage . review examine mechanism macrophage polarization diabetic vascular complication , elucidate key signal pathway and interaction metabolic dysfunction , and summarize current regulatory strategy and emerge therapeutic target . particular emphasis be place recent pharmacological approach modulate macrophage polarization , highlight potential novel strategy to delay or prevent onset and progression vascular complication diabetes .",Journal of translational medicine,03/10/2025
10.1016/j.jhep.2025.09.022,target cell-state plasticity drive foxm1/cebpb axis disrupt developmental,"Zhang XF, Zuo XY, Zhu Y, Li JX, Xian JS, Zhang WX, Cheng W, Yuan J, Gong YF, Tang H, Yang XQ, Su YY, Zhang CY, Liu SS, Huang L, Wang H, Li MM, Xi SY, Tang YQ, Zhou L, Wah Lee TK, Ma S, Guan XY, Ma NF, Zhang Y, Liu M","background & aims : heterogeneous cellular state traverse developmental hierarchy induce phenotypic plasticity and be emerge key driver therapeutic resistance hcc . however , factor govern developmental heterogeneity be not clear , and therapeutic intervention be lack . method : autoregulatory network analysis be perform public dataset bulk rna-seq and scrna-seq datum patient hcc , as well hepatocyte differentiation model , to identify key transcriptional regulator govern transition cellular state hepatic differentiation . vitro and vivo model be use to investigate molecular mechanism and evaluate therapeutic potential . result : demonstrate dynamic cell-state transition chaotic developmental trajectory malignant progression hepatocellular carcinoma . high developmental diversity be closely link activation drug resistance gene and immune evasion , significantly affect patient prognosis . identify foxm1/cebpb axis apex control developmental heterogeneity dynamic . form master decision toggle switch mutually suppress other and compete control downstream state-specific network . inhibit foxm1 restore tumor developmental homogeneity , expose tumor cell back immune surveillance . likely mechanism be activation ifn-γ signal and antigen presentation . galnac-conjugated , chemically modify sirna lead compound target hepatic foxm1 be design and show strong potency and tolerability therapeutic mouse model . conclusion : tumor cell-state plasticity drive foxm1/cebpb axis induce developmental heterogeneity and therapeutic resistance hepatocellular carcinoma . rnai-base therapy target hepatic foxm1 show strong potential further clinical testing . impact and implication : tumor heterogeneity and therapeutic resistance remain major barrier cancer treatment , largely drive dynamic transition multiple cellular state . study reveal foxm1/cebpb axis be crucial regulator hierarchical cellular transition and play key role sustain developmental heterogeneity and promote resistance therapy . target axis , demonstrate restoration developmental homogeneity and significant disruption therapeutic resistance preclinical model . furthermore , finding highlight strong efficacy rnai-base therapeutic direct hepatic foxm1 , highlight promising potential pioneer small nucleic acid drug cancer therapy .",Journal of hepatology,01/10/2025
10.1016/j.freeradbiomed.2025.09.056,mots-c attenuate mitochondrial dysfunction induce pyroptosis and cartilage,"Li K, Yang T, Chen F, Lou C, Chen Y, Chen Z, Ye L, Sun X, Liu G, Xie C, Fang J, Hu X, Zhu Y, Liu B, He D, Ma H","osteoarthritis , common chronic degenerative disease field orthopedic , be cause interaction mechanical stress , traumatic inflammation , and metabolic imbalance , and interaction progress time .",Free radical biology & medicine,01/10/2025
10.7326/ANNALS-24-01863,association body composition and cardiometabolic outcomes : prospective,"Jung M, Reisert M, Rieder H, Rospleszcz S, Lu MT, Bamberg F, Raghu VK, Weiss J","background : current measure adiposity have limitation . artificial intelligence ( ai ) model may accurately and efficiently estimate body composition ( bc ) routine imaging . objective : to assess association ai-derived bc compartment magnetic resonance imaging ( mri ) cardiometabolic outcome . design : prospective cohort study . setting : uk biobank ( ukb ) observational cohort study . participant : 33 432 ukb participant history diabetes , myocardial infarction , or ischemic stroke ( mean age , 65 . 0 year [ sd , 7 . 8 ] ; mean body mass index [ bmi ] , 25 . 8 kg/m(2 ) [ sd , 4 . 2 ] ; 52 . 8 % female ) undergo whole-body mri . measurement : ai tool be apply mri to derive 3-dimensional ( 3d ) bc measure , include subcutaneous adipose tissue ( sat ) , visceral adipose tissue ( vat ) , skeletal muscle ( sm ) , and sm fat fraction ( smff ) , and then calculate relative distribution . sex-stratified association relative compartment incident diabete mellitus ( dm ) and major adverse cardiovascular event ( mace ) be assess use restrict cubic spline . result : adipose tissue compartment and smff increase and sm decrease age . adjustment age , smoking , and hypertension , great adiposity and low sm proportion be associate high incidence dm and mace median follow-up 4 . 2 year sex-stratified analysis ; however , additional adjustment bmi and waist circumference ( wc ) , only elevated vat proportion and high smff ( top fifth percentile cohort ) be associate increase risk dm ( respective adjust hazard ratio [ ahrs ] , 2 . 16 [ 95 % ci , 1 . 59 to 2 . 94 ] and 1 . 27 [ ci , 0 . 89 to 1 . 80 ] female and 1 . 84 [ ci , 1 . 48 to 2 . 27 ] and 1 . 84 [ ci , 1 . 43 to 2 . 37 ] male ) and mace ( 1 . 37 [ ci , 1 . 00 1 . 88 ] and 1 . 72 [ ci , 1 . 23 to 2 . 41 ] female and 1 . 22 [ ci , 0 . 99 to 1 . 50 ] and 1 . 25 [ ci , 0 . 98 to 1 . 60 ] male ) . addition , male only , bottom fifth percentile sm proportion have increase risk dm ( ahr bottom fifth percentile cohort , 1 . 96 [ ci , 1 . 45 to 2 . 65 ] ) and mace ( ahr , 1 . 55 [ ci , 1 . 15 to 2 . 09 ] ) . limitation : result may not be generalizable non-white or people united kingdom . conclusion : artificial intelligence-derived bc proportion be strongly associate cardiometabolic risk , but bmi and wc be account , only vat proportion and smff ( both sex ) and sm proportion ( male only ) add prognostic information . primary funding source : none .",Annals of internal medicine,30/09/2025
10.1016/j.celrep.2025.116384,spliceosome inhibition induce z-rna and cell death small cell,"Jiang X, Ma X, Zhou Y, Liu X, Zhang T, Kim W, Balachandran S, Cañadas I","spliceosome inhibitor emerge promising anticancer agent . recent study have demonstrate spliceosome-targeted therapy ( stts ) trigger antitumor immune response induce accumulation right-handed double-stranded ( ds)rna ( a-rna ) , result activation rig-i-like receptor ( rlrs ) and type interferon-driven antiviral response . here , show spliceosome inhibition pharmacological or genetic neutralization sf3b1 activity induce accumulation endogenous left-handed dsrnas ( z-rnas ) derive intron-retained rnas . z-rnas activate z-form nucleic acid-sensor zbp1 , trigger cell death mouse embryonic fibroblast and small cell lung cancer ( sclc ) cell . spliceosome inhibition induce potent zbp1-dependent cell death cancer-associated fibroblast , be essential enhance immunotherapy response mouse model sclc . collectively , result demonstrate spliceosome inhibitor can be use to generate z-rna and trigger on-demand zbp1-dependent cell death cell tumor microenvironment ( tme ) therapeutic strategy to enhance immunotherapy response resistant cancer .",Cell reports,04/10/2025
10.1016/j.phymed.2025.157341,juglone promote spinal cord injury recovery suppress pyroptosis and,"Chen L, Chang Y, Zhang S, Wang Z, Liu H, Wang H, Shi L, Li N, Feng S","background : spinal cord injury ( sci ) be central nervous system ( cns ) disorder , and often result severe neuronal damage . however , be still effective treatment sci , be important to explore and identify effective therapeutic strategy . natural compound extract walnut , juglone have be previously report to exhibit various biological activity , include anti-tumor and anti-inflammatory effect , but effect central nerve system be still blank . purpose : study aim to evaluate therapeutic effect juglone spinal cord injury and elucidate molecular mechanism neuroprotection . study design : vitro neuronal ogd/r experiment and vivo spinal cord injury model experiment be employ to investigate neuroprotective effect juglone neuron . methods : neuronal ogd/r model and spinal cord injury model be use to detect neuroprotective effect juglone . immunofluorescence , western blot and elisa be employ to investigate effect juglone necroptosis and pyroptosis neuron . rna-seq analysis , immunoprecipitation , western blot , qrt-pcr , immunofluorescence and chip-qpcr be utilize to elucidate molecular mechanism neuroprotective effect . result : juglone can inhibit necroptosis and pyroptosis vivo and vitro , thereby exert neuroprotective effect . mechanistically , identify novel fos/usp53 signal axis , juglone suppress expression fos directly regulate deubiquitinate usp53 . reduced fos expression lead downregulation usp53 , thereby promote ubiquitination and degradation mlkl and gsdmd . cascade ultimately alleviate necroptosis and pyroptosis injure neuron . conclusion : juglone be potential neuroprotective drug exert effect inhibit necroptosi and pyroptosis fos/usp53/ubiquitination signal axis . finding provide novel potential drug target treatment spinal cord injury .",Phytomedicine : international journal of phytotherapy and phytopharmacology,27/09/2025
10.1038/s41591-025-03933-y,clinical validation ai-based blood testing device diagnosis and,"Liesenfeld O, Arora S, Aufderheide TP, Clements CM, DeVos E, Fischer M, Giamarellos-Bourboulis EJ, House S, Humphries RL, Gill JK, Liu E, Mace SE, May L, Michelson E, Osborn TM, Panacek E, Rothman RE, Self WH, Smithline HA, Steingrub J, Van Heukelom P, Weissman A, Wilson M, Wolk DM, Wright DW, Buturovic L, Hasin-Brumshtein Y, Damaraju N, Lu C, Shak JR, Whitfield NN, Khatri P, Sweeney TE, Shapiro NI","lack reliable diagnostic presence , type and severity infection patient present emergency department non-specific symptom pose considerable challenge . develop triverity , use isothermal amplification 29 mrnas and machine learning algorithm myrna instrument to determine likelihood bacterial infection , viral infection and need critical care intervention 7 day . to validate triverity , sepsis-shield study enrol 1 , 222 patient clinically adjudicate infection status and need critical care intervention 7 day endpoint . triverity bacterial and viral score have high accuracy c-reactive protein , procalcitonin or white blood cell count diagnosis bacterial infection area receiver operating characteristic ( auroc ) 0 . 83 , and viral infection ( auroc = 0 . 91 ) . triverity severity score have auroc 0 . 78 predict illness severity and allow reclassification risk critical care intervention compare clinical assessment ( quick sequential organ failure assessment ) alone . three score have rule-in specificity > 92 % and rule-out sensitivity > 95 % . comparison antibiotic administration presentation post-follow-up adjudication find triverity could potentially reduce false positive and false negative inappropriate antibiotic use 60-70 % . further clinical testing interventional setting be need to prove actionability and clinical benefit triverity .",Nature medicine,30/09/2025
10.1038/s41551-025-01496-4,large-scale visualization α-synuclein oligomer parkinson 's disease brain,"Andrews R, Fu B, Toomey CE, Breiter JC, Lachica J, Beckwith JS, Tian R, Brock EE, Needham LM, Chant GJ, Loiseau C, Deconfin A, Baspin K, Popovic R, Evans J, Goh Y, Kurt B, Senicar L, Edmonds M, Bartels T, Bengoa-Vergniory N, Magill PJ, Jaunmuktane Z, Freeman OJ, Taylor BJM, Hardy J, Lashley T, Ryten M, Vendruscolo M, Wood NW, Weiss LE, Gandhi S, Lee SF","parkinson 's disease ( pd ) be neurodegenerative condition characterize presence intraneuronal aggregate contain fibrillar ɑ-synuclein know lewy body . large end-stage specie be form small soluble protein nanoscale assembly , often term oligomer , be propose early driver pathogenesis . now , hypothesis have remain controversial , least part have not be possible to directly visualize nanoscale assembly human brain tissue . here present advanced sensing aggregates-parkinson 's disease , imaging method to generate large-scale α-synuclein aggregate map post-mortem human brain tissue . combine autofluorescence suppression single-molecule fluorescence microscopy , together enable detection nanoscale α-synuclein aggregate . to demonstrate use platform , analyse ~1 . 2 million nanoscale aggregate anterior cingulate cortex human post-mortem brain sample patient pd and healthy control . datum reveal disease-specific shift subpopulation nanoscale assembly represent early feature proteinopathy underlie pd . anticipate quantitative information distribution provide advanced sensing aggregates-parkinson 's disease will enable mechanistic study to reveal pathological process cause α-synuclein aggregation .",Nature biomedical engineering,01/10/2025
